{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-001","record":{"id":"src-001","title":"Form D notice of exempt offering filed by Theranos Inc (July 8, 2010)","url":"https://www.sec.gov/Archives/edgar/data/1313697/000131369710000004/xslFormDX01/primary_doc.xml","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2010-07-08","locator":"Items 1-16 and signature","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Form D notice of exempt offering filed by Theranos Inc (July 8, 2010), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-002","record":{"id":"src-002","title":"Complaint, SEC v. Elizabeth Holmes and Theranos, Inc., N.D. Cal. Case 5:18-cv-01602","url":"https://www.sec.gov/files/litigation/complaints/2018/comp-pr2018-41-theranos-holmes.pdf","publisher":"U.S. Securities and Exchange Commission","date":"2018-03-14","locator":"Complaint, paragraphs 1-94 and prayer","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"court_record","publisher_type":"regulator"},"reading":"Complaint, SEC v. Elizabeth Holmes and Theranos, Inc., N.D. Cal. Case 5:18-cv-01602, U.S. Securities and Exchange Commission"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-003","record":{"id":"src-003","title":"Complaint, SEC v. Ramesh \"Sunny\" Balwani, N.D. Cal. Case 5:18-cv-01603","url":"https://www.sec.gov/files/litigation/complaints/2018/comp-pr2018-41-balwani.pdf","publisher":"U.S. Securities and Exchange Commission","date":"2018-03-14","locator":"Complaint","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"court_record","publisher_type":"regulator"},"reading":"Complaint, SEC v. Ramesh \"Sunny\" Balwani, N.D. Cal. Case 5:18-cv-01603, U.S. Securities and Exchange Commission"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-004","record":{"id":"src-004","title":"SEC EDGAR submissions record for Theranos Inc (CIK 0001313697)","url":"https://data.sec.gov/submissions/CIK0001313697.json","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"","locator":"Registrant metadata and filing index","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"corporate_registry","publisher_type":"regulator"},"reading":"SEC EDGAR submissions record for Theranos Inc (CIK 0001313697), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-005","record":{"id":"src-005","title":"Form D notice of exempt offering filed by Theranos Inc (May 2017)","url":"https://www.sec.gov/Archives/edgar/data/1313697/000131369717000003/xslFormDX01/primary_doc.xml","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2017-05-30","locator":"Items 1-16 and signature","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Form D notice of exempt offering filed by Theranos Inc (May 2017), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-006","record":{"id":"src-006","title":"Corporate registry source · src-006","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"corporate_registry","publisher_type":"unknown"},"reading":"Corporate registry source · src-006"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-007","record":{"id":"src-007","title":"SEC press release 2018-41: Theranos, CEO Holmes, and Former President Balwani Charged With Massive Fraud","url":"https://www.sec.gov/newsroom/press-releases/2018-41","publisher":"U.S. Securities and Exchange Commission","date":"2018-03-14","locator":"Release","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"SEC press release 2018-41: Theranos, CEO Holmes, and Former President Balwani Charged With Massive Fraud, U.S. Securities and Exchange Commission"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-008","record":{"id":"src-008","title":"Media source · src-008","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-008"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-009","record":{"id":"src-009","title":"Company statement source · src-009","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"company_statement","publisher_type":"corporate"},"reading":"Company statement source · src-009"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-010","record":{"id":"src-010","title":"U.S. Attorney release on the indictment of Holmes and Balwani (June 15, 2018)","url":"https://www.justice.gov/usao-ndca/pr/theranos-founder-and-former-chief-operating-officer-charged-alleged-wire-fraud-schemes","publisher":"U.S. Attorney's Office, Northern District of California","date":"2018-06-15","locator":"Release","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"regulatory_record","publisher_type":"government"},"reading":"U.S. Attorney release on the indictment of Holmes and Balwani (June 15, 2018), U.S. Attorney's Office, Northern District of California"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-011","record":{"id":"src-011","title":"Media source · src-011","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-011"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-012","record":{"id":"src-012","title":"Media source · src-012","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-012"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-013","record":{"id":"src-013","title":"Media source · src-013","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-013"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-014","record":{"id":"src-014","title":"U.S. Attorney release on the sentencing of Ramesh Balwani (December 7, 2022)","url":"https://www.justice.gov/usao-ndca/pr/theranos-president-sentenced-more-12-years-fraud-jeopardized-patient-health-and-bilked","publisher":"U.S. Attorney's Office, Northern District of California","date":"2022-12-07","locator":"Release","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"regulatory_record","publisher_type":"government"},"reading":"U.S. Attorney release on the sentencing of Ramesh Balwani (December 7, 2022), U.S. Attorney's Office, Northern District of California"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-015","record":{"id":"src-015","title":"Media source · src-015","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-015"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-016","record":{"id":"src-016","title":"Appendix to the petition for a writ of certiorari, Balwani v. United States, No. 25-1330: Ninth Circuit opinions of 2025, district court judgments and the July 28, 2020 third superseding indictment","url":"https://www.supremecourt.gov/DocketPDF/25/25-1330/409549/20260521155143157_2026-05-21%20Appendix.pdf","publisher":"Supreme Court of the United States (docket)","date":"2026-05-21","locator":"Appendices A-F","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"court_record","publisher_type":"government"},"reading":"Appendix to the petition for a writ of certiorari, Balwani v. United States, No. 25-1330: Ninth Circuit opinions of 2025, district court judgments and the July 28, 2020 third superseding indictment, Supreme Court of the United States (docket)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-017","record":{"id":"src-017","title":"Media source · src-017","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-017"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-018","record":{"id":"src-018","title":"Media source · src-018","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-018"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-019","record":{"id":"src-019","title":"Media source · src-019","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-019"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-020","record":{"id":"src-020","title":"Media source · src-020","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-020"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-021","record":{"id":"src-021","title":"Company statement source · src-021","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"company_statement","publisher_type":"corporate"},"reading":"Company statement source · src-021"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-022","record":{"id":"src-022","title":"Media source · src-022","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-022"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-023","record":{"id":"src-023","title":"SEC EDGAR submissions record for Walgreen Co (CIK 0000104207)","url":"https://data.sec.gov/submissions/CIK0000104207.json","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"","locator":"Registrant metadata","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"corporate_registry","publisher_type":"regulator"},"reading":"SEC EDGAR submissions record for Walgreen Co (CIK 0000104207), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-024","record":{"id":"src-024","title":"SEC EDGAR submissions record for Safeway Inc (CIK 0000086144)","url":"https://data.sec.gov/submissions/CIK0000086144.json","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"","locator":"Registrant metadata","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"corporate_registry","publisher_type":"regulator"},"reading":"SEC EDGAR submissions record for Safeway Inc (CIK 0000086144), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-025","record":{"id":"src-025","title":"SEC EDGAR submissions record for Fortress Investment Group LLC (CIK 0001380393)","url":"https://data.sec.gov/submissions/CIK0001380393.json","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"","locator":"Registrant metadata","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"corporate_registry","publisher_type":"regulator"},"reading":"SEC EDGAR submissions record for Fortress Investment Group LLC (CIK 0001380393), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-026","record":{"id":"src-026","title":"Company statement source · src-026","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"company_statement","publisher_type":"corporate"},"reading":"Company statement source · src-026"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-027","record":{"id":"src-027","title":"Company statement source · src-027","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"company_statement","publisher_type":"corporate"},"reading":"Company statement source · src-027"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-028","record":{"id":"src-028","title":"Regulatory record source · src-028","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Regulatory record source · src-028"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-029","record":{"id":"src-029","title":"Letter of members of the House Committee on Energy and Commerce to the acting CMS administrator on Theranos (July 26, 2016)","url":"https://democrats-energycommerce.house.gov/sites/evo-subsites/democrats-energycommerce.house.gov/files/documents/CMS%20Slavitt%20Theranos%20Letter%202016%2007%2026.pdf","publisher":"U.S. House Committee on Energy and Commerce (minority members)","date":"2016-07-26","locator":"Letter","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"other","publisher_type":"government"},"reading":"Letter of members of the House Committee on Energy and Commerce to the acting CMS administrator on Theranos (July 26, 2016), U.S. House Committee on Energy and Commerce (minority members)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-030","record":{"id":"src-030","title":"Media source · src-030","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-030"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-031","record":{"id":"src-031","title":"Arizona Attorney General list of past consumer settlements (Theranos entry)","url":"https://www.azag.gov/consumer/past-settlements","publisher":"Arizona Attorney General","date":"","locator":"Theranos entry","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"regulatory_record","publisher_type":"government"},"reading":"Arizona Attorney General list of past consumer settlements (Theranos entry), Arizona Attorney General"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-032","record":{"id":"src-032","title":"Memorandum opinion, Partner Investments, L.P. v. Theranos, Inc., Del. Ch. C.A. No. 12816-VCL and No. 2017-0262-JTL (April 23, 2018)","url":"https://courts.delaware.gov/Opinions/Download.aspx?id=271800","publisher":"Court of Chancery of the State of Delaware","date":"2018-04-23","locator":"Memorandum opinion","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"court_record","publisher_type":"government"},"reading":"Memorandum opinion, Partner Investments, L.P. v. Theranos, Inc., Del. Ch. C.A. No. 12816-VCL and No. 2017-0262-JTL (April 23, 2018), Court of Chancery of the State of Delaware"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-033","record":{"id":"src-033","title":"USPTO assignment record, Reel/Frame 44838/0909 (Theranos Inc. to Theranos IP Company, LLC)","url":"https://assignmentcenter.uspto.gov/search/patent/reelFrameDetail%3FreelFrame%3D44838-909","publisher":"U.S. Patent and Trademark Office","date":"2017-12-12","locator":"Assignment record and property list","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"corporate_registry","publisher_type":"registry_operator"},"reading":"USPTO assignment record, Reel/Frame 44838/0909 (Theranos Inc. to Theranos IP Company, LLC), U.S. Patent and Trademark Office"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-034","record":{"id":"src-034","title":"USPTO assignment records listing Theranos, Inc. as assignee","url":"https://assignmentcenter.uspto.gov/search/patent/assigneeAssignorDetails%3FexactAssignorName%3DTHERANOS%20IP%20COMPANY,%20LLC","publisher":"U.S. Patent and Trademark Office","date":"","locator":"Assignment records","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"corporate_registry","publisher_type":"registry_operator"},"reading":"USPTO assignment records listing Theranos, Inc. as assignee, U.S. Patent and Trademark Office"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-035","record":{"id":"src-035","title":"USPTO assignment record, Reel/Frame 44839/0568 (security interest to Fortress Credit Corp.)","url":"https://assignmentcenter.uspto.gov/search/patent/reelFrameDetail%3FreelFrame%3D44839-568","publisher":"U.S. Patent and Trademark Office","date":"2017-12-12","locator":"Assignment record","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"corporate_registry","publisher_type":"registry_operator"},"reading":"USPTO assignment record, Reel/Frame 44839/0568 (security interest to Fortress Credit Corp.), U.S. Patent and Trademark Office"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-036","record":{"id":"src-036","title":"CMS CLIA Annual Laboratory Registry 2017","url":"https://www.cms.gov/regulations-and-guidance/legislation/clia/downloads/2017-laboratory-registry.pdf","publisher":"Centers for Medicare & Medicaid Services","date":"2017","locator":"Sanctions sections","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"CMS CLIA Annual Laboratory Registry 2017, Centers for Medicare & Medicaid Services"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-037","record":{"id":"src-037","title":"Form D/A filed by Partner Investments L P (2014)","url":"https://www.sec.gov/Archives/edgar/data/1343211/000093583614000074/xslFormDX01/primary_doc.xml","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2014-02-04","locator":"Items 1-3","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Form D/A filed by Partner Investments L P (2014), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-038","record":{"id":"src-038","title":"Research source · src-038","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"research","publisher_type":"academic"},"reading":"Research source · src-038"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-039","record":{"id":"src-039","title":"Palo Alto Networks definitive proxy statement for fiscal 2018","url":"https://www.sec.gov/Archives/edgar/data/0001327567/000119312518304252/d621751ddef14a.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2018","locator":"Director biographies","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"company_statement","publisher_type":"regulator"},"reading":"Palo Alto Networks definitive proxy statement for fiscal 2018, U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-040","record":{"id":"src-040","title":"Media source · src-040","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-040"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-041","record":{"id":"src-041","title":"Report and recommendation, Walgreen Co. v. Theranos, Inc., D. Del. C.A. No. 16-1040-RGA-MPT (July 27, 2017)","url":"https://www.ded.uscourts.gov/sites/ded/files/opinions/16-1040.pdf","publisher":"U.S. District Court for the District of Delaware","date":"2017-07-27","locator":"Report and recommendation","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"court_record","publisher_type":"government"},"reading":"Report and recommendation, Walgreen Co. v. Theranos, Inc., D. Del. C.A. No. 16-1040-RGA-MPT (July 27, 2017), U.S. District Court for the District of Delaware"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-042","record":{"id":"src-042","title":"Media source · src-042","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-042"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-043","record":{"id":"src-043","title":"Media source · src-043","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-043"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-044","record":{"id":"src-044","title":"Commerce One, Inc. Form 8-K with the CommerceBid.com merger agreement (November 1999)","url":"https://www.sec.gov/Archives/edgar/data/0001069450/000091205799007348/0000912057-99-007348.txt","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"1999-11-24","locator":"Item 5 and exhibits","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"company_statement","publisher_type":"regulator"},"reading":"Commerce One, Inc. Form 8-K with the CommerceBid.com merger agreement (November 1999), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-045","record":{"id":"src-045","title":"Regulatory record source · src-045","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Regulatory record source · src-045"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-046","record":{"id":"src-046","title":"Media source · src-046","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-046"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-047","record":{"id":"src-047","title":"Media source · src-047","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-047"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-048","record":{"id":"src-048","title":"Media source · src-048","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-048"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-049","record":{"id":"src-049","title":"Media source · src-049","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-049"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-050","record":{"id":"src-050","title":"Media source · src-050","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-050"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-051","record":{"id":"src-051","title":"Media source · src-051","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-051"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-052","record":{"id":"src-052","title":"Court record source · src-052","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"court_record","publisher_type":"media"},"reading":"Court record source · src-052"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-053","record":{"id":"src-053","title":"Schedule 13D filed by Bechtel Group, Inc. and affiliates (October 2001)","url":"https://www.sec.gov/Archives/edgar/data/0001043533/000094787101500831/sch13d_100901.txt","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2001-10-11","locator":"Items 2 and Schedule A","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Schedule 13D filed by Bechtel Group, Inc. and affiliates (October 2001), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-054","record":{"id":"src-054","title":"Media source · src-054","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-054"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-055","record":{"id":"src-055","title":"Media source · src-055","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-055"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-056","record":{"id":"src-056","title":"Media source · src-056","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-056"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-057","record":{"id":"src-057","title":"Supreme Court docket No. 25-1330, Ramesh Sunny Balwani v. United States","url":"https://www.supremecourt.gov/docket/docketfiles/html/public/25-1330.html","publisher":"Supreme Court of the United States (docket)","date":"2026-10-05","locator":"Docket entries","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"court_record","publisher_type":"government"},"reading":"Supreme Court docket No. 25-1330, Ramesh Sunny Balwani v. United States, Supreme Court of the United States (docket)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-058","record":{"id":"src-058","title":"Order on motions to dismiss, In re Arizona Theranos, Inc., Litigation, D. Ariz. No. 2:16-cv-2138 (April 10, 2018)","url":"https://www.govinfo.gov/content/pkg/USCOURTS-azd-2_16-cv-02138/pdf/USCOURTS-azd-2_16-cv-02138-2.pdf","publisher":"U.S. District Court for the District of Arizona (GPO copy)","date":"2018-04-10","locator":"Order","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"court_record","publisher_type":"government"},"reading":"Order on motions to dismiss, In re Arizona Theranos, Inc., Litigation, D. Ariz. No. 2:16-cv-2138 (April 10, 2018), U.S. District Court for the District of Arizona (GPO copy)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-059","record":{"id":"src-059","title":"Court record source · src-059","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"court_record","publisher_type":"unknown"},"reading":"Court record source · src-059"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-060","record":{"id":"src-060","title":"Media source · src-060","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-060"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-061","record":{"id":"src-061","title":"Media source · src-061","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-061"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-062","record":{"id":"src-062","title":"U.S. Attorney case page, United States v. Elizabeth A. Holmes, et al., 18-CR-00258-EJD","url":"https://www.justice.gov/usao-ndca/us-v-elizabeth-holmes-et-al","publisher":"U.S. Attorney's Office, Northern District of California","date":"2022-12-12","locator":"Case page","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"regulatory_record","publisher_type":"government"},"reading":"U.S. Attorney case page, United States v. Elizabeth A. Holmes, et al., 18-CR-00258-EJD, U.S. Attorney's Office, Northern District of California"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-063","record":{"id":"src-063","title":"Court record source · src-063","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"court_record","publisher_type":"nonprofit"},"reading":"Court record source · src-063"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-064","record":{"id":"src-064","title":"Other source · src-064","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"unknown"},"reading":"Other source · src-064"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-065","record":{"id":"src-065","title":"Media source · src-065","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-065"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-066","record":{"id":"src-066","title":"Media source · src-066","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-066"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-067","record":{"id":"src-067","title":"Media source · src-067","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-067"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-068","record":{"id":"src-068","title":"Media source · src-068","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-068"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-069","record":{"id":"src-069","title":"Media source · src-069","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-069"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-070","record":{"id":"src-070","title":"Media source · src-070","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-070"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-071","record":{"id":"src-071","title":"HHS Departmental Appeals Board Decision No. 3222, Elizabeth A. Holmes (January 16, 2026)","url":"https://www.hhs.gov/about/agencies/dab/decisions/board-decisions/2026/board-dab-3222/index.html","publisher":"HHS Departmental Appeals Board","date":"2026-01-16","locator":"Decision","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"regulatory_record","publisher_type":"government"},"reading":"HHS Departmental Appeals Board Decision No. 3222, Elizabeth A. Holmes (January 16, 2026), HHS Departmental Appeals Board"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-072","record":{"id":"src-072","title":"HHS-OIG release on the exclusion of the founder and CEO of Theranos, Inc. (January 2024)","url":"https://oig.hhs.gov/newsroom/news-releases-articles/hhs-oig-issues-notice-of-exclusion-to-founder-and-ceo-of-theranos-inc/","publisher":"HHS Office of Inspector General","date":"2024-01-19","locator":"Release","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"regulatory_record","publisher_type":"government"},"reading":"HHS-OIG release on the exclusion of the founder and CEO of Theranos, Inc. (January 2024), HHS Office of Inspector General"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-073","record":{"id":"src-073","title":"Court record source · src-073","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"court_record","publisher_type":"unknown"},"reading":"Court record source · src-073"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-074","record":{"id":"src-074","title":"Court record source · src-074","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"court_record","publisher_type":"corporate"},"reading":"Court record source · src-074"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-075","record":{"id":"src-075","title":"Court record source · src-075","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"court_record","publisher_type":"unknown"},"reading":"Court record source · src-075"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-076","record":{"id":"src-076","title":"Exhibit 21 (subsidiaries) to the Walgreen Co. annual report for fiscal 2012","url":"https://www.sec.gov/Archives/edgar/data/104207/000010420712000098/exhibit_21.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2012","locator":"Exhibit 21","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"company_statement","publisher_type":"regulator"},"reading":"Exhibit 21 (subsidiaries) to the Walgreen Co. annual report for fiscal 2012, U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-077","record":{"id":"src-077","title":"Other source · src-077","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"nonprofit"},"reading":"Other source · src-077"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-078","record":{"id":"src-078","title":"Media source · src-078","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-078"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-079","record":{"id":"src-079","title":"Regulatory record source · src-079","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Regulatory record source · src-079"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-080","record":{"id":"src-080","title":"Court record source · src-080","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"court_record","publisher_type":"corporate"},"reading":"Court record source · src-080"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-081","record":{"id":"src-081","title":"Company statement source · src-081","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"company_statement","publisher_type":"corporate"},"reading":"Company statement source · src-081"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-082","record":{"id":"src-082","title":"Media source · src-082","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-082"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-083","record":{"id":"src-083","title":"Other source · src-083","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"nonprofit"},"reading":"Other source · src-083"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-084","record":{"id":"src-084","title":"Company statement source · src-084","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"company_statement","publisher_type":"corporate"},"reading":"Company statement source · src-084"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-085","record":{"id":"src-085","title":"Other source · src-085","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"nonprofit"},"reading":"Other source · src-085"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-086","record":{"id":"src-086","title":"Corporate registry source · src-086","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"corporate_registry","publisher_type":"registry_operator"},"reading":"Corporate registry source · src-086"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-087","record":{"id":"src-087","title":"Company statement source · src-087","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"company_statement","publisher_type":"corporate"},"reading":"Company statement source · src-087"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-088","record":{"id":"src-088","title":"Other source · src-088","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"academic"},"reading":"Other source · src-088"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-089","record":{"id":"src-089","title":"Company statement source · src-089","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"company_statement","publisher_type":"corporate"},"reading":"Company statement source · src-089"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-090","record":{"id":"src-090","title":"Media source · src-090","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-090"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-091","record":{"id":"src-091","title":"Media source · src-091","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-091"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-092","record":{"id":"src-092","title":"Oracle Corporation definitive proxy statement (1999)","url":"https://www.sec.gov/Archives/edgar/data/0000777676/000101287099003095/0001012870-99-003095.txt","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"1999","locator":"Director biographies and letter","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"company_statement","publisher_type":"regulator"},"reading":"Oracle Corporation definitive proxy statement (1999), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-093","record":{"id":"src-093","title":"Media source · src-093","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-093"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-094","record":{"id":"src-094","title":"At Road, Inc. definitive proxy statement (2003)","url":"https://www.sec.gov/Archives/edgar/data/1109537/000089161803001999/f87255dedef14a.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2003","locator":"Director biographies","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"company_statement","publisher_type":"regulator"},"reading":"At Road, Inc. definitive proxy statement (2003), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-095","record":{"id":"src-095","title":"Other source · src-095","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"nonprofit"},"reading":"Other source · src-095"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-096","record":{"id":"src-096","title":"Florida corporation record of THERANOS, INC. (F12000001870)","url":"https://search.sunbiz.org/Inquiry/CorporationSearch/SearchResults?InquiryType=EntityName&InquiryDirectionType=ForwardRecord&SearchTerm=THERANKINE+LLC&SearchNameOrder=THERANOMICS+P060000221340&ListNameOrder=THERANKINE+L180000077110&Detail=FL.DOS.Corporations.Shared.Contracts.FilingRecord","publisher":"Florida Division of Corporations","date":"","locator":"Detail by entity name","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"corporate_registry","publisher_type":"registry_operator"},"reading":"Florida corporation record of THERANOS, INC. (F12000001870), Florida Division of Corporations"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-097","record":{"id":"src-097","title":"Dolby Laboratories, Inc. definitive proxy statement (2025)","url":"https://www.sec.gov/Archives/edgar/data/1308547/000119312525320032/d32653ddef14a.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2025","locator":"Director biographies","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"company_statement","publisher_type":"regulator"},"reading":"Dolby Laboratories, Inc. definitive proxy statement (2025), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-098","record":{"id":"src-098","title":"Media source · src-098","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-098"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-099","record":{"id":"src-099","title":"Office of the Historian biography of Henry A. Kissinger","url":"https://history.state.gov/departmenthistory/people/kissinger-henry-a","publisher":"U.S. Department of State, Office of the Historian","date":"","locator":"Biography","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"other","publisher_type":"government"},"reading":"Office of the Historian biography of Henry A. Kissinger, U.S. Department of State, Office of the Historian"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-100","record":{"id":"src-100","title":"Defense Department historical biography of William J. Perry","url":"https://history.defense.gov/Multimedia/Biographies/Article-View/article/571282/william-j-perry/","publisher":"Office of the Secretary of Defense Historical Office","date":"","locator":"Biography","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"other","publisher_type":"government"},"reading":"Defense Department historical biography of William J. Perry, Office of the Secretary of Defense Historical Office"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-101","record":{"id":"src-101","title":"U.S. Senate featured biography of William H. Frist","url":"https://www.senate.gov/senators/FeaturedBios/Featured_Bio_FristBill.htm","publisher":"United States Senate","date":"","locator":"Biography","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"other","publisher_type":"government"},"reading":"U.S. Senate featured biography of William H. Frist, United States Senate"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-102","record":{"id":"src-102","title":"Company statement source · src-102","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"company_statement","publisher_type":"corporate"},"reading":"Company statement source · src-102"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-103","record":{"id":"src-103","title":"Other source · src-103","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"academic"},"reading":"Other source · src-103"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-104","record":{"id":"src-104","title":"Cisco Systems, Inc. definitive proxy statement (2012)","url":"https://www.sec.gov/Archives/edgar/data/858877/000119312512404925/d406637ddef14a.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2012","locator":"Director biographies","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"company_statement","publisher_type":"regulator"},"reading":"Cisco Systems, Inc. definitive proxy statement (2012), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-105","record":{"id":"src-105","title":"General Dynamics Corporation definitive proxy statement (2015)","url":"https://www.sec.gov/Archives/edgar/data/40533/000119312515100185/d846114ddef14a.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2015","locator":"Letter and director biographies","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"company_statement","publisher_type":"regulator"},"reading":"General Dynamics Corporation definitive proxy statement (2015), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-106","record":{"id":"src-106","title":"WHO in memoriam notice for Dr William H. Foege (January 25, 2026)","url":"https://www.who.int/news/item/25-01-2026-in-memoriam-dr-william-h.-foege-(1936-2026)","publisher":"World Health Organization","date":"2026-01-25","locator":"News item","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"other","publisher_type":"intergovernmental"},"reading":"WHO in memoriam notice for Dr William H. Foege (January 25, 2026), World Health Organization"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-107","record":{"id":"src-107","title":"Other source · src-107","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"nonprofit"},"reading":"Other source · src-107"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-108","record":{"id":"src-108","title":"Other source · src-108","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"nonprofit"},"reading":"Other source · src-108"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-109","record":{"id":"src-109","title":"Other source · src-109","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"academic"},"reading":"Other source · src-109"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-110","record":{"id":"src-110","title":"Form 4 filed by T. Peter Thomas for NeoPhotonics Corp (February 2011)","url":"https://www.sec.gov/Archives/edgar/data/1227025/000118143111008206/xslF345X03/rrd299122.xml","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2011-02-07","locator":"Explanation of responses","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"regulatory_record","publisher_type":"regulator"},"reading":"Form 4 filed by T. Peter Thomas for NeoPhotonics Corp (February 2011), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-111","record":{"id":"src-111","title":"Florida annual report of Theranos, Inc. for 2013 (July 30, 2013)","url":"https://search.sunbiz.org/Inquiry/CorporationSearch/GetDocument?aggregateId=forp-f12000001870-457ce98e-9dda-4254-a0d7-333d4e7e896e&transactionId=f12000001870-4ec21e37-6d4b-456e-921d-9d805c9b0598&formatType=PDF","publisher":"Florida Division of Corporations","date":"2013-07-30","locator":"Annual report","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"corporate_registry","publisher_type":"registry_operator"},"reading":"Florida annual report of Theranos, Inc. for 2013 (July 30, 2013), Florida Division of Corporations"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-112","record":{"id":"src-112","title":"Other source · src-112","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"unknown"},"reading":"Other source · src-112"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-113","record":{"id":"src-113","title":"Florida annual report of Theranos, Inc. for 2014 (August 6, 2014)","url":"https://search.sunbiz.org/Inquiry/CorporationSearch/GetDocument?aggregateId=forp-f12000001870-457ce98e-9dda-4254-a0d7-333d4e7e896e&transactionId=f12000001870-6f3b2d79-ced8-449b-bdcc-a04b01d049a5&formatType=PDF","publisher":"Florida Division of Corporations","date":"2014-08-06","locator":"Annual report","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"corporate_registry","publisher_type":"registry_operator"},"reading":"Florida annual report of Theranos, Inc. for 2014 (August 6, 2014), Florida Division of Corporations"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-114","record":{"id":"src-114","title":"The Coca-Cola Company definitive proxy statement (1997)","url":"https://www.sec.gov/Archives/edgar/data/0000021344/000093176397000247/0000931763-97-000247.txt","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"1997","locator":"Director biographies","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"company_statement","publisher_type":"regulator"},"reading":"The Coca-Cola Company definitive proxy statement (1997), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-115","record":{"id":"src-115","title":"Stevanato Group S.p.A. IPO prospectus, Form 424B4 (July 2021)","url":"https://www.sec.gov/Archives/edgar/data/1849853/000119312521217250/d87447d424b4.htm","publisher":"U.S. Securities and Exchange Commission (EDGAR)","date":"2021-07","locator":"Management section","basis":"Retained copy of the document in the frozen case database, read in the passages cited by the claims.","accessed":"2026-10-21","source_type":"company_statement","publisher_type":"regulator"},"reading":"Stevanato Group S.p.A. IPO prospectus, Form 424B4 (July 2021), U.S. Securities and Exchange Commission (EDGAR)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-116","record":{"id":"src-116","title":"Other source · src-116","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"other","publisher_type":"corporate"},"reading":"Other source · src-116"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-117","record":{"id":"src-117","title":"Media source · src-117","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-117"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"sources","id":"src-118","record":{"id":"src-118","title":"Media source · src-118","url":"","publisher":"","date":"","locator":"","basis":"Source classification retained; identifying metadata omitted.","accessed":"","source_type":"media","publisher_type":"media"},"reading":"Media source · src-118"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-id-incorporation","record":{"id":"c-id-incorporation","kind":"fact","text":"Theranos was incorporated in Delaware as RealTime Cures, Inc.: its original certificate of incorporation was filed with the Delaware Secretary of State on April 13, 2004. An amended and restated certificate, signed by Elizabeth Holmes as President on December 15, 2004 and filed that day under Delaware file number 3789976, changed the corporation's name to Theranos, Inc.","source_ids":["src-086"],"entity_ids":["theranos","holmes"],"qualification":"","response":"","outcome":""},"reading":"Fact: Theranos was incorporated in Delaware as RealTime Cures, Inc.: its original certificate of incorporation was filed with the Delaware Secretary of State on April 13, 2004. An amended and restated certificate, signed by Elizabeth Holmes as President on December 15, 2004 and filed that day under Delaware file number 3789976, changed the corporation's name to Theranos, Inc."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-id-founding-date","record":{"id":"c-id-founding-date","kind":"fact","text":"The SEC's 2018 complaint describes Theranos, Inc. as a Delaware corporation established by Elizabeth Holmes in 2003; the Department of Justice and the federal courts likewise date the company's founding to 2003, the year before the Delaware certificate of incorporation was filed.","source_ids":["src-002","src-016"],"entity_ids":["theranos","holmes"],"qualification":"","response":"","outcome":""},"reading":"Fact: The SEC's 2018 complaint describes Theranos, Inc. as a Delaware corporation established by Elizabeth Holmes in 2003; the Department of Justice and the federal courts likewise date the company's founding to 2003, the year before the Delaware certificate of incorporation was filed."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-id-capital-2004","record":{"id":"c-id-capital-2004","kind":"fact","text":"The December 2004 restated certificate authorised Theranos to issue 53,500,000 shares with a par value of $0.0001: 40,000,000 shares of common stock and 13,500,000 shares of preferred stock, all designated Series A Preferred Stock with a conversion price of $0.75 per share.","source_ids":["src-086"],"entity_ids":["theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: The December 2004 restated certificate authorised Theranos to issue 53,500,000 shares with a par value of $0.0001: 40,000,000 shares of common stock and 13,500,000 shares of preferred stock, all designated Series A Preferred Stock with a conversion price of $0.75 per share."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-id-california-qualification","record":{"id":"c-id-california-qualification","kind":"fact","text":"An Amended Statement by Foreign Corporation filed with the California Secretary of State records that Theranos, Inc., a Delaware corporation qualified to transact intrastate business in California, had changed its name from RealTime Cures, Inc.; it was signed by J. Casey McGlynn as Secretary. The California file also holds the Delaware Secretary of State's certified copy of the name change, dated January 6, 2005 (01-06-05).","source_ids":["src-086"],"entity_ids":["theranos","casey-mcglynn"],"qualification":"","response":"","outcome":""},"reading":"Fact: An Amended Statement by Foreign Corporation filed with the California Secretary of State records that Theranos, Inc., a Delaware corporation qualified to transact intrastate business in California, had changed its name from RealTime Cures, Inc.; it was signed by J. Casey McGlynn as Secretary. The California file also holds the Delaware Secretary of State's certified copy of the name change, dated January 6, 2005 (01-06-05)."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-id-sec-registrant","record":{"id":"c-id-sec-registrant","kind":"fact","text":"The SEC's EDGAR record for Central Index Key 0001313697 identifies the registrant as Theranos Inc, with employer identification number 20-1231826 (written 201231826), state of incorporation Delaware and a December 31 fiscal year end; it lists no ticker or exchange, and gives 1701 Page Mill Road, Palo Alto, California 94304 as its business address.","source_ids":["src-004"],"entity_ids":["theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: The SEC's EDGAR record for Central Index Key 0001313697 identifies the registrant as Theranos Inc, with employer identification number 20-1231826 (written 201231826), state of incorporation Delaware and a December 31 fiscal year end; it lists no ticker or exchange, and gives 1701 Page Mill Road, Palo Alto, California 94304 as its business address."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-id-sec-filings","record":{"id":"c-id-sec-filings","kind":"fact","text":"Theranos's EDGAR filing index contains two electronic Form D notices of exempt securities offerings, filed on July 8, 2010 and May 30, 2017, and seven paper Regulation D filings (REGDEX and REGDEX/A) from January 2005 to November 2006. It contains no annual or quarterly reports: Theranos remained a private company, and the Ninth Circuit noted that its shares were not publicly traded.","source_ids":["src-004","src-016"],"entity_ids":["theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: Theranos's EDGAR filing index contains two electronic Form D notices of exempt securities offerings, filed on July 8, 2010 and May 30, 2017, and seven paper Regulation D filings (REGDEX and REGDEX/A) from January 2005 to November 2006. It contains no annual or quarterly reports: Theranos remained a private company, and the Ninth Circuit noted that its shares were not publicly traded."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-id-form-d-2010","record":{"id":"c-id-form-d-2010","kind":"fact","text":"In its Form D of July 8, 2010 Theranos Inc reported its previous name as RealTime Cures, Inc., its form as a corporation organised in Delaware more than five years earlier, and its principal place of business as 3200 Hillview Avenue, Palo Alto, California 94304.","source_ids":["src-001"],"entity_ids":["theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: In its Form D of July 8, 2010 Theranos Inc reported its previous name as RealTime Cures, Inc., its form as a corporation organised in Delaware more than five years earlier, and its principal place of business as 3200 Hillview Avenue, Palo Alto, California 94304."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-id-principal-places","record":{"id":"c-id-principal-places","kind":"fact","text":"The SEC's 2018 complaint gives Theranos's principal place of business as Newark, California, and as Palo Alto, California during 2013 to 2015. The 2020 superseding indictment describes a Delaware corporation with its principal place of business in Palo Alto, and the Justice Department's 2022 release calls Theranos a now-defunct blood testing company based in Palo Alto and Newark.","source_ids":["src-002","src-016","src-014"],"entity_ids":["theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: The SEC's 2018 complaint gives Theranos's principal place of business as Newark, California, and as Palo Alto, California during 2013 to 2015. The 2020 superseding indictment describes a Delaware corporation with its principal place of business in Palo Alto, and the Justice Department's 2022 release calls Theranos a now-defunct blood testing company based in Palo Alto and Newark."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-id-addresses-registry","record":{"id":"c-id-addresses-registry","kind":"fact","text":"Patent assignment records at the USPTO give Theranos, Inc.'s address as 1430 O'Brien Drive, Suite H, Menlo Park, California in an assignment recorded on December 14, 2005, and as 3200 Hillview Avenue, Palo Alto in a later assignment record. Theranos's annual reports to the Florida corporate registry list 1601 S California Ave, Palo Alto in 2013 and 2014 and 1701 Page Mill Road, Palo Alto from April 27, 2015.","source_ids":["src-034","src-111","src-113","src-096"],"entity_ids":["theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: Patent assignment records at the USPTO give Theranos, Inc.'s address as 1430 O'Brien Drive, Suite H, Menlo Park, California in an assignment recorded on December 14, 2005, and as 3200 Hillview Avenue, Palo Alto in a later assignment record. Theranos's annual reports to the Florida corporate registry list 1601 S California Ave, Palo Alto in 2013 and 2014 and 1701 Page Mill Road, Palo Alto from April 27, 2015."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-id-moves-attributed","record":{"id":"c-id-moves-attributed","kind":"attributed","text":"According to an online encyclopaedia article on Theranos, the company moved in June 2012 from 3200 Hillview Avenue to the former Facebook headquarters at 1601 S. California Avenue, was headquartered by 2017 at 1701 Page Mill Road in Palo Alto under a lease of $1 million a month, had laboratories in Newark, California and Scottsdale, Arizona, and in 2017 vacated the Page Mill building and moved its remaining staff to the Newark laboratory site.","source_ids":["src-083"],"entity_ids":["theranos"],"qualification":"A secondary encyclopaedia account citing press reports; the 1601 S California Avenue and 1701 Page Mill Road addresses are confirmed by Theranos's own Florida annual reports, but the lease amount and the 2017 move are not documented elsewhere in the record.","response":"","outcome":""},"reading":"Attributed: According to an online encyclopaedia article on Theranos, the company moved in June 2012 from 3200 Hillview Avenue to the former Facebook headquarters at 1601 S. California Avenue, was headquartered by 2017 at 1701 Page Mill Road in Palo Alto under a lease of $1 million a month, had laboratories in Newark, California and Scottsdale, Arizona, and in 2017 vacated the Page Mill building and moved its remaining staff to the Newark laboratory site."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-id-florida","record":{"id":"c-id-florida","kind":"fact","text":"The Florida Division of Corporations registered Theranos, Inc. on May 1, 2012 as a foreign profit corporation (document number F12000001870, FEI/EIN 20-1231826, state of incorporation Delaware). Annual reports were filed for 2013, 2014 and 2015; the registration was revoked for failure to file an annual report (event filed September 23, 2016) and is inactive, and its registered agent resigned on August 27, 2019.","source_ids":["src-096"],"entity_ids":["theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: The Florida Division of Corporations registered Theranos, Inc. on May 1, 2012 as a foreign profit corporation (document number F12000001870, FEI/EIN 20-1231826, state of incorporation Delaware). Annual reports were filed for 2013, 2014 and 2015; the registration was revoked for failure to file an annual report (event filed September 23, 2016) and is inactive, and its registered agent resigned on August 27, 2019."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-id-registrations-attributed","record":{"id":"c-id-registrations-attributed","kind":"attributed","text":"A company-data aggregator lists Theranos, Inc. as Delaware corporation number 3789976 with The Corporation Trust Company in Wilmington as registered agent, and shows registrations as a foreign corporation in Pennsylvania (4357259), Arizona (F19937947), Florida (F12000001870) and California (2651481).","source_ids":["src-006","src-096","src-009"],"entity_ids":["theranos"],"qualification":"Aggregator listing: the Delaware file number and the Florida registration are confirmed by the Delaware filing stamp and the Florida registry record, and the California number matches the identifier of the California Secretary of State filing retained in the record; the Pennsylvania and Arizona numbers were not checked against those states' registries.","response":"","outcome":"Florida revoked the registration on September 23, 2016 for failure to file an annual report, and in September 2018 Theranos told stockholders that after its assignment for the benefit of creditors it intended to file a certificate of dissolution under Delaware law."},"reading":"Attributed: A company-data aggregator lists Theranos, Inc. as Delaware corporation number 3789976 with The Corporation Trust Company in Wilmington as registered agent, and shows registrations as a foreign corporation in Pennsylvania (4357259), Arizona (F19937947), Florida (F12000001870) and California (2651481)."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-id-trademarks-attributed","record":{"id":"c-id-trademarks-attributed","kind":"attributed","text":"The same aggregator lists trademark registrations held by Theranos, Inc.: the international marks THE LAB TEST, REINVENTED, THE TINY BLOOD TEST and THERANOS WELLNESS CENTER, registered through the World Intellectual Property Organization in October 2015, and the U.S. mark THERANOS registered on June 1, 2010 and shown as historic.","source_ids":["src-006"],"entity_ids":["theranos"],"qualification":"Aggregator listing of trademark data; the registers themselves were not opened.","response":"","outcome":""},"reading":"Attributed: The same aggregator lists trademark registrations held by Theranos, Inc.: the international marks THE LAB TEST, REINVENTED, THE TINY BLOOD TEST and THERANOS WELLNESS CENTER, registered through the World Intellectual Property Organization in October 2015, and the U.S. mark THERANOS registered on June 1, 2010 and shown as historic."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-holmes-ceo","record":{"id":"c-ld-holmes-ceo","kind":"fact","text":"Elizabeth Holmes founded Theranos in 2003 and was its chief executive officer from 2003 until 2018, according to the 2020 superseding indictment, the Ninth Circuit's opinion and the HHS Departmental Appeals Board; the HHS Office of Inspector General describes her as the company's CEO and chairperson. The indictment states that she owned and operated the company.","source_ids":["src-016","src-071","src-072"],"entity_ids":["holmes","theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: Elizabeth Holmes founded Theranos in 2003 and was its chief executive officer from 2003 until 2018, according to the 2020 superseding indictment, the Ninth Circuit's opinion and the HHS Departmental Appeals Board; the HHS Office of Inspector General describes her as the company's CEO and chairperson. The indictment states that she owned and operated the company."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-holmes-stanford","record":{"id":"c-ld-holmes-stanford","kind":"fact","text":"A business magazine reported in June 2018 that Holmes had dropped out of Stanford University to start the company in 2003.","source_ids":["src-060"],"entity_ids":["holmes","theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: A business magazine reported in June 2018 that Holmes had dropped out of Stanford University to start the company in 2003."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-form-d-2010-persons","record":{"id":"c-ld-form-d-2010-persons","kind":"fact","text":"Theranos's Form D of July 8, 2010 lists Elizabeth Holmes and Ramesh Balwani as executive officers and directors, and Donald L. Lucas, Channing Robertson, Robert Shapiro and T. Peter Thomas as directors; Holmes signed the notice as President and CEO.","source_ids":["src-001"],"entity_ids":["theranos","holmes","balwani","donald-lucas","robertson","shapiro","peter-thomas"],"qualification":"","response":"","outcome":""},"reading":"Fact: Theranos's Form D of July 8, 2010 lists Elizabeth Holmes and Ramesh Balwani as executive officers and directors, and Donald L. Lucas, Channing Robertson, Robert Shapiro and T. Peter Thomas as directors; Holmes signed the notice as President and CEO."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-robertson-attributed","record":{"id":"c-ld-robertson-attributed","kind":"attributed","text":"According to an online encyclopaedia, Channing Robertson, a Stanford University chemical-engineering professor who taught Holmes, helped her start Theranos in 2003, served as a technical adviser and became the company's first board member; in 2017 Theranos named him co-leader of a technology advisory board. Stanford's own profile lists him as Ruth G. and William K. Bowes Professor in the School of Engineering, Emeritus, in chemical engineering.","source_ids":["src-083","src-108","src-088"],"entity_ids":["robertson","holmes","theranos"],"qualification":"The early roles are reported by a secondary encyclopaedia source; the Form D of July 2010 independently lists Robertson as a director.","response":"","outcome":""},"reading":"Attributed: According to an online encyclopaedia, Channing Robertson, a Stanford University chemical-engineering professor who taught Holmes, helped her start Theranos in 2003, served as a technical adviser and became the company's first board member; in 2017 Theranos named him co-leader of a technology advisory board. Stanford's own profile lists him as Ruth G. and William K. Bowes Professor in the School of Engineering, Emeritus, in chemical engineering."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-robertson-pay-attributed","record":{"id":"c-ld-robertson-pay-attributed","kind":"attributed","text":"An online encyclopaedia, citing records of the criminal case, reports that Theranos paid Robertson about $463,000 from March 2015 to February 2016 and that an investor witness from PFM said he relied on Robertson's expertise before investing $96 million; it also reports that Robertson worked for the company and sat on its board until 2018, and quotes an investors' lawyer as saying that Holmes paid him $500,000 a year from 2013 to 2017.","source_ids":["src-108"],"entity_ids":["robertson","theranos","holmes"],"qualification":"Reported only by a secondary encyclopaedia source; the research archive left the pay figures and the 2018 end date open for a second document, and no Theranos filing in the record confirms them.","response":"According to the same encyclopaedia, Robertson defended Theranos in an interview with a business magazine after the 2015 newspaper reports, and as late as May 2018 he believed the company had succeeded in developing novel blood-testing technology.","outcome":""},"reading":"Attributed: An online encyclopaedia, citing records of the criminal case, reports that Theranos paid Robertson about $463,000 from March 2015 to February 2016 and that an investor witness from PFM said he relied on Robertson's expertise before investing $96 million; it also reports that Robertson worked for the company and sat on its board until 2018, and quotes an investors' lawyer as saying that Holmes paid him $500,000 a year from 2013 to 2017."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-tevanian-attributed","record":{"id":"c-ld-tevanian-attributed","kind":"attributed","text":"According to an online encyclopaedia citing press reports, Avie Tevanian joined the boards of Dolby Laboratories and Theranos after leaving Apple on March 31, 2006, and resigned from the Theranos board in late 2007 after an acrimonious dispute in which he faced legal threats and was made to waive his right to buy shares from a co-founder.","source_ids":["src-083"],"entity_ids":["tevanian","theranos"],"qualification":"Reported by a secondary encyclopaedia source only; the research found no second document on Tevanian's Theranos directorship because Theranos's 2005-2006 Regulation D filings exist only as paper records.","response":"","outcome":""},"reading":"Attributed: According to an online encyclopaedia citing press reports, Avie Tevanian joined the boards of Dolby Laboratories and Theranos after leaving Apple on March 31, 2006, and resigned from the Theranos board in late 2007 after an acrimonious dispute in which he faced legal threats and was made to waive his right to buy shares from a co-founder."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-balwani-guarantee","record":{"id":"c-ld-balwani-guarantee","kind":"fact","text":"According to the SEC's 2018 complaints, in 2009, as Theranos was on the verge of running out of money, Holmes turned to Ramesh \"Sunny\" Balwani, then her boyfriend, to guarantee a line of credit for the company; Balwani guaranteed it, joined Theranos and became its President and Chief Operating Officer that same year.","source_ids":["src-002","src-003"],"entity_ids":["balwani","holmes","theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: According to the SEC's 2018 complaints, in 2009, as Theranos was on the verge of running out of money, Holmes turned to Ramesh \"Sunny\" Balwani, then her boyfriend, to guarantee a line of credit for the company; Balwani guaranteed it, joined Theranos and became its President and Chief Operating Officer that same year."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-balwani-tenure","record":{"id":"c-ld-balwani-tenure","kind":"fact","text":"The SEC complaint states that Balwani was President and Chief Operating Officer of Theranos from September 2009 to May 2016. The U.S. Attorney's Office said in 2018 that he worked at Theranos from September 2009 through 2016 and at times served as a member of the board of directors, as president and as chief operating officer.","source_ids":["src-002","src-010","src-014"],"entity_ids":["balwani","theranos"],"qualification":"The U.S. Attorney's 2022 sentencing release gives his employment as running from September 2009 through July 2016, while the SEC complaint and Theranos's own May 2016 announcement place his departure in May 2016; Theranos's May 2016 announcement said he would continue to support the transition process through its completion.","response":"","outcome":""},"reading":"Fact: The SEC complaint states that Balwani was President and Chief Operating Officer of Theranos from September 2009 to May 2016. The U.S. Attorney's Office said in 2018 that he worked at Theranos from September 2009 through 2016 and at times served as a member of the board of directors, as president and as chief operating officer."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-balwani-responsibilities","record":{"id":"c-ld-balwani-responsibilities","kind":"fact","text":"The Ninth Circuit's opinion states that the precise division of responsibilities between Holmes and Balwani was disputed at their trials, but that evidence at both trials showed Balwani oversaw operations in Theranos's patient-testing laboratory and was the primary contact for its relationships with retailers, including Safeway and Walgreens.","source_ids":["src-016"],"entity_ids":["balwani","holmes","theranos","safeway","walgreen-co"],"qualification":"","response":"","outcome":""},"reading":"Fact: The Ninth Circuit's opinion states that the precise division of responsibilities between Holmes and Balwani was disputed at their trials, but that evidence at both trials showed Balwani oversaw operations in Theranos's patient-testing laboratory and was the primary contact for its relationships with retailers, including Safeway and Walgreens."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-holmes-balwani-relationship","record":{"id":"c-ld-holmes-balwani-relationship","kind":"fact","text":"The Ninth Circuit's opinion states that Balwani was in a romantic relationship with Holmes from 2004 to 2016, and the HHS Departmental Appeals Board described it as an \"on and off\" relationship.","source_ids":["src-016","src-071"],"entity_ids":["holmes","balwani"],"qualification":"","response":"","outcome":""},"reading":"Fact: The Ninth Circuit's opinion states that Balwani was in a romantic relationship with Holmes from 2004 to 2016, and the HHS Departmental Appeals Board described it as an \"on and off\" relationship."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-sole-executives","record":{"id":"c-ld-sole-executives","kind":"fact","text":"The SEC alleged that from the time Balwani joined Theranos until his departure in 2016 the company had no senior managing executives other than Holmes and Balwani, and that they were its sole managing executives during 2013 to 2015.","source_ids":["src-002"],"entity_ids":["theranos","holmes","balwani"],"qualification":"","response":"","outcome":""},"reading":"Fact: The SEC alleged that from the time Balwani joined Theranos until his departure in 2016 the company had no senior managing executives other than Holmes and Balwani, and that they were its sole managing executives during 2013 to 2015."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-pay-holmes","record":{"id":"c-ld-pay-holmes","kind":"fact","text":"The SEC's complaint states that Holmes, as CEO and Chairman of the Board, was paid a salary of about $200,000 to $390,000 a year between 2013 and 2015, exercised about 53.7 million stock options in the same period and received super-majority voting Class B common shares that gave her almost complete voting control; it adds that she had never sold any Theranos stock.","source_ids":["src-002"],"entity_ids":["holmes","theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: The SEC's complaint states that Holmes, as CEO and Chairman of the Board, was paid a salary of about $200,000 to $390,000 a year between 2013 and 2015, exercised about 53.7 million stock options in the same period and received super-majority voting Class B common shares that gave her almost complete voting control; it adds that she had never sold any Theranos stock."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-pay-balwani","record":{"id":"c-ld-pay-balwani","kind":"fact","text":"According to the SEC's complaint against him, Balwani received a salary of between about $99,000 and $200,000 from 2013 through 2015.","source_ids":["src-003"],"entity_ids":["balwani","theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: According to the SEC's complaint against him, Balwani received a salary of between about $99,000 and $200,000 from 2013 through 2015."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-options-email","record":{"id":"c-ld-options-email","kind":"attributed","text":"Television news coverage of Holmes's trial reported that her defence showed a February 2015 email in which Holmes told James Mattis that she and Balwani, her top executive and for a time her romantic partner, wanted to be paid in stock options rather than a salary.","source_ids":["src-013"],"entity_ids":["holmes","balwani","mattis"],"qualification":"Trial evidence as reported by the press; the email itself is not in the record.","response":"","outcome":""},"reading":"Attributed: Television news coverage of Holmes's trial reported that her defence showed a February 2015 email in which Holmes told James Mattis that she and Balwani, her top executive and for a time her romantic partner, wanted to be paid in stock options rather than a salary."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-shultz-joins","record":{"id":"c-ld-shultz-joins","kind":"attributed","text":"A business magazine reported in June 2014 that Holmes was introduced to George Shultz at Stanford's Hoover Institution in July 2011 and that he joined Theranos's board that same month. Three years later, it reported, nearly all of the other outside directors had been introduced to the company through Shultz: Bill Perry, Henry Kissinger, Sam Nunn, Bill Frist, Gary Roughead, James Mattis, Dick Kovacevich and Riley Bechtel.","source_ids":["src-019"],"entity_ids":["shultz","holmes","theranos","perry","kissinger","nunn","frist","roughead","mattis","kovacevich","riley-bechtel"],"qualification":"A magazine account based on interviews; the board membership itself is confirmed by Theranos's annual reports to the Florida registry from 2013 to 2015.","response":"","outcome":""},"reading":"Attributed: A business magazine reported in June 2014 that Holmes was introduced to George Shultz at Stanford's Hoover Institution in July 2011 and that he joined Theranos's board that same month. Three years later, it reported, nearly all of the other outside directors had been introduced to the company through Shultz: Bill Perry, Henry Kissinger, Sam Nunn, Bill Frist, Gary Roughead, James Mattis, Dick Kovacevich and Riley Bechtel."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-board-2013-release","record":{"id":"c-ld-board-2013-release","kind":"fact","text":"A 2018 order in the indirect-investor class action against Theranos (N.D. Cal. No. 16-cv-06822-NC) records that Theranos's first website press release, dated July 29, 2013, announced James Mattis and Richard Kovacevich as board members, joining a board that already included Henry Kissinger, Samuel Nunn and William Perry. The same order describes Holmes as Theranos's CEO and Chairwoman and Balwani as its former President, Chief Operating Officer and board member.","source_ids":["src-073"],"entity_ids":["theranos","mattis","kovacevich","kissinger","nunn","perry","holmes","balwani"],"qualification":"","response":"","outcome":""},"reading":"Fact: A 2018 order in the indirect-investor class action against Theranos (N.D. Cal. No. 16-cv-06822-NC) records that Theranos's first website press release, dated July 29, 2013, announced James Mattis and Richard Kovacevich as board members, joining a board that already included Henry Kissinger, Samuel Nunn and William Perry. The same order describes Holmes as Theranos's CEO and Chairwoman and Balwani as its former President, Chief Operating Officer and board member."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-florida-2013","record":{"id":"c-ld-florida-2013","kind":"fact","text":"Theranos's 2013 annual report to the Florida corporate registry, filed on July 30, 2013 and signed by Ramesh Balwani as President, lists Elizabeth Holmes as CEO and Chairman, Balwani as President and COO, and George Shultz, Gary Roughead, William Perry, Samuel Nunn, Richard Kovacevich, James Mattis and Henry Kissinger as directors.","source_ids":["src-111"],"entity_ids":["theranos","holmes","balwani","shultz","roughead","perry","nunn","kovacevich","mattis","kissinger"],"qualification":"","response":"","outcome":""},"reading":"Fact: Theranos's 2013 annual report to the Florida corporate registry, filed on July 30, 2013 and signed by Ramesh Balwani as President, lists Elizabeth Holmes as CEO and Chairman, Balwani as President and COO, and George Shultz, Gary Roughead, William Perry, Samuel Nunn, Richard Kovacevich, James Mattis and Henry Kissinger as directors."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-florida-2014","record":{"id":"c-ld-florida-2014","kind":"fact","text":"The 2014 annual report to the Florida registry, filed on August 6, 2014, lists the same officers and directors and adds William Frist, William Foege and Riley Bechtel as directors, so that these three joined the board between July 30, 2013 and August 6, 2014.","source_ids":["src-113"],"entity_ids":["theranos","holmes","balwani","shultz","roughead","perry","nunn","kovacevich","mattis","kissinger","frist","foege","riley-bechtel"],"qualification":"","response":"","outcome":""},"reading":"Fact: The 2014 annual report to the Florida registry, filed on August 6, 2014, lists the same officers and directors and adds William Frist, William Foege and Riley Bechtel as directors, so that these three joined the board between July 30, 2013 and August 6, 2014."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-florida-2015","record":{"id":"c-ld-florida-2015","kind":"fact","text":"The Florida registry record of Theranos, Inc., updated by the annual report of April 27, 2015, lists Elizabeth Holmes as CEO and Chairman, Ramesh Balwani as President and COO, and ten directors: George Shultz, Gary Roughead, William Perry, Samuel Nunn, James Mattis, Richard Kovacevich, Henry Kissinger, William Frist, William Foege and Riley Bechtel.","source_ids":["src-096"],"entity_ids":["theranos","holmes","balwani","shultz","roughead","perry","nunn","mattis","kovacevich","kissinger","frist","foege","riley-bechtel"],"qualification":"","response":"","outcome":""},"reading":"Fact: The Florida registry record of Theranos, Inc., updated by the annual report of April 27, 2015, lists Elizabeth Holmes as CEO and Chairman, Ramesh Balwani as President and COO, and ten directors: George Shultz, Gary Roughead, William Perry, Samuel Nunn, James Mattis, Richard Kovacevich, Henry Kissinger, William Frist, William Foege and Riley Bechtel."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-board-pay-testimony","record":{"id":"c-ld-board-pay-testimony","kind":"attributed","text":"At her 2021 trial Holmes testified, as reported by a national newspaper, that George Shultz recommended Richard Kovacevich, Jim Mattis, Gary Roughead, Sam Nunn, Henry Kissinger and William Perry for the board, that Theranos paid each board member $150,000 a year plus 500,000 shares, and that Kissinger received another $500,000 a year as a consulting salary.","source_ids":["src-022"],"entity_ids":["holmes","shultz","kovacevich","mattis","roughead","nunn","kissinger","perry","theranos"],"qualification":"Holmes's own testimony as reported by the press.","response":"","outcome":""},"reading":"Attributed: At her 2021 trial Holmes testified, as reported by a national newspaper, that George Shultz recommended Richard Kovacevich, Jim Mattis, Gary Roughead, Sam Nunn, Henry Kissinger and William Perry for the board, that Theranos paid each board member $150,000 a year plus 500,000 shares, and that Kissinger received another $500,000 a year as a consulting salary."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-board-oct-2015","record":{"id":"c-ld-board-oct-2015","kind":"fact","text":"A business magazine described Theranos's board on October 15, 2015 as twelve people: CEO and Chairwoman Elizabeth Holmes, Henry Kissinger, Bill Perry, George Shultz, Sam Nunn, Bill Frist, Gary Roughead, James Mattis, Dick Kovacevich, Riley Bechtel, William Foege and Sunny Balwani.","source_ids":["src-011"],"entity_ids":["theranos","holmes","kissinger","perry","shultz","nunn","frist","roughead","mattis","kovacevich","riley-bechtel","foege","balwani"],"qualification":"The magazine called Balwani the company's \"president and CEO\"; his title was President and Chief Operating Officer. Two weeks later Theranos said the board had already been reduced in July 2015.","response":"","outcome":""},"reading":"Fact: A business magazine described Theranos's board on October 15, 2015 as twelve people: CEO and Chairwoman Elizabeth Holmes, Henry Kissinger, Bill Perry, George Shultz, Sam Nunn, Bill Frist, Gary Roughead, James Mattis, Dick Kovacevich, Riley Bechtel, William Foege and Sunny Balwani."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-board-restructure-2015","record":{"id":"c-ld-board-restructure-2015","kind":"attributed","text":"In late October 2015 Theranos told a national newspaper that it had reduced its board in July 2015 to five members, Elizabeth Holmes, Sunny Balwani, Riley P. Bechtel, James N. Mattis and David Boies, the company's outside legal adviser and a new director, and that the former directors, including Henry Kissinger and George Shultz, had become members of a new board of counselors that would still advise the company.","source_ids":["src-049","src-020"],"entity_ids":["theranos","holmes","balwani","riley-bechtel","mattis","boies","kissinger","shultz"],"qualification":"The company's account as relayed by business news outlets from that newspaper; Holmes said the changes happened in the summer of 2015, before the critical press coverage of October 2015.","response":"","outcome":""},"reading":"Attributed: In late October 2015 Theranos told a national newspaper that it had reduced its board in July 2015 to five members, Elizabeth Holmes, Sunny Balwani, Riley P. Bechtel, James N. Mattis and David Boies, the company's outside legal adviser and a new director, and that the former directors, including Henry Kissinger and George Shultz, had become members of a new board of counselors that would still advise the company."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-board-counselors","record":{"id":"c-ld-board-counselors","kind":"fact","text":"A life-sciences news site described Theranos's board of counselors, created in 2015, as consisting largely of members with strong political and government ties, including Henry Kissinger, George Shultz and Sam Nunn. Theranos's May 2016 announcement states that William Foege and Richard Kovacevich had moved from the board of directors to this advisory group before returning to the board, and that Foege also sat on the company's Scientific and Medical Advisory Board.","source_ids":["src-051","src-027"],"entity_ids":["theranos","kissinger","shultz","nunn","foege","kovacevich"],"qualification":"","response":"","outcome":""},"reading":"Fact: A life-sciences news site described Theranos's board of counselors, created in 2015, as consisting largely of members with strong political and government ties, including Henry Kissinger, George Shultz and Sam Nunn. Theranos's May 2016 announcement states that William Foege and Richard Kovacevich had moved from the board of directors to this advisory group before returning to the board, and that Foege also sat on the company's Scientific and Medical Advisory Board."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-boies-counsel","record":{"id":"c-ld-boies-counsel","kind":"fact","text":"According to a national newspaper, David Boies, chairman of the law firm Boies, Schiller & Flexner LLP that he founded, became Theranos's outside counsel after two of the company's investors approached him in 2011; in November 2016 he and the firm stopped doing legal work for Theranos after a disagreement over the strategy for handling government investigations. A life-sciences news site reported in December 2016 that there was no indication he had given up his board seat.","source_ids":["src-066","src-051"],"entity_ids":["boies","boies-schiller","theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: According to a national newspaper, David Boies, chairman of the law firm Boies, Schiller & Flexner LLP that he founded, became Theranos's outside counsel after two of the company's investors approached him in 2011; in November 2016 he and the firm stopped doing legal work for Theranos after a disagreement over the strategy for handling government investigations. A life-sciences news site reported in December 2016 that there was no indication he had given up his board seat."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-boies-board","record":{"id":"c-ld-boies-board","kind":"fact","text":"Business press reports in October 2015 said that David Boies had joined Theranos's board and leadership, and a business news site wrote in March 2018 that Boies had served the company for a period both as outside counsel and as a board member.","source_ids":["src-049","src-020","src-040"],"entity_ids":["boies","theranos"],"qualification":"An online encyclopaedia dates Boies's agreement to join the board to February 2016, later than the October 2015 press reports.","response":"","outcome":""},"reading":"Fact: Business press reports in October 2015 said that David Boies had joined Theranos's board and leadership, and a business news site wrote in March 2018 that Boies had served the company for a period both as outside counsel and as a board member."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-boies-stock-attributed","record":{"id":"c-ld-boies-stock-attributed","kind":"attributed","text":"An online encyclopaedia, citing newspaper reports of 2016 and 2018, states that Boies agreed to be paid for his firm's work for Theranos in company stock, which raised conflict-of-interest concerns, and, citing a 2018 book about the company, that he left the board after federal investigations began.","source_ids":["src-107","src-066"],"entity_ids":["boies","theranos"],"qualification":"An encyclopaedia summary of press reports and a book; the stock arrangement is not documented elsewhere in the record, and no response from Boies to this account was found in the retained material.","response":"","outcome":"Boies and his firm stopped doing legal work for Theranos in November 2016 after disagreeing about the strategy for handling the government investigations, according to a national newspaper's report."},"reading":"Attributed: An online encyclopaedia, citing newspaper reports of 2016 and 2018, states that Boies agreed to be paid for his firm's work for Theranos in company stock, which raised conflict-of-interest concerns, and, citing a 2018 book about the company, that he left the board after federal investigations began."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-heather-king","record":{"id":"c-ld-heather-king","kind":"fact","text":"Boies, Schiller & Flexner announced on May 7, 2015 that Heather King, a litigation partner in its Washington, D.C. office, had been appointed general counsel of Theranos, a client of the firm. Press reports in November 2015 still identified her as Theranos's general counsel.","source_ids":["src-081","src-055"],"entity_ids":["heather-king","boies-schiller","theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: Boies, Schiller & Flexner announced on May 7, 2015 that Heather King, a litigation partner in its Washington, D.C. office, had been appointed general counsel of Theranos, a client of the firm. Press reports in November 2015 still identified her as Theranos's general counsel."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-may-2016","record":{"id":"c-ld-may-2016","kind":"fact","text":"On May 11, 2016 Theranos announced that President and Chief Operating Officer Sunny Balwani would retire and leave the board while supporting the transition, that it was searching for executives to lead new technology and clinical-operations divisions, and that three directors were joining the board: Fabrizio Bonanni, a former Amgen and Baxter International executive, William Foege, a former director of the Centers for Disease Control, and Richard Kovacevich, a former Wells Fargo chief executive.","source_ids":["src-027","src-018"],"entity_ids":["theranos","balwani","bonanni","foege","kovacevich"],"qualification":"","response":"","outcome":""},"reading":"Fact: On May 11, 2016 Theranos announced that President and Chief Operating Officer Sunny Balwani would retire and leave the board while supporting the transition, that it was searching for executives to lead new technology and clinical-operations divisions, and that three directors were joining the board: Fabrizio Bonanni, a former Amgen and Baxter International executive, William Foege, a former director of the Centers for Disease Control, and Richard Kovacevich, a former Wells Fargo chief executive."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-dec-2016","record":{"id":"c-ld-dec-2016","kind":"fact","text":"On December 1, 2016 Theranos announced the immediate appointment of technology executive Daniel J. Warmenhoven to its board in place of the retiring director Riley P. Bechtel, who had health issues and whom Holmes called a shareholder, and said that its Board of Counselors would be retired on January 1, 2017. A magazine reported that former senators Bill Frist and Sam Nunn, former secretaries of state Henry Kissinger and George P. Shultz and former Secretary of Defense William Perry would step down effective January 1.","source_ids":["src-026","src-017"],"entity_ids":["theranos","warmenhoven","riley-bechtel","holmes","frist","nunn","kissinger","shultz","perry"],"qualification":"","response":"","outcome":""},"reading":"Fact: On December 1, 2016 Theranos announced the immediate appointment of technology executive Daniel J. Warmenhoven to its board in place of the retiring director Riley P. Bechtel, who had health issues and whom Holmes called a shareholder, and said that its Board of Counselors would be retired on January 1, 2017. A magazine reported that former senators Bill Frist and Sam Nunn, former secretaries of state Henry Kissinger and George P. Shultz and former Secretary of Defense William Perry would step down effective January 1."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-board-dec-2016","record":{"id":"c-ld-board-dec-2016","kind":"fact","text":"A business news site listed Theranos's board of directors in December 2016 as Elizabeth Holmes, James N. Mattis, David Boies, Daniel Warmenhoven, William H. Foege, Richard Kovacevich and Fabrizio Bonanni, and named Henry A. Kissinger, William H. Frist, Sam Nunn, William J. Perry, George P. Shultz and Gary Roughead as the board of counselors members who would no longer be with the company.","source_ids":["src-012"],"entity_ids":["theranos","holmes","mattis","boies","warmenhoven","foege","kovacevich","bonanni","roughead","kissinger","frist","nunn","perry","shultz"],"qualification":"","response":"","outcome":""},"reading":"Fact: A business news site listed Theranos's board of directors in December 2016 as Elizabeth Holmes, James N. Mattis, David Boies, Daniel Warmenhoven, William H. Foege, Richard Kovacevich and Fabrizio Bonanni, and named Henry A. Kissinger, William H. Frist, Sam Nunn, William J. Perry, George P. Shultz and Gary Roughead as the board of counselors members who would no longer be with the company."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-warmenhoven-bechtel","record":{"id":"c-ld-warmenhoven-bechtel","kind":"attributed","text":"A regional newspaper reported, from an interview with Warmenhoven, that he came to know Holmes through Riley Bechtel, chairman of the Bechtel Group, on whose board Warmenhoven also sat, and that he had begun discussing joining the Theranos board before the company's troubles.","source_ids":["src-047"],"entity_ids":["warmenhoven","riley-bechtel","holmes","bechtel-group","theranos"],"qualification":"Press account based on an interview with Warmenhoven.","response":"","outcome":""},"reading":"Attributed: A regional newspaper reported, from an interview with Warmenhoven, that he came to know Holmes through Riley Bechtel, chairman of the Bechtel Group, on whose board Warmenhoven also sat, and that he had begun discussing joining the Theranos board before the company's troubles."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-mattis-tenure","record":{"id":"c-ld-mattis-tenure","kind":"fact","text":"James Mattis served on Theranos's board from 2013 until December 2016, according to television news coverage of the trial; a Pentagon spokesman told a business news site that he resigned from the board on December 16, 2016, before his confirmation as Secretary of Defense.","source_ids":["src-013","src-040"],"entity_ids":["mattis","theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: James Mattis served on Theranos's board from 2013 until December 2016, according to television news coverage of the trial; a Pentagon spokesman told a business news site that he resigned from the board on December 16, 2016, before his confirmation as Secretary of Defense."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-mattis-testimony","record":{"id":"c-ld-mattis-testimony","kind":"attributed","text":"Testifying at Holmes's trial in 2021, Mattis said he had invested $85,000 in Theranos and was paid $150,000 for serving on its board.","source_ids":["src-013","src-040","src-061"],"entity_ids":["mattis","theranos"],"qualification":"Trial testimony as reported by television news coverage.","response":"","outcome":"Mattis resigned from the board on December 16, 2016, before his confirmation as Secretary of Defense, a Pentagon spokesperson said, and he testified that by the time he left he had lost faith in Holmes."},"reading":"Attributed: Testifying at Holmes's trial in 2021, Mattis said he had invested $85,000 in Theranos and was paid $150,000 for serving on its board."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-bonanni-committee","record":{"id":"c-ld-bonanni-committee","kind":"fact","text":"Stevanato Group's 2021 IPO prospectus states that Fabrizio Bonanni's past board memberships include Theranos, where he chaired the Compliance and Quality Committee.","source_ids":["src-115"],"entity_ids":["bonanni","theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: Stevanato Group's 2021 IPO prospectus states that Fabrizio Bonanni's past board memberships include Theranos, where he chaired the Compliance and Quality Committee."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-form-d-2017","record":{"id":"c-ld-form-d-2017","kind":"fact","text":"Theranos's Form D signed on May 25, 2017 lists Elizabeth Anne Holmes as an executive officer and director, signing as Chief Executive Officer, and Fabrizio Bonanni, William Foege and Daniel Warmenhoven as directors.","source_ids":["src-005"],"entity_ids":["theranos","holmes","bonanni","foege","warmenhoven"],"qualification":"","response":"","outcome":""},"reading":"Fact: Theranos's Form D signed on May 25, 2017 lists Elizabeth Anne Holmes as an executive officer and director, signing as Chief Executive Officer, and Fabrizio Bonanni, William Foege and Daniel Warmenhoven as directors."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-board-2018","record":{"id":"c-ld-board-2018","kind":"fact","text":"A business news site reported in March 2018, citing Theranos's website, that William Foege remained a Theranos board member, and noted that Richard Kovacevich had also served on the board.","source_ids":["src-040"],"entity_ids":["foege","kovacevich","theranos"],"qualification":"Foege's continued membership in 2018 rests on the company website as reported by the press; Theranos made no later filing listing its directors.","response":"","outcome":""},"reading":"Fact: A business news site reported in March 2018, citing Theranos's website, that William Foege remained a Theranos board member, and noted that Richard Kovacevich had also served on the board."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-taylor-ceo","record":{"id":"c-ld-taylor-ceo","kind":"fact","text":"On June 15, 2018 Theranos's board announced that Elizabeth Holmes had stepped down as Chief Executive Officer and that David Taylor, the company's General Counsel, had been appointed Chief Executive Officer and General Counsel; Holmes remained with the company as Founder and Chair of the Board.","source_ids":["src-021"],"entity_ids":["theranos","holmes","david-taylor"],"qualification":"","response":"","outcome":""},"reading":"Fact: On June 15, 2018 Theranos's board announced that Elizabeth Holmes had stepped down as Chief Executive Officer and that David Taylor, the company's General Counsel, had been appointed Chief Executive Officer and General Counsel; Holmes remained with the company as Founder and Chair of the Board."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-ld-taylor-profile","record":{"id":"c-ld-taylor-profile","kind":"fact","text":"David Taylor's law-firm profile describes him as Theranos's last General Counsel (2016 to 2018) and ultimately its CEO, who led a team that secured $100 million in debt financing before winding the company down; it lists his later positions as owner of Taylor Strategic PC (2018 to 2020) and partner of Keller Benvenutti Kim LLP from 2020.","source_ids":["src-089"],"entity_ids":["david-taylor","theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: David Taylor's law-firm profile describes him as Theranos's last General Counsel (2016 to 2018) and ultimately its CEO, who led a team that secured $100 million in debt financing before winding the company down; it lists his later positions as owner of Taylor Strategic PC (2018 to 2020) and partner of Keller Benvenutti Kim LLP from 2020."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-pp-shultz","record":{"id":"c-pp-shultz","kind":"fact","text":"The Hoover Institution's profile of George Pratt Shultz, who died on February 6, 2021, describes him as a Distinguished Fellow of the institution, one of two people to have held four different federal cabinet posts, and for eight years president of a major engineering and construction company. Bechtel Group's 2001 Schedule 13D lists him as a director of Bechtel Group, Inc., a former U.S. Secretary of State and a former President of Bechtel Group.","source_ids":["src-103","src-053"],"entity_ids":["shultz","bechtel-group"],"qualification":"","response":"","outcome":""},"reading":"Fact: The Hoover Institution's profile of George Pratt Shultz, who died on February 6, 2021, describes him as a Distinguished Fellow of the institution, one of two people to have held four different federal cabinet posts, and for eight years president of a major engineering and construction company. Bechtel Group's 2001 Schedule 13D lists him as a director of Bechtel Group, Inc., a former U.S. Secretary of State and a former President of Bechtel Group."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-pp-bechtel-group","record":{"id":"c-pp-bechtel-group","kind":"fact","text":"Bechtel Group, Inc.'s 2001 Schedule 13D describes it as a Delaware holding company for companies providing engineering, construction and finance services, with its principal office at 50 Beale Street, San Francisco, and as the owner of 100% of the stock of Bechtel Corporation.","source_ids":["src-053"],"entity_ids":["bechtel-group"],"qualification":"","response":"","outcome":""},"reading":"Fact: Bechtel Group, Inc.'s 2001 Schedule 13D describes it as a Delaware holding company for companies providing engineering, construction and finance services, with its principal office at 50 Beale Street, San Francisco, and as the owner of 100% of the stock of Bechtel Corporation."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-pp-kissinger","record":{"id":"c-pp-kissinger","kind":"fact","text":"According to the U.S. Department of State's Office of the Historian, Henry A. Kissinger served as Secretary of State from September 23, 1973 to January 20, 1977 and as National Security Adviser from January 20, 1969 until November 3, 1975.","source_ids":["src-099"],"entity_ids":["kissinger"],"qualification":"","response":"","outcome":""},"reading":"Fact: According to the U.S. Department of State's Office of the Historian, Henry A. Kissinger served as Secretary of State from September 23, 1973 to January 20, 1977 and as National Security Adviser from January 20, 1969 until November 3, 1975."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-pp-perry","record":{"id":"c-pp-perry","kind":"fact","text":"The Defense Department's historical office records that William J. Perry co-founded and led the electronics firm ESL, Inc. from 1964 to 1977, was under secretary of defense for research and engineering from 1977 to 1981 and managing director of the investment bank Hambrecht and Quist until 1985, and served as Secretary of Defense from February 3, 1994 to January 23, 1997, after which he returned to Hambrecht and Quist as a senior adviser and to the Stanford University faculty.","source_ids":["src-100"],"entity_ids":["perry"],"qualification":"","response":"","outcome":""},"reading":"Fact: The Defense Department's historical office records that William J. Perry co-founded and led the electronics firm ESL, Inc. from 1964 to 1977, was under secretary of defense for research and engineering from 1977 to 1981 and managing director of the investment bank Hambrecht and Quist until 1985, and served as Secretary of Defense from February 3, 1994 to January 23, 1997, after which he returned to Hambrecht and Quist as a senior adviser and to the Stanford University faculty."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-pp-nunn","record":{"id":"c-pp-nunn","kind":"fact","text":"The Coca-Cola Company's 1997 proxy statement describes Sam Nunn as a member of the U.S. Senate from 1972 through 1996, a partner of the law firm King & Spalding since January 1997 and a Coca-Cola director since January 3, 1997.","source_ids":["src-114"],"entity_ids":["nunn"],"qualification":"","response":"","outcome":""},"reading":"Fact: The Coca-Cola Company's 1997 proxy statement describes Sam Nunn as a member of the U.S. Senate from 1972 through 1996, a partner of the law firm King & Spalding since January 1997 and a Coca-Cola director since January 3, 1997."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-pp-frist","record":{"id":"c-pp-frist","kind":"fact","text":"The U.S. Senate's biography of William H. Frist of Tennessee describes a heart and lung transplant surgeon who practised for 16 years, was elected to the Senate in 1994, chaired the National Republican Senatorial Committee from 2000, became Senate majority leader and retired in 2007.","source_ids":["src-101"],"entity_ids":["frist"],"qualification":"","response":"","outcome":""},"reading":"Fact: The U.S. Senate's biography of William H. Frist of Tennessee describes a heart and lung transplant surgeon who practised for 16 years, was elected to the Senate in 1994, chaired the National Republican Senatorial Committee from 2000, became Senate majority leader and retired in 2007."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-pp-roughead","record":{"id":"c-pp-roughead","kind":"fact","text":"Northrop Grumman's leadership page states that Admiral Gary Roughead retired in September 2011 after four years as the U.S. Navy's 29th chief of naval operations, was elected to Northrop Grumman's board in 2012 and is a fellow of the Hoover Institution at Stanford University.","source_ids":["src-102"],"entity_ids":["roughead"],"qualification":"","response":"","outcome":""},"reading":"Fact: Northrop Grumman's leadership page states that Admiral Gary Roughead retired in September 2011 after four years as the U.S. Navy's 29th chief of naval operations, was elected to Northrop Grumman's board in 2012 and is a fellow of the Hoover Institution at Stanford University."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-pp-mattis","record":{"id":"c-pp-mattis","kind":"fact","text":"General Dynamics' 2015 proxy statement describes James N. Mattis as a U.S. Marine Corps general who retired in 2013 after commanding U.S. Central Command from 2010 to 2013, and as one of three independent directors added to the General Dynamics board since 2013.","source_ids":["src-105"],"entity_ids":["mattis"],"qualification":"","response":"","outcome":""},"reading":"Fact: General Dynamics' 2015 proxy statement describes James N. Mattis as a U.S. Marine Corps general who retired in 2013 after commanding U.S. Central Command from 2010 to 2013, and as one of three independent directors added to the General Dynamics board since 2013."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-pp-kovacevich","record":{"id":"c-pp-kovacevich","kind":"fact","text":"Cisco Systems' 2012 proxy statement records that Richard M. Kovacevich was chairman of Wells Fargo & Company from April 2001 to December 2009 and its chief executive officer from November 1998 to June 2007, had been chief executive of Norwest Corporation from 1993 until its 1998 merger with Wells Fargo, and had been a Cisco director since January 2005.","source_ids":["src-104"],"entity_ids":["kovacevich"],"qualification":"","response":"","outcome":""},"reading":"Fact: Cisco Systems' 2012 proxy statement records that Richard M. Kovacevich was chairman of Wells Fargo & Company from April 2001 to December 2009 and its chief executive officer from November 1998 to June 2007, had been chief executive of Norwest Corporation from 1993 until its 1998 merger with Wells Fargo, and had been a Cisco director since January 2005."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-pp-riley-bechtel","record":{"id":"c-pp-riley-bechtel","kind":"fact","text":"Bechtel's leadership page states that Riley P. Bechtel was elected to the board of Bechtel Group, Inc. in August 1987, became its president and chief executive officer in June 1990 and chairman in January 1996, stepped down as chief executive in February 2014 and remained non-executive chairman until April 2017, when he became a non-executive director. Bechtel Group's 2001 Schedule 13D lists him as Chairman and Director.","source_ids":["src-087","src-053"],"entity_ids":["riley-bechtel","bechtel-group"],"qualification":"","response":"","outcome":""},"reading":"Fact: Bechtel's leadership page states that Riley P. Bechtel was elected to the board of Bechtel Group, Inc. in August 1987, became its president and chief executive officer in June 1990 and chairman in January 1996, stepped down as chief executive in February 2014 and remained non-executive chairman until April 2017, when he became a non-executive director. Bechtel Group's 2001 Schedule 13D lists him as Chairman and Director."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-pp-foege","record":{"id":"c-pp-foege","kind":"fact","text":"The World Health Organization reported that Dr William H. Foege, best known for devising the strategy that led to the eradication of smallpox, died on January 24, 2026. He was Director of the U.S. Centers for Disease Control and Prevention from 1977 to 1983, Executive Director of The Carter Center from 1986 to 1992 and President and CEO of the Task Force for Global Health.","source_ids":["src-106"],"entity_ids":["foege"],"qualification":"","response":"","outcome":""},"reading":"Fact: The World Health Organization reported that Dr William H. Foege, best known for devising the strategy that led to the eradication of smallpox, died on January 24, 2026. He was Director of the U.S. Centers for Disease Control and Prevention from 1977 to 1983, Executive Director of The Carter Center from 1986 to 1992 and President and CEO of the Task Force for Global Health."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-pp-boies","record":{"id":"c-pp-boies","kind":"fact","text":"David Boies became a partner of Cravath, Swaine & Moore in 1973 and left in 1997 to establish, with Jonathan Schiller, the firm now known as Boies, Schiller & Flexner LLP, according to an online encyclopaedia; the firm's own 2015 release identifies him as its Chairman.","source_ids":["src-107","src-081"],"entity_ids":["boies","boies-schiller"],"qualification":"","response":"","outcome":""},"reading":"Fact: David Boies became a partner of Cravath, Swaine & Moore in 1973 and left in 1997 to establish, with Jonathan Schiller, the firm now known as Boies, Schiller & Flexner LLP, according to an online encyclopaedia; the firm's own 2015 release identifies him as its Chairman."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-pp-warmenhoven","record":{"id":"c-pp-warmenhoven","kind":"fact","text":"Theranos's December 2016 announcement describes Daniel J. Warmenhoven as chief executive officer of NetApp from 1994 through 2009 and executive chairman of its board from 2009 through 2014, previously chairman, president and CEO of Network Equipment Technologies and a senior manager at Hewlett-Packard after more than ten years at IBM, and at that time a director of Bechtel Group, Inc. and Palo Alto Networks. Palo Alto Networks' 2018 proxy statement lists him as its lead independent director since March 2012 and a former director of Aruba Networks.","source_ids":["src-026","src-039"],"entity_ids":["warmenhoven","bechtel-group"],"qualification":"","response":"","outcome":""},"reading":"Fact: Theranos's December 2016 announcement describes Daniel J. Warmenhoven as chief executive officer of NetApp from 1994 through 2009 and executive chairman of its board from 2009 through 2014, previously chairman, president and CEO of Network Equipment Technologies and a senior manager at Hewlett-Packard after more than ten years at IBM, and at that time a director of Bechtel Group, Inc. and Palo Alto Networks. Palo Alto Networks' 2018 proxy statement lists him as its lead independent director since March 2012 and a former director of Aruba Networks."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-pp-warmenhoven-redback","record":{"id":"c-pp-warmenhoven-redback","kind":"fact","text":"A regional newspaper reported in December 2016 that Warmenhoven sat on the boards of Palo Alto Networks, the Bechtel Group and the Tech Museum of Innovation, and quoted him recalling the time when Redback Networks, where he was lead director, filed for Chapter 11 bankruptcy.","source_ids":["src-047"],"entity_ids":["warmenhoven","bechtel-group"],"qualification":"","response":"","outcome":""},"reading":"Fact: A regional newspaper reported in December 2016 that Warmenhoven sat on the boards of Palo Alto Networks, the Bechtel Group and the Tech Museum of Innovation, and quoted him recalling the time when Redback Networks, where he was lead director, filed for Chapter 11 bankruptcy."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-pp-bonanni","record":{"id":"c-pp-bonanni","kind":"fact","text":"According to Theranos's May 2016 announcement, Fabrizio Bonanni retired in 2013 as executive vice president of Amgen after 14 years in which he was senior vice president for quality and compliance and for manufacturing and then executive vice president for operations; from 1974 to 1999 he was a corporate vice president of Baxter International. Stevanato Group announced in September 2013 that he had joined its board.","source_ids":["src-027","src-084"],"entity_ids":["bonanni"],"qualification":"","response":"","outcome":""},"reading":"Fact: According to Theranos's May 2016 announcement, Fabrizio Bonanni retired in 2013 as executive vice president of Amgen after 14 years in which he was senior vice president for quality and compliance and for manufacturing and then executive vice president for operations; from 1974 to 1999 he was a corporate vice president of Baxter International. Stevanato Group announced in September 2013 that he had joined its board."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-pp-lucas","record":{"id":"c-pp-lucas","kind":"fact","text":"Oracle's 1999 proxy statement describes Donald L. Lucas as an Oracle director since March 1980 and chairman of its board from October 1980 to March 1990, a venture capitalist since 1960 and a director of Cadence Design Systems, Coulter Pharmaceutical, Macromedia, Transcend Services and Tricord Systems; the proxy's covering letter is signed by Lawrence J. Ellison as Oracle's chairman and chief executive. A Stanford institute's obituary describes Lucas, who died on December 27, 2019, as one of Silicon Valley's earliest venture capitalists.","source_ids":["src-092","src-109"],"entity_ids":["donald-lucas","oracle","ellison"],"qualification":"","response":"","outcome":""},"reading":"Fact: Oracle's 1999 proxy statement describes Donald L. Lucas as an Oracle director since March 1980 and chairman of its board from October 1980 to March 1990, a venture capitalist since 1960 and a director of Cadence Design Systems, Coulter Pharmaceutical, Macromedia, Transcend Services and Tricord Systems; the proxy's covering letter is signed by Lawrence J. Ellison as Oracle's chairman and chief executive. A Stanford institute's obituary describes Lucas, who died on December 27, 2019, as one of Silicon Valley's earliest venture capitalists."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-pp-thomas","record":{"id":"c-pp-thomas","kind":"fact","text":"At Road, Inc.'s 2003 proxy statement describes T. Peter Thomas as a managing director of the venture capital firm Institutional Venture Management since November 1985 and a director of Atmel and Transmeta. A 2011 SEC ownership filing states that he was a managing director of ATA Management I, LLC, the general partner of ATA Ventures I, L.P. and two related ATA funds.","source_ids":["src-094","src-110"],"entity_ids":["peter-thomas","ata-ventures"],"qualification":"","response":"","outcome":""},"reading":"Fact: At Road, Inc.'s 2003 proxy statement describes T. Peter Thomas as a managing director of the venture capital firm Institutional Venture Management since November 1985 and a director of Atmel and Transmeta. A 2011 SEC ownership filing states that he was a managing director of ATA Management I, LLC, the general partner of ATA Ventures I, L.P. and two related ATA funds."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-pp-shapiro","record":{"id":"c-pp-shapiro","kind":"attributed","text":"According to an online encyclopaedia, Robert B. Shapiro, who died in May 2025, was chief executive of Monsanto from 1995 to 2000 and chairman of Pharmacia Corp until February 2001, co-founded Sandbox Industries, and was an early member of Theranos's board of directors.","source_ids":["src-095"],"entity_ids":["shapiro","theranos"],"qualification":"An encyclopaedia account; Theranos's July 2010 Form D independently lists Robert Shapiro as a director.","response":"","outcome":""},"reading":"Attributed: According to an online encyclopaedia, Robert B. Shapiro, who died in May 2025, was chief executive of Monsanto from 1995 to 2000 and chairman of Pharmacia Corp until February 2001, co-founded Sandbox Industries, and was an early member of Theranos's board of directors."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-pp-tevanian","record":{"id":"c-pp-tevanian","kind":"fact","text":"Dolby Laboratories' 2025 proxy statement describes Avadis Tevanian, Jr. as a Dolby director since February 2009, co-founder in July 2015 of the venture firm NextEquity Partners, and earlier Apple's software chief technology officer from 2003 to 2006 and vice president of engineering at NeXT.","source_ids":["src-097"],"entity_ids":["tevanian"],"qualification":"","response":"","outcome":""},"reading":"Fact: Dolby Laboratories' 2025 proxy statement describes Avadis Tevanian, Jr. as a Dolby director since February 2009, co-founder in July 2015 of the venture firm NextEquity Partners, and earlier Apple's software chief technology officer from 2003 to 2006 and vice president of engineering at NeXT."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-pp-mcglynn","record":{"id":"c-pp-mcglynn","kind":"attributed","text":"A lawyer directory lists J. Casey McGlynn, who signed, as Secretary, the statement filed in California in early 2005 recording Theranos's December 2004 change of name, as a partner of the law firm Wilson Sonsini Goodrich & Rosati.","source_ids":["src-112"],"entity_ids":["casey-mcglynn","theranos"],"qualification":"A lawyer-directory profile; the record does not state whether he signed as an employee of Theranos or as outside counsel serving as corporate secretary.","response":"","outcome":""},"reading":"Attributed: A lawyer directory lists J. Casey McGlynn, who signed, as Secretary, the statement filed in California in early 2005 recording Theranos's December 2004 change of name, as a partner of the law firm Wilson Sonsini Goodrich & Rosati."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-fin-early-rounds-attributed","record":{"id":"c-fin-early-rounds-attributed","kind":"attributed","text":"According to start-up funding data reported by a start-up data publisher in 2021, Theranos raised about $1.3 billion of funding over its history, or $1.4 billion including debt: a $500,000 seed round led by Draper Fisher Jurvetson in June 2004, a $5.8 million Series A led by Rupert Murdoch in February 2005, a $9.1 million Series B led by ATA Ventures and a $28.5 million Series C, both in 2006, and $45 million of venture funding in July 2010. It lists Tim Draper, Larry Ellison, Walgreens and Partner Fund Management among the investors and says Fortress Investment Group led the last financing, $100 million of debt in December 2017.","source_ids":["src-054"],"entity_ids":["theranos","dfj","murdoch","ata-ventures","ellison","walgreen-co","partner-fund-mgmt","fortress"],"qualification":"Aggregated funding data. The attribution of the 2005 Series A to Murdoch conflicts with other accounts placing his investment much later (his restitution claim concerns a C-2 purchase), and the 2004-2006 rounds are not documented in Theranos's own filings, which survive for that period only as paper records.","response":"","outcome":""},"reading":"Attributed: According to start-up funding data reported by a start-up data publisher in 2021, Theranos raised about $1.3 billion of funding over its history, or $1.4 billion including debt: a $500,000 seed round led by Draper Fisher Jurvetson in June 2004, a $5.8 million Series A led by Rupert Murdoch in February 2005, a $9.1 million Series B led by ATA Ventures and a $28.5 million Series C, both in 2006, and $45 million of venture funding in July 2010. It lists Tim Draper, Larry Ellison, Walgreens and Partner Fund Management among the investors and says Fortress Investment Group led the last financing, $100 million of debt in December 2017."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-fin-form-d-2010","record":{"id":"c-fin-form-d-2010","kind":"fact","text":"Theranos's Form D of July 8, 2010 reported an offering of equity securities under the Rule 506 exemption with a total offering amount of $100,000,005, of which $45,000,000 had been sold by the filing date, the first sale having taken place on July 1, 2010; one investor had invested at the time of filing.","source_ids":["src-001"],"entity_ids":["theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: Theranos's Form D of July 8, 2010 reported an offering of equity securities under the Rule 506 exemption with a total offering amount of $100,000,005, of which $45,000,000 had been sold by the filing date, the first sale having taken place on July 1, 2010; one investor had invested at the time of filing."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-fin-c1-c2","record":{"id":"c-fin-c1-c2","kind":"fact","text":"The SEC alleged that from late 2013 to 2015 Holmes, Balwani and Theranos raised over $700 million from investors in two financing rounds, at a time when, in late 2013, Theranos had about $30 million in cash and short-term securities. The Justice Department said that by March 2015 Theranos had raised more than $730 million from \"Series C-1\" and \"Series C-2\" investors. The Ninth Circuit's opinion places the C-1 sales in late 2013 and the offer of C-2 shares to new investors in 2014.","source_ids":["src-002","src-014","src-016"],"entity_ids":["theranos","holmes","balwani"],"qualification":"","response":"","outcome":""},"reading":"Fact: The SEC alleged that from late 2013 to 2015 Holmes, Balwani and Theranos raised over $700 million from investors in two financing rounds, at a time when, in late 2013, Theranos had about $30 million in cash and short-term securities. The Justice Department said that by March 2015 Theranos had raised more than $730 million from \"Series C-1\" and \"Series C-2\" investors. The Ninth Circuit's opinion places the C-1 sales in late 2013 and the offer of C-2 shares to new investors in 2014."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-fin-series-order","record":{"id":"c-fin-series-order","kind":"fact","text":"The May 31, 2018 class-certification order in the indirect-investor class action against Theranos (N.D. Cal. No. 16-cv-06822-NC) records that Theranos had sold Series A, Series B and Series C Preferred stock and that from January 2013 to October 2016 it sold Series C-1 and C-2 Preferred Stock to more than 30 individuals and investment entities, in amounts from about $50,000 to about $125 million; one buyer, Lucas Venture Group XI, LLC, paid just over $7 million for 471,333 Series C-1 shares.","source_ids":["src-073"],"entity_ids":["theranos","lvg-xi"],"qualification":"","response":"","outcome":""},"reading":"Fact: The May 31, 2018 class-certification order in the indirect-investor class action against Theranos (N.D. Cal. No. 16-cv-06822-NC) records that Theranos had sold Series A, Series B and Series C Preferred stock and that from January 2013 to October 2016 it sold Series C-1 and C-2 Preferred Stock to more than 30 individuals and investment entities, in amounts from about $50,000 to about $125 million; one buyer, Lucas Venture Group XI, LLC, paid just over $7 million for 471,333 Series C-1 shares."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-fin-indirect-funds","record":{"id":"c-fin-indirect-funds","kind":"fact","text":"The same order describes investment funds that held or planned to buy Theranos stock with money from their own investors: Peer Ventures Group IV, LP (individual contributions from $15,000 to $17,350,200), Lucas Venture Group XI, LLC, Lucas Venture Group IV, LP and Black Diamond Ventures XII-B, LLC. Celadon Technology Fund VII, LLC bought 410,000 Series C Preferred shares from another investor on December 15, 2015.","source_ids":["src-073"],"entity_ids":["theranos","pvg-iv","lvg-xi","lvg-iv-lp","bdv-xii-b","celadon"],"qualification":"The order describes Celadon's 410,000 shares both as Series C Preferred and, in a later passage, as Series C-1 Preferred.","response":"","outcome":""},"reading":"Fact: The same order describes investment funds that held or planned to buy Theranos stock with money from their own investors: Peer Ventures Group IV, LP (individual contributions from $15,000 to $17,350,200), Lucas Venture Group XI, LLC, Lucas Venture Group IV, LP and Black Diamond Ventures XII-B, LLC. Celadon Technology Fund VII, LLC bought 410,000 Series C Preferred shares from another investor on December 15, 2015."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-fin-financial-position","record":{"id":"c-fin-financial-position","kind":"fact","text":"According to testimony summarised by the Ninth Circuit, Theranos had no revenue in 2012 and 2013 and net losses of $57 million and $92 million in those years; in November 2013 Balwani told Holmes that the company was down to $15 million in cash while spending up to $2 million a week. The SEC alleged that Theranos recorded little more than $100,000 of revenue in 2014, and the Ninth Circuit notes that it reported only $1,944,948 of total income to the IRS for 2015.","source_ids":["src-016","src-002"],"entity_ids":["theranos","balwani","holmes"],"qualification":"","response":"","outcome":""},"reading":"Fact: According to testimony summarised by the Ninth Circuit, Theranos had no revenue in 2012 and 2013 and net losses of $57 million and $92 million in those years; in November 2013 Balwani told Holmes that the company was down to $15 million in cash while spending up to $2 million a week. The SEC alleged that Theranos recorded little more than $100,000 of revenue in 2014, and the Ninth Circuit notes that it reported only $1,944,948 of total income to the IRS for 2015."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-fin-projections","record":{"id":"c-fin-projections","kind":"attributed","text":"The SEC's complaint alleges that in August 2015 Holmes gave a potential investor financial results showing 2014 net revenues of $108 million and projected net revenues of $240 million for 2015 and $750 million for 2016; an investor witness at Holmes's trial testified that documents from Holmes and Balwani projected a profit of $230 million by the end of 2015.","source_ids":["src-016","src-002"],"entity_ids":["holmes","balwani","theranos"],"qualification":"These are the allegations and trial testimony on which the fraud charges rested; Holmes and Theranos settled the SEC case without admitting or denying the allegations, and the jury's verdicts on the investor counts are set out in the account of the criminal case.","response":"","outcome":""},"reading":"Attributed: The SEC's complaint alleges that in August 2015 Holmes gave a potential investor financial results showing 2014 net revenues of $108 million and projected net revenues of $240 million for 2015 and $750 million for 2016; an investor witness at Holmes's trial testified that documents from Holmes and Balwani projected a profit of $230 million by the end of 2015."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-fin-class-b","record":{"id":"c-fin-class-b","kind":"fact","text":"According to the SEC, in early 2014 Holmes persuaded Theranos's board and shareholders to adopt a resolution that split the company's stock in a 1-to-5 ratio to allow for future fundraising and created Class B shares with 100 votes each, to be issued only to her; afterwards she owned just over half of the outstanding shares but over 99 percent of the voting power.","source_ids":["src-002"],"entity_ids":["holmes","theranos"],"qualification":"The SEC adds that shareholders were given only a few days to consider and vote on the resolution.","response":"","outcome":""},"reading":"Fact: According to the SEC, in early 2014 Holmes persuaded Theranos's board and shareholders to adopt a resolution that split the company's stock in a 1-to-5 ratio to allow for future fundraising and created Class B shares with 100 votes each, to be issued only to her; afterwards she owned just over half of the outstanding shares but over 99 percent of the voting power."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-fin-balwani-stake","record":{"id":"c-fin-balwani-stake","kind":"fact","text":"According to the Justice Department's account of the trial evidence, Balwani owned nearly 30 million Theranos shares, more than 6 percent of the company.","source_ids":["src-014"],"entity_ids":["balwani","theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: According to the Justice Department's account of the trial evidence, Balwani owned nearly 30 million Theranos shares, more than 6 percent of the company."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-fin-investors-press","record":{"id":"c-fin-investors-press","kind":"fact","text":"Press accounts name Theranos's investors differently: a magazine reported in December 2016 that it had raised more than $686 million from investors including Draper Fisher Jurvetson, Walgreens and Rupert Murdoch, reaching a $9 billion valuation; a business news site, citing a private-market data provider, wrote in March 2018 that it had raised more than $900 million, including $100 million of debt financing in December 2017, from investors including Larry Ellison, Draper Fisher Jurvetson, Betsy DeVos, Rupert Murdoch, Walgreens and BlueCross BlueShield.","source_ids":["src-017","src-040"],"entity_ids":["theranos","dfj","walgreen-co","murdoch","ellison","devos","bcbs"],"qualification":"Totals differ because the sources count different periods and instruments; the restitution order identifies the investors whose losses the court found.","response":"","outcome":""},"reading":"Fact: Press accounts name Theranos's investors differently: a magazine reported in December 2016 that it had raised more than $686 million from investors including Draper Fisher Jurvetson, Walgreens and Rupert Murdoch, reaching a $9 billion valuation; a business news site, citing a private-market data provider, wrote in March 2018 that it had raised more than $900 million, including $100 million of debt financing in December 2017, from investors including Larry Ellison, Draper Fisher Jurvetson, Betsy DeVos, Rupert Murdoch, Walgreens and BlueCross BlueShield."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-fin-bechtel-shareholder","record":{"id":"c-fin-bechtel-shareholder","kind":"fact","text":"Riley Bechtel was also a Theranos shareholder: Holmes called him one in the December 2016 announcement of his departure, and a business news site reported that a national newspaper had disclosed his previously undisclosed investment a few days earlier.","source_ids":["src-026","src-012"],"entity_ids":["riley-bechtel","theranos","holmes"],"qualification":"","response":"","outcome":""},"reading":"Fact: Riley Bechtel was also a Theranos shareholder: Holmes called him one in the December 2016 announcement of his departure, and a business news site reported that a national newspaper had disclosed his previously undisclosed investment a few days earlier."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-fin-partner-investments","record":{"id":"c-fin-partner-investments","kind":"fact","text":"Partner Investments, L.P., a San Francisco investment fund organised as a Delaware limited partnership (SEC Central Index Key 0001343211), reported in a 2014 Form D/A that its general partner is Partner Fund Management, LLC.","source_ids":["src-037"],"entity_ids":["partner-investments","partner-fund-mgmt"],"qualification":"","response":"","outcome":""},"reading":"Fact: Partner Investments, L.P., a San Francisco investment fund organised as a Delaware limited partnership (SEC Central Index Key 0001343211), reported in a 2014 Form D/A that its general partner is Partner Fund Management, LLC."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-fin-tender-offer","record":{"id":"c-fin-tender-offer","kind":"fact","text":"The SEC's complaint states that in 2017 Theranos conducted a tender offer to recapitalise certain investors from its later fundraising rounds, as part of which Holmes returned about 34 million of her shares to the company. The 2018 class-certification order in the indirect-investor class action records that between August 2016 and August 2017 Theranos negotiated a share offer and exchange with holders of Series C-1 and C-2 Preferred stock, and that Black Diamond Ventures XII-B, Lucas Venture Group XI and Peer Ventures Group IV took part and released their claims against Theranos; it also notes that Series C, C-1 and C-2 Preferred rank ahead of Series A and B Preferred.","source_ids":["src-002","src-073"],"entity_ids":["theranos","holmes","bdv-xii-b","lvg-xi","pvg-iv"],"qualification":"","response":"","outcome":""},"reading":"Fact: The SEC's complaint states that in 2017 Theranos conducted a tender offer to recapitalise certain investors from its later fundraising rounds, as part of which Holmes returned about 34 million of her shares to the company. The 2018 class-certification order in the indirect-investor class action records that between August 2016 and August 2017 Theranos negotiated a share offer and exchange with holders of Series C-1 and C-2 Preferred stock, and that Black Diamond Ventures XII-B, Lucas Venture Group XI and Peer Ventures Group IV took part and released their claims against Theranos; it also notes that Series C, C-1 and C-2 Preferred rank ahead of Series A and B Preferred."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-fin-form-d-2017","record":{"id":"c-fin-form-d-2017","kind":"fact","text":"Theranos's Form D of May 2017 reported a Rule 506(b) offering of $582,200,318, fully sold, with a first sale on May 15, 2017 and 34 investors; the amount represents the aggregate original issue price of the securities tendered in Theranos's exchange offer to existing holders of its preferred stock.","source_ids":["src-005"],"entity_ids":["theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: Theranos's Form D of May 2017 reported a Rule 506(b) offering of $582,200,318, fully sold, with a first sale on May 15, 2017 and 34 investors; the amount represents the aggregate original issue price of the securities tendered in Theranos's exchange offer to existing holders of its preferred stock."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-fin-murdoch-buyback","record":{"id":"c-fin-murdoch-buyback","kind":"attributed","text":"A business news site reported in March 2017, citing a national newspaper, that Theranos had bought back Rupert Murdoch's $125 million stake for $1 after he did not take part in a board-approved plan to give investors in the latest round additional shares, taken from Holmes's own holding, if they promised not to sue; director Daniel Warmenhoven praised Holmes's decision, and the arrangement could dilute her below majority control.","source_ids":["src-040","src-016","src-048"],"entity_ids":["murdoch","theranos","holmes","warmenhoven"],"qualification":"Press account based on an unnamed source familiar with the deal; the buyback price is not documented in any filing in the record.","response":"Murdoch declined to comment through a spokesperson when a business news site reported in March 2018 that his losses exceeded $100 million.","outcome":"The restitution schedule in the criminal case lists Murdoch as a payee for $124,999,997."},"reading":"Attributed: A business news site reported in March 2017, citing a national newspaper, that Theranos had bought back Rupert Murdoch's $125 million stake for $1 after he did not take part in a board-approved plan to give investors in the latest round additional shares, taken from Holmes's own holding, if they promised not to sue; director Daniel Warmenhoven praised Holmes's decision, and the arrangement could dilute her below majority control."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-fin-2017-valuation-attributed","record":{"id":"c-fin-2017-valuation-attributed","kind":"attributed","text":"A life-sciences news site reported in March 2017 that Theranos shares had been valued at $15 to $17, that the offer of two additional shares for each share held effectively lowered the price to $5, and that on an investor call in February 2017 the company said it had no material revenue in 2015 or 2016 and about $200 million in its bank accounts.","source_ids":["src-083","src-056"],"entity_ids":["theranos"],"qualification":"Press report relying on other reports; the figures are not documented in Theranos's own filings in the record.","response":"","outcome":"According to an online encyclopaedia, holders of more than 99% of the shares took part in the May 2017 recapitalisation, releasing potential claims against Theranos in exchange for new preferred stock."},"reading":"Attributed: A life-sciences news site reported in March 2017 that Theranos shares had been valued at $15 to $17, that the offer of two additional shares for each share held effectively lowered the price to $5, and that on an investor call in February 2017 the company said it had no material revenue in 2015 or 2016 and about $200 million in its bank accounts."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-fin-holmes-sec-equity","record":{"id":"c-fin-holmes-sec-equity","kind":"fact","text":"In announcing the March 2018 settlement, the SEC said that Holmes agreed to give up majority voting control of Theranos and to a reduction of her equity which, combined with shares she had previously returned, materially reduced her stake; because of the company's liquidation preference she would not profit from her ownership on a sale or liquidation until, assuming redemption of certain warrants, over $750 million had been returned to defrauded investors and other preferred shareholders.","source_ids":["src-007"],"entity_ids":["holmes","theranos","sec"],"qualification":"","response":"","outcome":""},"reading":"Fact: In announcing the March 2018 settlement, the SEC said that Holmes agreed to give up majority voting control of Theranos and to a reduction of her equity which, combined with shares she had previously returned, materially reduced her stake; because of the company's liquidation preference she would not profit from her ownership on a sale or liquidation until, assuming redemption of certain warrants, over $750 million had been returned to defrauded investors and other preferred shareholders."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wag-walgreen-co","record":{"id":"c-wag-walgreen-co","kind":"fact","text":"The Walgreens counterparty in the Theranos agreements and lawsuits is Walgreen Co., an Illinois corporation registered with the SEC under Central Index Key 0000104207 with its address at 108 Wilmot Road, Deerfield, Illinois; in a July 2018 court filing it identified Walgreens Boots Alliance, Inc. as its corporate parent.","source_ids":["src-023","src-059"],"entity_ids":["walgreen-co","wba"],"qualification":"","response":"","outcome":""},"reading":"Fact: The Walgreens counterparty in the Theranos agreements and lawsuits is Walgreen Co., an Illinois corporation registered with the SEC under Central Index Key 0000104207 with its address at 108 Wilmot Road, Deerfield, Illinois; in a July 2018 court filing it identified Walgreens Boots Alliance, Inc. as its corporate parent."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wag-subsidiaries","record":{"id":"c-wag-subsidiaries","kind":"fact","text":"Walgreen Co.'s list of subsidiaries as of August 31, 2012 includes WVC Investments, LLC, a Delaware company, and Walgreen Arizona Drug Co., an Arizona company whose direct parent is Walgreens Hastings Co.","source_ids":["src-076"],"entity_ids":["walgreen-co","wvc","walgreen-az"],"qualification":"","response":"","outcome":""},"reading":"Fact: Walgreen Co.'s list of subsidiaries as of August 31, 2012 includes WVC Investments, LLC, a Delaware company, and Walgreen Arizona Drug Co., an Arizona company whose direct parent is Walgreens Hastings Co."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wag-2010-agreement","record":{"id":"c-wag-2010-agreement","kind":"fact","text":"According to Walgreens' complaint as summarised in a 2017 report and recommendation of the U.S. District Court for the District of Delaware, Theranos sent Walgreens a Regulatory Summary on May 7, 2010 stating that its finger-stick technology had been approved for launch in clinical studies and that Theranos intended to open two laboratories; relying on these representations and its own due diligence, Walgreens entered into an initial Master Services Agreement with Theranos on July 30, 2010. The HHS Departmental Appeals Board describes the 2010 contract as a Master Purchase Agreement aimed at introducing a blood testing service in Walgreens stores nationwide.","source_ids":["src-041","src-071"],"entity_ids":["theranos","walgreen-co"],"qualification":"","response":"","outcome":""},"reading":"Fact: According to Walgreens' complaint as summarised in a 2017 report and recommendation of the U.S. District Court for the District of Delaware, Theranos sent Walgreens a Regulatory Summary on May 7, 2010 stating that its finger-stick technology had been approved for launch in clinical studies and that Theranos intended to open two laboratories; relying on these representations and its own due diligence, Walgreens entered into an initial Master Services Agreement with Theranos on July 30, 2010. The HHS Departmental Appeals Board describes the 2010 contract as a Master Purchase Agreement aimed at introducing a blood testing service in Walgreens stores nationwide."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wag-2010-meetings","record":{"id":"c-wag-2010-meetings","kind":"attributed","text":"Wade Miquelon, Walgreens' former chief financial officer, testified at Holmes's trial about a series of meetings with Holmes and Balwani in 2010 and said Walgreens was very excited about forming the partnership. Holmes testified that Balwani, together with lawyers, was involved in the negotiations with Walgreens.","source_ids":["src-043","src-050"],"entity_ids":["wade-miquelon","walgreen-co","holmes","balwani","theranos"],"qualification":"Trial testimony as reported by business news coverage.","response":"","outcome":""},"reading":"Attributed: Wade Miquelon, Walgreens' former chief financial officer, testified at Holmes's trial about a series of meetings with Holmes and Balwani in 2010 and said Walgreens was very excited about forming the partnership. Holmes testified that Balwani, together with lawyers, was involved in the negotiations with Walgreens."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wag-2010-representations","record":{"id":"c-wag-2010-representations","kind":"fact","text":"The HHS Departmental Appeals Board found that Theranos's 2010 agreements with Walgreens and Safeway stated that Theranos had developed devices that could run any blood test in real time for less than the cost of central laboratory tests, and that Theranos told Walgreens of a \"Medicaid/Medicare Opportunity\" while telling other investors that it billed Medicare and Medicaid.","source_ids":["src-071"],"entity_ids":["theranos","walgreen-co","safeway"],"qualification":"","response":"","outcome":""},"reading":"Fact: The HHS Departmental Appeals Board found that Theranos's 2010 agreements with Walgreens and Safeway stated that Theranos had developed devices that could run any blood test in real time for less than the cost of central laboratory tests, and that Theranos told Walgreens of a \"Medicaid/Medicare Opportunity\" while telling other investors that it billed Medicare and Medicaid."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wag-msa-2012","record":{"id":"c-wag-msa-2012","kind":"fact","text":"Under a Master Services Agreement signed on June 5, 2012, Theranos Wellness Centers were to operate inside Walgreens stores, where technicians would collect blood that was expected to be tested at one of two CLIA-certified laboratories owned and operated by Theranos, with results sent to the requesting physician. Walgreens agreed to pay an Innovation Fee of up to $100 million, which it paid in full under a December 2013 amendment, and to provide $40 million in exchange for a $40 million convertible note.","source_ids":["src-041"],"entity_ids":["theranos","walgreen-co"],"qualification":"","response":"","outcome":""},"reading":"Fact: Under a Master Services Agreement signed on June 5, 2012, Theranos Wellness Centers were to operate inside Walgreens stores, where technicians would collect blood that was expected to be tested at one of two CLIA-certified laboratories owned and operated by Theranos, with results sent to the requesting physician. Walgreens agreed to pay an Innovation Fee of up to $100 million, which it paid in full under a December 2013 amendment, and to provide $40 million in exchange for a $40 million convertible note."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wag-note-wvc","record":{"id":"c-wag-note-wvc","kind":"fact","text":"Walgreens exercised its right to purchase the convertible note through WVC Investments, a wholly owned subsidiary of Walgreen Co., with Wade Miquelon signing the purchase documents as WVC's President; in the 2016 lawsuit Theranos argued that it owed the note obligation to WVC rather than to Walgreens.","source_ids":["src-041"],"entity_ids":["wvc","walgreen-co","wade-miquelon","theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: Walgreens exercised its right to purchase the convertible note through WVC Investments, a wholly owned subsidiary of Walgreen Co., with Wade Miquelon signing the purchase documents as WVC's President; in the 2016 lawsuit Theranos argued that it owed the note obligation to WVC rather than to Walgreens."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wag-pilot","record":{"id":"c-wag-pilot","kind":"fact","text":"The Wellness Center pilot began on March 20, 2013 at a single Walgreens store in Phoenix, Arizona; on September 9, 2013 Theranos announced that it would roll out Wellness Centers inside Walgreens stores, and from late 2013 it offered tests to the public in Walgreens stores in Palo Alto, California and in Phoenix and the surrounding area. By the fall of 2015 there were 41 Theranos Wellness Centers.","source_ids":["src-041","src-016"],"entity_ids":["theranos","walgreen-co"],"qualification":"","response":"","outcome":""},"reading":"Fact: The Wellness Center pilot began on March 20, 2013 at a single Walgreens store in Phoenix, Arizona; on September 9, 2013 Theranos announced that it would roll out Wellness Centers inside Walgreens stores, and from late 2013 it offered tests to the public in Walgreens stores in Palo Alto, California and in Phoenix and the surrounding area. By the fall of 2015 there were 41 Theranos Wellness Centers."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wag-rollout-targets","record":{"id":"c-wag-rollout-targets","kind":"attributed","text":"Business news coverage of the trial reported from the testimony of a former Walgreens executive that the clinics were opened in 40 drugstores in Arizona and one in California and that in August 2014 Walgreens cut its rollout goal from 500 Wellness Centers to 200. The witness, Nimesh Jhaveri, said, as a national newspaper reported, that he had told Balwani a detailed plan to improve the patient experience was needed before any expansion, and that he had met Holmes only two or three times.","source_ids":["src-065","src-090"],"entity_ids":["walgreen-co","theranos","balwani","holmes"],"qualification":"Trial testimony as reported by several news outlets.","response":"","outcome":""},"reading":"Attributed: Business news coverage of the trial reported from the testimony of a former Walgreens executive that the clinics were opened in 40 drugstores in Arizona and one in California and that in August 2014 Walgreens cut its rollout goal from 500 Wellness Centers to 200. The witness, Nimesh Jhaveri, said, as a national newspaper reported, that he had told Balwani a detailed plan to improve the patient experience was needed before any expansion, and that he had met Holmes only two or three times."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wag-900-representation","record":{"id":"c-wag-900-representation","kind":"fact","text":"The Justice Department said that trial evidence showed representations to investors that Theranos would increase its Wellness Centers in Walgreens stores from a few dozen to 900 while Balwani and Holmes knew the relationship was stagnating; the SEC alleged that Balwani, who managed the relationship, told investors in late 2014 that Theranos expected to roll out to hundreds of stores of a national pharmacy chain in 2015 and drafted projections assuming 800 or 900 stores by the end of 2015.","source_ids":["src-003","src-014"],"entity_ids":["theranos","walgreen-co","balwani","holmes"],"qualification":"The SEC complaint does not name the pharmacy chain, which it calls \"Pharmacy A\".","response":"","outcome":""},"reading":"Fact: The Justice Department said that trial evidence showed representations to investors that Theranos would increase its Wellness Centers in Walgreens stores from a few dozen to 900 while Balwani and Holmes knew the relationship was stagnating; the SEC alleged that Balwani, who managed the relationship, told investors in late 2014 that Theranos expected to roll out to hundreds of stores of a national pharmacy chain in 2015 and drafted projections assuming 800 or 900 stores by the end of 2015."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wag-joint-marketing","record":{"id":"c-wag-joint-marketing","kind":"attributed","text":"Patients suing in Arizona alleged that in a joint press release with Theranos in September 2013 Walgreens promoted Theranos's \"CLIA-certified laboratory services\" and that in November 2013 the president of Walgreens told a newspaper that Theranos could perform tests \"more accurately\" than traditional blood tests.","source_ids":["src-058"],"entity_ids":["walgreen-co","theranos"],"qualification":"Allegations of the class-action plaintiffs as summarised by the District of Arizona; Walgreens did not admit liability when it settled the class action in 2024.","response":"","outcome":""},"reading":"Attributed: Patients suing in Arizona alleged that in a joint press release with Theranos in September 2013 Walgreens promoted Theranos's \"CLIA-certified laboratory services\" and that in November 2013 the president of Walgreens told a newspaper that Theranos could perform tests \"more accurately\" than traditional blood tests."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wag-payment-for-tests","record":{"id":"c-wag-payment-for-tests","kind":"fact","text":"According to the 2018 indictment as described by the U.S. Attorney's Office, Theranos blood tests were sold to the public at Walgreens stores in California and Arizona, and patients paid Theranos, or Walgreens acting on Theranos's behalf, for tests and results.","source_ids":["src-010"],"entity_ids":["theranos","walgreen-co"],"qualification":"These are allegations of the indictment; the jury acquitted Holmes on the patient counts and convicted Balwani on them.","response":"","outcome":""},"reading":"Fact: According to the 2018 indictment as described by the U.S. Attorney's Office, Theranos blood tests were sold to the public at Walgreens stores in California and Arizona, and patients paid Theranos, or Walgreens acting on Theranos's behalf, for tests and results."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wag-breach-notice","record":{"id":"c-wag-breach-notice","kind":"fact","text":"On January 28, 2016 Walgreens sent Theranos a notice of breach of the Master Services Agreement, citing the deficiencies CMS had found at Theranos's Newark laboratory. Walgreens terminated the agreement for cause by letter of June 12, 2016 and closed all Theranos Wellness Centers.","source_ids":["src-041"],"entity_ids":["walgreen-co","theranos"],"qualification":"","response":"Theranos answered on February 4, 2016 that many of the violations identified by CMS had already been corrected and that the CMS letter identified curable deficiencies, and accused Walgreens of breaching the agreement by closing the Wellness Center in California before the cure period had expired.","outcome":""},"reading":"Fact: On January 28, 2016 Walgreens sent Theranos a notice of breach of the Master Services Agreement, citing the deficiencies CMS had found at Theranos's Newark laboratory. Walgreens terminated the agreement for cause by letter of June 12, 2016 and closed all Theranos Wellness Centers."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wag-corrected-reports","record":{"id":"c-wag-corrected-reports","kind":"fact","text":"The Delaware court's account records that in May 2016 Theranos issued corrected reports for every test run in 2014 and 2015 on its proprietary technology at both of its laboratories; its replacement Newark laboratory director, Kingshuk Das, estimated the corrected reports at 50,000, while Theranos put the number of voided or corrected tests at 31,000 and confirmed it had known of quality issues since September 2015.","source_ids":["src-041"],"entity_ids":["theranos","das"],"qualification":"","response":"","outcome":""},"reading":"Fact: The Delaware court's account records that in May 2016 Theranos issued corrected reports for every test run in 2014 and 2015 on its proprietary technology at both of its laboratories; its replacement Newark laboratory director, Kingshuk Das, estimated the corrected reports at 50,000, while Theranos put the number of voided or corrected tests at 31,000 and confirmed it had known of quality issues since September 2015."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wag-suit-2016","record":{"id":"c-wag-suit-2016","kind":"fact","text":"Walgreen Co. sued Theranos, Inc. in the U.S. District Court for the District of Delaware on November 8, 2016 (C.A. No. 16-1040), alleging breach of the Amended and Restated Master Services Agreement and seeking repayment of the $100 million Innovation Fee and the $40 million paid for the convertible note, together with damages. On July 27, 2017 Magistrate Judge Mary Pat Thynge recommended denying Theranos's motion to dismiss the counts concerning the note and the claim for breach of the implied covenant of good faith.","source_ids":["src-041","src-042","src-059"],"entity_ids":["walgreen-co","theranos"],"qualification":"","response":"","outcome":"Theranos announced on August 1, 2017 that it had settled with Walgreens, which would dismiss the suit with no finding or implication of liability; a second Walgreens suit in 2018 ended in a $5,000,000 judgment against Theranos.","adverse_subject_ids":["theranos"]},"reading":"Fact: Walgreen Co. sued Theranos, Inc. in the U.S. District Court for the District of Delaware on November 8, 2016 (C.A. No. 16-1040), alleging breach of the Amended and Restated Master Services Agreement and seeking repayment of the $100 million Innovation Fee and the $40 million paid for the convertible note, together with damages. On July 27, 2017 Magistrate Judge Mary Pat Thynge recommended denying Theranos's motion to dismiss the counts concerning the note and the claim for breach of the implied covenant of good faith."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wag-settlement-2017","record":{"id":"c-wag-settlement-2017","kind":"fact","text":"Theranos announced on August 1, 2017 that it had settled with Walgreens, which would dismiss its lawsuit \"with no finding or implication of liability\"; the terms were confidential. A national newspaper reported the settlement at less than $30 million, against the $140 million Walgreens said it had spent on the partnership.","source_ids":["src-042","src-054"],"entity_ids":["theranos","walgreen-co"],"qualification":"The settlement amount is the newspaper's report, not a disclosed term.","response":"","outcome":"","adverse_subject_ids":["theranos"]},"reading":"Fact: Theranos announced on August 1, 2017 that it had settled with Walgreens, which would dismiss its lawsuit \"with no finding or implication of liability\"; the terms were confidential. A national newspaper reported the settlement at less than $30 million, against the $140 million Walgreens said it had spent on the partnership."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wag-suit-2018","record":{"id":"c-wag-suit-2018","kind":"fact","text":"Walgreen Co. sued Theranos again in the District of Delaware on July 2, 2018 (Case 1:2018cv00989) for breach of contract under seal; on October 1, 2018 Judge Richard G. Andrews granted Walgreens summary judgment and ordered Theranos to pay $5,000,000 in damages with prejudgment interest at 7.5% and post-judgment interest at 2.5%, and the case was closed.","source_ids":["src-059"],"entity_ids":["walgreen-co","theranos"],"qualification":"The basis of the $5 million claim, apparently a payment due under the 2017 settlement, was not retrieved; the research left it as an open question.","response":"","outcome":"","adverse_subject_ids":["theranos"]},"reading":"Fact: Walgreen Co. sued Theranos again in the District of Delaware on July 2, 2018 (Case 1:2018cv00989) for breach of contract under seal; on October 1, 2018 Judge Richard G. Andrews granted Walgreens summary judgment and ordered Theranos to pay $5,000,000 in damages with prejudgment interest at 7.5% and post-judgment interest at 2.5%, and the case was closed."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wag-abc-claim","record":{"id":"c-wag-abc-claim","kind":"fact","text":"On March 11, 2019, the deadline for claims against the assignment estate, Walgreens filed a general unsecured claim against Theranos's assignee for the benefit of creditors based on a promissory note and a judgment for payment arising from a settlement agreement. Under a 2023 settlement the Walgreens claim was allowed at $45,000,000 for pro rata distribution with other unsecured claims.","source_ids":["src-080"],"entity_ids":["walgreen-co","theranos-abc","theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: On March 11, 2019, the deadline for claims against the assignment estate, Walgreens filed a general unsecured claim against Theranos's assignee for the benefit of creditors based on a promissory note and a judgment for payment arising from a settlement agreement. Under a 2023 settlement the Walgreens claim was allowed at $45,000,000 for pro rata distribution with other unsecured claims."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wag-investment-figures","record":{"id":"c-wag-investment-figures","kind":"attributed","text":"Accounts of Walgreens' financial exposure differ: the Delaware court records a $100 million Innovation Fee and a $40 million convertible note; a start-up data publisher, citing a national newspaper, says Walgreens invested $50 million and spent $140 million on the partnership; trial reporting describes a $140 million investment; and the criminal restitution order awarded Walgreens $40 million.","source_ids":["src-054","src-065","src-016"],"entity_ids":["walgreen-co","theranos"],"qualification":"The figures partly measure different things: the Innovation Fee was a payment under the services agreement and the note an investment, together $140 million; the $50 million investment figure does not match the $40 million note in the court record; and the restitution award is the loss the court found on the investment.","response":"","outcome":""},"reading":"Attributed: Accounts of Walgreens' financial exposure differ: the Delaware court records a $100 million Innovation Fee and a $40 million convertible note; a start-up data publisher, citing a national newspaper, says Walgreens invested $50 million and spent $140 million on the partnership; trial reporting describes a $140 million investment; and the criminal restitution order awarded Walgreens $40 million."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-prt-safeway-entity","record":{"id":"c-prt-safeway-entity","kind":"fact","text":"Safeway Inc., the supermarket chain that contracted with Theranos, is a Delaware corporation registered with the SEC under Central Index Key 0000086144, with employer identification number 94-3019135 (written 943019135) and its address at 5918 Stoneridge Mall Road, Pleasanton, California.","source_ids":["src-024"],"entity_ids":["safeway"],"qualification":"","response":"","outcome":""},"reading":"Fact: Safeway Inc., the supermarket chain that contracted with Theranos, is a Delaware corporation registered with the SEC under Central Index Key 0000086144, with employer identification number 94-3019135 (written 943019135) and its address at 5918 Stoneridge Mall Road, Pleasanton, California."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-prt-safeway-2010","record":{"id":"c-prt-safeway-2010","kind":"fact","text":"Theranos entered into a Master Purchase Agreement with Safeway, Inc. in 2010, according to the HHS Departmental Appeals Board; in it Theranos represented that it was a \"health care provider\" and \"covered entity\" under HIPAA. The SEC's complaint states that in September 2010 a national grocery chain, which it calls \"Grocery A\", contracted with Theranos to offer patient testing in its stores after Holmes told its then-CEO that Theranos had miniaturised the conventional laboratory and that its analysers were being deployed on the battlefield.","source_ids":["src-071","src-002"],"entity_ids":["theranos","safeway","holmes"],"qualification":"The SEC complaint does not name the grocery chain.","response":"","outcome":""},"reading":"Fact: Theranos entered into a Master Purchase Agreement with Safeway, Inc. in 2010, according to the HHS Departmental Appeals Board; in it Theranos represented that it was a \"health care provider\" and \"covered entity\" under HIPAA. The SEC's complaint states that in September 2010 a national grocery chain, which it calls \"Grocery A\", contracted with Theranos to offer patient testing in its stores after Holmes told its then-CEO that Theranos had miniaturised the conventional laboratory and that its analysers were being deployed on the battlefield."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-prt-safeway-burd","record":{"id":"c-prt-safeway-burd","kind":"attributed","text":"Steve Burd, who led Safeway for more than 20 years, testified at Holmes's trial that Safeway carried out an extensive independent investigation of Theranos's technology claims before signing the agreement in 2010 and prepared more than 900 stores for the blood-testing machines; business news coverage of his testimony added that the deal was valued at nearly $400 million, that 969 stores were remodelled, and that Safeway ended the partnership in 2015, two years after he retired.","source_ids":["src-043","src-071","src-016"],"entity_ids":["steve-burd","safeway","theranos"],"qualification":"Trial testimony as reported by business news coverage.","response":"In cross-examination Holmes's defence sought to show that Safeway, a large national chain, had not been duped in its negotiations; Burd agreed that he knew Theranos did not have many customers.","outcome":"The 2023 restitution order counted Safeway among the victims of the investor fraud and awarded it $14,500,000."},"reading":"Attributed: Steve Burd, who led Safeway for more than 20 years, testified at Holmes's trial that Safeway carried out an extensive independent investigation of Theranos's technology claims before signing the agreement in 2010 and prepared more than 900 stores for the blood-testing machines; business news coverage of his testimony added that the deal was valued at nearly $400 million, that 969 stores were remodelled, and that Safeway ended the partnership in 2015, two years after he retired."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-prt-safeway-trex","record":{"id":"c-prt-safeway-trex","kind":"attributed","text":"Citing a national newspaper's unnamed sources, a regional business journal reported in November 2015 that Safeway was negotiating to end a program, code-named T-Rex and reportedly dating to 2011, under which it was to be the exclusive supermarket provider of Theranos tests in 800 in-store clinics; Safeway had spent $350 million on clinics that never performed the envisaged blood tests and instead offered flu shots and vaccines, and it had also invested more than $10 million in Theranos. Safeway executives were reported to have questioned the accuracy of results given to employees tested at a clinic in the company's headquarters.","source_ids":["src-055"],"entity_ids":["safeway","theranos","heather-king"],"qualification":"Reported from unnamed sources; no statement by Safeway is in the record.","response":"Theranos's general counsel Heather King declined to comment on the Safeway executives' statements, but said in an emailed statement that Theranos did not comment on discussions with other companies and that the questions and information presented to it were \"inaccurate and defamatory\".","outcome":""},"reading":"Attributed: Citing a national newspaper's unnamed sources, a regional business journal reported in November 2015 that Safeway was negotiating to end a program, code-named T-Rex and reportedly dating to 2011, under which it was to be the exclusive supermarket provider of Theranos tests in 800 in-store clinics; Safeway had spent $350 million on clinics that never performed the envisaged blood tests and instead offered flu shots and vaccines, and it had also invested more than $10 million in Theranos. Safeway executives were reported to have questioned the accuracy of results given to employees tested at a clinic in the company's headquarters."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-prt-safeway-unwind","record":{"id":"c-prt-safeway-unwind","kind":"attributed","text":"A regional news site, summarising national newspaper reporting, wrote in 2021 that Safeway began hiring phlebotomists for the clinics in 2013 but that the deal began to fizzle by the spring of 2013 after testing at its Pleasanton headquarters produced at least one faulty result, and that the companies unwound the partnership as Albertsons' acquisition of Safeway closed; before Holmes's trial, prosecutors sought to define Safeway and Walgreens as investors.","source_ids":["src-093"],"entity_ids":["safeway","theranos","walgreen-co"],"qualification":"A secondary account of press reporting; the reported test result concerns an unnamed executive.","response":"","outcome":""},"reading":"Attributed: A regional news site, summarising national newspaper reporting, wrote in 2021 that Safeway began hiring phlebotomists for the clinics in 2013 but that the deal began to fizzle by the spring of 2013 after testing at its Pleasanton headquarters produced at least one faulty result, and that the companies unwound the partnership as Albertsons' acquisition of Safeway closed; before Holmes's trial, prosecutors sought to define Safeway and Walgreens as investors."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-prt-retail-outreach","record":{"id":"c-prt-retail-outreach","kind":"attributed","text":"Holmes testified in 2021 that an early goal of Theranos was to partner with retail giants and that she approached all of them, including Target, CVS, Walmart, Walgreens and Safeway; Balwani testified to the SEC that from around 2010, when Theranos began working with Safeway and Walgreens, he built and owned the company's financial model.","source_ids":["src-050","src-016"],"entity_ids":["holmes","balwani","theranos","walgreen-co","safeway"],"qualification":"Holmes's trial testimony as reported by business news coverage, and Balwani's SEC testimony as quoted in the Ninth Circuit's opinion.","response":"","outcome":""},"reading":"Attributed: Holmes testified in 2021 that an early goal of Theranos was to partner with retail giants and that she approached all of them, including Target, CVS, Walmart, Walgreens and Safeway; Balwani testified to the SEC that from around 2010, when Theranos began working with Safeway and Walgreens, he built and owned the company's financial model."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-prt-pharma","record":{"id":"c-prt-pharma","kind":"fact","text":"The Ninth Circuit's opinion states that Theranos's partnerships with pharmaceutical companies began in 2008 and 2009 to study its technology and quickly soured; a Pfizer representative testified that Theranos's answers to technical due-diligence questions were evasive and that after 2008 Pfizer and Theranos had no meaningful business dealings, while Holmes admitted that she had personally put the logos of Pfizer, GlaxoSmithKline and Schering-Plough on reports about Theranos's technology.","source_ids":["src-016"],"entity_ids":["theranos","pfizer","holmes"],"qualification":"","response":"","outcome":""},"reading":"Fact: The Ninth Circuit's opinion states that Theranos's partnerships with pharmaceutical companies began in 2008 and 2009 to study its technology and quickly soured; a Pfizer representative testified that Theranos's answers to technical due-diligence questions were evasive and that after 2008 Pfizer and Theranos had no meaningful business dealings, while Holmes admitted that she had personally put the logos of Pfizer, GlaxoSmithKline and Schering-Plough on reports about Theranos's technology."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-prt-dod","record":{"id":"c-prt-dod","kind":"fact","text":"The Ninth Circuit's opinion states that Theranos developed a relationship with the Department of Defense to explore using its Edison device in combat settings but that the application never materialised; James Mattis testified that the device was never put into the field, installed on a military medevac or used to treat service members on the battlefield.","source_ids":["src-016"],"entity_ids":["theranos","dod","mattis"],"qualification":"","response":"","outcome":""},"reading":"Fact: The Ninth Circuit's opinion states that Theranos developed a relationship with the Department of Defense to explore using its Edison device in combat settings but that the application never materialised; James Mattis testified that the device was never put into the field, installed on a military medevac or used to treat service members on the battlefield."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-prt-health-partners","record":{"id":"c-prt-health-partners","kind":"fact","text":"A health-care trade publication reported in July 2015 that Theranos planned to partner with the Harrisburg, Pennsylvania insurer Capital BlueCross to offer direct-to-consumer blood testing to its 1.3 million enrollees through Capital BlueCross stores and Theranos Wellness Centers in Central Pennsylvania, and that Theranos had signed a strategic alliance with the Cleveland Clinic earlier that year. A start-up data publisher lists the Cleveland Clinic as a partner and AmeriHealth Caritas and Capital BlueCross as insurers for which Theranos became the laboratory provider in Pennsylvania.","source_ids":["src-091","src-054"],"entity_ids":["theranos","capital-bluecross","cleveland-clinic","amerihealth"],"qualification":"The company's claims quoted in the July 2015 report, including that its technology was FDA-approved and could screen for hundreds of conditions, are its own statements at the time.","response":"","outcome":""},"reading":"Fact: A health-care trade publication reported in July 2015 that Theranos planned to partner with the Harrisburg, Pennsylvania insurer Capital BlueCross to offer direct-to-consumer blood testing to its 1.3 million enrollees through Capital BlueCross stores and Theranos Wellness Centers in Central Pennsylvania, and that Theranos had signed a strategic alliance with the Cleveland Clinic earlier that year. A start-up data publisher lists the Cleveland Clinic as a partner and AmeriHealth Caritas and Capital BlueCross as insurers for which Theranos became the laboratory provider in Pennsylvania."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-prt-horizon-media","record":{"id":"c-prt-horizon-media","kind":"fact","text":"Count 12 of the 2020 superseding indictment concerns an electronic funds transfer of $1,126,661 on August 3, 2015 from Theranos's Wells Fargo Bank account in California to Horizon Media, Inc.'s account in New York to buy advertisements for Theranos Wellness Centers.","source_ids":["src-016"],"entity_ids":["theranos","horizon-media"],"qualification":"The transfer is the wire charged in a patient-fraud count; Holmes was acquitted of the patient counts and Balwani convicted of them. Horizon Media is named only as the payee for advertising.","response":"","outcome":""},"reading":"Fact: Count 12 of the 2020 superseding indictment concerns an electronic funds transfer of $1,126,661 on August 3, 2015 from Theranos's Wells Fargo Bank account in California to Horizon Media, Inc.'s account in New York to buy advertisements for Theranos Wellness Centers."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-newark-clia","record":{"id":"c-lab-newark-clia","kind":"fact","text":"CMS correspondence of 2016 identifies Theranos's clinical laboratory at 7333 Gateway Boulevard, Newark, California under CLIA number 05D2025714, with Sunil Dhawan, M.D. as laboratory director and Elizabeth Holmes and Ramesh Balwani as owners.","source_ids":["src-028"],"entity_ids":["theranos","dhawan","holmes","balwani","cms"],"qualification":"","response":"","outcome":""},"reading":"Fact: CMS correspondence of 2016 identifies Theranos's clinical laboratory at 7333 Gateway Boulevard, Newark, California under CLIA number 05D2025714, with Sunil Dhawan, M.D. as laboratory director and Elizabeth Holmes and Ramesh Balwani as owners."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-other-labs","record":{"id":"c-lab-other-labs","kind":"fact","text":"Theranos also had a laboratory in Palo Alto, California and laboratories in Arizona, about which members of the House Committee on Energy and Commerce asked CMS in July 2016. CMS's 2017 laboratory registry lists Theranos's laboratory at 1365 N Scottsdale Road, Suite 350, Scottsdale, Arizona under CLIA number 03D2077896, with Daniel Young as director.","source_ids":["src-029","src-036"],"entity_ids":["theranos","daniel-young","cms"],"qualification":"","response":"","outcome":""},"reading":"Fact: Theranos also had a laboratory in Palo Alto, California and laboratories in Arizona, about which members of the House Committee on Energy and Commerce asked CMS in July 2016. CMS's 2017 laboratory registry lists Theranos's laboratory at 1365 N Scottsdale Road, Suite 350, Scottsdale, Arizona under CLIA number 03D2077896, with Daniel Young as director."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-operating-period","record":{"id":"c-lab-operating-period","kind":"fact","text":"Holmes testified in the HHS exclusion proceedings that Theranos provided blood-testing services to the public and operated a clinical blood-testing laboratory from 2011 to 2016.","source_ids":["src-071"],"entity_ids":["holmes","theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: Holmes testified in the HHS exclusion proceedings that Theranos provided blood-testing services to the public and operated a clinical blood-testing laboratory from 2011 to 2016."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-scottsdale-volume","record":{"id":"c-lab-scottsdale-volume","kind":"attributed","text":"Patients suing Theranos in Arizona alleged that the company performed 90 percent of its blood testing at the Scottsdale laboratory, which only analysed samples drawn by venipuncture.","source_ids":["src-058"],"entity_ids":["theranos"],"qualification":"An allegation of the class-action plaintiffs as summarised by the District of Arizona.","response":"","outcome":""},"reading":"Attributed: Patients suing Theranos in Arizona alleged that the company performed 90 percent of its blood testing at the Scottsdale laboratory, which only analysed samples drawn by venipuncture."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-dhawan-testimony","record":{"id":"c-lab-dhawan-testimony","kind":"attributed","text":"Sunil Dhawan, a dermatologist, testified at Holmes's trial that Balwani, who knew him personally, recruited him in 2014 as laboratory director, describing the role in a November 2014 email as \"mostly an on-call consulting role\"; Dhawan said that between November 2014 and the summer of 2015 he went to the laboratory twice and worked a total of five to ten hours, never met employees, physicians or patients, and had served in a largely figurehead role by the September 2015 inspection. Business news coverage noted that he met the federal and state requirements for a laboratory director; he said he never cashed the $5,000 monthly checks his contract provided for.","source_ids":["src-065","src-090"],"entity_ids":["dhawan","balwani","theranos","holmes","rosendorff"],"qualification":"Dhawan's own testimony as reported by several news outlets; he replaced Adam Rosendorff, who left in 2014.","response":"","outcome":""},"reading":"Attributed: Sunil Dhawan, a dermatologist, testified at Holmes's trial that Balwani, who knew him personally, recruited him in 2014 as laboratory director, describing the role in a November 2014 email as \"mostly an on-call consulting role\"; Dhawan said that between November 2014 and the summer of 2015 he went to the laboratory twice and worked a total of five to ten hours, never met employees, physicians or patients, and had served in a largely figurehead role by the September 2015 inspection. Business news coverage noted that he met the federal and state requirements for a laboratory director; he said he never cashed the $5,000 monthly checks his contract provided for."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-sawyer","record":{"id":"c-lab-sawyer","kind":"attributed","text":"Holmes's defence showed at trial that the name of Lynette Sawyer had been added to Theranos's laboratory licence in November 2014, so that Dhawan was not the only person acting as laboratory director; Dhawan said he did not know her. A laboratory-industry newsletter reported that Sawyer testified she never set foot inside the laboratory while serving as co-director.","source_ids":["src-082","src-118"],"entity_ids":["sawyer","theranos","dhawan"],"qualification":"Trial evidence and testimony as reported by the press.","response":"","outcome":""},"reading":"Attributed: Holmes's defence showed at trial that the name of Lynette Sawyer had been added to Theranos's laboratory licence in November 2014, so that Dhawan was not the only person acting as laboratory director; Dhawan said he did not know her. A laboratory-industry newsletter reported that Sawyer testified she never set foot inside the laboratory while serving as co-director."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-das","record":{"id":"c-lab-das","kind":"fact","text":"Kingshuk Das became director of the Newark laboratory in 2016: Theranos told CMS in a February 12, 2016 submission that he had been appointed, CMS noted that he did not begin his regulatory responsibilities until March 11, 2016, and the Ninth Circuit records that he began working at Theranos in March 2016. According to trial reporting, he worked there until June 2018 and testified that he voided every test run on the Edison devices in 2014 and 2015.","source_ids":["src-045","src-028","src-016","src-118"],"entity_ids":["das","theranos","cms"],"qualification":"","response":"","outcome":""},"reading":"Fact: Kingshuk Das became director of the Newark laboratory in 2016: Theranos told CMS in a February 12, 2016 submission that he had been appointed, CMS noted that he did not begin his regulatory responsibilities until March 11, 2016, and the Ninth Circuit records that he began working at Theranos in March 2016. According to trial reporting, he worked there until June 2018 and testified that he voided every test run on the Edison devices in 2014 and 2015."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-former-directors","record":{"id":"c-lab-former-directors","kind":"fact","text":"The Ninth Circuit's opinion refers to Dr. Adam Rosendorff and Dr. Mark Pandori as two former Theranos laboratory directors whose testimony Balwani challenged on appeal; a laboratory-industry newsletter reported that Rosendorff, a pathologist, had testified that he quit because the technology did not work.","source_ids":["src-016","src-118"],"entity_ids":["rosendorff","pandori","theranos","balwani"],"qualification":"The reason Rosendorff gave for leaving is his testimony as reported by the press.","response":"","outcome":""},"reading":"Fact: The Ninth Circuit's opinion refers to Dr. Adam Rosendorff and Dr. Mark Pandori as two former Theranos laboratory directors whose testimony Balwani challenged on appeal; a laboratory-industry newsletter reported that Rosendorff, a pathologist, had testified that he quit because the technology did not work."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-fda-483","record":{"id":"c-lab-fda-483","kind":"fact","text":"FDA investigators inspected Theranos's Newark site, as a medical device manufacturer, from August 25 to September 16, 2015 and issued a Form FDA-483 addressed to Ramesh Balwani as President and Chief Operations Officer. Its first observation states that devices requiring listing had not been listed and that Theranos was shipping an uncleared medical device, which it identified as Class I exempt, in interstate commerce between California, Arizona and Pennsylvania.","source_ids":["src-079"],"entity_ids":["theranos","balwani","fda"],"qualification":"The device is named in press reports as the Nanotainer blood-collection tube.","response":"","outcome":"","adverse_subject_ids":["theranos"]},"reading":"Fact: FDA investigators inspected Theranos's Newark site, as a medical device manufacturer, from August 25 to September 16, 2015 and issued a Form FDA-483 addressed to Ramesh Balwani as President and Chief Operations Officer. Its first observation states that devices requiring listing had not been listed and that Theranos was shipping an uncleared medical device, which it identified as Class I exempt, in interstate commerce between California, Arizona and Pennsylvania."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-fda-press","record":{"id":"c-lab-fda-press","kind":"fact","text":"A life-sciences news site reported in October 2015 that the FDA's inspection reports, released that week, called Theranos's Nanotainer tubes an uncleared medical device not properly filed as a Class II device and that the agency had listed 13 concerns in its Form 483s.","source_ids":["src-067","src-020"],"entity_ids":["theranos","fda"],"qualification":"","response":"Theranos published a response saying that for several years it had been moving from CLIA laboratory guidelines to FDA guidelines, that it had sought FDA guidance for its laboratory structure and that it was working closely with regulators on clearance.","outcome":"A business news site reported at the end of October 2015 that Theranos had announced earlier that month that it would stop using its finger-prick method for all tests except the herpes test the FDA had cleared in July."},"reading":"Fact: A life-sciences news site reported in October 2015 that the FDA's inspection reports, released that week, called Theranos's Nanotainer tubes an uncleared medical device not properly filed as a Class II device and that the agency had listed 13 concerns in its Form 483s."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-fda-requirement","record":{"id":"c-lab-fda-requirement","kind":"attributed","text":"The 2020 superseding indictment alleges that Holmes and Balwani told investors that Theranos did not need FDA approval for its analyser and tests and was applying voluntarily, when they knew that by late 2013 and throughout 2014 the FDA was requiring Theranos to apply for clearance or approval.","source_ids":["src-016"],"entity_ids":["holmes","balwani","theranos","fda"],"qualification":"An allegation of the indictment; the trial verdicts on the investor counts are set out in the account of the criminal case.","response":"","outcome":""},"reading":"Attributed: The 2020 superseding indictment alleges that Holmes and Balwani told investors that Theranos did not need FDA approval for its analyser and tests and was applying voluntarily, when they knew that by late 2013 and throughout 2014 the FDA was requiring Theranos to apply for clearance or approval."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-arizona-inspection","record":{"id":"c-lab-arizona-inspection","kind":"attributed","text":"Patients in the Arizona class action alleged, citing a November 2015 newspaper article, that inspectors of the Arizona Department of Health Services found multiple deficiencies at Theranos's Scottsdale laboratory in April 2015; the same article reported Theranos's response that the findings were routine and all issues were addressed or corrected within days or weeks.","source_ids":["src-058"],"entity_ids":["theranos"],"qualification":"The plaintiffs' allegation and Theranos's response, as summarised by the court.","response":"Theranos said the inspection findings were routine and had been addressed or corrected within days or weeks.","outcome":""},"reading":"Attributed: Patients in the Arizona class action alleged, citing a November 2015 newspaper article, that inspectors of the Arizona Department of Health Services found multiple deficiencies at Theranos's Scottsdale laboratory in April 2015; the same article reported Theranos's response that the findings were routine and all issues were addressed or corrected within days or weeks."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-cms-survey","record":{"id":"c-lab-cms-survey","kind":"fact","text":"CMS conducted a CLIA recertification and complaint survey of Theranos's Newark laboratory in 2015; the onsite part ended on November 20, 2015 and the survey concluded on December 23, 2015. CMS found the laboratory out of compliance with five CLIA Condition-level requirements and numerous Standard-level requirements, and by letter of January 25, 2016 it notified Theranos that deficiencies in hematology amounted to immediate jeopardy to patient health and safety.","source_ids":["src-028"],"entity_ids":["cms","theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: CMS conducted a CLIA recertification and complaint survey of Theranos's Newark laboratory in 2015; the onsite part ended on November 20, 2015 and the survey concluded on December 23, 2015. CMS found the laboratory out of compliance with five CLIA Condition-level requirements and numerous Standard-level requirements, and by letter of January 25, 2016 it notified Theranos that deficiencies in hematology amounted to immediate jeopardy to patient health and safety."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-cms-proposed","record":{"id":"c-lab-cms-proposed","kind":"fact","text":"On March 18, 2016 CMS proposed sanctions against the Newark laboratory's CLIA certificate, with revocation as the principal sanction, citing immediate jeopardy, the failure to meet all Condition-level requirements and the failure of the laboratory's owners and director to comply with certificate requirements; the laboratory had until March 28, 2016 to respond. CMS found many of the laboratory's claims of correction not credible and its evidence not acceptable, including the absence of documentation that corrected reports had been issued to patients. In proposing a civil money penalty of $10,000 a day, it cited the five Condition-level failures, the immediate jeopardy in hematology that the laboratory had not removed, and its failure to meet the requirements for the director of a high-complexity laboratory.","source_ids":["src-028","src-045"],"entity_ids":["cms","theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: On March 18, 2016 CMS proposed sanctions against the Newark laboratory's CLIA certificate, with revocation as the principal sanction, citing immediate jeopardy, the failure to meet all Condition-level requirements and the failure of the laboratory's owners and director to comply with certificate requirements; the laboratory had until March 28, 2016 to respond. CMS found many of the laboratory's claims of correction not credible and its evidence not acceptable, including the absence of documentation that corrected reports had been issued to patients. In proposing a civil money penalty of $10,000 a day, it cited the five Condition-level failures, the immediate jeopardy in hematology that the laboratory had not removed, and its failure to meet the requirements for the director of a high-complexity laboratory."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-cms-personnel","record":{"id":"c-lab-cms-personnel","kind":"fact","text":"In its March 2016 notice CMS stated that it had confirmed with the California Department of Public Health that unlicensed personnel may not operate moderately complex testing instruments in California, that the laboratory relied on its written policies and procedures to ensure that appropriately licensed staff performed and reported patient tests, and that it questioned whether that mechanism would prevent the deficiencies from recurring if those policies were inconsistent with state requirements. CMS also noted that Theranos's February 12, 2016 submission said the laboratory directors of the survey period no longer held positions, but addressed the notice to Dr. Dhawan as director when the survey concluded. In July 2016 CMS rejected Theranos's statement that the absence of a full-time, on-site director had affected its corrections, noting that the survey-period director remained director until the new director took up his regulatory duties on March 11, 2016.","source_ids":["src-045","src-028"],"entity_ids":["cms","theranos","dhawan"],"qualification":"","response":"","outcome":""},"reading":"Fact: In its March 2016 notice CMS stated that it had confirmed with the California Department of Public Health that unlicensed personnel may not operate moderately complex testing instruments in California, that the laboratory relied on its written policies and procedures to ensure that appropriately licensed staff performed and reported patient tests, and that it questioned whether that mechanism would prevent the deficiencies from recurring if those policies were inconsistent with state requirements. CMS also noted that Theranos's February 12, 2016 submission said the laboratory directors of the survey period no longer held positions, but addressed the notice to Dr. Dhawan as director when the survey concluded. In July 2016 CMS rejected Theranos's statement that the absence of a full-time, on-site director had affected its corrections, noting that the survey-period director remained director until the new director took up his regulatory duties on March 11, 2016."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-tps-voided","record":{"id":"c-lab-tps-voided","kind":"fact","text":"CMS's July 2016 letter quotes Theranos's own conclusion that there was a possible patient impact for every test reported from the laboratory's TPS 3.5 instruments, that the fraction of results truly affected was unknown, and that it had voided all patient test results reported from those instruments.","source_ids":["src-028"],"entity_ids":["theranos","cms"],"qualification":"","response":"","outcome":""},"reading":"Fact: CMS's July 2016 letter quotes Theranos's own conclusion that there was a possible patient impact for every test reported from the laboratory's TPS 3.5 instruments, that the fraction of results truly affected was unknown, and that it had voided all patient test results reported from those instruments."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-cms-sanctions","record":{"id":"c-lab-cms-sanctions","kind":"fact","text":"By letter of July 7, 2016 CMS determined that the Newark laboratory was not in compliance with CLIA Condition-level requirements and had not removed the immediate jeopardy, and imposed sanctions: revocation of its CLIA certificate and cancellation of its approval to receive Medicare payments, both effective September 5, 2016; limitation of the certificate for hematology and suspension of hematology payments from July 15, 2016; a civil money penalty of $10,000 a day from July 12, 2016; and a directed plan of correction requiring a list of all physicians and clients served since January 2014.","source_ids":["src-028","src-041","src-029","src-078"],"entity_ids":["cms","theranos"],"qualification":"CMS stated that the cancellation of Medicare approval would take effect even if the laboratory appealed; Theranos had 60 days to appeal to the Departmental Appeals Board.","response":"Before the sanctions Theranos made several submissions to correct the deficiencies, all of which CMS rejected, and in response to CMS's action it voided two years of results from its Edison devices and issued corrected reports; it appealed the sanctions.","outcome":"In April 2017 Theranos said it had settled with CMS: it would stay out of the blood-testing business for at least two years, CMS had withdrawn the revocation of its CLIA certificates and reduced the civil money penalty to $30,000, and Theranos would withdraw its appeal.","adverse_subject_ids":["theranos"]},"reading":"Fact: By letter of July 7, 2016 CMS determined that the Newark laboratory was not in compliance with CLIA Condition-level requirements and had not removed the immediate jeopardy, and imposed sanctions: revocation of its CLIA certificate and cancellation of its approval to receive Medicare payments, both effective September 5, 2016; limitation of the certificate for hematology and suspension of hematology payments from July 15, 2016; a civil money penalty of $10,000 a day from July 12, 2016; and a directed plan of correction requiring a list of all physicians and clients served since January 2014."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-owner-ban","record":{"id":"c-lab-owner-ban","kind":"fact","text":"The July 2016 CMS letter states that on revocation of the CLIA certificate the laboratory's owners and operators, including its director, are prohibited from owning or operating a laboratory for at least two years; the letter lists Elizabeth Holmes and Ramesh Balwani as owners and Sunil Dhawan as director. A technology news site had reported in May 2016 that such sanctions could bar Balwani and Holmes from owning or running a lab for at least two years.","source_ids":["src-028","src-078"],"entity_ids":["cms","theranos","holmes","balwani","dhawan"],"qualification":"The ban was tied to the revocation; Theranos said in April 2017 that under its settlement CMS had withdrawn the revocation and that it would stay out of the blood-testing business for at least two years. A 2017 news agency report nonetheless said that Holmes had been barred in 2016.","response":"","outcome":""},"reading":"Fact: The July 2016 CMS letter states that on revocation of the CLIA certificate the laboratory's owners and operators, including its director, are prohibited from owning or operating a laboratory for at least two years; the letter lists Elizabeth Holmes and Ramesh Balwani as owners and Sunil Dhawan as director. A technology news site had reported in May 2016 that such sanctions could bar Balwani and Holmes from owning or running a lab for at least two years."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-house-letter","record":{"id":"c-lab-house-letter","kind":"fact","text":"On July 26, 2016 Democratic members of the House Committee on Energy and Commerce wrote to CMS that they were conducting oversight of Theranos's failure to comply with federal clinical laboratory standards, noting that Theranos had recently voided two years of results from its Edison device, affecting thousands of patients.","source_ids":["src-029"],"entity_ids":["theranos","cms"],"qualification":"","response":"","outcome":""},"reading":"Fact: On July 26, 2016 Democratic members of the House Committee on Energy and Commerce wrote to CMS that they were conducting oversight of Theranos's failure to comply with federal clinical laboratory standards, noting that Theranos had recently voided two years of results from its Edison device, affecting thousands of patients."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-investigations-2016","record":{"id":"c-lab-investigations-2016","kind":"attributed","text":"A technology news site reported in May 2016 that Theranos was under investigation by the SEC, the U.S. Attorney's Office for the Northern District of California and the state health departments of Pennsylvania and Arizona, and that CMS was investigating serious deficiencies in its testing practices.","source_ids":["src-018"],"entity_ids":["theranos","sec","cms"],"qualification":"Press report; the federal investigations led to the 2018 SEC actions and indictment.","response":"","outcome":""},"reading":"Attributed: A technology news site reported in May 2016 that Theranos was under investigation by the SEC, the U.S. Attorney's Office for the Northern District of California and the state health departments of Pennsylvania and Arizona, and that CMS was investigating serious deficiencies in its testing practices."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-cms-settlement","record":{"id":"c-lab-cms-settlement","kind":"attributed","text":"In April 2017 Theranos announced a settlement resolving all outstanding proceedings with CMS: it would stay out of the blood-testing business for at least two years, CMS withdrew the revocation of its CLIA certificates and reduced the civil money penalty to $30,000, and Theranos withdrew its appeal of the sanctions on the Newark laboratory.","source_ids":["src-078"],"entity_ids":["theranos","cms"],"qualification":"Terms as stated by Theranos and reported by a news agency; the report dates the withdrawn appeal to \"September 2015\", before the sanctions were imposed in July 2016, which appears to be an error in the report.","response":"","outcome":"","adverse_subject_ids":["theranos"]},"reading":"Attributed: In April 2017 Theranos announced a settlement resolving all outstanding proceedings with CMS: it would stay out of the blood-testing business for at least two years, CMS withdrew the revocation of its CLIA certificates and reduced the civil money penalty to $30,000, and Theranos withdrew its appeal of the sanctions on the Newark laboratory."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-scottsdale-sanctions","record":{"id":"c-lab-scottsdale-sanctions","kind":"fact","text":"CMS's 2017 laboratory registry lists sanctions against Theranos's Scottsdale laboratory (CLIA 03D2077896) for Condition-level non-compliance with immediate jeopardy: a directed plan of correction from February 1, 2017, suspension of all Medicare and Medicaid payments and of the CLIA certificate from February 4, 2017, and cancellation of Medicare and Medicaid approval from March 28, 2017.","source_ids":["src-036"],"entity_ids":["cms","theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: CMS's 2017 laboratory registry lists sanctions against Theranos's Scottsdale laboratory (CLIA 03D2077896) for Condition-level non-compliance with immediate jeopardy: a directed plan of correction from February 1, 2017, suspension of all Medicare and Medicaid payments and of the CLIA certificate from February 4, 2017, and cancellation of Medicare and Medicaid approval from March 28, 2017."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-closure-attributed","record":{"id":"c-lab-closure-attributed","kind":"attributed","text":"According to an online encyclopaedia, Theranos withdrew its request for emergency clearance of a Zika virus test in August 2016 after federal inspectors found a lack of safeguards, announced in October 2016 that it would close its laboratories and Wellness Centers and lay off about 40 percent of its staff, and in January 2017 laid off a further 41 percent, about 155 people, closing its last testing facility after a second failed federal inspection.","source_ids":["src-083"],"entity_ids":["theranos"],"qualification":"An encyclopaedia summary of press reports; the January 2017 Scottsdale sanctions in CMS's registry are consistent with the failed inspection it describes.","response":"","outcome":""},"reading":"Attributed: According to an online encyclopaedia, Theranos withdrew its request for emergency clearance of a Zika virus test in August 2016 after federal inspectors found a lack of safeguards, announced in October 2016 that it would close its laboratories and Wellness Centers and lay off about 40 percent of its staff, and in January 2017 laid off a further 41 percent, about 155 people, closing its last testing facility after a second failed federal inspection."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-lab-az-ag","record":{"id":"c-lab-az-ag","kind":"fact","text":"In April 2017 the Arizona Attorney General sued Theranos in Maricopa County Superior Court under the Arizona Consumer Fraud Act, alleging that between 2013 and 2016 it sold about 1,545,339 blood tests to about 175,940 Arizona consumers, yielding 7,862,146 results, of which it voided or corrected about 834,233, and that it misrepresented its testing's methodology, accuracy and reliability. Theranos denied the allegations but entered into a consent decree to pay $4,652,000 in restitution, $200,000 in civil penalties and $25,000 in attorney's fees.","source_ids":["src-031","src-058"],"entity_ids":["az-ag","theranos"],"qualification":"","response":"Theranos denied the allegations.","outcome":"The Attorney General's office began mailing restitution checks in December 2017 and describes the settlement as closed, with a full refund for every Arizonan who bought a Theranos blood test.","adverse_subject_ids":["theranos"]},"reading":"Fact: In April 2017 the Arizona Attorney General sued Theranos in Maricopa County Superior Court under the Arizona Consumer Fraud Act, alleging that between 2013 and 2016 it sold about 1,545,339 blood tests to about 175,940 Arizona consumers, yielding 7,862,146 results, of which it voided or corrected about 834,233, and that it misrepresented its testing's methodology, accuracy and reliability. Theranos denied the allegations but entered into a consent decree to pay $4,652,000 in restitution, $200,000 in civil penalties and $25,000 in attorney's fees."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-sec-charges","record":{"id":"c-sec-charges","kind":"attributed","text":"On March 14, 2018 the Securities and Exchange Commission charged Theranos Inc., its founder and CEO Elizabeth Holmes and its former President Ramesh \"Sunny\" Balwani with raising more than $700 million from investors from late 2013 to 2015 through an elaborate, years-long fraud in which they exaggerated or made false statements about the company's technology, business and financial performance. It filed two civil complaints in the U.S. District Court for the Northern District of California, San Jose Division: SEC v. Elizabeth Holmes and Theranos, Inc. (Case 5:18-cv-01602) and SEC v. Ramesh \"Sunny\" Balwani (Case 5:18-cv-01603).","source_ids":["src-002","src-003","src-007","src-008"],"entity_ids":["sec","theranos","holmes","balwani"],"qualification":"These are the SEC's charges, not findings of a court.","response":"Theranos and Holmes settled the same day without admitting or denying the allegations. The SEC said it would litigate its claims against Balwani, and a public radio report in September 2018 said that he continued to fight the charges.","outcome":"","adverse_subject_ids":["theranos","holmes","balwani"]},"reading":"Attributed: On March 14, 2018 the Securities and Exchange Commission charged Theranos Inc., its founder and CEO Elizabeth Holmes and its former President Ramesh \"Sunny\" Balwani with raising more than $700 million from investors from late 2013 to 2015 through an elaborate, years-long fraud in which they exaggerated or made false statements about the company's technology, business and financial performance. It filed two civil complaints in the U.S. District Court for the Northern District of California, San Jose Division: SEC v. Elizabeth Holmes and Theranos, Inc. (Case 5:18-cv-01602) and SEC v. Ramesh \"Sunny\" Balwani (Case 5:18-cv-01603)."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-sec-allegations","record":{"id":"c-sec-allegations","kind":"attributed","text":"The SEC alleged that Holmes, Balwani and Theranos made investors believe that Theranos had a commercially ready portable analyser able to run a full range of laboratory tests from a few drops of blood from a finger, while they knew that in its clinical laboratory the proprietary analyser performed only about 12 of the more than 200 tests on its patient menu and that the rest were run on third-party commercial analysers, some modified for fingerstick samples. It further alleged false claims that the technology had been deployed by the U.S. Department of Defense on the battlefield in Afghanistan and on medevac helicopters and that Theranos would generate more than $100 million of revenue in 2014, when its technology was never deployed by the Department and it earned a little more than $100,000 from operations that year.","source_ids":["src-002","src-007"],"entity_ids":["sec","holmes","balwani","theranos","dod"],"qualification":"Allegations of the SEC's complaints; Holmes and Theranos neither admitted nor denied them in their settlement.","response":"","outcome":""},"reading":"Attributed: The SEC alleged that Holmes, Balwani and Theranos made investors believe that Theranos had a commercially ready portable analyser able to run a full range of laboratory tests from a few drops of blood from a finger, while they knew that in its clinical laboratory the proprietary analyser performed only about 12 of the more than 200 tests on its patient menu and that the rest were run on third-party commercial analysers, some modified for fingerstick samples. It further alleged false claims that the technology had been deployed by the U.S. Department of Defense on the battlefield in Afghanistan and on medevac helicopters and that Theranos would generate more than $100 million of revenue in 2014, when its technology was never deployed by the Department and it earned a little more than $100,000 from operations that year."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-sec-relief-sought","record":{"id":"c-sec-relief-sought","kind":"fact","text":"In the complaint against Holmes and Theranos the SEC sought injunctions against future violations, a civil penalty from Holmes, a bar on her serving as an officer or director of any publicly listed company, the return of the shares she obtained in the period, including 18,897,137 Class B shares, and the relinquishment of her super-majority voting shares; against Balwani it sought an injunction, a civil penalty and an officer-and-director bar.","source_ids":["src-002","src-003"],"entity_ids":["sec","holmes","theranos","balwani"],"qualification":"","response":"","outcome":""},"reading":"Fact: In the complaint against Holmes and Theranos the SEC sought injunctions against future violations, a civil penalty from Holmes, a bar on her serving as an officer or director of any publicly listed company, the return of the shares she obtained in the period, including 18,897,137 Class B shares, and the relinquishment of her super-majority voting shares; against Balwani it sought an injunction, a civil penalty and an officer-and-director bar."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-sec-settlement","record":{"id":"c-sec-settlement","kind":"fact","text":"Theranos and Holmes agreed on March 14, 2018 to settle the SEC's fraud charges without admitting or denying the allegations: Holmes agreed to pay a $500,000 penalty, to be barred from serving as an officer or director of a public company for 10 years, to return the remaining 18.9 million shares she obtained during the fraud and to give up her voting control by converting her Class B shares into Class A shares. The settlements were subject to court approval.","source_ids":["src-007","src-075"],"entity_ids":["sec","theranos","holmes"],"qualification":"","response":"","outcome":"Judge Edward J. Davila signed final judgments against Elizabeth Anne Holmes and Theranos, Inc. on March 27, 2018 and the case was closed.","adverse_subject_ids":["theranos","holmes"]},"reading":"Fact: Theranos and Holmes agreed on March 14, 2018 to settle the SEC's fraud charges without admitting or denying the allegations: Holmes agreed to pay a $500,000 penalty, to be barred from serving as an officer or director of a public company for 10 years, to return the remaining 18.9 million shares she obtained during the fraud and to give up her voting control by converting her Class B shares into Class A shares. The settlements were subject to court approval."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-sec-balwani-case","record":{"id":"c-sec-balwani-case","kind":"fact","text":"The SEC said it would litigate its claims against Balwani in the Northern District of California. On July 2, 2018 the court ordered SEC v. Balwani (5:18-cv-01603) related to SEC v. Holmes and reassigned it to Judge Edward J. Davila.","source_ids":["src-075","src-007"],"entity_ids":["sec","balwani"],"qualification":"The final outcome of the SEC's case against Balwani is not documented in the retained record.","response":"","outcome":"","adverse_subject_ids":["balwani"]},"reading":"Fact: The SEC said it would litigate its claims against Balwani in the Northern District of California. On July 2, 2018 the court ordered SEC v. Balwani (5:18-cv-01603) related to SEC v. Holmes and reassigned it to Judge Edward J. Davila."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-sec-two-phase","record":{"id":"c-sec-two-phase","kind":"fact","text":"The SEC's complaint states that in 2012, after concerns at the national pharmacy chain it calls \"Pharmacy A\", the two companies modified their contract into a two-phase roll-out: until Theranos obtained regulatory approval for its analysers, samples from the chain's stores would be transported to centralised laboratories operated by Theranos and tested on its miniLab there, and Theranos opened and operated two such laboratories.","source_ids":["src-002"],"entity_ids":["sec","theranos"],"qualification":"The SEC complaint does not name the chain; the Delaware court's account of the Walgreens agreement of June 2012 likewise describes testing at two Theranos laboratories.","response":"","outcome":""},"reading":"Fact: The SEC's complaint states that in 2012, after concerns at the national pharmacy chain it calls \"Pharmacy A\", the two companies modified their contract into a two-phase roll-out: until Theranos obtained regulatory approval for its analysers, samples from the chain's stores would be transported to centralised laboratories operated by Theranos and tested on its miniLab there, and Theranos opened and operated two such laboratories."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-sec-prior-settlements","record":{"id":"c-sec-prior-settlements","kind":"fact","text":"The SEC's complaints record that in 2017 Theranos, Holmes and Balwani settled a lawsuit by an investor alleging securities fraud, and that Theranos settled a breach-of-contract suit by a national pharmacy chain it called \"Pharmacy A\".","source_ids":["src-003","src-002"],"entity_ids":["sec","theranos","holmes","balwani"],"qualification":"","response":"","outcome":""},"reading":"Fact: The SEC's complaints record that in 2017 Theranos, Holmes and Balwani settled a lawsuit by an investor alleging securities fraud, and that Theranos settled a breach-of-contract suit by a national pharmacy chain it called \"Pharmacy A\"."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-sec-retail-exit","record":{"id":"c-sec-retail-exit","kind":"fact","text":"According to the SEC's complaints, in 2016, after regulatory inspections of Theranos's clinical laboratories and manufacturing facility, Theranos and Holmes left the retail laboratory business to refocus on developing the miniLab, the two retail partners ended their relationships with Theranos, and Balwani left the company in May 2016.","source_ids":["src-002","src-003"],"entity_ids":["sec","theranos","holmes","balwani"],"qualification":"","response":"","outcome":""},"reading":"Fact: According to the SEC's complaints, in 2016, after regulatory inspections of Theranos's clinical laboratories and manufacturing facility, Theranos and Holmes left the retail laboratory business to refocus on developing the miniLab, the two retail partners ended their relationships with Theranos, and Balwani left the company in May 2016."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-crim-indictment-2018","record":{"id":"c-crim-indictment-2018","kind":"attributed","text":"On June 14, 2018 a federal grand jury in the Northern District of California indicted Elizabeth Holmes and Ramesh \"Sunny\" Balwani in connection with two multi-million-dollar schemes to promote Theranos (United States v. Elizabeth A. Holmes, et al., 18-CR-00258-EJD). Each was charged with two counts of conspiracy to commit wire fraud under 18 U.S.C. § 1349 and nine counts of wire fraud under 18 U.S.C. § 1343; the case was first assigned to U.S. District Judge Lucy H. Koh.","source_ids":["src-062","src-010","src-043","src-065","src-014","src-016"],"entity_ids":["united-states","holmes","balwani","theranos"],"qualification":"An indictment is an accusation, not a finding of guilt.","response":"Both pleaded not guilty. At Holmes's trial her lawyer Lance Wade told the jury that, despite some mistakes, leading a failed start-up did not make her a criminal.","outcome":"Tried separately, Holmes was convicted on January 3, 2022 of conspiracy and three counts of wire fraud on investors and acquitted of the patient counts, and Balwani was convicted on July 7, 2022 of all counts; the Ninth Circuit affirmed both convictions in 2025."},"reading":"Attributed: On June 14, 2018 a federal grand jury in the Northern District of California indicted Elizabeth Holmes and Ramesh \"Sunny\" Balwani in connection with two multi-million-dollar schemes to promote Theranos (United States v. Elizabeth A. Holmes, et al., 18-CR-00258-EJD). Each was charged with two counts of conspiracy to commit wire fraud under 18 U.S.C. § 1349 and nine counts of wire fraud under 18 U.S.C. § 1343; the case was first assigned to U.S. District Judge Lucy H. Koh."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-crim-superseding","record":{"id":"c-crim-superseding","kind":"attributed","text":"The indictment was superseded on July 14, 2020 and again on July 28, 2020. The third superseding indictment charged both defendants with conspiracy to commit wire fraud against investors from 2010 to 2015 (Count 1), conspiracy to commit wire fraud against patients from 2013 to 2016 (Count 2), six wire-fraud counts concerning investors who invested in 2013 and 2014 (Counts 3 to 8) and four wire-fraud counts concerning patients (Counts 9 to 12).","source_ids":["src-016","src-014"],"entity_ids":["united-states","holmes","balwani","theranos"],"qualification":"These were the government's charges; the juries' verdicts differed for the two defendants.","response":"","outcome":""},"reading":"Attributed: The indictment was superseded on July 14, 2020 and again on July 28, 2020. The third superseding indictment charged both defendants with conspiracy to commit wire fraud against investors from 2010 to 2015 (Count 1), conspiracy to commit wire fraud against patients from 2013 to 2016 (Count 2), six wire-fraud counts concerning investors who invested in 2013 and 2014 (Counts 3 to 8) and four wire-fraud counts concerning patients (Counts 9 to 12)."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-crim-investor-wires","record":{"id":"c-crim-investor-wires","kind":"fact","text":"The investor counts of the third superseding indictment are tied to wire transfers into Theranos's Comerica Bank account in Palo Alto: $99,990 on December 30, 2013 (Investor #1), $5,349,900 (Investor #6) and $4,875,000 (Investor #2) on December 31, 2013, $38,336,632 on February 6, 2014 (Investor #3), and $99,999,984 (Investor #4) and $5,999,997 (Investor #5) on October 31, 2014.","source_ids":["src-016"],"entity_ids":["theranos"],"qualification":"The indictment identifies the investors only by number; investor funds were deposited in the Comerica Bank account, according to the indictment.","response":"","outcome":""},"reading":"Fact: The investor counts of the third superseding indictment are tied to wire transfers into Theranos's Comerica Bank account in Palo Alto: $99,990 on December 30, 2013 (Investor #1), $5,349,900 (Investor #6) and $4,875,000 (Investor #2) on December 31, 2013, $38,336,632 on February 6, 2014 (Investor #3), and $99,999,984 (Investor #4) and $5,999,997 (Investor #5) on October 31, 2014."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-crim-holmes-verdict","record":{"id":"c-crim-holmes-verdict","kind":"fact","text":"On January 3, 2022 a jury convicted Holmes of conspiracy to defraud investors (Count 1) and three counts of wire fraud on individual investors (Counts 6 to 8), involving wire transfers totalling more than $140 million. It acquitted her of the patient-fraud conspiracy (Count 2) and three counts of fraud on patients (Counts 10 to 12), and could not reach a verdict on three investor counts concerning C-1 investors (Counts 3 to 5); a further patient count (Count 9) had been dismissed during the trial.","source_ids":["src-014","src-016","src-071"],"entity_ids":["holmes","united-states","theranos"],"qualification":"","response":"","outcome":"The amended judgment of May 30, 2023 recorded her as guilty on Counts 1, 6, 7 and 8, not guilty on Counts 2, 10, 11 and 12, and dismissed Counts 3, 4, 5 and 9.","adverse_subject_ids":["holmes"]},"reading":"Fact: On January 3, 2022 a jury convicted Holmes of conspiracy to defraud investors (Count 1) and three counts of wire fraud on individual investors (Counts 6 to 8), involving wire transfers totalling more than $140 million. It acquitted her of the patient-fraud conspiracy (Count 2) and three counts of fraud on patients (Counts 10 to 12), and could not reach a verdict on three investor counts concerning C-1 investors (Counts 3 to 5); a further patient count (Count 9) had been dismissed during the trial."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-crim-holmes-sentence","record":{"id":"c-crim-holmes-sentence","kind":"fact","text":"On November 18, 2022 U.S. District Judge Edward J. Davila sentenced Holmes to 135 months (11 years and 3 months) in federal prison and three years of supervised release, without a fine, and ordered her to surrender on April 27, 2023. The court found that the offence involved ten or more victims and caused a loss of $120 million, giving a guideline range of 135 to 168 months.","source_ids":["src-062","src-016"],"entity_ids":["holmes","united-states"],"qualification":"","response":"","outcome":"","adverse_subject_ids":["holmes"]},"reading":"Fact: On November 18, 2022 U.S. District Judge Edward J. Davila sentenced Holmes to 135 months (11 years and 3 months) in federal prison and three years of supervised release, without a fine, and ordered her to surrender on April 27, 2023. The court found that the offence involved ten or more victims and caused a loss of $120 million, giving a guideline range of 135 to 168 months."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-crim-balwani-verdict","record":{"id":"c-crim-balwani-verdict","kind":"fact","text":"Tried separately in a four-month trial, Balwani was convicted on July 7, 2022 on all twelve counts: conspiracy to defraud Theranos investors (Count 1), conspiracy to defraud Theranos patients (Count 2), investor wire fraud (Counts 3 to 8) and patient wire fraud (Counts 9 to 12).","source_ids":["src-014","src-016"],"entity_ids":["balwani","united-states","theranos"],"qualification":"","response":"","outcome":"","adverse_subject_ids":["balwani"]},"reading":"Fact: Tried separately in a four-month trial, Balwani was convicted on July 7, 2022 on all twelve counts: conspiracy to defraud Theranos investors (Count 1), conspiracy to defraud Theranos patients (Count 2), investor wire fraud (Counts 3 to 8) and patient wire fraud (Counts 9 to 12)."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-crim-balwani-sentence","record":{"id":"c-crim-balwani-sentence","kind":"fact","text":"On December 7, 2022 Judge Davila sentenced Balwani to 155 months (12 years and 11 months) in federal prison, to be followed by three years of supervised release, for fraud that, in the U.S. Attorney's words, risked patient health by misrepresenting the accuracy of Theranos's blood analysis and defrauded Theranos investors of millions of dollars; his guideline range was the same 135 to 168 months as Holmes's. His judgment (USDC Case Number CR-18-00258-002 EJD) imposes 155 months on each of Counts 1 to 12, to run concurrently, a special assessment of $1,200 and a monetary penalty of $25,000.","source_ids":["src-014","src-016"],"entity_ids":["balwani","united-states","theranos"],"qualification":"","response":"","outcome":"","adverse_subject_ids":["balwani"]},"reading":"Fact: On December 7, 2022 Judge Davila sentenced Balwani to 155 months (12 years and 11 months) in federal prison, to be followed by three years of supervised release, for fraud that, in the U.S. Attorney's words, risked patient health by misrepresenting the accuracy of Theranos's blood analysis and defrauded Theranos investors of millions of dollars; his guideline range was the same 135 to 168 months as Holmes's. His judgment (USDC Case Number CR-18-00258-002 EJD) imposes 155 months on each of Counts 1 to 12, to run concurrently, a special assessment of $1,200 and a monetary penalty of $25,000."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-crim-surrender","record":{"id":"c-crim-surrender","kind":"fact","text":"Balwani was ordered at sentencing to surrender on March 15, 2023, and in March 2023 Judge Davila denied his motion to remain free pending appeal; the second amended judgment in his case gives a surrender date of April 20, 2023. A business news site reported that Balwani reported to a California prison in April 2023 and Holmes to a Texas prison on May 30, 2023.","source_ids":["src-014","src-016","src-015","src-070","src-046"],"entity_ids":["balwani","holmes","united-states"],"qualification":"The sources give different surrender dates for Balwani, March 15 in the 2022 sentencing announcement and April 20, 2023 in the amended judgment; the press reported that he entered prison in April.","response":"","outcome":""},"reading":"Fact: Balwani was ordered at sentencing to surrender on March 15, 2023, and in March 2023 Judge Davila denied his motion to remain free pending appeal; the second amended judgment in his case gives a surrender date of April 20, 2023. A business news site reported that Balwani reported to a California prison in April 2023 and Holmes to a Texas prison on May 30, 2023."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-crim-doj-evidence","record":{"id":"c-crim-doj-evidence","kind":"attributed","text":"In announcing Balwani's sentence, the U.S. Attorney's Office summarised the trial evidence: although Theranos had no revenue in 2012 and 2013, Balwani and Holmes told investors in late 2013 and 2014 that it had hundreds of millions in revenue from pharmaceutical companies and the military, and Balwani conspired to induce Walgreens and Safeway to invest on the strength of false pharmaceutical endorsements and fantastical revenue projections.","source_ids":["src-014"],"entity_ids":["united-states","balwani","holmes","theranos","walgreen-co","safeway"],"qualification":"The prosecutor's summary of the evidence after the jury convicted Balwani on all counts.","response":"","outcome":""},"reading":"Attributed: In announcing Balwani's sentence, the U.S. Attorney's Office summarised the trial evidence: although Theranos had no revenue in 2012 and 2013, Balwani and Holmes told investors in late 2013 and 2014 that it had hundreds of millions in revenue from pharmaceutical companies and the military, and Balwani conspired to induce Walgreens and Safeway to invest on the strength of false pharmaceutical endorsements and fantastical revenue projections."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-crim-restitution","record":{"id":"c-crim-restitution","kind":"fact","text":"In May 2023 the district court ordered Holmes and Balwani, jointly and severally, to pay $452,047,268 in restitution: about $397 million to the twelve investors identified at sentencing and $54.5 million to two further victims, Safeway and Walgreens. The court credited amounts Theranos had already paid three investors in civil settlements but did not treat the residual value of Theranos shares as returned property.","source_ids":["src-016","src-071"],"entity_ids":["holmes","balwani","safeway","walgreen-co","united-states"],"qualification":"","response":"","outcome":""},"reading":"Fact: In May 2023 the district court ordered Holmes and Balwani, jointly and severally, to pay $452,047,268 in restitution: about $397 million to the twelve investors identified at sentencing and $54.5 million to two further victims, Safeway and Walgreens. The court credited amounts Theranos had already paid three investors in civil settlements but did not treat the residual value of Theranos shares as returned property."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-crim-restitution-payees","record":{"id":"c-crim-restitution-payees","kind":"fact","text":"The restitution schedule attached to Balwani's judgment lists, among the payees, Keith Rupert Murdoch ($124,999,997), RDV Corporation ($99,999,984), Peer Ventures Group ($93,499,912), PFM Funds ($52,639,998), Walgreens ($40,000,000), Safeway ($14,500,000), Lucas Venture Group ($7,570,005), Moseley Family Holdings ($5,999,997), Black Diamond Ventures ($5,349,900), Richard Kovacevich ($4,149,990), Hall Group ($1,875,000) and Mendenhall TF Partners ($1,312,500), together with two further individual investors.","source_ids":["src-016"],"entity_ids":["murdoch","rdv","peer-ventures","pfm-funds","walgreen-co","safeway","lucas-venture-group","moseley","black-diamond","kovacevich","hall-group","mendenhall","theranos"],"qualification":"The schedule's printed total reads $453,047,268.00, $1,000,000 more than the sum of its rows and the $452,047,268 ordered; the two further individual investors are private persons and are not named here.","response":"","outcome":""},"reading":"Fact: The restitution schedule attached to Balwani's judgment lists, among the payees, Keith Rupert Murdoch ($124,999,997), RDV Corporation ($99,999,984), Peer Ventures Group ($93,499,912), PFM Funds ($52,639,998), Walgreens ($40,000,000), Safeway ($14,500,000), Lucas Venture Group ($7,570,005), Moseley Family Holdings ($5,999,997), Black Diamond Ventures ($5,349,900), Richard Kovacevich ($4,149,990), Hall Group ($1,875,000) and Mendenhall TF Partners ($1,312,500), together with two further individual investors."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-crim-restitution-split","record":{"id":"c-crim-restitution-split","kind":"fact","text":"The HHS Departmental Appeals Board noted that Holmes's restitution obligation comprised $322,747,296 owed to business entities and $129,299,972 owed to individuals.","source_ids":["src-071"],"entity_ids":["holmes"],"qualification":"","response":"","outcome":""},"reading":"Fact: The HHS Departmental Appeals Board noted that Holmes's restitution obligation comprised $322,747,296 owed to business entities and $129,299,972 owed to individuals."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-crim-ninth-circuit","record":{"id":"c-crim-ninth-circuit","kind":"fact","text":"On February 24, 2025 a Ninth Circuit panel (Judges Schroeder, Nguyen and Nelson; opinion by Judge Nguyen) affirmed Holmes's and Balwani's convictions, their sentences and the $452 million restitution order (Nos. 22-10312, 22-10338, 23-1040, 23-1166 and 23-1167; 129 F.4th 636). On December 22, 2025 the court amended the opinion and denied Balwani's petitions for panel rehearing and rehearing en banc. On appeal Holmes was represented by Williams & Connolly LLP and John D. Cline, and Balwani by Corr Cronin LLP and Orrick Herrington & Sutcliffe LLP, among others.","source_ids":["src-016"],"entity_ids":["holmes","balwani","united-states"],"qualification":"","response":"","outcome":"","adverse_subject_ids":["holmes","balwani"]},"reading":"Fact: On February 24, 2025 a Ninth Circuit panel (Judges Schroeder, Nguyen and Nelson; opinion by Judge Nguyen) affirmed Holmes's and Balwani's convictions, their sentences and the $452 million restitution order (Nos. 22-10312, 22-10338, 23-1040, 23-1166 and 23-1167; 129 F.4th 636). On December 22, 2025 the court amended the opinion and denied Balwani's petitions for panel rehearing and rehearing en banc. On appeal Holmes was represented by Williams & Connolly LLP and John D. Cline, and Balwani by Corr Cronin LLP and Orrick Herrington & Sutcliffe LLP, among others."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-crim-holmes-rehearing","record":{"id":"c-crim-holmes-rehearing","kind":"fact","text":"A television news network reported that on May 8, 2025 the Ninth Circuit, in a four-sentence order, unanimously denied Holmes's petition for further hearings on her appeal.","source_ids":["src-070"],"entity_ids":["holmes","united-states"],"qualification":"","response":"","outcome":""},"reading":"Fact: A television news network reported that on May 8, 2025 the Ninth Circuit, in a four-sentence order, unanimously denied Holmes's petition for further hearings on her appeal."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-crim-balwani-cert","record":{"id":"c-crim-balwani-cert","kind":"fact","text":"Balwani petitioned the U.S. Supreme Court for a writ of certiorari on May 21, 2026 (No. 25-1330, Ramesh Sunny Balwani v. United States), after Justice Kagan extended the filing deadline; the United States waived its right to respond, and on October 5, 2026 the Court denied the petition, Justice Thomas taking no part.","source_ids":["src-057"],"entity_ids":["balwani","united-states"],"qualification":"","response":"","outcome":"","adverse_subject_ids":["balwani"]},"reading":"Fact: Balwani petitioned the U.S. Supreme Court for a writ of certiorari on May 21, 2026 (No. 25-1330, Ramesh Sunny Balwani v. United States), after Justice Kagan extended the filing deadline; the United States waived its right to respond, and on October 5, 2026 the Court denied the petition, Justice Thomas taking no part."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-crim-holmes-reduction","record":{"id":"c-crim-holmes-reduction","kind":"fact","text":"On March 26, 2026 Judge Davila reduced Holmes's sentence by one year, to 10¼ years, under a retroactive guideline amendment (U.S.S.G. § 4C1.1) available to defendants who did not personally cause substantial financial hardship, accepting her argument that no individual investor-victim had shown such hardship. The government opposed the reduction, arguing that she had not accepted responsibility, had paid minimal restitution and was advising her partner on raising capital for a start-up whose prototype diagnostic device resembled Theranos's; the court was not persuaded.","source_ids":["src-069"],"entity_ids":["holmes","united-states"],"qualification":"Reported through an excerpt of the decision published on a legal blog.","response":"","outcome":"","adverse_subject_ids":["holmes"]},"reading":"Fact: On March 26, 2026 Judge Davila reduced Holmes's sentence by one year, to 10¼ years, under a retroactive guideline amendment (U.S.S.G. § 4C1.1) available to defendants who did not personally cause substantial financial hardship, accepting her argument that no individual investor-victim had shown such hardship. The government opposed the reduction, arguing that she had not accepted responsibility, had paid minimal restitution and was advising her partner on raising capital for a start-up whose prototype diagnostic device resembled Theranos's; the court was not persuaded."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-crim-release-date","record":{"id":"c-crim-release-date","kind":"fact","text":"Before the 2026 reduction, a television news network reported in May 2025 that Holmes's original sentence of 11¼ years had been reduced for good behaviour and that she was scheduled for release in August 2032.","source_ids":["src-070"],"entity_ids":["holmes"],"qualification":"","response":"","outcome":""},"reading":"Fact: Before the 2026 reduction, a television news network reported in May 2025 that Holmes's original sentence of 11¼ years had been reduced for good behaviour and that she was scheduled for release in August 2032."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-exc-holmes","record":{"id":"c-exc-holmes","kind":"fact","text":"The HHS Office of Inspector General notified Holmes on October 26, 2023 of its intent to exclude her from federal health care programs because of her conviction, and on December 29, 2023 excluded her from Medicare, Medicaid and all federal health care programs under section 1128(a)(3) of the Social Security Act, extending the exclusion beyond the five-year minimum to 90 years on the basis of four aggravating factors.","source_ids":["src-071"],"entity_ids":["hhs-oig","holmes"],"qualification":"","response":"Holmes appealed, arguing that the exclusion rested on an interpretation of \"in connection with the delivery of health care services\" that depended on Chevron deference, that the 90-year period amounted to an unlawful lifetime bar, and that the amounts invested were an improper measure of the risk to federal programs.","outcome":"An administrative law judge upheld the exclusion on April 25, 2025, and the Departmental Appeals Board affirmed it on January 16, 2026 (Decision No. 3222), noting that the Ninth Circuit had affirmed her conviction and that the record contained no evidence of a further appeal.","adverse_subject_ids":["holmes"]},"reading":"Fact: The HHS Office of Inspector General notified Holmes on October 26, 2023 of its intent to exclude her from federal health care programs because of her conviction, and on December 29, 2023 excluded her from Medicare, Medicaid and all federal health care programs under section 1128(a)(3) of the Social Security Act, extending the exclusion beyond the five-year minimum to 90 years on the basis of four aggravating factors."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-exc-oig-release","record":{"id":"c-exc-oig-release","kind":"fact","text":"Announcing the exclusion, HHS-OIG said that Holmes was excluded for 90 years because of her January 2022 conviction for wire fraud and conspiracy to commit wire fraud against Theranos investors, and that it had previously excluded Theranos's President, Ramesh Balwani, for 90 years following his conviction for conspiracy to commit wire fraud against Theranos's patients and investors.","source_ids":["src-072"],"entity_ids":["hhs-oig","holmes","balwani","theranos"],"qualification":"","response":"","outcome":"","adverse_subject_ids":["holmes","balwani"]},"reading":"Fact: Announcing the exclusion, HHS-OIG said that Holmes was excluded for 90 years because of her January 2022 conviction for wire fraud and conspiracy to commit wire fraud against Theranos investors, and that it had previously excluded Theranos's President, Ramesh Balwani, for 90 years following his conviction for conspiracy to commit wire fraud against Theranos's patients and investors."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-civ-delaware-suits","record":{"id":"c-civ-delaware-suits","kind":"attributed","text":"In October 2016 the investors Partner Investments, L.P., PFM Healthcare Master Fund, L.P. (a Cayman Islands partnership) and PFM Healthcare Principals Fund, L.P. (a Delaware partnership) sued Theranos, Elizabeth Holmes and Ramesh Balwani in the Delaware Court of Chancery (C.A. No. 12816-VCL), asserting fraud, negligent misrepresentation, indemnification and violations of Delaware and California law. In April 2017 they brought a second action (C.A. No. 2017-0262-JTL) against Theranos, Holmes and directors Fabrizio Bonanni, William H. Foege and Daniel J. Warmenhoven for breach of fiduciary duty, self-dealing and waste.","source_ids":["src-032","src-083"],"entity_ids":["partner-investments","pfm-master","pfm-principals","theranos","holmes","balwani","bonanni","foege","warmenhoven"],"qualification":"These were the plaintiffs' claims; no court decided them on the merits.","response":"According to an online encyclopaedia, when the funds alleged in April 2017 that Theranos had threatened bankruptcy unless investors accepted extra shares instead of suing, Theranos said they had mischaracterised its exchange offer; on settling, its general counsel David Taylor said the company was confident it would have prevailed at trial.","outcome":"The parties settled in May 2017 and both actions were dismissed by stipulation. In April 2018 Vice Chancellor Laster denied a documentary filmmaker's request for access to unfiled deposition videos from the cases.","adverse_subject_ids":["theranos","holmes","balwani"]},"reading":"Attributed: In October 2016 the investors Partner Investments, L.P., PFM Healthcare Master Fund, L.P. (a Cayman Islands partnership) and PFM Healthcare Principals Fund, L.P. (a Delaware partnership) sued Theranos, Elizabeth Holmes and Ramesh Balwani in the Delaware Court of Chancery (C.A. No. 12816-VCL), asserting fraud, negligent misrepresentation, indemnification and violations of Delaware and California law. In April 2017 they brought a second action (C.A. No. 2017-0262-JTL) against Theranos, Holmes and directors Fabrizio Bonanni, William H. Foege and Daniel J. Warmenhoven for breach of fiduciary duty, self-dealing and waste."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-civ-indirect-class","record":{"id":"c-civ-indirect-class","kind":"attributed","text":"In an indirect-investor class action against Theranos, Inc. (N.D. Cal. No. 16-cv-06822-NC), filed as a class action on November 28, 2016, two indirect investors who had bought interests in funds that purchased Theranos stock sued Theranos, Holmes and Balwani for fraud, misrepresentation and market manipulation. The court dismissed the claim under California Corporations Code sections 25401 and 25501, excluded direct investors from the putative class, and refused a July 2017 request to certify a limited-fund class and freeze the defendants' funds over fears of insolvency after settlements in other cases.","source_ids":["src-073"],"entity_ids":["theranos","holmes","balwani"],"qualification":"Allegations of the plaintiffs; the case summary is taken from the court's order of May 31, 2018.","response":"","outcome":"On May 31, 2018 Magistrate Judge Nathanael M. Cousins denied class certification, finding that reliance issues defeated predominance and that individual actions were superior.","adverse_subject_ids":["theranos","holmes","balwani"]},"reading":"Attributed: In an indirect-investor class action against Theranos, Inc. (N.D. Cal. No. 16-cv-06822-NC), filed as a class action on November 28, 2016, two indirect investors who had bought interests in funds that purchased Theranos stock sued Theranos, Holmes and Balwani for fraud, misrepresentation and market manipulation. The court dismissed the claim under California Corporations Code sections 25401 and 25501, excluded direct investors from the putative class, and refused a July 2017 request to certify a limited-fund class and freeze the defendants' funds over fears of insolvency after settlements in other cases."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-civ-arizona-class","record":{"id":"c-civ-arizona-class","kind":"attributed","text":"Patients who bought Theranos tests brought a consolidated class action in the U.S. District Court for the District of Arizona, In re Arizona Theranos, Inc., Litigation (No. 2:16-cv-2138, consolidated with four other 2016 cases), against Theranos, Elizabeth Holmes, Ramesh Balwani, Walgreens Boots Alliance, Inc. and Walgreen Arizona Drug Company. The plaintiffs alleged among other things that Walgreens invested $140 million in Theranos, marketed its unreliable tests, concealed material information and performed the blood draws in its stores.","source_ids":["src-058"],"entity_ids":["theranos","holmes","balwani","wba","walgreen-az"],"qualification":"The plaintiffs' allegations as summarised by the court; Walgreens and Balwani denied all allegations when they settled.","response":"","outcome":"","adverse_subject_ids":["theranos","holmes","balwani","wba","walgreen-az"]},"reading":"Attributed: Patients who bought Theranos tests brought a consolidated class action in the U.S. District Court for the District of Arizona, In re Arizona Theranos, Inc., Litigation (No. 2:16-cv-2138, consolidated with four other 2016 cases), against Theranos, Elizabeth Holmes, Ramesh Balwani, Walgreens Boots Alliance, Inc. and Walgreen Arizona Drug Company. The plaintiffs alleged among other things that Walgreens invested $140 million in Theranos, marketed its unreliable tests, concealed material information and performed the blood draws in its stores."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-civ-arizona-dismissal-ruling","record":{"id":"c-civ-arizona-dismissal-ruling","kind":"fact","text":"On April 10, 2018 the Arizona court (Judge H. Russel Holland) granted the motions to dismiss in part and denied them in part. It dismissed without leave to amend the RICO claims based on mail fraud against all defendants and several plaintiffs' affirmative-misrepresentation claims against Walgreens and Theranos for lack of particularity, but allowed fraud-by-omission claims against all defendants, negligence, breach-of-contract and unjust-enrichment claims against Walgreens and Theranos, aiding-and-abetting claims against Walgreens and RICO claims based on wire fraud against all defendants to proceed.","source_ids":["src-058"],"entity_ids":["theranos","holmes","balwani","wba","walgreen-az"],"qualification":"","response":"","outcome":""},"reading":"Fact: On April 10, 2018 the Arizona court (Judge H. Russel Holland) granted the motions to dismiss in part and denied them in part. It dismissed without leave to amend the RICO claims based on mail fraud against all defendants and several plaintiffs' affirmative-misrepresentation claims against Walgreens and Theranos for lack of particularity, but allowed fraud-by-omission claims against all defendants, negligence, breach-of-contract and unjust-enrichment claims against Walgreens and Theranos, aiding-and-abetting claims against Walgreens and RICO claims based on wire fraud against all defendants to proceed."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-civ-consent-decree-not-moot","record":{"id":"c-civ-consent-decree-not-moot","kind":"fact","text":"The Arizona court held that the Attorney General's consent decree did not moot the consumers' claims: it repaid their out-of-pocket costs, but Walgreens, Holmes and Balwani had disgorged no profits and the decree did not address punitive damages.","source_ids":["src-058"],"entity_ids":["theranos","holmes","balwani","wba","az-ag"],"qualification":"","response":"","outcome":""},"reading":"Fact: The Arizona court held that the Attorney General's consent decree did not moot the consumers' claims: it repaid their out-of-pocket costs, but Walgreens, Holmes and Balwani had disgorged no profits and the decree did not address punitive damages."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-civ-arizona-settlement","record":{"id":"c-civ-arizona-settlement","kind":"fact","text":"The court certified a class of purchasers of Theranos tests by an order of March 6, 2020. All parties except Elizabeth Holmes settled: Walgreens Boots Alliance, Inc. and Walgreen Arizona Drug Co. agreed to pay $44 million into a settlement fund, Ramesh Balwani withdrew his claims to Theranos's remaining assets, and Theranos (assignment for the benefit of creditors), LLC, the entity holding the remaining assets of the dissolved company, allocated about $1.33 million. U.S. District Judge David G. Campbell gave final approval on February 6, 2024.","source_ids":["src-074","src-080","src-116"],"entity_ids":["wba","walgreen-az","balwani","theranos-abc","theranos","holmes"],"qualification":"","response":"Walgreens and Balwani deny all allegations in the lawsuit.","outcome":"The settlement created a non-reversionary $44 million fund intended to repay consumers about double their Theranos testing costs, with about $1,000 more for subclass members who had blood drawn at Walgreens.","adverse_subject_ids":["theranos","holmes","balwani","wba","walgreen-az"]},"reading":"Fact: The court certified a class of purchasers of Theranos tests by an order of March 6, 2020. All parties except Elizabeth Holmes settled: Walgreens Boots Alliance, Inc. and Walgreen Arizona Drug Co. agreed to pay $44 million into a settlement fund, Ramesh Balwani withdrew his claims to Theranos's remaining assets, and Theranos (assignment for the benefit of creditors), LLC, the entity holding the remaining assets of the dissolved company, allocated about $1.33 million. U.S. District Judge David G. Campbell gave final approval on February 6, 2024."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wd-fortress-entity","record":{"id":"c-wd-fortress-entity","kind":"fact","text":"Fortress Investment Group LLC is a Delaware company registered with the SEC under Central Index Key 0001380393, with its offices at 1345 Avenue of the Americas, 46th Floor, New York.","source_ids":["src-025"],"entity_ids":["fortress"],"qualification":"","response":"","outcome":""},"reading":"Fact: Fortress Investment Group LLC is a Delaware company registered with the SEC under Central Index Key 0001380393, with its offices at 1345 Avenue of the Americas, 46th Floor, New York."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wd-loan","record":{"id":"c-wd-loan","kind":"fact","text":"According to the SEC's complaint, in late 2017, on the verge of bankruptcy, Theranos obtained a term loan secured on the value of its patent portfolio that it expected to fund about one more year of work on the miniLab. Theranos's 2018 letter to stockholders identifies the lender as Fortress, and David Taylor's law-firm profile says he led the team that secured $100 million of debt financing before the company was wound down.","source_ids":["src-002","src-009","src-089"],"entity_ids":["theranos","fortress","david-taylor"],"qualification":"","response":"","outcome":""},"reading":"Fact: According to the SEC's complaint, in late 2017, on the verge of bankruptcy, Theranos obtained a term loan secured on the value of its patent portfolio that it expected to fund about one more year of work on the miniLab. Theranos's 2018 letter to stockholders identifies the lender as Fortress, and David Taylor's law-firm profile says he led the team that secured $100 million of debt financing before the company was wound down."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wd-loan-terms-attributed","record":{"id":"c-wd-loan-terms-attributed","kind":"attributed","text":"A 2020 law-review article states that by December 2017 Fortress Investment Group, a division of SoftBank, lent Theranos $100 million secured in part by its patent portfolio, and notes news reports that Fortress disbursed only $65 million before Theranos defaulted; a trade journal, citing a national newspaper, reported a $65 million loan and a covenant allowing Fortress to foreclose if Theranos's cash fell below a threshold. An online encyclopaedia states that the loan was made in exchange for 4% of the company.","source_ids":["src-038","src-030","src-083"],"entity_ids":["fortress","theranos"],"qualification":"Secondary accounts; the loan agreement itself is not in the record, and the amount drawn and any equity component are reported rather than documented.","response":"","outcome":""},"reading":"Attributed: A 2020 law-review article states that by December 2017 Fortress Investment Group, a division of SoftBank, lent Theranos $100 million secured in part by its patent portfolio, and notes news reports that Fortress disbursed only $65 million before Theranos defaulted; a trade journal, citing a national newspaper, reported a $65 million loan and a covenant allowing Fortress to foreclose if Theranos's cash fell below a threshold. An online encyclopaedia states that the loan was made in exchange for 4% of the company."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wd-patent-assignment","record":{"id":"c-wd-patent-assignment","kind":"fact","text":"On December 11, 2017 Theranos Inc. assigned its interest in 284 patent properties to Theranos IP Company, LLC, of 7333 Gateway Boulevard, Newark, California; the assignment was recorded at the USPTO on December 12, 2017 (Reel/Frame 44838/0909). The assigned patents include U.S. Patent 9,858,660 on collecting and transmitting assay results, issued on January 2, 2018, with Elizabeth Holmes as inventor.","source_ids":["src-033"],"entity_ids":["theranos","tipc","holmes"],"qualification":"","response":"","outcome":""},"reading":"Fact: On December 11, 2017 Theranos Inc. assigned its interest in 284 patent properties to Theranos IP Company, LLC, of 7333 Gateway Boulevard, Newark, California; the assignment was recorded at the USPTO on December 12, 2017 (Reel/Frame 44838/0909). The assigned patents include U.S. Patent 9,858,660 on collecting and transmitting assay results, issued on January 2, 2018, with Elizabeth Holmes as inventor."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wd-security-interest","record":{"id":"c-wd-security-interest","kind":"fact","text":"On the same day Theranos IP Company, LLC granted a security interest in the 284 patent properties to Fortress Credit Corp., care of Fortress Investment Group at 1345 Avenue of the Americas, New York; the 128-page instrument was recorded on December 12, 2017 (Reel/Frame 44839/0568), with Kirkland & Ellis LLP as correspondent for both recordings.","source_ids":["src-035"],"entity_ids":["tipc","fortress-credit","fortress"],"qualification":"","response":"","outcome":""},"reading":"Fact: On the same day Theranos IP Company, LLC granted a security interest in the 284 patent properties to Fortress Credit Corp., care of Fortress Investment Group at 1345 Avenue of the Americas, New York; the 128-page instrument was recorded on December 12, 2017 (Reel/Frame 44839/0568), with Kirkland & Ellis LLP as correspondent for both recordings."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wd-tipc-subsidiary-attributed","record":{"id":"c-wd-tipc-subsidiary-attributed","kind":"attributed","text":"The law-review article states that when Fortress made its loan in 2017 Theranos assigned its patents to a wholly owned subsidiary, Theranos IP Company LLC (TIPC), and granted Fortress a security interest in the portfolio; Theranos's 2018 letter to stockholders says its intellectual property was owned by an unnamed \"special purpose subsidiary\".","source_ids":["src-038","src-009"],"entity_ids":["theranos","tipc","fortress"],"qualification":"The article names Theranos IP Company as the subsidiary; the company letter does not name it, and no registry record of Theranos IP Company was retrieved.","response":"","outcome":""},"reading":"Attributed: The law-review article states that when Fortress made its loan in 2017 Theranos assigned its patents to a wholly owned subsidiary, Theranos IP Company LLC (TIPC), and granted Fortress a security interest in the portfolio; Theranos's 2018 letter to stockholders says its intellectual property was owned by an unnamed \"special purpose subsidiary\"."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wd-headcount-attributed","record":{"id":"c-wd-headcount-attributed","kind":"attributed","text":"According to an online encyclopaedia, Theranos laid off most of its remaining workers on April 10, 2018, leaving fewer than 25 employees, against about 800 at its peak.","source_ids":["src-083","src-009"],"entity_ids":["theranos"],"qualification":"An encyclopaedia account; Theranos's September 2018 letter confirms that it had updated stockholders on April 10, 2018 about an imminent cash shortage.","response":"","outcome":""},"reading":"Attributed: According to an online encyclopaedia, Theranos laid off most of its remaining workers on April 10, 2018, leaving fewer than 25 employees, against about 800 at its peak."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wd-letter-2018","record":{"id":"c-wd-letter-2018","kind":"fact","text":"In a letter to stockholders in September 2018, CEO and General Counsel David Taylor wrote that Theranos was in default under the Fortress credit facility, that Fortress had the right to foreclose on all of the company's assets, including the intellectual property owned by a \"special purpose subsidiary\", and that Theranos owed at least $60 million to unsecured creditors. After an unsuccessful search for new investment and a sale through the investment bank Jefferies, the company proposed a settlement under which Fortress would take the company's interest in the subsidiary and its intellectual property but give up its rights to the remaining cash, estimated at about $5 million net of fees, for distribution to unsecured creditors.","source_ids":["src-009"],"entity_ids":["theranos","david-taylor","fortress","tipc"],"qualification":"","response":"","outcome":"","adverse_subject_ids":["theranos"]},"reading":"Fact: In a letter to stockholders in September 2018, CEO and General Counsel David Taylor wrote that Theranos was in default under the Fortress credit facility, that Fortress had the right to foreclose on all of the company's assets, including the intellectual property owned by a \"special purpose subsidiary\", and that Theranos owed at least $60 million to unsecured creditors. After an unsuccessful search for new investment and a sale through the investment bank Jefferies, the company proposed a settlement under which Fortress would take the company's interest in the subsidiary and its intellectual property but give up its rights to the remaining cash, estimated at about $5 million net of fees, for distribution to unsecured creditors."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wd-abc-plan","record":{"id":"c-wd-abc-plan","kind":"fact","text":"The letter said Theranos intended to make an assignment for the benefit of creditors under California law and then file a certificate of dissolution under Delaware law, to seek board and shareholder consent that week and to proceed from Monday, September 10, 2018; because the cash was far from sufficient to pay creditors in full, there would be no distributions to shareholders.","source_ids":["src-009","src-008"],"entity_ids":["theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: The letter said Theranos intended to make an assignment for the benefit of creditors under California law and then file a certificate of dissolution under Delaware law, to seek board and shareholder consent that week and to proceed from Monday, September 10, 2018; because the cash was far from sufficient to pay creditors in full, there would be no distributions to shareholders."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wd-dissolution-2018","record":{"id":"c-wd-dissolution-2018","kind":"fact","text":"A public radio network reported on September 5, 2018 that David Taylor, who had become CEO in June, said Theranos would dissolve after attempting to pay creditors with its remaining cash of about $5 million.","source_ids":["src-008"],"entity_ids":["david-taylor","theranos"],"qualification":"","response":"","outcome":""},"reading":"Fact: A public radio network reported on September 5, 2018 that David Taylor, who had become CEO in June, said Theranos would dissolve after attempting to pay creditors with its remaining cash of about $5 million."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wd-general-assignment","record":{"id":"c-wd-general-assignment","kind":"fact","text":"On September 12, 2018 Theranos, Inc. executed a General Assignment of all its assets and liabilities to Theranos (assignment for the benefit of creditors), LLC (\"Theranos ABC\"), a California limited liability company acting solely as assignee for the benefit of Theranos's creditors; its manager, Michael A. Maidy, signed a 2023 settlement on its behalf.","source_ids":["src-080"],"entity_ids":["theranos","theranos-abc","michael-maidy"],"qualification":"","response":"","outcome":"","adverse_subject_ids":["theranos"]},"reading":"Fact: On September 12, 2018 Theranos, Inc. executed a General Assignment of all its assets and liabilities to Theranos (assignment for the benefit of creditors), LLC (\"Theranos ABC\"), a California limited liability company acting solely as assignee for the benefit of Theranos's creditors; its manager, Michael A. Maidy, signed a 2023 settlement on its behalf."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wd-shutdown-attributed","record":{"id":"c-wd-shutdown-attributed","kind":"attributed","text":"According to an online encyclopaedia, Theranos told investors by email on September 4, 2018 that it would cease operations after failing to find a buyer, most remaining employees having been laid off on August 31, while David Taylor and a few staff stayed on for some days; on September 12 it transferred its patents to Fortress Investment Group in exchange for its cash being distributed to creditors.","source_ids":["src-083"],"entity_ids":["theranos","david-taylor","fortress"],"qualification":"An encyclopaedia summary; the September 12, 2018 date matches the General Assignment recorded in the 2023 settlement agreement.","response":"","outcome":""},"reading":"Attributed: According to an online encyclopaedia, Theranos told investors by email on September 4, 2018 that it would cease operations after failing to find a buyer, most remaining employees having been laid off on August 31, while David Taylor and a few staff stayed on for some days; on September 12 it transferred its patents to Fortress Investment Group in exchange for its cash being distributed to creditors."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wd-patents-to-fortress","record":{"id":"c-wd-patents-to-fortress","kind":"attributed","text":"The law-review article states that when Theranos defaulted on the loan conditions it assigned ownership of TIPC to Fortress, and that when Theranos ceased operations in September 2018 Fortress took ownership of more than 700 Theranos patents worldwide.","source_ids":["src-038"],"entity_ids":["theranos","tipc","fortress"],"qualification":"A secondary account citing press reports; the transfer documents are not in the record.","response":"","outcome":""},"reading":"Attributed: The law-review article states that when Theranos defaulted on the loan conditions it assigned ownership of TIPC to Fortress, and that when Theranos ceased operations in September 2018 Fortress took ownership of more than 700 Theranos patents worldwide."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wd-labrador-rename-attributed","record":{"id":"c-wd-labrador-rename-attributed","kind":"attributed","text":"According to the law-review article, in March 2020, a few days before suing BioFire and bioMérieux, Fortress changed the name of Theranos IP Company to Labrador Diagnostics LLC.","source_ids":["src-038"],"entity_ids":["tipc","labrador","fortress","biofire","biomerieux"],"qualification":"Stated by a law-review article; the research did not retrieve a registry record of the name change. Patents issued in 2020 still name Theranos IP Company, LLC as assignee in a patent database, and Labrador's complaint says it owns the patents in suit by assignment.","response":"","outcome":""},"reading":"Attributed: According to the law-review article, in March 2020, a few days before suing BioFire and bioMérieux, Fortress changed the name of Theranos IP Company to Labrador Diagnostics LLC."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wd-tipc-patents-2020","record":{"id":"c-wd-tipc-patents-2020","kind":"fact","text":"Patents continued to issue to Theranos IP Company, LLC after the wind-down, including U.S. Patent 10,533,994 on sample processing and fluid control (January 14, 2020) and U.S. Patents 10,634,667 and 10,670,588 on modular point-of-care devices (April and June 2020), with Elizabeth A. Holmes among the named inventors. Labrador Diagnostics' March 2020 complaint asserts ownership of the '994 patent by assignment.","source_ids":["src-064"],"entity_ids":["tipc","holmes","labrador"],"qualification":"","response":"","outcome":""},"reading":"Fact: Patents continued to issue to Theranos IP Company, LLC after the wind-down, including U.S. Patent 10,533,994 on sample processing and fluid control (January 14, 2020) and U.S. Patents 10,634,667 and 10,670,588 on modular point-of-care devices (April and June 2020), with Elizabeth A. Holmes among the named inventors. Labrador Diagnostics' March 2020 complaint asserts ownership of the '994 patent by assignment."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wd-labrador-suit","record":{"id":"c-wd-labrador-suit","kind":"fact","text":"On March 9, 2020 Labrador Diagnostics LLC, a Delaware limited liability company, sued BioFire Diagnostics, LLC and its parent bioMérieux S.A. (described in the complaint, on information and belief, as a Delaware company and a French company respectively) in the U.S. District Court for the District of Delaware (Case 1:20-cv-00348-MN) for infringing U.S. Patents 8,283,155 (\"Point-of-Care Fluidic Systems and Uses Thereof\", issued October 9, 2012) and 10,533,994, which it said it owned by assignment. The complaint alleged that bioMérieux, Inc. had agreed with the former owner of the '155 patent on or about June 5, 2018 to inspect patent assets.","source_ids":["src-052"],"entity_ids":["labrador","biofire","biomerieux"],"qualification":"","response":"","outcome":""},"reading":"Fact: On March 9, 2020 Labrador Diagnostics LLC, a Delaware limited liability company, sued BioFire Diagnostics, LLC and its parent bioMérieux S.A. (described in the complaint, on information and belief, as a Delaware company and a French company respectively) in the U.S. District Court for the District of Delaware (Case 1:20-cv-00348-MN) for infringing U.S. Patents 8,283,155 (\"Point-of-Care Fluidic Systems and Uses Thereof\", issued October 9, 2012) and 10,533,994, which it said it owned by assignment. The complaint alleged that bioMérieux, Inc. had agreed with the former owner of the '155 patent on or about June 5, 2018 to inspect patent assets."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-wd-labrador-reaction","record":{"id":"c-wd-labrador-reaction","kind":"attributed","text":"A technology news site reported that the suit against BioFire and bioMérieux sought to block BioFire from using its technology, apparently including newly developed COVID-19 tests, and quoted Stanford patent scholar Mark Lemley's sharp criticism of the suit's timing. Facing criticism, Labrador announced royalty-free licences for companies developing COVID-19 tests and said it had not known BioFire was working on a coronavirus test.","source_ids":["src-117","src-063"],"entity_ids":["labrador","biofire","biomerieux","fortress"],"qualification":"Press account and commentary; Labrador's response is its own statement as reported.","response":"Labrador said it had not known that BioFire was developing a coronavirus test when it sued, and offered royalty-free licences for COVID-19 tests.","outcome":"Labrador filed a notice of voluntary dismissal on June 28, 2020 and the case was closed."},"reading":"Attributed: A technology news site reported that the suit against BioFire and bioMérieux sought to block BioFire from using its technology, apparently including newly developed COVID-19 tests, and quoted Stanford patent scholar Mark Lemley's sharp criticism of the suit's timing. Facing criticism, Labrador announced royalty-free licences for companies developing COVID-19 tests and said it had not known BioFire was working on a coronavirus test."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-aft-haemanthus","record":{"id":"c-aft-haemanthus","kind":"attributed","text":"Haemanthus is a privately held diagnostics start-up based in Austin, Texas, founded and run by Billy Evans, Elizabeth Holmes's partner. According to an online encyclopaedia, it was incorporated in Delaware in February 2024 (Evans having listed himself as its chief executive since 2022), says it is developing a device to test blood, urine and saliva for disease, similar to Theranos's Edison, and holds one patent filed in January 2025; the company reported raising $3.5 million from friends and family and seeking a further $15 million.","source_ids":["src-077","src-085"],"entity_ids":["haemanthus","billy-evans","holmes"],"qualification":"Company and encyclopaedia accounts; two encyclopaedia articles differ on the incorporation date (February 2024 and by late 2023), and the research did not retrieve a registry record of Haemanthus.","response":"","outcome":""},"reading":"Attributed: Haemanthus is a privately held diagnostics start-up based in Austin, Texas, founded and run by Billy Evans, Elizabeth Holmes's partner. According to an online encyclopaedia, it was incorporated in Delaware in February 2024 (Evans having listed himself as its chief executive since 2022), says it is developing a device to test blood, urine and saliva for disease, similar to Theranos's Edison, and holds one patent filed in January 2025; the company reported raising $3.5 million from friends and family and seeking a further $15 million."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-aft-holmes-advice","record":{"id":"c-aft-holmes-advice","kind":"attributed","text":"A public radio network reported on May 10, 2025, citing sources, that Holmes had been advising Evans on Haemanthus from prison, that the nature of her support was unclear and that she did not plan to take a formal role; a business magazine reported that the company said she has no \"formal\" role, and a person familiar with the business told a national newspaper that she is not involved. Haemanthus acknowledged on X that its CEO is Holmes's partner and said, \"This is not Theranos 2.0.\"","source_ids":["src-098","src-085","src-077"],"entity_ids":["holmes","haemanthus","billy-evans"],"qualification":"Reports based on unnamed sources and the company's own posts; a lawyer for Holmes did not reply to the radio network's request for comment. Her SEC bar covers officer and director roles in public companies only, and Haemanthus is private.","response":"Haemanthus said Holmes has no formal role and that it is \"not Theranos 2.0\".","outcome":""},"reading":"Attributed: A public radio network reported on May 10, 2025, citing sources, that Holmes had been advising Evans on Haemanthus from prison, that the nature of her support was unclear and that she did not plan to take a formal role; a business magazine reported that the company said she has no \"formal\" role, and a person familiar with the business told a national newspaper that she is not involved. Haemanthus acknowledged on X that its CEO is Holmes's partner and said, \"This is not Theranos 2.0.\""}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-aft-government-argument","record":{"id":"c-aft-government-argument","kind":"attributed","text":"In opposing the 2026 sentence reduction, the government argued that Holmes had been advising her partner on raising capital for a start-up whose prototype diagnostic device it said bore striking similarities to Theranos's.","source_ids":["src-069"],"entity_ids":["holmes","united-states"],"qualification":"The government's argument as quoted in the court's decision.","response":"","outcome":"The court found that the scrutiny her notoriety brings reduced the likelihood that she could reoffend in the same way, and granted the reduction."},"reading":"Attributed: In opposing the 2026 sentence reduction, the government argued that Holmes had been advising her partner on raising capital for a start-up whose prototype diagnostic device it said bore striking similarities to Theranos's."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-bal-commercebid","record":{"id":"c-bal-commercebid","kind":"fact","text":"Under an Agreement and Plan of Reorganization of November 4, 1999, filed with Commerce One, Inc.'s Form 8-K, COMMERCEBID.COM, Inc., a Delaware corporation whose principal shareholders included its chief executive Liron Petrushka and Ramesh Balwani, was to merge into a wholly owned subsidiary of Commerce One and become its wholly owned subsidiary in exchange for up to 785,714 shares of Commerce One common stock.","source_ids":["src-044"],"entity_ids":["balwani","commercebid","commerce-one"],"qualification":"","response":"","outcome":""},"reading":"Fact: Under an Agreement and Plan of Reorganization of November 4, 1999, filed with Commerce One, Inc.'s Form 8-K, COMMERCEBID.COM, Inc., a Delaware corporation whose principal shareholders included its chief executive Liron Petrushka and Ramesh Balwani, was to merge into a wholly owned subsidiary of Commerce One and become its wholly owned subsidiary in exchange for up to 785,714 shares of Commerce One common stock."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-bal-commerce-one-role","record":{"id":"c-bal-commerce-one-role","kind":"fact","text":"Commerce One's 1999 announcement stated that CommerceBid.com's CEO Liron Petrushka and President Ramesh Balwani would join Commerce One's executive management team, reporting to the vice president of the Commerce One Global Trading Web.","source_ids":["src-044"],"entity_ids":["balwani","commercebid","commerce-one"],"qualification":"","response":"","outcome":""},"reading":"Fact: Commerce One's 1999 announcement stated that CommerceBid.com's CEO Liron Petrushka and President Ramesh Balwani would join Commerce One's executive management team, reporting to the vice president of the Commerce One Global Trading Web."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"c-bal-career-attributed","record":{"id":"c-bal-career-attributed","kind":"attributed","text":"A newspaper reported in 2022 that Balwani began in software as a sales manager at Microsoft, that CommerceBid.com was reportedly bought by Commerce One for $225 million and that he left the business with almost $40 million, and that he met Holmes while studying for a master's degree in computer science at Stanford University, leaving the programme in 2008 and joining her company as president in 2009, later becoming chief operating officer.","source_ids":["src-068"],"entity_ids":["balwani","commercebid","commerce-one","holmes","theranos"],"qualification":"Press account relying on earlier reports; the purchase price and his proceeds are not documented in the Commerce One filing, which gives the consideration in shares.","response":"","outcome":""},"reading":"Attributed: A newspaper reported in 2022 that Balwani began in software as a sales manager at Microsoft, that CommerceBid.com was reportedly bought by Commerce One for $225 million and that he left the business with almost $40 million, and that he met Holmes while studying for a master's degree in computer science at Stanford University, leaving the programme in 2008 and joining her company as president in 2009, later becoming chief operating officer."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-3dbb00fb237ef3fdf297efc9","record":{"id":"display-claim-3dbb00fb237ef3fdf297efc9","kind":"analysis","text":"The dossier follows Theranos through confirmed legal entities, roles and dates: its Delaware incorporation and registrations, the executives and the dated board lists, the funding rounds and Holmes's Class B control, the Walgreens and Safeway agreements, the FDA and CMS findings and sanctions at its laboratories, the investor, patient and Walgreens suits, the SEC actions, the criminal case through the 2026 Supreme Court denial and sentence reduction, the HHS exclusions, and the Fortress loan, patent transfers and assignment for the benefit of creditors that ended the company. Each allegation is kept with the defendant's answer and the result found in the record.","source_ids":["src-002","src-016","src-071","src-072","src-086","src-004","src-001","src-034","src-111","src-113","src-096","src-083","src-014","src-006","src-009","src-028","src-029","src-036","src-041","src-055","src-079","src-078","src-032","src-042","src-059","src-058","src-031","src-003","src-007","src-008","src-075","src-062","src-010","src-043","src-065","src-057","src-089","src-033","src-038","src-021","src-080","src-064","src-052","src-117","src-063"],"entity_ids":["theranos","holmes","casey-mcglynn","dhawan","balwani","cms","daniel-young","walgreen-co","safeway","heather-king","fda","partner-investments","pfm-master","pfm-principals","bonanni","foege","warmenhoven","wba","walgreen-az","az-ag","sec","united-states","fortress","david-taylor","tipc","theranos-abc","michael-maidy","labrador","biofire","biomerieux"],"premise_claim_ids":["c-id-founding-date","c-ld-holmes-ceo","c-id-incorporation","c-id-capital-2004","c-id-california-qualification","c-id-sec-registrant","c-id-sec-filings","c-id-form-d-2010","c-id-addresses-registry","c-id-moves-attributed","c-id-principal-places","c-id-florida","c-id-registrations-attributed","c-id-trademarks-attributed","c-lab-operating-period","c-lab-newark-clia","c-lab-other-labs","c-wag-msa-2012","c-wag-pilot","c-wag-2010-representations","c-prt-safeway-trex","c-fin-financial-position","c-fin-c1-c2","c-fin-class-b","c-lab-fda-483","c-lab-cms-survey","c-wag-breach-notice","c-lab-cms-sanctions","c-civ-delaware-suits","c-wag-suit-2016","c-civ-arizona-class","c-lab-az-ag","c-sec-charges","c-sec-settlement","c-crim-indictment-2018","c-crim-holmes-verdict","c-crim-balwani-verdict","c-crim-holmes-sentence","c-crim-balwani-sentence","c-crim-restitution","c-crim-ninth-circuit","c-crim-balwani-cert","c-wd-loan","c-wd-patent-assignment","c-wd-tipc-subsidiary-attributed","c-ld-taylor-ceo","c-wd-letter-2018","c-wd-general-assignment","c-wd-tipc-patents-2020","c-wd-labrador-suit","c-wd-labrador-reaction"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The dossier follows Theranos through confirmed legal entities, roles and dates: its Delaware incorporation and registrations, the executives and the dated board lists, the funding rounds and Holmes's Class B control, the Walgreens and Safeway agreements, the FDA and CMS findings and sanctions at its laboratories, the investor, patient and Walgreens suits, the SEC actions, the criminal case through the 2026 Supreme Court denial and sentence reduction, the HHS exclusions, and the Fortress loan, patent transfers and assignment for the benefit of creditors that ended the company. Each allegation is kept with the defendant's answer and the result found in the record."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-9a9f7522129c58ed2c6b883c","record":{"id":"display-claim-9a9f7522129c58ed2c6b883c","kind":"analysis","text":"Elizabeth Holmes founded Theranos in 2003, the year to which the SEC, the Justice Department and the federal courts date the company, and was its chief executive officer until 2018. The legal entity was incorporated in Delaware as RealTime Cures, Inc. on April 13, 2004. A restated certificate signed by Holmes as President and filed on December 15, 2004 under Delaware file number 3789976 renamed it Theranos, Inc. and authorised 53,500,000 shares with a par value of $0.0001: 40,000,000 common shares and 13,500,000 Series A Preferred shares convertible at $0.75. In California, where Theranos was qualified to do business, an amended statement signed by J. Casey McGlynn as Secretary recorded the change of name.","source_ids":["src-002","src-016","src-071","src-072","src-086"],"entity_ids":["theranos","holmes","casey-mcglynn"],"premise_claim_ids":["c-id-founding-date","c-ld-holmes-ceo","c-id-incorporation","c-id-capital-2004","c-id-california-qualification"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Elizabeth Holmes founded Theranos in 2003, the year to which the SEC, the Justice Department and the federal courts date the company, and was its chief executive officer until 2018. The legal entity was incorporated in Delaware as RealTime Cures, Inc. on April 13, 2004. A restated certificate signed by Holmes as President and filed on December 15, 2004 under Delaware file number 3789976 renamed it Theranos, Inc. and authorised 53,500,000 shares with a par value of $0.0001: 40,000,000 common shares and 13,500,000 Series A Preferred shares convertible at $0.75. In California, where Theranos was qualified to do business, an amended statement signed by J. Casey McGlynn as Secretary recorded the change of name."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-4452710545fbfe813fbe721d","record":{"id":"display-claim-4452710545fbfe813fbe721d","kind":"analysis","text":"Theranos never became a public company. The SEC's EDGAR record for Central Index Key 0001313697 gives employer identification number 20-1231826, Delaware incorporation, a December 31 fiscal year end and no ticker or exchange. Its filings are seven paper Regulation D notices from January 2005 to November 2006 and two electronic Form D notices of private offerings, filed on July 8, 2010 and May 30, 2017; there are no annual or quarterly reports, and the Ninth Circuit noted that its shares were not publicly traded. The 2010 Form D recorded the former name RealTime Cures, Inc.","source_ids":["src-004","src-016","src-001"],"entity_ids":["theranos"],"premise_claim_ids":["c-id-sec-registrant","c-id-sec-filings","c-id-form-d-2010"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Theranos never became a public company. The SEC's EDGAR record for Central Index Key 0001313697 gives employer identification number 20-1231826, Delaware incorporation, a December 31 fiscal year end and no ticker or exchange. Its filings are seven paper Regulation D notices from January 2005 to November 2006 and two electronic Form D notices of private offerings, filed on July 8, 2010 and May 30, 2017; there are no annual or quarterly reports, and the Ninth Circuit noted that its shares were not publicly traded. The 2010 Form D recorded the former name RealTime Cures, Inc."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-d33fd4a3143bbee88ffa2c5a","record":{"id":"display-claim-d33fd4a3143bbee88ffa2c5a","kind":"analysis","text":"The company's address changed as it grew. Patent assignment records give 1430 O'Brien Drive in Menlo Park in 2005 and later 3200 Hillview Avenue in Palo Alto, the principal place of business also given in the 2010 Form D. Theranos's annual reports to the Florida registry list 1601 S California Avenue in Palo Alto in 2013 and 2014 and 1701 Page Mill Road from April 2015, the address that remains on its EDGAR record. An online encyclopaedia adds that the 2012 move was into Facebook's former headquarters, that the Page Mill lease cost $1 million a month and that the remaining staff moved to the Newark laboratory site in 2017; the lease amount and the 2017 move are not documented elsewhere in the record. The SEC's complaint gives the principal place of business as Newark, California, and as Palo Alto during 2013 to 2015.","source_ids":["src-034","src-111","src-113","src-096","src-001","src-004","src-083","src-002","src-016","src-014"],"entity_ids":["theranos"],"premise_claim_ids":["c-id-addresses-registry","c-id-form-d-2010","c-id-sec-registrant","c-id-moves-attributed","c-id-principal-places"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The company's address changed as it grew. Patent assignment records give 1430 O'Brien Drive in Menlo Park in 2005 and later 3200 Hillview Avenue in Palo Alto, the principal place of business also given in the 2010 Form D. Theranos's annual reports to the Florida registry list 1601 S California Avenue in Palo Alto in 2013 and 2014 and 1701 Page Mill Road from April 2015, the address that remains on its EDGAR record. An online encyclopaedia adds that the 2012 move was into Facebook's former headquarters, that the Page Mill lease cost $1 million a month and that the remaining staff moved to the Newark laboratory site in 2017; the lease amount and the 2017 move are not documented elsewhere in the record. The SEC's complaint gives the principal place of business as Newark, California, and as Palo Alto during 2013 to 2015."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-3220e4a251946163a625a636","record":{"id":"display-claim-3220e4a251946163a625a636","kind":"analysis","text":"Outside Delaware, the Florida Division of Corporations registered Theranos on May 1, 2012 as a foreign corporation (document number F12000001870). Annual reports were filed for 2013 to 2015; the registration was revoked on September 23, 2016 for failure to file an annual report, and the registered agent resigned in 2019. A company-data aggregator also lists foreign registrations in Pennsylvania (4357259), Arizona (F19937947) and California (2651481); the California number matches the identifier of the California filing in the record, while the Pennsylvania and Arizona numbers were not checked against those states' registries. The same directory lists trademarks including THERANOS, registered in the United States in 2010, and THE TINY BLOOD TEST and THERANOS WELLNESS CENTER, registered internationally in 2015; the registers themselves were not opened. In September 2018 Theranos told stockholders that, after assigning its assets for the benefit of creditors, it intended to file a certificate of dissolution under Delaware law.","source_ids":["src-096","src-006","src-009"],"entity_ids":["theranos"],"premise_claim_ids":["c-id-florida","c-id-registrations-attributed","c-id-trademarks-attributed"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Outside Delaware, the Florida Division of Corporations registered Theranos on May 1, 2012 as a foreign corporation (document number F12000001870). Annual reports were filed for 2013 to 2015; the registration was revoked on September 23, 2016 for failure to file an annual report, and the registered agent resigned in 2019. A company-data aggregator also lists foreign registrations in Pennsylvania (4357259), Arizona (F19937947) and California (2651481); the California number matches the identifier of the California filing in the record, while the Pennsylvania and Arizona numbers were not checked against those states' registries. The same directory lists trademarks including THERANOS, registered in the United States in 2010, and THE TINY BLOOD TEST and THERANOS WELLNESS CENTER, registered internationally in 2015; the registers themselves were not opened. In September 2018 Theranos told stockholders that, after assigning its assets for the benefit of creditors, it intended to file a certificate of dissolution under Delaware law."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-208c5a42992c890e0a6c632b","record":{"id":"display-claim-208c5a42992c890e0a6c632b","kind":"analysis","text":"Theranos offered blood tests to the public and ran a clinical laboratory from 2011 to 2016, Holmes testified. Its clinical laboratory was at 7333 Gateway Boulevard in Newark, California (CLIA 05D2025714); it also had laboratories in Palo Alto and in Scottsdale, Arizona. The main retail channel was Walgreens: under a Master Services Agreement of June 2012, Theranos Wellness Centers inside Walgreens stores collected blood for testing at Theranos's own laboratories. A pilot opened in a Phoenix store on March 20, 2013, and by the fall of 2015 there were 41 centres. A 2010 agreement with the supermarket chain Safeway led to clinics in Safeway stores that, according to press reports from unnamed sources, never performed the blood tests envisaged; no statement by Safeway is in the record, and Theranos's general counsel called the questions put to the company inaccurate and defamatory.","source_ids":["src-071","src-028","src-029","src-036","src-041","src-016","src-055"],"entity_ids":["holmes","theranos","dhawan","balwani","cms","daniel-young","walgreen-co","safeway","heather-king"],"premise_claim_ids":["c-lab-operating-period","c-lab-newark-clia","c-lab-other-labs","c-wag-msa-2012","c-wag-pilot","c-wag-2010-representations","c-prt-safeway-trex"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Theranos offered blood tests to the public and ran a clinical laboratory from 2011 to 2016, Holmes testified. Its clinical laboratory was at 7333 Gateway Boulevard in Newark, California (CLIA 05D2025714); it also had laboratories in Palo Alto and in Scottsdale, Arizona. The main retail channel was Walgreens: under a Master Services Agreement of June 2012, Theranos Wellness Centers inside Walgreens stores collected blood for testing at Theranos's own laboratories. A pilot opened in a Phoenix store on March 20, 2013, and by the fall of 2015 there were 41 centres. A 2010 agreement with the supermarket chain Safeway led to clinics in Safeway stores that, according to press reports from unnamed sources, never performed the blood tests envisaged; no statement by Safeway is in the record, and Theranos's general counsel called the questions put to the company inaccurate and defamatory."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-fa32041542d242c5b1194606","record":{"id":"display-claim-fa32041542d242c5b1194606","kind":"analysis","text":"The business ran on investors' money. According to trial testimony summarised by the Ninth Circuit, Theranos had no revenue in 2012 and 2013 and net losses of $57 million and $92 million in those years; the SEC alleged that it recorded little more than $100,000 of revenue in 2014. From late 2013 to 2015 it raised more than $700 million in its Series C-1 and C-2 rounds, according to the SEC and the Justice Department. Walgreens paid the full $100 million Innovation Fee under a December 2013 amendment to the 2012 agreement and provided $40 million for a convertible note. After a 2014 reorganisation of the shares, on which shareholders were given only a few days to vote, Holmes held just over half of the shares and over 99 percent of the votes, the SEC said.","source_ids":["src-016","src-002","src-014","src-041"],"entity_ids":["theranos","balwani","holmes","walgreen-co"],"premise_claim_ids":["c-fin-financial-position","c-fin-c1-c2","c-wag-msa-2012","c-fin-class-b"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The business ran on investors' money. According to trial testimony summarised by the Ninth Circuit, Theranos had no revenue in 2012 and 2013 and net losses of $57 million and $92 million in those years; the SEC alleged that it recorded little more than $100,000 of revenue in 2014. From late 2013 to 2015 it raised more than $700 million in its Series C-1 and C-2 rounds, according to the SEC and the Justice Department. Walgreens paid the full $100 million Innovation Fee under a December 2013 amendment to the 2012 agreement and provided $40 million for a convertible note. After a 2014 reorganisation of the shares, on which shareholders were given only a few days to vote, Holmes held just over half of the shares and over 99 percent of the votes, the SEC said."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-06bb1603f1cff928bc6af92b","record":{"id":"display-claim-06bb1603f1cff928bc6af92b","kind":"analysis","text":"In August and September 2015 FDA investigators found that Theranos was shipping an uncleared medical device, named in press reports as its Nanotainer blood-collection tube, and a CMS survey of the Newark laboratory completed in November and December 2015 found it out of compliance with five Condition-level requirements; in January 2016 CMS notified the company that deficiencies in hematology posed immediate jeopardy to patient health and safety. Walgreens sent a notice of breach days later; Theranos replied that many of the deficiencies had been corrected and accused Walgreens of breaching the agreement itself, and Walgreens ended the partnership on June 12, 2016. On July 7, 2016 CMS imposed sanctions: revocation of the laboratory's certificate and cancellation of its approval to receive Medicare payments, both effective September 5, 2016, the cancellation even if Theranos appealed, and a civil money penalty of $10,000 a day. Theranos, whose earlier corrections CMS had rejected, voided two years of Edison results, issued corrected reports and appealed. In April 2017 Theranos said it had settled with CMS: it would stay out of the blood-testing business for at least two years, and CMS had withdrawn the revocation and reduced the penalty to $30,000.","source_ids":["src-079","src-028","src-041","src-029","src-078"],"entity_ids":["theranos","balwani","fda","cms","walgreen-co"],"premise_claim_ids":["c-lab-fda-483","c-lab-cms-survey","c-wag-breach-notice","c-lab-cms-sanctions"],"qualification":"","response":"","outcome":""},"reading":"Analysis: In August and September 2015 FDA investigators found that Theranos was shipping an uncleared medical device, named in press reports as its Nanotainer blood-collection tube, and a CMS survey of the Newark laboratory completed in November and December 2015 found it out of compliance with five Condition-level requirements; in January 2016 CMS notified the company that deficiencies in hematology posed immediate jeopardy to patient health and safety. Walgreens sent a notice of breach days later; Theranos replied that many of the deficiencies had been corrected and accused Walgreens of breaching the agreement itself, and Walgreens ended the partnership on June 12, 2016. On July 7, 2016 CMS imposed sanctions: revocation of the laboratory's certificate and cancellation of its approval to receive Medicare payments, both effective September 5, 2016, the cancellation even if Theranos appealed, and a civil money penalty of $10,000 a day. Theranos, whose earlier corrections CMS had rejected, voided two years of Edison results, issued corrected reports and appealed. In April 2017 Theranos said it had settled with CMS: it would stay out of the blood-testing business for at least two years, and CMS had withdrawn the revocation and reduced the penalty to $30,000."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-2061d0682eb729de029097ec","record":{"id":"display-claim-2061d0682eb729de029097ec","kind":"analysis","text":"Lawsuits followed. In October 2016 Partner Fund investors sued Theranos, Holmes and Balwani in Delaware for fraud, and in April 2017 they sued Theranos, Holmes and three directors, alleging among other things that Theranos had threatened bankruptcy unless investors took extra shares instead of suing; according to an online encyclopaedia, Theranos said the funds had mischaracterised its exchange offer. Both suits were settled in May 2017 and dismissed without a ruling on the merits. Walgreen Co. sued in November 2016 for the return of the $100 million Innovation Fee and the $40 million note; Theranos announced in August 2017 a settlement \"with no finding or implication of liability\", and a second Walgreens suit ended in a $5,000,000 judgment against Theranos in 2018. Patients who had bought Theranos tests brought a class action in Arizona against Theranos, Holmes, Balwani and two Walgreens companies; Walgreens and Balwani denied the allegations when they settled. The Arizona Attorney General sued under the state's Consumer Fraud Act; Theranos denied the allegations but entered into a consent decree to pay $4,652,000 in restitution to Arizona consumers, and the Attorney General's office began mailing refunds in December 2017.","source_ids":["src-032","src-083","src-041","src-042","src-059","src-058","src-031"],"entity_ids":["partner-investments","pfm-master","pfm-principals","theranos","holmes","balwani","bonanni","foege","warmenhoven","walgreen-co","wba","walgreen-az","az-ag"],"premise_claim_ids":["c-civ-delaware-suits","c-wag-suit-2016","c-civ-arizona-class","c-lab-az-ag"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Lawsuits followed. In October 2016 Partner Fund investors sued Theranos, Holmes and Balwani in Delaware for fraud, and in April 2017 they sued Theranos, Holmes and three directors, alleging among other things that Theranos had threatened bankruptcy unless investors took extra shares instead of suing; according to an online encyclopaedia, Theranos said the funds had mischaracterised its exchange offer. Both suits were settled in May 2017 and dismissed without a ruling on the merits. Walgreen Co. sued in November 2016 for the return of the $100 million Innovation Fee and the $40 million note; Theranos announced in August 2017 a settlement \"with no finding or implication of liability\", and a second Walgreens suit ended in a $5,000,000 judgment against Theranos in 2018. Patients who had bought Theranos tests brought a class action in Arizona against Theranos, Holmes, Balwani and two Walgreens companies; Walgreens and Balwani denied the allegations when they settled. The Arizona Attorney General sued under the state's Consumer Fraud Act; Theranos denied the allegations but entered into a consent decree to pay $4,652,000 in restitution to Arizona consumers, and the Attorney General's office began mailing refunds in December 2017."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-37fa1ce7aa0f8cd4d65db0e7","record":{"id":"display-claim-37fa1ce7aa0f8cd4d65db0e7","kind":"analysis","text":"On March 14, 2018 the SEC charged Theranos, Holmes and Balwani with raising more than $700 million through a years-long fraud. Theranos and Holmes settled the same day without admitting or denying the allegations, and final judgments were entered on March 27, 2018; Balwani contested the charges. On June 14, 2018 a federal grand jury indicted Holmes and Balwani, who pleaded not guilty; at her trial Holmes's lawyer told the jury that leading a failed start-up did not make her a criminal. Tried separately, Holmes was convicted in January 2022 of conspiracy and three counts of wire fraud against investors and acquitted of the patient counts, and the investor counts on which the jury could not agree were dismissed in the amended judgment of May 2023; Balwani was convicted in July 2022 on all twelve counts, including the patient counts. They were sentenced to 135 and 155 months in prison and ordered to pay $452,047,268 in restitution, jointly and severally. The Ninth Circuit affirmed the convictions, sentences and restitution in 2025, and the Supreme Court denied Balwani's petition on October 5, 2026.","source_ids":["src-002","src-003","src-007","src-008","src-075","src-062","src-010","src-043","src-065","src-014","src-016","src-071","src-057"],"entity_ids":["sec","theranos","holmes","balwani","united-states","safeway","walgreen-co"],"premise_claim_ids":["c-sec-charges","c-sec-settlement","c-crim-indictment-2018","c-crim-holmes-verdict","c-crim-balwani-verdict","c-crim-holmes-sentence","c-crim-balwani-sentence","c-crim-restitution","c-crim-ninth-circuit","c-crim-balwani-cert"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On March 14, 2018 the SEC charged Theranos, Holmes and Balwani with raising more than $700 million through a years-long fraud. Theranos and Holmes settled the same day without admitting or denying the allegations, and final judgments were entered on March 27, 2018; Balwani contested the charges. On June 14, 2018 a federal grand jury indicted Holmes and Balwani, who pleaded not guilty; at her trial Holmes's lawyer told the jury that leading a failed start-up did not make her a criminal. Tried separately, Holmes was convicted in January 2022 of conspiracy and three counts of wire fraud against investors and acquitted of the patient counts, and the investor counts on which the jury could not agree were dismissed in the amended judgment of May 2023; Balwani was convicted in July 2022 on all twelve counts, including the patient counts. They were sentenced to 135 and 155 months in prison and ordered to pay $452,047,268 in restitution, jointly and severally. The Ninth Circuit affirmed the convictions, sentences and restitution in 2025, and the Supreme Court denied Balwani's petition on October 5, 2026."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-8bb9288a1cfc05e4182c63cd","record":{"id":"display-claim-8bb9288a1cfc05e4182c63cd","kind":"analysis","text":"By then the company had shrunk. In late 2017 Theranos borrowed from Fortress against its patents, which it assigned to Theranos IP Company, LLC, described in a 2020 law-review article as a wholly owned subsidiary; the company's 2018 letter says its intellectual property was held by a \"special purpose subsidiary\" (no registry record of it was retrieved). Holmes stepped down as chief executive on June 15, 2018 and was succeeded by the general counsel, David Taylor. In September 2018, in default under the Fortress facility and owing at least $60 million to unsecured creditors, Theranos proposed that Fortress take the patent subsidiary and leave about $5 million of cash for other creditors, and on September 12, 2018 it assigned all its assets and liabilities to Theranos (assignment for the benefit of creditors), LLC.","source_ids":["src-002","src-009","src-089","src-033","src-038","src-021","src-080"],"entity_ids":["theranos","fortress","david-taylor","tipc","holmes","theranos-abc","michael-maidy"],"premise_claim_ids":["c-wd-loan","c-wd-patent-assignment","c-wd-tipc-subsidiary-attributed","c-ld-taylor-ceo","c-wd-letter-2018","c-wd-general-assignment"],"qualification":"","response":"","outcome":""},"reading":"Analysis: By then the company had shrunk. In late 2017 Theranos borrowed from Fortress against its patents, which it assigned to Theranos IP Company, LLC, described in a 2020 law-review article as a wholly owned subsidiary; the company's 2018 letter says its intellectual property was held by a \"special purpose subsidiary\" (no registry record of it was retrieved). Holmes stepped down as chief executive on June 15, 2018 and was succeeded by the general counsel, David Taylor. In September 2018, in default under the Fortress facility and owing at least $60 million to unsecured creditors, Theranos proposed that Fortress take the patent subsidiary and leave about $5 million of cash for other creditors, and on September 12, 2018 it assigned all its assets and liabilities to Theranos (assignment for the benefit of creditors), LLC."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-fe20e82e829ba814234978e4","record":{"id":"display-claim-fe20e82e829ba814234978e4","kind":"analysis","text":"Patents kept issuing to Theranos IP Company after the wind-down. In March 2020 Labrador Diagnostics LLC sued BioFire Diagnostics and its parent bioMérieux for infringing two patents, one of them issued to Theranos IP Company in January 2020; after press criticism that the suit appeared to target new COVID-19 tests, Labrador said it had not known BioFire was developing a coronavirus test, offered royalty-free licences for such tests and dismissed the case on June 28, 2020.","source_ids":["src-064","src-052","src-117","src-063"],"entity_ids":["tipc","holmes","labrador","biofire","biomerieux","fortress"],"premise_claim_ids":["c-wd-tipc-patents-2020","c-wd-labrador-suit","c-wd-labrador-reaction"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Patents kept issuing to Theranos IP Company after the wind-down. In March 2020 Labrador Diagnostics LLC sued BioFire Diagnostics and its parent bioMérieux for infringing two patents, one of them issued to Theranos IP Company in January 2020; after press criticism that the suit appeared to target new COVID-19 tests, Labrador said it had not known BioFire was developing a coronavirus test, offered royalty-free licences for such tests and dismissed the case on June 28, 2020."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-2c2ae7def5279cead38d94c8","record":{"id":"display-claim-2c2ae7def5279cead38d94c8","kind":"analysis","text":"Holmes founded Theranos in 2003, after leaving Stanford University, a business magazine reported. The superseding indictment, the Ninth Circuit and the HHS Departmental Appeals Board describe her as chief executive officer from 2003 until 2018, and the indictment adds that she owned and operated the company. She signed the 2004 restated certificate as President. Between 2013 and 2015, according to the SEC, she was paid a salary of about $200,000 to $390,000 a year, exercised about 53.7 million stock options and received the Class B shares that gave her almost complete voting control; she had never sold any Theranos stock.","source_ids":["src-016","src-071","src-072","src-060","src-086","src-002"],"entity_ids":["holmes","theranos"],"premise_claim_ids":["c-ld-holmes-ceo","c-ld-holmes-stanford","c-id-incorporation","c-ld-pay-holmes"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Holmes founded Theranos in 2003, after leaving Stanford University, a business magazine reported. The superseding indictment, the Ninth Circuit and the HHS Departmental Appeals Board describe her as chief executive officer from 2003 until 2018, and the indictment adds that she owned and operated the company. She signed the 2004 restated certificate as President. Between 2013 and 2015, according to the SEC, she was paid a salary of about $200,000 to $390,000 a year, exercised about 53.7 million stock options and received the Class B shares that gave her almost complete voting control; she had never sold any Theranos stock."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-9766df5bf804506bf019fb09","record":{"id":"display-claim-9766df5bf804506bf019fb09","kind":"analysis","text":"Balwani joined in 2009. According to the SEC's complaints, Holmes, then his girlfriend, asked him to guarantee a line of credit as Theranos was running out of money; he did so and became President and Chief Operating Officer that year. The SEC alleged that until his departure in 2016 the company had no other senior managing executives. According to the Ninth Circuit, evidence at both criminal trials showed that he oversaw the patient-testing laboratory and was the main contact for the retail partners, Safeway and Walgreens, although the precise division of responsibilities between the two was disputed. Their romantic relationship lasted from 2004 to 2016, according to the Ninth Circuit. The SEC put his salary for 2013 to 2015 at between about $99,000 and $200,000, and at Holmes's trial the defence showed a February 2015 email, reported in television news coverage, in which Holmes told James Mattis that she and Balwani wanted to be paid in stock options rather than salary; the email itself is not in the record.","source_ids":["src-002","src-003","src-016","src-071","src-013"],"entity_ids":["balwani","holmes","theranos","safeway","walgreen-co","mattis"],"premise_claim_ids":["c-ld-balwani-guarantee","c-ld-sole-executives","c-ld-balwani-responsibilities","c-ld-holmes-balwani-relationship","c-ld-pay-balwani","c-ld-options-email"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Balwani joined in 2009. According to the SEC's complaints, Holmes, then his girlfriend, asked him to guarantee a line of credit as Theranos was running out of money; he did so and became President and Chief Operating Officer that year. The SEC alleged that until his departure in 2016 the company had no other senior managing executives. According to the Ninth Circuit, evidence at both criminal trials showed that he oversaw the patient-testing laboratory and was the main contact for the retail partners, Safeway and Walgreens, although the precise division of responsibilities between the two was disputed. Their romantic relationship lasted from 2004 to 2016, according to the Ninth Circuit. The SEC put his salary for 2013 to 2015 at between about $99,000 and $200,000, and at Holmes's trial the defence showed a February 2015 email, reported in television news coverage, in which Holmes told James Mattis that she and Balwani wanted to be paid in stock options rather than salary; the email itself is not in the record."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-f67924ac2795018a8554c191","record":{"id":"display-claim-f67924ac2795018a8554c191","kind":"analysis","text":"The U.S. Attorney's Office said in 2018 that Balwani worked at Theranos from September 2009 and at times served as a member of the board of directors as well as president and chief operating officer. The dates of his departure differ by source. The SEC complaint and Theranos's own announcement place it in May 2016, while the U.S. Attorney's 2022 release says he worked there through July 2016; Theranos's May 2016 announcement said he would continue to support the transition through its completion.","source_ids":["src-002","src-010","src-014"],"entity_ids":["balwani","theranos"],"premise_claim_ids":["c-ld-balwani-tenure"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The U.S. Attorney's Office said in 2018 that Balwani worked at Theranos from September 2009 and at times served as a member of the board of directors as well as president and chief operating officer. The dates of his departure differ by source. The SEC complaint and Theranos's own announcement place it in May 2016, while the U.S. Attorney's 2022 release says he worked there through July 2016; Theranos's May 2016 announcement said he would continue to support the transition through its completion."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-b45b3ed2de3094a4cb0e0f5a","record":{"id":"display-claim-b45b3ed2de3094a4cb0e0f5a","kind":"analysis","text":"Lawyers served as company officers. J. Casey McGlynn, listed in a lawyer directory as a partner of Wilson Sonsini Goodrich & Rosati, signed, as Secretary, the statement filed in California in early 2005 recording Theranos's 2004 change of name; the record does not say whether as an employee or as outside counsel. Heather King, a litigation partner at Boies, Schiller & Flexner, was appointed general counsel in May 2015 and still held the post that November. David Taylor, general counsel from 2016, became chief executive and general counsel on June 15, 2018, when Holmes stepped down as chief executive but remained chair; his firm profile says he led the team that secured $100 million of debt financing before winding the company down.","source_ids":["src-112","src-086","src-081","src-055","src-021","src-089"],"entity_ids":["casey-mcglynn","theranos","heather-king","boies-schiller","holmes","david-taylor"],"premise_claim_ids":["c-pp-mcglynn","c-id-california-qualification","c-ld-heather-king","c-ld-taylor-ceo","c-ld-taylor-profile"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Lawyers served as company officers. J. Casey McGlynn, listed in a lawyer directory as a partner of Wilson Sonsini Goodrich & Rosati, signed, as Secretary, the statement filed in California in early 2005 recording Theranos's 2004 change of name; the record does not say whether as an employee or as outside counsel. Heather King, a litigation partner at Boies, Schiller & Flexner, was appointed general counsel in May 2015 and still held the post that November. David Taylor, general counsel from 2016, became chief executive and general counsel on June 15, 2018, when Holmes stepped down as chief executive but remained chair; his firm profile says he led the team that secured $100 million of debt financing before winding the company down."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-4a4929967740cee99a28d222","record":{"id":"display-claim-4a4929967740cee99a28d222","kind":"analysis","text":"Theranos's 2010 Form D, which Holmes signed as President and CEO, lists, besides Holmes and Balwani, four directors: Donald L. Lucas, Channing Robertson, Robert Shapiro and T. Peter Thomas. Lucas, who died in 2019, was one of Silicon Valley's earliest venture capitalists and a former chairman of Oracle; Thomas was a managing director of Institutional Venture Management and of the general partner of the ATA Ventures funds; Shapiro, who died in 2025, had been chief executive of Monsanto and chairman of Pharmacia, according to an online encyclopaedia.","source_ids":["src-001","src-092","src-109","src-094","src-110","src-095"],"entity_ids":["theranos","holmes","balwani","donald-lucas","robertson","shapiro","peter-thomas","oracle","ellison","ata-ventures"],"premise_claim_ids":["c-ld-form-d-2010-persons","c-pp-lucas","c-pp-thomas","c-pp-shapiro"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Theranos's 2010 Form D, which Holmes signed as President and CEO, lists, besides Holmes and Balwani, four directors: Donald L. Lucas, Channing Robertson, Robert Shapiro and T. Peter Thomas. Lucas, who died in 2019, was one of Silicon Valley's earliest venture capitalists and a former chairman of Oracle; Thomas was a managing director of Institutional Venture Management and of the general partner of the ATA Ventures funds; Shapiro, who died in 2025, had been chief executive of Monsanto and chairman of Pharmacia, according to an online encyclopaedia."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-00e8727d6e7c1d849c9af79a","record":{"id":"display-claim-00e8727d6e7c1d849c9af79a","kind":"analysis","text":"Robertson, a Stanford chemical-engineering professor who taught Holmes, helped her start the company, was a technical adviser and its first board member, according to an online encyclopaedia, which also reports, citing records of the criminal case, that Theranos paid him about $463,000 from March 2015 to February 2016 and that he remained on the board until 2018. An investors' lawyer was quoted as saying Holmes paid him $500,000 a year from 2013 to 2017. These figures and the 2018 end date rest on the encyclopaedia alone; no Theranos filing in the record confirms them. According to the same encyclopaedia, Robertson defended the company after the 2015 newspaper reports and still believed in its technology in May 2018. His place on the board is independently confirmed by the 2010 Form D, which lists him as a director, but the later board lists described below do not include him.","source_ids":["src-083","src-108","src-088"],"entity_ids":["robertson","holmes","theranos"],"premise_claim_ids":["c-ld-robertson-attributed","c-ld-robertson-pay-attributed"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Robertson, a Stanford chemical-engineering professor who taught Holmes, helped her start the company, was a technical adviser and its first board member, according to an online encyclopaedia, which also reports, citing records of the criminal case, that Theranos paid him about $463,000 from March 2015 to February 2016 and that he remained on the board until 2018. An investors' lawyer was quoted as saying Holmes paid him $500,000 a year from 2013 to 2017. These figures and the 2018 end date rest on the encyclopaedia alone; no Theranos filing in the record confirms them. According to the same encyclopaedia, Robertson defended the company after the 2015 newspaper reports and still believed in its technology in May 2018. His place on the board is independently confirmed by the 2010 Form D, which lists him as a director, but the later board lists described below do not include him."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-e95861979783109883fb922e","record":{"id":"display-claim-e95861979783109883fb922e","kind":"analysis","text":"According to an online encyclopaedia citing press reports, Avie Tevanian, Apple's former software chief, joined the board after leaving Apple in 2006 and resigned in late 2007 after a dispute in which he faced legal threats and waived a right to buy shares from a co-founder. No second document on his directorship was found, because Theranos's filings for 2005–2006 survive only on paper.","source_ids":["src-083","src-097"],"entity_ids":["tevanian","theranos"],"premise_claim_ids":["c-ld-tevanian-attributed","c-pp-tevanian"],"qualification":"","response":"","outcome":""},"reading":"Analysis: According to an online encyclopaedia citing press reports, Avie Tevanian, Apple's former software chief, joined the board after leaving Apple in 2006 and resigned in late 2007 after a dispute in which he faced legal threats and waived a right to buy shares from a co-founder. No second document on his directorship was found, because Theranos's filings for 2005–2006 survive only on paper."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-7ffc4d22b16d487385eed795","record":{"id":"display-claim-7ffc4d22b16d487385eed795","kind":"analysis","text":"George Shultz, a former Secretary of State and president of Bechtel Group, joined the board in July 2011, a business magazine reported, after Holmes was introduced to him at Stanford's Hoover Institution; the magazine added that by 2014 nearly all the other outside directors had come to the company through him. According to a 2018 federal court order, Theranos's first website press release, of July 29, 2013, announced James Mattis and Richard Kovacevich as directors joining Henry Kissinger, Sam Nunn and William Perry. The company's annual reports to the Florida registry list Shultz, Gary Roughead, Perry, Nunn, Kovacevich, Mattis and Kissinger as directors in July 2013, and add William Frist, William Foege and Riley Bechtel in August 2014; the April 2015 report lists all ten, with Holmes as chief executive and chairman and Balwani as President and Chief Operating Officer.","source_ids":["src-019","src-103","src-053","src-073","src-111","src-113","src-096"],"entity_ids":["shultz","holmes","theranos","perry","kissinger","nunn","frist","roughead","mattis","kovacevich","riley-bechtel","bechtel-group","balwani","foege"],"premise_claim_ids":["c-ld-shultz-joins","c-pp-shultz","c-ld-board-2013-release","c-ld-florida-2013","c-ld-florida-2014","c-ld-florida-2015"],"qualification":"","response":"","outcome":""},"reading":"Analysis: George Shultz, a former Secretary of State and president of Bechtel Group, joined the board in July 2011, a business magazine reported, after Holmes was introduced to him at Stanford's Hoover Institution; the magazine added that by 2014 nearly all the other outside directors had come to the company through him. According to a 2018 federal court order, Theranos's first website press release, of July 29, 2013, announced James Mattis and Richard Kovacevich as directors joining Henry Kissinger, Sam Nunn and William Perry. The company's annual reports to the Florida registry list Shultz, Gary Roughead, Perry, Nunn, Kovacevich, Mattis and Kissinger as directors in July 2013, and add William Frist, William Foege and Riley Bechtel in August 2014; the April 2015 report lists all ten, with Holmes as chief executive and chairman and Balwani as President and Chief Operating Officer."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-c02d61eecc8961aa0aacd7e3","record":{"id":"display-claim-c02d61eecc8961aa0aacd7e3","kind":"analysis","text":"Their careers were in government and large companies: Kissinger was Secretary of State from 1973 to 1977; Perry was Secretary of Defense from 1994 to 1997; Nunn was a senator from 1972 to 1996; Frist, a transplant surgeon, was Senate majority leader before retiring in 2007; Roughead was the Navy's chief of naval operations until 2011; Mattis commanded U.S. Central Command until 2013; Kovacevich was chief executive of Wells Fargo from 1998 to 2007; Riley Bechtel led Bechtel Group, a holding company for engineering and construction businesses, as chief executive from 1990 to 2014; and Foege was director of the Centers for Disease Control and Prevention from 1977 to 1983.","source_ids":["src-099","src-100","src-114","src-101","src-102","src-105","src-104","src-087","src-053","src-106"],"entity_ids":["kissinger","perry","nunn","frist","roughead","mattis","kovacevich","riley-bechtel","bechtel-group","foege"],"premise_claim_ids":["c-pp-kissinger","c-pp-perry","c-pp-nunn","c-pp-frist","c-pp-roughead","c-pp-mattis","c-pp-kovacevich","c-pp-riley-bechtel","c-pp-bechtel-group","c-pp-foege"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Their careers were in government and large companies: Kissinger was Secretary of State from 1973 to 1977; Perry was Secretary of Defense from 1994 to 1997; Nunn was a senator from 1972 to 1996; Frist, a transplant surgeon, was Senate majority leader before retiring in 2007; Roughead was the Navy's chief of naval operations until 2011; Mattis commanded U.S. Central Command until 2013; Kovacevich was chief executive of Wells Fargo from 1998 to 2007; Riley Bechtel led Bechtel Group, a holding company for engineering and construction businesses, as chief executive from 1990 to 2014; and Foege was director of the Centers for Disease Control and Prevention from 1977 to 1983."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-0cfc8d2f923c1eab8a06c5b3","record":{"id":"display-claim-0cfc8d2f923c1eab8a06c5b3","kind":"analysis","text":"Holmes testified at her 2021 trial, as a national newspaper reported, that Theranos paid each director $150,000 a year plus 500,000 shares and paid Kissinger another $500,000 a year as a consultant. Mattis, a director from 2013, testified that he invested $85,000 and received $150,000 for his board service; he resigned on December 16, 2016, before his confirmation as Secretary of Defense, and said that by then he had lost faith in Holmes. A business magazine described the board on October 15, 2015 as twelve people, adding Holmes and Balwani to the ten outside directors and calling Balwani president and CEO, though his title was President and Chief Operating Officer; two weeks later Theranos said the board had already been reduced in July 2015.","source_ids":["src-022","src-013","src-040","src-061","src-011"],"entity_ids":["holmes","shultz","kovacevich","mattis","roughead","nunn","kissinger","perry","theranos","frist","riley-bechtel","foege","balwani"],"premise_claim_ids":["c-ld-board-pay-testimony","c-ld-mattis-testimony","c-ld-mattis-tenure","c-ld-board-oct-2015"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Holmes testified at her 2021 trial, as a national newspaper reported, that Theranos paid each director $150,000 a year plus 500,000 shares and paid Kissinger another $500,000 a year as a consultant. Mattis, a director from 2013, testified that he invested $85,000 and received $150,000 for his board service; he resigned on December 16, 2016, before his confirmation as Secretary of Defense, and said that by then he had lost faith in Holmes. A business magazine described the board on October 15, 2015 as twelve people, adding Holmes and Balwani to the ten outside directors and calling Balwani president and CEO, though his title was President and Chief Operating Officer; two weeks later Theranos said the board had already been reduced in July 2015."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-c074db8949d1cf1e799ed9ec","record":{"id":"display-claim-c074db8949d1cf1e799ed9ec","kind":"analysis","text":"At the end of October 2015, after critical press coverage began, Theranos told a national newspaper that it had reduced the board in July 2015 to five members, Holmes, Balwani, Riley Bechtel, Mattis and David Boies, and that the former directors, including Kissinger and Shultz, had become a board of counselors that would still advise the company; Holmes said the change had come in the summer. A life-sciences news site described the counselors as largely people with strong political and government ties. Foege and Kovacevich later returned from the counselors to the board.","source_ids":["src-049","src-020","src-051","src-027"],"entity_ids":["theranos","holmes","balwani","riley-bechtel","mattis","boies","kissinger","shultz","nunn","foege","kovacevich"],"premise_claim_ids":["c-ld-board-restructure-2015","c-ld-board-counselors"],"qualification":"","response":"","outcome":""},"reading":"Analysis: At the end of October 2015, after critical press coverage began, Theranos told a national newspaper that it had reduced the board in July 2015 to five members, Holmes, Balwani, Riley Bechtel, Mattis and David Boies, and that the former directors, including Kissinger and Shultz, had become a board of counselors that would still advise the company; Holmes said the change had come in the summer. A life-sciences news site described the counselors as largely people with strong political and government ties. Foege and Kovacevich later returned from the counselors to the board."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-08678c7d6f18f70f72f46291","record":{"id":"display-claim-08678c7d6f18f70f72f46291","kind":"analysis","text":"Boies is chairman of Boies, Schiller & Flexner, which according to an online encyclopaedia he founded with Jonathan Schiller in 1997. A national newspaper reported that he became Theranos's outside counsel in 2011 after two investors approached him. He joined the board by October 2015 according to business press reports, or in February 2016 according to the encyclopaedia, which, citing newspaper reports, says he agreed to be paid for his firm's work in Theranos stock, raising conflict-of-interest concerns; the arrangement is not documented elsewhere in the record, and no response from Boies to that account was found. The same newspaper reported that he and his firm stopped doing legal work for Theranos in November 2016 after disagreeing about the strategy for the government investigations; a life-sciences news site reported that December that there was no indication he had given up his board seat.","source_ids":["src-107","src-081","src-066","src-051","src-049","src-020","src-040"],"entity_ids":["boies","boies-schiller","theranos"],"premise_claim_ids":["c-pp-boies","c-ld-boies-counsel","c-ld-boies-board","c-ld-boies-stock-attributed"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Boies is chairman of Boies, Schiller & Flexner, which according to an online encyclopaedia he founded with Jonathan Schiller in 1997. A national newspaper reported that he became Theranos's outside counsel in 2011 after two investors approached him. He joined the board by October 2015 according to business press reports, or in February 2016 according to the encyclopaedia, which, citing newspaper reports, says he agreed to be paid for his firm's work in Theranos stock, raising conflict-of-interest concerns; the arrangement is not documented elsewhere in the record, and no response from Boies to that account was found. The same newspaper reported that he and his firm stopped doing legal work for Theranos in November 2016 after disagreeing about the strategy for the government investigations; a life-sciences news site reported that December that there was no indication he had given up his board seat."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-bc6d307bd47ed34824568eb9","record":{"id":"display-claim-bc6d307bd47ed34824568eb9","kind":"analysis","text":"On May 11, 2016 Theranos announced Balwani's retirement and the appointment of Fabrizio Bonanni, a former Amgen operations executive, with Foege and Kovacevich, to the board; Bonanni chaired its Compliance and Quality Committee. On December 1, 2016 it appointed Daniel Warmenhoven, a former NetApp chief executive who sat on the boards of Bechtel Group and Palo Alto Networks, in place of Riley Bechtel, whom Holmes called a shareholder, and said it would retire the board of counselors on January 1, 2017. Warmenhoven, who also sat on the board of the Tech Museum of Innovation and had been lead director of Redback Networks when it filed for Chapter 11, told a regional newspaper that he had come to know Holmes through Bechtel. A business news site listed the board that month as Holmes, Mattis, Boies, Warmenhoven, Foege, Kovacevich and Bonanni.","source_ids":["src-027","src-018","src-084","src-115","src-026","src-017","src-039","src-047","src-012"],"entity_ids":["theranos","balwani","bonanni","foege","kovacevich","warmenhoven","riley-bechtel","holmes","frist","nunn","kissinger","shultz","perry","bechtel-group","mattis","boies","roughead"],"premise_claim_ids":["c-ld-may-2016","c-pp-bonanni","c-ld-bonanni-committee","c-ld-dec-2016","c-pp-warmenhoven","c-pp-warmenhoven-redback","c-ld-warmenhoven-bechtel","c-fin-bechtel-shareholder","c-ld-board-dec-2016"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On May 11, 2016 Theranos announced Balwani's retirement and the appointment of Fabrizio Bonanni, a former Amgen operations executive, with Foege and Kovacevich, to the board; Bonanni chaired its Compliance and Quality Committee. On December 1, 2016 it appointed Daniel Warmenhoven, a former NetApp chief executive who sat on the boards of Bechtel Group and Palo Alto Networks, in place of Riley Bechtel, whom Holmes called a shareholder, and said it would retire the board of counselors on January 1, 2017. Warmenhoven, who also sat on the board of the Tech Museum of Innovation and had been lead director of Redback Networks when it filed for Chapter 11, told a regional newspaper that he had come to know Holmes through Bechtel. A business news site listed the board that month as Holmes, Mattis, Boies, Warmenhoven, Foege, Kovacevich and Bonanni."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-a2f64549d4592819e1e4cd46","record":{"id":"display-claim-a2f64549d4592819e1e4cd46","kind":"analysis","text":"The last filing to list directors, a Form D signed on May 25, 2017, names Holmes as chief executive and director and Bonanni, Foege and Warmenhoven as directors; Channing Robertson is not among them. A business news site reported in March 2018, citing the company's website, that Foege remained a director; no later filing lists the board.","source_ids":["src-005","src-040"],"entity_ids":["theranos","holmes","bonanni","foege","warmenhoven","kovacevich"],"premise_claim_ids":["c-ld-form-d-2017","c-ld-board-2018"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The last filing to list directors, a Form D signed on May 25, 2017, names Holmes as chief executive and director and Bonanni, Foege and Warmenhoven as directors; Channing Robertson is not among them. A business news site reported in March 2018, citing the company's website, that Foege remained a director; no later filing lists the board."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-9127093bdcad87a56c3f3a1c","record":{"id":"display-claim-9127093bdcad87a56c3f3a1c","kind":"analysis","text":"Theranos's early private placements are recorded only as seven paper Regulation D notices filed between January 2005 and November 2006. Start-up funding data, reported by a start-up data publisher in 2021, describe a $500,000 seed round led by Draper Fisher Jurvetson in June 2004, a $5.8 million Series A led by Rupert Murdoch in February 2005, a $9.1 million Series B led by ATA Ventures and a $28.5 million Series C in 2006, and $45 million of venture funding in July 2010, about $1.3 billion in all, or $1.4 billion with debt. The attribution of the 2005 round to Murdoch conflicts with other accounts that place his investment much later. The amounts, dates and lead investors of the 2004–2006 rounds are not documented in the filings retrieved, although the December 2004 restated certificate created a class of 13,500,000 Series A Preferred shares convertible at $0.75.","source_ids":["src-004","src-016","src-054","src-086"],"entity_ids":["theranos","dfj","murdoch","ata-ventures","ellison","walgreen-co","partner-fund-mgmt","fortress"],"premise_claim_ids":["c-id-sec-filings","c-fin-early-rounds-attributed","c-id-capital-2004"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Theranos's early private placements are recorded only as seven paper Regulation D notices filed between January 2005 and November 2006. Start-up funding data, reported by a start-up data publisher in 2021, describe a $500,000 seed round led by Draper Fisher Jurvetson in June 2004, a $5.8 million Series A led by Rupert Murdoch in February 2005, a $9.1 million Series B led by ATA Ventures and a $28.5 million Series C in 2006, and $45 million of venture funding in July 2010, about $1.3 billion in all, or $1.4 billion with debt. The attribution of the 2005 round to Murdoch conflicts with other accounts that place his investment much later. The amounts, dates and lead investors of the 2004–2006 rounds are not documented in the filings retrieved, although the December 2004 restated certificate created a class of 13,500,000 Series A Preferred shares convertible at $0.75."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-856f7ac869e4f35de3f033b2","record":{"id":"display-claim-856f7ac869e4f35de3f033b2","kind":"analysis","text":"The first electronic filing, a Form D of July 8, 2010, reported an equity offering under the Rule 506 exemption of $100,000,005, of which $45,000,000 had been sold to one investor, with a first sale on July 1, 2010.","source_ids":["src-001"],"entity_ids":["theranos"],"premise_claim_ids":["c-fin-form-d-2010"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The first electronic filing, a Form D of July 8, 2010, reported an equity offering under the Rule 506 exemption of $100,000,005, of which $45,000,000 had been sold to one investor, with a first sale on July 1, 2010."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-6c37927918106426eaee7430","record":{"id":"display-claim-6c37927918106426eaee7430","kind":"analysis","text":"The large rounds came while the company had little income. According to testimony summarised by the Ninth Circuit, Theranos had no revenue in 2012 and 2013 and net losses of $57 million and $92 million, and in November 2013 Balwani told Holmes it was down to $15 million in cash while spending up to $2 million a week. The SEC alleged that it recorded little more than $100,000 of revenue in 2014; it reported $1,944,948 of total income to the IRS for 2015.","source_ids":["src-016","src-002"],"entity_ids":["theranos","balwani","holmes"],"premise_claim_ids":["c-fin-financial-position"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The large rounds came while the company had little income. According to testimony summarised by the Ninth Circuit, Theranos had no revenue in 2012 and 2013 and net losses of $57 million and $92 million, and in November 2013 Balwani told Holmes it was down to $15 million in cash while spending up to $2 million a week. The SEC alleged that it recorded little more than $100,000 of revenue in 2014; it reported $1,944,948 of total income to the IRS for 2015."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-f97194d490af87c01fae8586","record":{"id":"display-claim-f97194d490af87c01fae8586","kind":"analysis","text":"From late 2013 to 2015 Holmes, Balwani and Theranos raised more than $700 million in two rounds, the SEC alleged, when, the SEC said, the company had about $30 million in cash and short-term securities in late 2013; the Justice Department put the total from Series C-1 and C-2 investors at more than $730 million by March 2015. A 2018 order in the indirect-investor class action records that Theranos had earlier sold Series A, Series B and Series C Preferred stock, and that from January 2013 to October 2016 it sold C-1 and C-2 Preferred stock to more than 30 individuals and entities in amounts from about $50,000 to about $125 million. Some buyers were funds pooling other people's money, such as Peer Ventures Group IV, Lucas Venture Group XI, which paid just over $7 million for 471,333 C-1 shares, and Black Diamond Ventures XII-B; Celadon Technology Fund VII bought 410,000 shares from another investor in December 2015, described in one passage of the order as Series C Preferred and in another as Series C-1. Partner Investments, L.P., one of the investors that later sued, is a San Francisco fund whose general partner is Partner Fund Management.","source_ids":["src-002","src-014","src-016","src-073","src-037"],"entity_ids":["theranos","holmes","balwani","lvg-xi","pvg-iv","lvg-iv-lp","bdv-xii-b","celadon","partner-investments","partner-fund-mgmt"],"premise_claim_ids":["c-fin-c1-c2","c-fin-series-order","c-fin-indirect-funds","c-fin-partner-investments"],"qualification":"","response":"","outcome":""},"reading":"Analysis: From late 2013 to 2015 Holmes, Balwani and Theranos raised more than $700 million in two rounds, the SEC alleged, when, the SEC said, the company had about $30 million in cash and short-term securities in late 2013; the Justice Department put the total from Series C-1 and C-2 investors at more than $730 million by March 2015. A 2018 order in the indirect-investor class action records that Theranos had earlier sold Series A, Series B and Series C Preferred stock, and that from January 2013 to October 2016 it sold C-1 and C-2 Preferred stock to more than 30 individuals and entities in amounts from about $50,000 to about $125 million. Some buyers were funds pooling other people's money, such as Peer Ventures Group IV, Lucas Venture Group XI, which paid just over $7 million for 471,333 C-1 shares, and Black Diamond Ventures XII-B; Celadon Technology Fund VII bought 410,000 shares from another investor in December 2015, described in one passage of the order as Series C Preferred and in another as Series C-1. Partner Investments, L.P., one of the investors that later sued, is a San Francisco fund whose general partner is Partner Fund Management."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-63d4c5a95a476c608e224580","record":{"id":"display-claim-63d4c5a95a476c608e224580","kind":"analysis","text":"The SEC alleged that in August 2015 Holmes gave a potential investor results showing $108 million of net revenue for 2014 and projections of $240 million for 2015 and $750 million for 2016, and an investor witness testified that documents from Holmes and Balwani projected a $230 million profit by the end of 2015. These were allegations and testimony on which the fraud charges rested; Holmes and Theranos settled with the SEC without admitting or denying them, and the jury's verdicts are set out in the account of the criminal case. The investor counts of the indictment are tied to six wire transfers, from $99,990 to $99,999,984, made into Theranos's Comerica Bank account between December 30, 2013 and October 31, 2014 by investors the indictment identifies only by number.","source_ids":["src-016","src-002"],"entity_ids":["holmes","balwani","theranos"],"premise_claim_ids":["c-fin-projections","c-crim-investor-wires"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The SEC alleged that in August 2015 Holmes gave a potential investor results showing $108 million of net revenue for 2014 and projections of $240 million for 2015 and $750 million for 2016, and an investor witness testified that documents from Holmes and Balwani projected a $230 million profit by the end of 2015. These were allegations and testimony on which the fraud charges rested; Holmes and Theranos settled with the SEC without admitting or denying them, and the jury's verdicts are set out in the account of the criminal case. The investor counts of the indictment are tied to six wire transfers, from $99,990 to $99,999,984, made into Theranos's Comerica Bank account between December 30, 2013 and October 31, 2014 by investors the indictment identifies only by number."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-77cfa553165327e2a5bb37db","record":{"id":"display-claim-77cfa553165327e2a5bb37db","kind":"analysis","text":"In early 2014, according to the SEC, Holmes persuaded the board and shareholders to split the stock in a 1-to-5 ratio, to allow for future fundraising, and create Class B shares carrying 100 votes each, to be issued only to her, after which she owned just over half of the shares but over 99 percent of the votes; shareholders had only a few days to vote on the resolution. Balwani owned nearly 30 million shares, more than 6 percent of the company, according to the Justice Department's account of the trial evidence.","source_ids":["src-002","src-014"],"entity_ids":["holmes","theranos","balwani"],"premise_claim_ids":["c-fin-class-b","c-fin-balwani-stake"],"qualification":"","response":"","outcome":""},"reading":"Analysis: In early 2014, according to the SEC, Holmes persuaded the board and shareholders to split the stock in a 1-to-5 ratio, to allow for future fundraising, and create Class B shares carrying 100 votes each, to be issued only to her, after which she owned just over half of the shares but over 99 percent of the votes; shareholders had only a few days to vote on the resolution. Balwani owned nearly 30 million shares, more than 6 percent of the company, according to the Justice Department's account of the trial evidence."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-771b2bd0311d1c8b4b28ce4c","record":{"id":"display-claim-771b2bd0311d1c8b4b28ce4c","kind":"analysis","text":"Holmes gave up that control in March 2018. Under her settlement with the SEC she agreed to convert her Class B shares and to accept a reduction of her equity which, with shares returned earlier, materially reduced her stake; because of the liquidation preference she would not profit from her shares on a sale or liquidation until over $750 million had been returned to what the SEC called defrauded investors and other preferred shareholders, assuming certain warrants were redeemed. The court entered final judgment on the settlement on March 27, 2018.","source_ids":["src-007","src-075"],"entity_ids":["holmes","theranos","sec"],"premise_claim_ids":["c-fin-holmes-sec-equity","c-sec-settlement"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Holmes gave up that control in March 2018. Under her settlement with the SEC she agreed to convert her Class B shares and to accept a reduction of her equity which, with shares returned earlier, materially reduced her stake; because of the liquidation preference she would not profit from her shares on a sale or liquidation until over $750 million had been returned to what the SEC called defrauded investors and other preferred shareholders, assuming certain warrants were redeemed. The court entered final judgment on the settlement on March 27, 2018."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-e15a7f0368d9c20f6981a73d","record":{"id":"display-claim-e15a7f0368d9c20f6981a73d","kind":"analysis","text":"Press accounts name the investors differently. A magazine wrote in December 2016 that Theranos had raised more than $686 million from investors including Draper Fisher Jurvetson, Walgreens and Rupert Murdoch, reaching a $9 billion valuation; a business news site, citing a private-market data provider, wrote in March 2018 that it had raised more than $900 million, including $100 million of debt in December 2017, from investors including Larry Ellison, Draper Fisher Jurvetson, Betsy DeVos, Murdoch, Walgreens and BlueCross BlueShield. The totals differ because the sources count different periods and instruments. Directors invested too: the investment of Riley Bechtel, previously undisclosed, was reported in December 2016.","source_ids":["src-017","src-040","src-026","src-012"],"entity_ids":["theranos","dfj","walgreen-co","murdoch","ellison","devos","bcbs","riley-bechtel","holmes"],"premise_claim_ids":["c-fin-investors-press","c-fin-bechtel-shareholder"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Press accounts name the investors differently. A magazine wrote in December 2016 that Theranos had raised more than $686 million from investors including Draper Fisher Jurvetson, Walgreens and Rupert Murdoch, reaching a $9 billion valuation; a business news site, citing a private-market data provider, wrote in March 2018 that it had raised more than $900 million, including $100 million of debt in December 2017, from investors including Larry Ellison, Draper Fisher Jurvetson, Betsy DeVos, Murdoch, Walgreens and BlueCross BlueShield. The totals differ because the sources count different periods and instruments. Directors invested too: the investment of Riley Bechtel, previously undisclosed, was reported in December 2016."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-dc24e555db76939e01b34c61","record":{"id":"display-claim-dc24e555db76939e01b34c61","kind":"analysis","text":"The restitution schedule in the criminal case identifies the investors whose losses the court found. It lists Keith Rupert Murdoch ($124,999,997), RDV Corporation ($99,999,984), Peer Ventures Group ($93,499,912), PFM Funds ($52,639,998), Walgreens ($40,000,000), Safeway ($14,500,000), Lucas Venture Group ($7,570,005), Moseley Family Holdings ($5,999,997), Black Diamond Ventures ($5,349,900), Richard Kovacevich ($4,149,990), Hall Group ($1,875,000) and Mendenhall TF Partners ($1,312,500), together with two individual investors who are not named here. The schedule's printed total, $453,047,268, is $1 million more than the sum of its rows and the amount ordered.","source_ids":["src-016"],"entity_ids":["murdoch","rdv","peer-ventures","pfm-funds","walgreen-co","safeway","lucas-venture-group","moseley","black-diamond","kovacevich","hall-group","mendenhall","theranos"],"premise_claim_ids":["c-crim-restitution-payees"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The restitution schedule in the criminal case identifies the investors whose losses the court found. It lists Keith Rupert Murdoch ($124,999,997), RDV Corporation ($99,999,984), Peer Ventures Group ($93,499,912), PFM Funds ($52,639,998), Walgreens ($40,000,000), Safeway ($14,500,000), Lucas Venture Group ($7,570,005), Moseley Family Holdings ($5,999,997), Black Diamond Ventures ($5,349,900), Richard Kovacevich ($4,149,990), Hall Group ($1,875,000) and Mendenhall TF Partners ($1,312,500), together with two individual investors who are not named here. The schedule's printed total, $453,047,268, is $1 million more than the sum of its rows and the amount ordered."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-d12352fa7a00cdcfc0ec2e35","record":{"id":"display-claim-d12352fa7a00cdcfc0ec2e35","kind":"analysis","text":"Walgreens' exposure is reported in several ways that measure different things: a $100 million Innovation Fee paid under the services agreement and a $40 million convertible note, according to the Delaware court; $50 million invested and $140 million spent on the partnership, according to a start-up data publisher citing a national newspaper; a $140 million investment in trial reporting; and a $40 million restitution award for its loss on the note.","source_ids":["src-054","src-065","src-016"],"entity_ids":["walgreen-co","theranos"],"premise_claim_ids":["c-wag-investment-figures"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Walgreens' exposure is reported in several ways that measure different things: a $100 million Innovation Fee paid under the services agreement and a $40 million convertible note, according to the Delaware court; $50 million invested and $140 million spent on the partnership, according to a start-up data publisher citing a national newspaper; a $140 million investment in trial reporting; and a $40 million restitution award for its loss on the note."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-7486e09aa7efa7685cf8e9f7","record":{"id":"display-claim-7486e09aa7efa7685cf8e9f7","kind":"analysis","text":"In 2017, while investor suits were pending, Theranos recapitalised. The SEC records a tender offer to recapitalise investors from the later rounds, as part of which Holmes returned about 34 million of her shares; the 2018 class-certification order describes a share offer and exchange negotiated with C-1 and C-2 holders between August 2016 and August 2017, in which funds such as Black Diamond Ventures XII-B, Lucas Venture Group XI and Peer Ventures Group IV released their claims. A Form D of May 2017 reported the exchange as a $582,200,318 offering, fully sold to 34 investors.","source_ids":["src-002","src-073","src-005"],"entity_ids":["theranos","holmes","bdv-xii-b","lvg-xi","pvg-iv"],"premise_claim_ids":["c-fin-tender-offer","c-fin-form-d-2017"],"qualification":"","response":"","outcome":""},"reading":"Analysis: In 2017, while investor suits were pending, Theranos recapitalised. The SEC records a tender offer to recapitalise investors from the later rounds, as part of which Holmes returned about 34 million of her shares; the 2018 class-certification order describes a share offer and exchange negotiated with C-1 and C-2 holders between August 2016 and August 2017, in which funds such as Black Diamond Ventures XII-B, Lucas Venture Group XI and Peer Ventures Group IV released their claims. A Form D of May 2017 reported the exchange as a $582,200,318 offering, fully sold to 34 investors."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-8c9ba5f9991bb58b80476746","record":{"id":"display-claim-8c9ba5f9991bb58b80476746","kind":"analysis","text":"A life-sciences news site reported in March 2017 that the offer of two additional shares for each share held, conditional on not suing, effectively cut the share value from $15–$17 to $5, and that on a February 2017 investor call the company reported no material revenue in 2015 or 2016 and about $200 million in the bank; these figures are not documented in Theranos's filings. According to an online encyclopaedia, holders of more than 99 percent of the shares took part in the May 2017 recapitalisation, releasing potential claims against Theranos in exchange for new preferred stock. A business news site, citing a national newspaper and an unnamed source, reported that Murdoch did not take part and that Theranos bought back his $125 million stake for $1; the price is not documented in any filing. Murdoch declined to comment when a business news site reported his losses in 2018, and the criminal court later listed him as a restitution payee for $124,999,997.","source_ids":["src-083","src-056","src-040","src-016","src-048"],"entity_ids":["theranos","murdoch","holmes","warmenhoven"],"premise_claim_ids":["c-fin-2017-valuation-attributed","c-fin-murdoch-buyback"],"qualification":"","response":"","outcome":""},"reading":"Analysis: A life-sciences news site reported in March 2017 that the offer of two additional shares for each share held, conditional on not suing, effectively cut the share value from $15–$17 to $5, and that on a February 2017 investor call the company reported no material revenue in 2015 or 2016 and about $200 million in the bank; these figures are not documented in Theranos's filings. According to an online encyclopaedia, holders of more than 99 percent of the shares took part in the May 2017 recapitalisation, releasing potential claims against Theranos in exchange for new preferred stock. A business news site, citing a national newspaper and an unnamed source, reported that Murdoch did not take part and that Theranos bought back his $125 million stake for $1; the price is not documented in any filing. Murdoch declined to comment when a business news site reported his losses in 2018, and the criminal court later listed him as a restitution payee for $124,999,997."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-3ea6ca7fa2db8c393125fc08","record":{"id":"display-claim-3ea6ca7fa2db8c393125fc08","kind":"analysis","text":"In late 2017, according to the SEC, Theranos was near bankruptcy when it took a term loan from Fortress secured on its patent portfolio, which it expected to fund about a year of work on its miniLab. A 2020 law-review article puts the loan at $100 million and notes reports that only $65 million was disbursed before Theranos defaulted; a trade journal reported a $65 million loan with a covenant allowing foreclosure if cash fell below a threshold, and an online encyclopaedia says the loan was made for 4 percent of the company. The loan agreement itself is not in the record, so the amount drawn and any equity component are reported rather than documented.","source_ids":["src-002","src-009","src-089","src-038","src-030","src-083"],"entity_ids":["theranos","fortress","david-taylor"],"premise_claim_ids":["c-wd-loan","c-wd-loan-terms-attributed"],"qualification":"","response":"","outcome":""},"reading":"Analysis: In late 2017, according to the SEC, Theranos was near bankruptcy when it took a term loan from Fortress secured on its patent portfolio, which it expected to fund about a year of work on its miniLab. A 2020 law-review article puts the loan at $100 million and notes reports that only $65 million was disbursed before Theranos defaulted; a trade journal reported a $65 million loan with a covenant allowing foreclosure if cash fell below a threshold, and an online encyclopaedia says the loan was made for 4 percent of the company. The loan agreement itself is not in the record, so the amount drawn and any equity component are reported rather than documented."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-dd58e439003b0023697fe82f","record":{"id":"display-claim-dd58e439003b0023697fe82f","kind":"analysis","text":"The 2018 wind-down plan provided for no distributions to shareholders, because the remaining cash was far from enough to pay creditors in full. In May 2023 the criminal court ordered Holmes and Balwani to pay $452,047,268 in restitution, about $397 million to twelve investors and $54.5 million to Safeway and Walgreens, crediting what Theranos had paid three investors in civil settlements but not crediting any residual value of the Theranos shares.","source_ids":["src-009","src-008","src-016","src-071"],"entity_ids":["theranos","holmes","balwani","safeway","walgreen-co","united-states"],"premise_claim_ids":["c-wd-abc-plan","c-crim-restitution"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The 2018 wind-down plan provided for no distributions to shareholders, because the remaining cash was far from enough to pay creditors in full. In May 2023 the criminal court ordered Holmes and Balwani to pay $452,047,268 in restitution, about $397 million to twelve investors and $54.5 million to Safeway and Walgreens, crediting what Theranos had paid three investors in civil settlements but not crediting any residual value of the Theranos shares."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-83a38712938288019aa9d945","record":{"id":"display-claim-83a38712938288019aa9d945","kind":"analysis","text":"The counterparty in the Theranos agreements and lawsuits is Walgreen Co., an Illinois corporation based in Deerfield, Illinois (SEC Central Index Key 0000104207), which in a July 2018 filing named Walgreens Boots Alliance, Inc. as its corporate parent. Two companies listed as its subsidiaries in 2012 appear in the record: WVC Investments, LLC, a Delaware company that bought the Theranos convertible note, and Walgreen Arizona Drug Co., an Arizona company that was later sued with Walgreens Boots Alliance by Arizona patients; the Walgreens defendants denied the patients' allegations when they settled. Wade Miquelon, as WVC's President, signed the documents by which WVC purchased the note, and in the 2016 lawsuit Theranos argued that it owed the note obligation to WVC rather than to Walgreen Co.","source_ids":["src-023","src-059","src-076","src-041","src-058"],"entity_ids":["walgreen-co","wba","wvc","walgreen-az","wade-miquelon","theranos","holmes","balwani"],"premise_claim_ids":["c-wag-walgreen-co","c-wag-subsidiaries","c-wag-note-wvc","c-civ-arizona-class"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The counterparty in the Theranos agreements and lawsuits is Walgreen Co., an Illinois corporation based in Deerfield, Illinois (SEC Central Index Key 0000104207), which in a July 2018 filing named Walgreens Boots Alliance, Inc. as its corporate parent. Two companies listed as its subsidiaries in 2012 appear in the record: WVC Investments, LLC, a Delaware company that bought the Theranos convertible note, and Walgreen Arizona Drug Co., an Arizona company that was later sued with Walgreens Boots Alliance by Arizona patients; the Walgreens defendants denied the patients' allegations when they settled. Wade Miquelon, as WVC's President, signed the documents by which WVC purchased the note, and in the 2016 lawsuit Theranos argued that it owed the note obligation to WVC rather than to Walgreen Co."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-1e4cd5640ce5fca3b72b8a04","record":{"id":"display-claim-1e4cd5640ce5fca3b72b8a04","kind":"analysis","text":"The partnership began with meetings in 2010 between Holmes, Balwani and Walgreens executives, which Wade Miquelon, Walgreens' former chief financial officer, described at Holmes's trial, saying Walgreens was very excited about the partnership, and Holmes testified that Balwani and some lawyers were involved in the negotiations, according to business news coverage of the trial; and Balwani told the SEC, in testimony quoted by the Ninth Circuit, that he built the company's financial model with Safeway and Walgreens from around 2010. According to Walgreens' complaint, as summarised by the Delaware court in 2017, Theranos sent Walgreens a Regulatory Summary on May 7, 2010 stating that its finger-stick technology had been approved for launch in clinical studies; relying on this and its own due diligence, Walgreens signed an initial Master Services Agreement on July 30, 2010, aimed at a blood-testing service in its stores nationwide. The HHS Departmental Appeals Board later found that the 2010 agreement said Theranos had developed devices that could run any blood test in real time, and that Theranos presented Walgreens with a \"Medicaid/Medicare Opportunity\".","source_ids":["src-043","src-050","src-016","src-041","src-071"],"entity_ids":["wade-miquelon","walgreen-co","holmes","balwani","theranos","safeway"],"premise_claim_ids":["c-wag-2010-meetings","c-prt-retail-outreach","c-wag-2010-agreement","c-wag-2010-representations"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The partnership began with meetings in 2010 between Holmes, Balwani and Walgreens executives, which Wade Miquelon, Walgreens' former chief financial officer, described at Holmes's trial, saying Walgreens was very excited about the partnership, and Holmes testified that Balwani and some lawyers were involved in the negotiations, according to business news coverage of the trial; and Balwani told the SEC, in testimony quoted by the Ninth Circuit, that he built the company's financial model with Safeway and Walgreens from around 2010. According to Walgreens' complaint, as summarised by the Delaware court in 2017, Theranos sent Walgreens a Regulatory Summary on May 7, 2010 stating that its finger-stick technology had been approved for launch in clinical studies; relying on this and its own due diligence, Walgreens signed an initial Master Services Agreement on July 30, 2010, aimed at a blood-testing service in its stores nationwide. The HHS Departmental Appeals Board later found that the 2010 agreement said Theranos had developed devices that could run any blood test in real time, and that Theranos presented Walgreens with a \"Medicaid/Medicare Opportunity\"."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-d3f300ac50f93d5e4446a3f9","record":{"id":"display-claim-d3f300ac50f93d5e4446a3f9","kind":"analysis","text":"The June 5, 2012 Master Services Agreement provided for Theranos Wellness Centers inside Walgreens stores, where technicians would collect blood to be tested at one of two CLIA-certified laboratories owned and operated by Theranos. Walgreens agreed to pay an Innovation Fee of up to $100 million, paid in full under a December 2013 amendment, and to provide $40 million for a convertible note. The SEC's complaint, which does not name the chain, describes the same arrangement at a national pharmacy chain in 2012: after the chain raised concerns, the contract became a two-phase roll-out in which samples went to central Theranos laboratories until its analysers obtained regulatory approval.","source_ids":["src-041","src-002"],"entity_ids":["theranos","walgreen-co","sec"],"premise_claim_ids":["c-wag-msa-2012","c-sec-two-phase"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The June 5, 2012 Master Services Agreement provided for Theranos Wellness Centers inside Walgreens stores, where technicians would collect blood to be tested at one of two CLIA-certified laboratories owned and operated by Theranos. Walgreens agreed to pay an Innovation Fee of up to $100 million, paid in full under a December 2013 amendment, and to provide $40 million for a convertible note. The SEC's complaint, which does not name the chain, describes the same arrangement at a national pharmacy chain in 2012: after the chain raised concerns, the contract became a two-phase roll-out in which samples went to central Theranos laboratories until its analysers obtained regulatory approval."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-39fddbdd553ac3111586d023","record":{"id":"display-claim-39fddbdd553ac3111586d023","kind":"analysis","text":"The pilot opened on March 20, 2013 in a Phoenix store, and on September 9, 2013 Theranos announced the roll-out; from late 2013 tests were sold to the public in Walgreens stores in Palo Alto and the Phoenix area, where, according to the indictment, patients paid Theranos, or Walgreens on its behalf; on the patient counts the jury acquitted Holmes and convicted Balwani. By the fall of 2015 there were 41 centres (40 in Arizona and one in California, according to trial reporting). A former Walgreens executive, Nimesh Jhaveri, testified about the roll-out; according to business news coverage of his testimony, Walgreens cut its roll-out goal from 500 centres to 200 in August 2014, and he said he had told Balwani that a plan to improve the patient experience was needed before any expansion.","source_ids":["src-041","src-016","src-010","src-065","src-090"],"entity_ids":["theranos","walgreen-co","balwani","holmes"],"premise_claim_ids":["c-wag-pilot","c-wag-payment-for-tests","c-wag-rollout-targets"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The pilot opened on March 20, 2013 in a Phoenix store, and on September 9, 2013 Theranos announced the roll-out; from late 2013 tests were sold to the public in Walgreens stores in Palo Alto and the Phoenix area, where, according to the indictment, patients paid Theranos, or Walgreens on its behalf; on the patient counts the jury acquitted Holmes and convicted Balwani. By the fall of 2015 there were 41 centres (40 in Arizona and one in California, according to trial reporting). A former Walgreens executive, Nimesh Jhaveri, testified about the roll-out; according to business news coverage of his testimony, Walgreens cut its roll-out goal from 500 centres to 200 in August 2014, and he said he had told Balwani that a plan to improve the patient experience was needed before any expansion."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-35d49b3789166b8e1d368301","record":{"id":"display-claim-35d49b3789166b8e1d368301","kind":"analysis","text":"What investors were told about the partnership is part of the fraud cases. The Justice Department said trial evidence showed representations that the centres would grow from a few dozen to 900 while Holmes and Balwani knew the relationship was stagnating, and the SEC alleged that Balwani, who managed the relationship with the pharmacy chain it calls \"Pharmacy A\", drafted projections assuming 800 or 900 of its stores by the end of 2015. After Balwani's conviction the prosecutor also said he had conspired to induce Walgreens to invest on the strength of false pharmaceutical endorsements and revenue projections. Arizona patients alleged that Walgreens itself promoted Theranos's \"CLIA-certified laboratory services\" in 2013; Walgreens did not admit liability when it settled their suit.","source_ids":["src-003","src-014","src-058"],"entity_ids":["theranos","walgreen-co","balwani","holmes","united-states","safeway"],"premise_claim_ids":["c-wag-900-representation","c-crim-doj-evidence","c-wag-joint-marketing"],"qualification":"","response":"","outcome":""},"reading":"Analysis: What investors were told about the partnership is part of the fraud cases. The Justice Department said trial evidence showed representations that the centres would grow from a few dozen to 900 while Holmes and Balwani knew the relationship was stagnating, and the SEC alleged that Balwani, who managed the relationship with the pharmacy chain it calls \"Pharmacy A\", drafted projections assuming 800 or 900 of its stores by the end of 2015. After Balwani's conviction the prosecutor also said he had conspired to induce Walgreens to invest on the strength of false pharmaceutical endorsements and revenue projections. Arizona patients alleged that Walgreens itself promoted Theranos's \"CLIA-certified laboratory services\" in 2013; Walgreens did not admit liability when it settled their suit."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-9c5fcd8ff781212eed6281c4","record":{"id":"display-claim-9c5fcd8ff781212eed6281c4","kind":"analysis","text":"On January 28, 2016, three days after CMS notified Theranos of immediate jeopardy at the Newark laboratory, Walgreens sent a notice of breach, according to the Delaware court's summary of Walgreens' complaint. Theranos replied on February 4 that many of the violations had been corrected and that the deficiencies were curable, and accused Walgreens of breaching the agreement by closing the California centre before the cure period expired. Walgreens terminated the agreement for cause on June 12, 2016 and closed all the centres. In May 2016 Theranos had issued corrected reports for every test run on its proprietary technology in 2014 and 2015.","source_ids":["src-041","src-028"],"entity_ids":["walgreen-co","theranos","cms","das"],"premise_claim_ids":["c-wag-breach-notice","c-lab-cms-survey","c-wag-corrected-reports"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On January 28, 2016, three days after CMS notified Theranos of immediate jeopardy at the Newark laboratory, Walgreens sent a notice of breach, according to the Delaware court's summary of Walgreens' complaint. Theranos replied on February 4 that many of the violations had been corrected and that the deficiencies were curable, and accused Walgreens of breaching the agreement by closing the California centre before the cure period expired. Walgreens terminated the agreement for cause on June 12, 2016 and closed all the centres. In May 2016 Theranos had issued corrected reports for every test run on its proprietary technology in 2014 and 2015."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-8c8a289da981011c17c55c75","record":{"id":"display-claim-8c8a289da981011c17c55c75","kind":"analysis","text":"Walgreen Co. sued in the District of Delaware on November 8, 2016, seeking repayment of the $100 million Innovation Fee and the $40 million paid for the note. In July 2017 a magistrate judge recommended denying Theranos's motion to dismiss the counts on the note and on the implied covenant of good faith. Theranos announced on August 1, 2017 that Walgreens would dismiss the suit with no finding or implication of liability; the terms were confidential, although a national newspaper had reported that the settlement was for less than $30 million. A second suit, filed under seal on July 2, 2018, ended on October 1, 2018 with a $5,000,000 judgment for Walgreens; a 2023 settlement document describes it as a judgment for payment arising from a settlement agreement, but the sealed complaint was not retrieved.","source_ids":["src-041","src-042","src-059","src-054","src-080"],"entity_ids":["walgreen-co","theranos","theranos-abc"],"premise_claim_ids":["c-wag-suit-2016","c-wag-settlement-2017","c-wag-suit-2018","c-wag-abc-claim"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Walgreen Co. sued in the District of Delaware on November 8, 2016, seeking repayment of the $100 million Innovation Fee and the $40 million paid for the note. In July 2017 a magistrate judge recommended denying Theranos's motion to dismiss the counts on the note and on the implied covenant of good faith. Theranos announced on August 1, 2017 that Walgreens would dismiss the suit with no finding or implication of liability; the terms were confidential, although a national newspaper had reported that the settlement was for less than $30 million. A second suit, filed under seal on July 2, 2018, ended on October 1, 2018 with a $5,000,000 judgment for Walgreens; a 2023 settlement document describes it as a judgment for payment arising from a settlement agreement, but the sealed complaint was not retrieved."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-9126b7e438e3b58d81b9f3be","record":{"id":"display-claim-9126b7e438e3b58d81b9f3be","kind":"analysis","text":"After Theranos assigned its assets for the benefit of creditors, Walgreens filed a claim on March 11, 2019, based on a promissory note and the judgment, which a 2023 settlement allowed at $45,000,000 for pro rata distribution. In the Arizona patients' class action, Walgreens Boots Alliance and Walgreen Arizona Drug Co. agreed to pay $44 million into a settlement fund, approved on February 6, 2024, while denying the allegations; the fund was intended to repay consumers about double what they had paid for Theranos tests.","source_ids":["src-080","src-074","src-116"],"entity_ids":["walgreen-co","theranos-abc","theranos","wba","walgreen-az","balwani","holmes"],"premise_claim_ids":["c-wag-abc-claim","c-civ-arizona-settlement"],"qualification":"","response":"","outcome":""},"reading":"Analysis: After Theranos assigned its assets for the benefit of creditors, Walgreens filed a claim on March 11, 2019, based on a promissory note and the judgment, which a 2023 settlement allowed at $45,000,000 for pro rata distribution. In the Arizona patients' class action, Walgreens Boots Alliance and Walgreen Arizona Drug Co. agreed to pay $44 million into a settlement fund, approved on February 6, 2024, while denying the allegations; the fund was intended to repay consumers about double what they had paid for Theranos tests."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-ec9aec97ab4a07890f2c7c81","record":{"id":"display-claim-ec9aec97ab4a07890f2c7c81","kind":"analysis","text":"Accounts of what Walgreens put into Theranos differ, partly because they measure different things: the court record shows the $100 million fee and the $40 million note, together $140 million, the figure in trial reporting; a start-up data publisher, citing a national newspaper, reports a $50 million investment, which does not match the note, and $140 million spent on the partnership; and in the criminal case the court awarded Walgreens $40,000,000 in restitution, the loss it found on the investment.","source_ids":["src-054","src-065","src-016"],"entity_ids":["walgreen-co","theranos"],"premise_claim_ids":["c-wag-investment-figures"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Accounts of what Walgreens put into Theranos differ, partly because they measure different things: the court record shows the $100 million fee and the $40 million note, together $140 million, the figure in trial reporting; a start-up data publisher, citing a national newspaper, reports a $50 million investment, which does not match the note, and $140 million spent on the partnership; and in the criminal case the court awarded Walgreens $40,000,000 in restitution, the loss it found on the investment."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-ff04934536f9b04c04a4991e","record":{"id":"display-claim-ff04934536f9b04c04a4991e","kind":"analysis","text":"Safeway Inc., the supermarket chain, is a Delaware corporation based in Pleasanton, California (SEC Central Index Key 0000086144). Theranos signed a Master Purchase Agreement with it in 2010, in which, according to the HHS Departmental Appeals Board, Theranos represented that it was a \"health care provider\" and \"covered entity\" under health-privacy law. The SEC's complaint describes a national grocery chain, which it calls \"Grocery A\" without naming it, that contracted with Theranos in September 2010 after Holmes told its chief executive that Theranos had miniaturised the conventional laboratory and that its analysers were deployed on the battlefield.","source_ids":["src-024","src-071","src-002"],"entity_ids":["safeway","theranos","holmes"],"premise_claim_ids":["c-prt-safeway-entity","c-prt-safeway-2010"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Safeway Inc., the supermarket chain, is a Delaware corporation based in Pleasanton, California (SEC Central Index Key 0000086144). Theranos signed a Master Purchase Agreement with it in 2010, in which, according to the HHS Departmental Appeals Board, Theranos represented that it was a \"health care provider\" and \"covered entity\" under health-privacy law. The SEC's complaint describes a national grocery chain, which it calls \"Grocery A\" without naming it, that contracted with Theranos in September 2010 after Holmes told its chief executive that Theranos had miniaturised the conventional laboratory and that its analysers were deployed on the battlefield."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-ffac025141c553f85111cd3c","record":{"id":"display-claim-ffac025141c553f85111cd3c","kind":"analysis","text":"Steve Burd, who led Safeway for more than 20 years, testified at Holmes's trial that Safeway investigated Theranos's claims before signing and prepared more than 900 stores for the machines; business news coverage of his testimony added that the deal was valued at nearly $400 million, that 969 stores were remodelled, and that Safeway ended the partnership in 2015, two years after his retirement. In cross-examination the defence sought to show that Safeway had not been duped, and Burd agreed that he knew Theranos did not have many customers. The criminal court later counted Safeway among the victims of the investor fraud and awarded it $14,500,000.","source_ids":["src-043","src-071","src-016"],"entity_ids":["steve-burd","safeway","theranos"],"premise_claim_ids":["c-prt-safeway-burd"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Steve Burd, who led Safeway for more than 20 years, testified at Holmes's trial that Safeway investigated Theranos's claims before signing and prepared more than 900 stores for the machines; business news coverage of his testimony added that the deal was valued at nearly $400 million, that 969 stores were remodelled, and that Safeway ended the partnership in 2015, two years after his retirement. In cross-examination the defence sought to show that Safeway had not been duped, and Burd agreed that he knew Theranos did not have many customers. The criminal court later counted Safeway among the victims of the investor fraud and awarded it $14,500,000."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-96be7390117cfbcbf937880b","record":{"id":"display-claim-96be7390117cfbcbf937880b","kind":"analysis","text":"Press reports describe the programme from the outside. Citing a national newspaper's unnamed sources, a regional business journal reported in November 2015 that Safeway was negotiating to end a programme, code-named T-Rex, for Theranos tests in 800 in-store clinics, on which it had spent $350 million without the clinics ever performing the planned blood tests, and that it had also invested more than $10 million in Theranos; Safeway executives were reported to have doubted results given to employees tested at headquarters; no statement by Safeway is in the record. Theranos's general counsel declined to discuss the executives' statements but called the newspaper's questions and information \"inaccurate and defamatory\". A regional news site, summarising that newspaper's reporting in 2021, wrote that the deal began to fizzle by the spring of 2013 after at least one faulty result for an unnamed executive at the headquarters clinic and was unwound as Albertsons acquired Safeway.","source_ids":["src-055","src-093"],"entity_ids":["safeway","theranos","heather-king","walgreen-co"],"premise_claim_ids":["c-prt-safeway-trex","c-prt-safeway-unwind"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Press reports describe the programme from the outside. Citing a national newspaper's unnamed sources, a regional business journal reported in November 2015 that Safeway was negotiating to end a programme, code-named T-Rex, for Theranos tests in 800 in-store clinics, on which it had spent $350 million without the clinics ever performing the planned blood tests, and that it had also invested more than $10 million in Theranos; Safeway executives were reported to have doubted results given to employees tested at headquarters; no statement by Safeway is in the record. Theranos's general counsel declined to discuss the executives' statements but called the newspaper's questions and information \"inaccurate and defamatory\". A regional news site, summarising that newspaper's reporting in 2021, wrote that the deal began to fizzle by the spring of 2013 after at least one faulty result for an unnamed executive at the headquarters clinic and was unwound as Albertsons acquired Safeway."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-8e5717e499fc1fedba89541b","record":{"id":"display-claim-8e5717e499fc1fedba89541b","kind":"analysis","text":"Safeway figures in the fraud cases as an investor and a victim. Before Holmes's trial, according to the same regional news site's summary of press reporting, prosecutors sought to define Safeway and Walgreens as investors; after Balwani's conviction the U.S. Attorney said he had conspired to induce both to invest on the strength of false pharmaceutical endorsements and revenue projections.","source_ids":["src-093","src-014"],"entity_ids":["safeway","theranos","walgreen-co","united-states","balwani","holmes"],"premise_claim_ids":["c-prt-safeway-unwind","c-crim-doj-evidence"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Safeway figures in the fraud cases as an investor and a victim. Before Holmes's trial, according to the same regional news site's summary of press reporting, prosecutors sought to define Safeway and Walgreens as investors; after Balwani's conviction the U.S. Attorney said he had conspired to induce both to invest on the strength of false pharmaceutical endorsements and revenue projections."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-c883eeea5caab026ca9fafa5","record":{"id":"display-claim-c883eeea5caab026ca9fafa5","kind":"analysis","text":"According to the Ninth Circuit, Theranos's partnerships with pharmaceutical companies began in 2008 and 2009 to study its technology and soon soured: a Pfizer representative testified that he believed Theranos's answers to technical due-diligence questions were oblique, deflective or evasive and that the companies had no meaningful dealings after 2008, and Holmes admitted that she had put the logos of Pfizer, GlaxoSmithKline and Schering-Plough on reports about Theranos's technology. A relationship with the Department of Defense to explore the Edison device in combat never materialised; General James Mattis testified that the device was never put into the field.","source_ids":["src-016"],"entity_ids":["theranos","pfizer","holmes","dod","mattis"],"premise_claim_ids":["c-prt-pharma","c-prt-dod"],"qualification":"","response":"","outcome":""},"reading":"Analysis: According to the Ninth Circuit, Theranos's partnerships with pharmaceutical companies began in 2008 and 2009 to study its technology and soon soured: a Pfizer representative testified that he believed Theranos's answers to technical due-diligence questions were oblique, deflective or evasive and that the companies had no meaningful dealings after 2008, and Holmes admitted that she had put the logos of Pfizer, GlaxoSmithKline and Schering-Plough on reports about Theranos's technology. A relationship with the Department of Defense to explore the Edison device in combat never materialised; General James Mattis testified that the device was never put into the field."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-99c4f7cd2b809a1024f81ae0","record":{"id":"display-claim-99c4f7cd2b809a1024f81ae0","kind":"analysis","text":"Holmes testified at her trial, as business news coverage reported, that an early goal was to partner with large retailers and that she approached all of them, including Target, CVS, Walmart, Walgreens and Safeway. A health-care trade publication reported in July 2015 that Theranos had signed a strategic alliance with the Cleveland Clinic earlier that year and planned to offer direct-to-consumer tests with the Harrisburg insurer Capital BlueCross to its 1.3 million enrollees in Central Pennsylvania; a start-up data publisher lists AmeriHealth Caritas and Capital BlueCross as insurers for which Theranos became the laboratory provider in Pennsylvania. The company's claims at the time, including that its technology was FDA-approved, were its own statements.","source_ids":["src-050","src-016","src-091","src-054"],"entity_ids":["holmes","balwani","theranos","walgreen-co","safeway","capital-bluecross","cleveland-clinic","amerihealth"],"premise_claim_ids":["c-prt-retail-outreach","c-prt-health-partners"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Holmes testified at her trial, as business news coverage reported, that an early goal was to partner with large retailers and that she approached all of them, including Target, CVS, Walmart, Walgreens and Safeway. A health-care trade publication reported in July 2015 that Theranos had signed a strategic alliance with the Cleveland Clinic earlier that year and planned to offer direct-to-consumer tests with the Harrisburg insurer Capital BlueCross to its 1.3 million enrollees in Central Pennsylvania; a start-up data publisher lists AmeriHealth Caritas and Capital BlueCross as insurers for which Theranos became the laboratory provider in Pennsylvania. The company's claims at the time, including that its technology was FDA-approved, were its own statements."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-48e313c3a1b300c76082d416","record":{"id":"display-claim-48e313c3a1b300c76082d416","kind":"analysis","text":"One patient-fraud count of the indictment concerns a transfer of $1,126,661 on August 3, 2015 from Theranos's Wells Fargo account to the media agency Horizon Media, Inc. to buy advertisements for the Wellness Centers. Holmes was acquitted on the patient counts and Balwani convicted on them; Horizon Media appears only as the payee.","source_ids":["src-016"],"entity_ids":["theranos","horizon-media"],"premise_claim_ids":["c-prt-horizon-media"],"qualification":"","response":"","outcome":""},"reading":"Analysis: One patient-fraud count of the indictment concerns a transfer of $1,126,661 on August 3, 2015 from Theranos's Wells Fargo account to the media agency Horizon Media, Inc. to buy advertisements for the Wellness Centers. Holmes was acquitted on the patient counts and Balwani convicted on them; Horizon Media appears only as the payee."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-b785066dab3438c94a8fba10","record":{"id":"display-claim-b785066dab3438c94a8fba10","kind":"analysis","text":"Theranos provided blood tests to the public and operated a clinical laboratory from 2011 to 2016, Holmes testified. CMS records identify a laboratory at 7333 Gateway Boulevard, Newark, California (CLIA 05D2025714), with Elizabeth Holmes and Ramesh Balwani as owners, and a laboratory at 1365 N Scottsdale Road, Scottsdale, Arizona (CLIA 03D2077896), directed by Daniel Young in 2017; there was also a laboratory in Palo Alto. Patients suing in Arizona alleged that 90 percent of Theranos's testing was done in Scottsdale, which analysed only venous blood samples.","source_ids":["src-071","src-028","src-029","src-036","src-058"],"entity_ids":["holmes","theranos","dhawan","balwani","cms","daniel-young"],"premise_claim_ids":["c-lab-operating-period","c-lab-newark-clia","c-lab-other-labs","c-lab-scottsdale-volume"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Theranos provided blood tests to the public and operated a clinical laboratory from 2011 to 2016, Holmes testified. CMS records identify a laboratory at 7333 Gateway Boulevard, Newark, California (CLIA 05D2025714), with Elizabeth Holmes and Ramesh Balwani as owners, and a laboratory at 1365 N Scottsdale Road, Scottsdale, Arizona (CLIA 03D2077896), directed by Daniel Young in 2017; there was also a laboratory in Palo Alto. Patients suing in Arizona alleged that 90 percent of Theranos's testing was done in Scottsdale, which analysed only venous blood samples."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-7b8eb5d297c76163c125e767","record":{"id":"display-claim-7b8eb5d297c76163c125e767","kind":"analysis","text":"The laboratory directors' roles were contested at trial. Adam Rosendorff and Mark Pandori were former directors whose testimony Balwani challenged on appeal; Rosendorff, a pathologist, testified that he quit because the technology did not work, a laboratory-industry newsletter reported. His successor, the dermatologist Sunil Dhawan, testified, according to business news coverage, that Balwani, who knew him personally, recruited him in 2014 for what an email called \"mostly an on-call consulting role\", that he visited the laboratory twice and worked five to ten hours between November 2014 and the summer of 2015, and that he never cashed his $5,000 monthly checks; the coverage noted that he met the federal and state requirements for the post. The defence showed that Lynette Sawyer had been added to the licence as co-director in November 2014; she testified that she never set foot in the laboratory, according to a laboratory-industry newsletter.","source_ids":["src-016","src-118","src-065","src-090","src-082"],"entity_ids":["rosendorff","pandori","theranos","balwani","dhawan","holmes","sawyer"],"premise_claim_ids":["c-lab-former-directors","c-lab-dhawan-testimony","c-lab-sawyer"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The laboratory directors' roles were contested at trial. Adam Rosendorff and Mark Pandori were former directors whose testimony Balwani challenged on appeal; Rosendorff, a pathologist, testified that he quit because the technology did not work, a laboratory-industry newsletter reported. His successor, the dermatologist Sunil Dhawan, testified, according to business news coverage, that Balwani, who knew him personally, recruited him in 2014 for what an email called \"mostly an on-call consulting role\", that he visited the laboratory twice and worked five to ten hours between November 2014 and the summer of 2015, and that he never cashed his $5,000 monthly checks; the coverage noted that he met the federal and state requirements for the post. The defence showed that Lynette Sawyer had been added to the licence as co-director in November 2014; she testified that she never set foot in the laboratory, according to a laboratory-industry newsletter."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-fe15b4cc35d9377ba213c7e5","record":{"id":"display-claim-fe15b4cc35d9377ba213c7e5","kind":"analysis","text":"Kingshuk Das took over in 2016: Theranos told CMS on February 12, 2016 that he had been appointed, and CMS treated him as director from March 11, 2016. He worked at Theranos until June 2018 and, according to trial reporting, testified that he voided every test run on the Edison devices in 2014 and 2015.","source_ids":["src-045","src-028","src-016","src-118"],"entity_ids":["das","theranos","cms"],"premise_claim_ids":["c-lab-das"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Kingshuk Das took over in 2016: Theranos told CMS on February 12, 2016 that he had been appointed, and CMS treated him as director from March 11, 2016. He worked at Theranos until June 2018 and, according to trial reporting, testified that he voided every test run on the Edison devices in 2014 and 2015."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-104b2e30fa86f47f91d4a236","record":{"id":"display-claim-104b2e30fa86f47f91d4a236","kind":"analysis","text":"FDA investigators inspected the Newark site as a medical-device manufacturer from August 25 to September 16, 2015 and issued a Form FDA-483, addressed to Balwani as President, stating that Theranos was shipping an uncleared device, which it treated as Class I exempt, between California, Arizona and Pennsylvania; press reports identified it as the Nanotainer blood-collection tube. When the reports were released in October 2015, a life-sciences news site said they called the Nanotainer an uncleared Class II device and listed 13 concerns. Theranos responded that it had been moving from laboratory to FDA guidelines for several years and was working with regulators; earlier that month it had announced that it would stop using finger-prick samples for all tests except a herpes test the FDA had cleared.","source_ids":["src-079","src-067","src-020"],"entity_ids":["theranos","balwani","fda"],"premise_claim_ids":["c-lab-fda-483","c-lab-fda-press"],"qualification":"","response":"","outcome":""},"reading":"Analysis: FDA investigators inspected the Newark site as a medical-device manufacturer from August 25 to September 16, 2015 and issued a Form FDA-483, addressed to Balwani as President, stating that Theranos was shipping an uncleared device, which it treated as Class I exempt, between California, Arizona and Pennsylvania; press reports identified it as the Nanotainer blood-collection tube. When the reports were released in October 2015, a life-sciences news site said they called the Nanotainer an uncleared Class II device and listed 13 concerns. Theranos responded that it had been moving from laboratory to FDA guidelines for several years and was working with regulators; earlier that month it had announced that it would stop using finger-prick samples for all tests except a herpes test the FDA had cleared."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-8cc3c27525a13f1af9dbf8c8","record":{"id":"display-claim-8cc3c27525a13f1af9dbf8c8","kind":"analysis","text":"The superseding indictment alleged that Holmes and Balwani told investors that Theranos did not need FDA approval and was applying voluntarily, when the FDA had required it to seek clearance or approval since late 2013; the verdicts on the investor counts are set out in the account of the criminal case.","source_ids":["src-016"],"entity_ids":["holmes","balwani","theranos","fda"],"premise_claim_ids":["c-lab-fda-requirement"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The superseding indictment alleged that Holmes and Balwani told investors that Theranos did not need FDA approval and was applying voluntarily, when the FDA had required it to seek clearance or approval since late 2013; the verdicts on the investor counts are set out in the account of the criminal case."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-28c040ccdb7b2ddb306d2644","record":{"id":"display-claim-28c040ccdb7b2ddb306d2644","kind":"analysis","text":"CMS surveyed the Newark laboratory in 2015; the on-site work ended on November 20 and the survey on December 23, 2015. It found the laboratory out of compliance with five Condition-level requirements, and on January 25, 2016 notified Theranos that its hematology deficiencies amounted to immediate jeopardy to patient health and safety. On March 18, 2016 CMS proposed revoking the laboratory's certificate and a $10,000-a-day penalty, finding many of Theranos's claims of correction not credible, including the lack of documentation that corrected reports had been issued, and citing the failure to meet the requirements for a high-complexity laboratory director. Having confirmed that California bars unlicensed personnel from operating moderately complex instruments, CMS questioned whether, if Theranos's written procedures were inconsistent with state requirements, they could ensure that only licensed staff performed tests; in July it also rejected Theranos's explanation that the lack of a full-time, on-site director had slowed its corrections, since the survey-period director remained director until March 11, 2016.","source_ids":["src-028","src-045"],"entity_ids":["cms","theranos","dhawan"],"premise_claim_ids":["c-lab-cms-survey","c-lab-cms-proposed","c-lab-cms-personnel"],"qualification":"","response":"","outcome":""},"reading":"Analysis: CMS surveyed the Newark laboratory in 2015; the on-site work ended on November 20 and the survey on December 23, 2015. It found the laboratory out of compliance with five Condition-level requirements, and on January 25, 2016 notified Theranos that its hematology deficiencies amounted to immediate jeopardy to patient health and safety. On March 18, 2016 CMS proposed revoking the laboratory's certificate and a $10,000-a-day penalty, finding many of Theranos's claims of correction not credible, including the lack of documentation that corrected reports had been issued, and citing the failure to meet the requirements for a high-complexity laboratory director. Having confirmed that California bars unlicensed personnel from operating moderately complex instruments, CMS questioned whether, if Theranos's written procedures were inconsistent with state requirements, they could ensure that only licensed staff performed tests; in July it also rejected Theranos's explanation that the lack of a full-time, on-site director had slowed its corrections, since the survey-period director remained director until March 11, 2016."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-d3c94c4cff1d4eaed480354a","record":{"id":"display-claim-d3c94c4cff1d4eaed480354a","kind":"analysis","text":"Theranos concluded that every result reported from its TPS 3.5 instruments might have affected patients and voided them all. In May 2016 it issued corrected reports for every test run on its own technology in 2014 and 2015; Das estimated 50,000 corrected reports, while Theranos counted 31,000 voided or corrected tests and confirmed it had known of quality issues since September 2015. Members of the House Committee on Energy and Commerce told CMS in July 2016 that Theranos had voided two years of Edison results affecting thousands of patients. A technology news site had reported in May 2016 that the SEC, federal prosecutors and the Pennsylvania and Arizona health departments were investigating the company; those federal inquiries led to the 2018 SEC actions and indictment.","source_ids":["src-028","src-041","src-029","src-018"],"entity_ids":["theranos","cms","das","sec"],"premise_claim_ids":["c-lab-tps-voided","c-wag-corrected-reports","c-lab-house-letter","c-lab-investigations-2016"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Theranos concluded that every result reported from its TPS 3.5 instruments might have affected patients and voided them all. In May 2016 it issued corrected reports for every test run on its own technology in 2014 and 2015; Das estimated 50,000 corrected reports, while Theranos counted 31,000 voided or corrected tests and confirmed it had known of quality issues since September 2015. Members of the House Committee on Energy and Commerce told CMS in July 2016 that Theranos had voided two years of Edison results affecting thousands of patients. A technology news site had reported in May 2016 that the SEC, federal prosecutors and the Pennsylvania and Arizona health departments were investigating the company; those federal inquiries led to the 2018 SEC actions and indictment."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-6aed449cd674cf2465505cd1","record":{"id":"display-claim-6aed449cd674cf2465505cd1","kind":"analysis","text":"On July 7, 2016 CMS found the laboratory still out of compliance and imposed sanctions: revocation of its CLIA certificate and cancellation of its Medicare approval from September 5, 2016, a limit on hematology testing and payments from July 15, a civil money penalty of $10,000 a day from July 12, and a directed plan of correction requiring a list of all physicians and clients served since January 2014. Medicare cancellation would apply even if Theranos appealed, which it could do within 60 days. Before the sanctions Theranos had made several correction submissions, all rejected, and it had voided two years of Edison results and issued corrected reports; it appealed the sanctions, and Theranos said in April 2017 that the appeal would be withdrawn under the settlement described below.","source_ids":["src-028","src-041","src-029","src-078"],"entity_ids":["cms","theranos"],"premise_claim_ids":["c-lab-cms-sanctions"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On July 7, 2016 CMS found the laboratory still out of compliance and imposed sanctions: revocation of its CLIA certificate and cancellation of its Medicare approval from September 5, 2016, a limit on hematology testing and payments from July 15, a civil money penalty of $10,000 a day from July 12, and a directed plan of correction requiring a list of all physicians and clients served since January 2014. Medicare cancellation would apply even if Theranos appealed, which it could do within 60 days. Before the sanctions Theranos had made several correction submissions, all rejected, and it had voided two years of Edison results and issued corrected reports; it appealed the sanctions, and Theranos said in April 2017 that the appeal would be withdrawn under the settlement described below."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-2d6a3678a5e1d20acdd21ddf","record":{"id":"display-claim-2d6a3678a5e1d20acdd21ddf","kind":"analysis","text":"The July letter also said that on revocation the laboratory's owners and operators, including its director, would be barred from owning or operating a laboratory for at least two years, and listed Holmes and Balwani as owners and Dhawan as director. That bar was tied to the revocation, which CMS withdrew in the 2017 settlement with Theranos, although a 2017 news report said Holmes had been barred in 2016.","source_ids":["src-028","src-078"],"entity_ids":["cms","theranos","holmes","balwani","dhawan"],"premise_claim_ids":["c-lab-owner-ban"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The July letter also said that on revocation the laboratory's owners and operators, including its director, would be barred from owning or operating a laboratory for at least two years, and listed Holmes and Balwani as owners and Dhawan as director. That bar was tied to the revocation, which CMS withdrew in the 2017 settlement with Theranos, although a 2017 news report said Holmes had been barred in 2016."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-fcf98e91bc98ce5ae438ef6f","record":{"id":"display-claim-fcf98e91bc98ce5ae438ef6f","kind":"analysis","text":"According to an online encyclopaedia, Theranos withdrew a request for emergency clearance of a Zika test in August 2016, announced in October 2016 that it would close its laboratories and Wellness Centers and lay off about 40 percent of its staff, and in January 2017 cut a further 41 percent, about 155 people, closing its last testing facility after a second failed inspection. CMS's 2017 registry is consistent with that inspection: it lists sanctions against the Scottsdale laboratory for Condition-level non-compliance with immediate jeopardy, including suspension of its certificate and Medicare payments from February 4, 2017 and cancellation of Medicare approval from March 28, 2017.","source_ids":["src-083","src-036"],"entity_ids":["theranos","cms"],"premise_claim_ids":["c-lab-closure-attributed","c-lab-scottsdale-sanctions"],"qualification":"","response":"","outcome":""},"reading":"Analysis: According to an online encyclopaedia, Theranos withdrew a request for emergency clearance of a Zika test in August 2016, announced in October 2016 that it would close its laboratories and Wellness Centers and lay off about 40 percent of its staff, and in January 2017 cut a further 41 percent, about 155 people, closing its last testing facility after a second failed inspection. CMS's 2017 registry is consistent with that inspection: it lists sanctions against the Scottsdale laboratory for Condition-level non-compliance with immediate jeopardy, including suspension of its certificate and Medicare payments from February 4, 2017 and cancellation of Medicare approval from March 28, 2017."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-62da6b4a5a742cdd2efee0f1","record":{"id":"display-claim-62da6b4a5a742cdd2efee0f1","kind":"analysis","text":"In April 2017 Theranos announced a settlement of all proceedings with CMS: it would stay out of the blood-testing business for at least two years, CMS withdrew the revocation of its certificates and cut the penalty to $30,000, and Theranos withdrew its appeal. The terms are Theranos's own account as reported; the report dates the withdrawn appeal to September 2015, before the sanctions existed, which appears to be an error.","source_ids":["src-078"],"entity_ids":["theranos","cms"],"premise_claim_ids":["c-lab-cms-settlement"],"qualification":"","response":"","outcome":""},"reading":"Analysis: In April 2017 Theranos announced a settlement of all proceedings with CMS: it would stay out of the blood-testing business for at least two years, CMS withdrew the revocation of its certificates and cut the penalty to $30,000, and Theranos withdrew its appeal. The terms are Theranos's own account as reported; the report dates the withdrawn appeal to September 2015, before the sanctions existed, which appears to be an error."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-e42cc40ce239f79282e34f51","record":{"id":"display-claim-e42cc40ce239f79282e34f51","kind":"analysis","text":"Arizona acted separately. Patients alleged that state health inspectors had found multiple deficiencies at the Scottsdale laboratory in April 2015, which Theranos called routine and said had been fixed within days or weeks. In April 2017 the Arizona Attorney General sued under the Consumer Fraud Act, alleging that between 2013 and 2016 Theranos sold about 1,545,339 tests to about 175,940 Arizona consumers and voided or corrected about 834,233 of 7,862,146 results, and that it misrepresented its testing. Theranos denied the allegations but entered a consent decree to pay $4,652,000 in restitution, $200,000 in penalties and $25,000 in fees; the Attorney General began mailing refunds in December 2017 and describes the settlement as closed.","source_ids":["src-058","src-031"],"entity_ids":["theranos","az-ag"],"premise_claim_ids":["c-lab-arizona-inspection","c-lab-az-ag"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Arizona acted separately. Patients alleged that state health inspectors had found multiple deficiencies at the Scottsdale laboratory in April 2015, which Theranos called routine and said had been fixed within days or weeks. In April 2017 the Arizona Attorney General sued under the Consumer Fraud Act, alleging that between 2013 and 2016 Theranos sold about 1,545,339 tests to about 175,940 Arizona consumers and voided or corrected about 834,233 of 7,862,146 results, and that it misrepresented its testing. Theranos denied the allegations but entered a consent decree to pay $4,652,000 in restitution, $200,000 in penalties and $25,000 in fees; the Attorney General began mailing refunds in December 2017 and describes the settlement as closed."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-1fecb7ea2223a67a74063470","record":{"id":"display-claim-1fecb7ea2223a67a74063470","kind":"analysis","text":"The SEC filed two civil complaints in the Northern District of California on March 14, 2018: SEC v. Elizabeth Holmes and Theranos, Inc. (5:18-cv-01602) and SEC v. Ramesh \"Sunny\" Balwani (5:18-cv-01603). It charged that the three raised more than $700 million from investors from late 2013 to 2015 through an elaborate, years-long fraud in which they exaggerated or misstated the company's technology, business and financial performance. These were the SEC's charges, not findings of a court. Theranos and Holmes settled the same day without admitting or denying them; the SEC said it would litigate against Balwani, and a public radio report in September 2018 said he was still contesting the charges.","source_ids":["src-002","src-003","src-007","src-008"],"entity_ids":["sec","theranos","holmes","balwani"],"premise_claim_ids":["c-sec-charges"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The SEC filed two civil complaints in the Northern District of California on March 14, 2018: SEC v. Elizabeth Holmes and Theranos, Inc. (5:18-cv-01602) and SEC v. Ramesh \"Sunny\" Balwani (5:18-cv-01603). It charged that the three raised more than $700 million from investors from late 2013 to 2015 through an elaborate, years-long fraud in which they exaggerated or misstated the company's technology, business and financial performance. These were the SEC's charges, not findings of a court. Theranos and Holmes settled the same day without admitting or denying them; the SEC said it would litigate against Balwani, and a public radio report in September 2018 said he was still contesting the charges."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-e5752a26cbf51805e1b96207","record":{"id":"display-claim-e5752a26cbf51805e1b96207","kind":"analysis","text":"The complaints allege that investors were led to believe Theranos had a commercially ready portable analyser that could run a full range of tests from a few drops of blood, when its proprietary analyser performed only about 12 of the more than 200 tests on its menu and the rest ran on third-party analysers, some modified for fingerstick samples. They also allege false claims that the technology had been used by the Department of Defense in Afghanistan and on medevac helicopters, and that Theranos would generate more than $100 million in revenue in 2014, when it generated a little more than $100,000 in revenue from operations. In August 2015, the SEC alleged, Holmes gave a potential investor results showing $108 million of 2014 revenue and projections of $240 million for 2015 and $750 million for 2016. Holmes and Theranos neither admitted nor denied these allegations in their settlement.","source_ids":["src-002","src-007","src-016"],"entity_ids":["sec","holmes","balwani","theranos","dod"],"premise_claim_ids":["c-sec-allegations","c-fin-projections"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The complaints allege that investors were led to believe Theranos had a commercially ready portable analyser that could run a full range of tests from a few drops of blood, when its proprietary analyser performed only about 12 of the more than 200 tests on its menu and the rest ran on third-party analysers, some modified for fingerstick samples. They also allege false claims that the technology had been used by the Department of Defense in Afghanistan and on medevac helicopters, and that Theranos would generate more than $100 million in revenue in 2014, when it generated a little more than $100,000 in revenue from operations. In August 2015, the SEC alleged, Holmes gave a potential investor results showing $108 million of 2014 revenue and projections of $240 million for 2015 and $750 million for 2016. Holmes and Theranos neither admitted nor denied these allegations in their settlement."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-f5311e842e856fcc925c8b08","record":{"id":"display-claim-f5311e842e856fcc925c8b08","kind":"analysis","text":"The complaints also tell the company's history. They state that Holmes and Balwani were its only senior managing executives during 2013 to 2015; that in 2012, after concerns at a national pharmacy chain the SEC calls \"Pharmacy A\", the contract became a two-phase roll-out with testing at two central Theranos laboratories; that in 2016, after regulatory inspections, Theranos left the retail testing business, both retail partners ended their relationships and Balwani left in May 2016; and that in 2017 Theranos, Holmes and Balwani settled an investor's securities-fraud suit and Theranos settled the pharmacy chain's breach-of-contract suit.","source_ids":["src-002","src-003"],"entity_ids":["theranos","holmes","balwani","sec"],"premise_claim_ids":["c-ld-sole-executives","c-sec-two-phase","c-sec-retail-exit","c-sec-prior-settlements"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The complaints also tell the company's history. They state that Holmes and Balwani were its only senior managing executives during 2013 to 2015; that in 2012, after concerns at a national pharmacy chain the SEC calls \"Pharmacy A\", the contract became a two-phase roll-out with testing at two central Theranos laboratories; that in 2016, after regulatory inspections, Theranos left the retail testing business, both retail partners ended their relationships and Balwani left in May 2016; and that in 2017 Theranos, Holmes and Balwani settled an investor's securities-fraud suit and Theranos settled the pharmacy chain's breach-of-contract suit."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-29cbd92d1891e88f97e77df8","record":{"id":"display-claim-29cbd92d1891e88f97e77df8","kind":"analysis","text":"Against Holmes and Theranos the SEC sought injunctions, a civil penalty from Holmes, a bar on her serving as an officer or director of any listed company, the return of shares including 18,897,137 Class B shares and the surrender of her super-majority voting shares; against Balwani it sought an injunction, a civil penalty and an officer-and-director bar.","source_ids":["src-002","src-003"],"entity_ids":["sec","holmes","theranos","balwani"],"premise_claim_ids":["c-sec-relief-sought"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Against Holmes and Theranos the SEC sought injunctions, a civil penalty from Holmes, a bar on her serving as an officer or director of any listed company, the return of shares including 18,897,137 Class B shares and the surrender of her super-majority voting shares; against Balwani it sought an injunction, a civil penalty and an officer-and-director bar."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-962ce481426ba200cee3871b","record":{"id":"display-claim-962ce481426ba200cee3871b","kind":"analysis","text":"Theranos and Holmes settled the same day without admitting or denying the allegations. Holmes agreed to pay a $500,000 penalty, to be barred for ten years from serving as an officer or director of a public company, to return the remaining 18.9 million shares she obtained in the period and to convert her Class B shares, giving up voting control. The SEC said this reduction, combined with shares she had returned earlier, materially reduced her stake, and that because of the company's liquidation preference she would not profit from it on a sale or liquidation until, assuming redemption of certain warrants, over $750 million had been returned to what it called defrauded investors and other preferred shareholders. Judge Edward J. Davila signed final judgments against Holmes and Theranos on March 27, 2018 and closed the case.","source_ids":["src-007","src-075"],"entity_ids":["sec","theranos","holmes"],"premise_claim_ids":["c-sec-settlement","c-fin-holmes-sec-equity"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Theranos and Holmes settled the same day without admitting or denying the allegations. Holmes agreed to pay a $500,000 penalty, to be barred for ten years from serving as an officer or director of a public company, to return the remaining 18.9 million shares she obtained in the period and to convert her Class B shares, giving up voting control. The SEC said this reduction, combined with shares she had returned earlier, materially reduced her stake, and that because of the company's liquidation preference she would not profit from it on a sale or liquidation until, assuming redemption of certain warrants, over $750 million had been returned to what it called defrauded investors and other preferred shareholders. Judge Edward J. Davila signed final judgments against Holmes and Theranos on March 27, 2018 and closed the case."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-344a2d178196cfdf298d9867","record":{"id":"display-claim-344a2d178196cfdf298d9867","kind":"analysis","text":"The SEC said it would litigate its claims against Balwani in the Northern District of California. On July 2, 2018 the court related his case to SEC v. Holmes and reassigned it to Judge Davila; its final outcome is not documented in the record.","source_ids":["src-075","src-007"],"entity_ids":["sec","balwani"],"premise_claim_ids":["c-sec-balwani-case"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The SEC said it would litigate its claims against Balwani in the Northern District of California. On July 2, 2018 the court related his case to SEC v. Holmes and reassigned it to Judge Davila; its final outcome is not documented in the record."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-9003cd30f426e7a54e77e9c7","record":{"id":"display-claim-9003cd30f426e7a54e77e9c7","kind":"analysis","text":"On June 14, 2018 a grand jury in the Northern District of California indicted Holmes and Balwani in connection with two multi-million-dollar schemes to promote Theranos (United States v. Elizabeth A. Holmes, et al., 18-CR-00258-EJD), charging each with two counts of conspiracy to commit wire fraud and nine counts of wire fraud. The case was first assigned to Judge Lucy H. Koh. Both pleaded not guilty; at Holmes's trial her lawyer told the jury that, despite some mistakes, leading a failed start-up did not make her a criminal. An indictment is an accusation, not a finding of guilt: tried separately, Holmes was convicted on four of the investor counts and Balwani on every count, and the Ninth Circuit affirmed both convictions in 2025.","source_ids":["src-062","src-010","src-043","src-065","src-014","src-016"],"entity_ids":["united-states","holmes","balwani","theranos"],"premise_claim_ids":["c-crim-indictment-2018"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On June 14, 2018 a grand jury in the Northern District of California indicted Holmes and Balwani in connection with two multi-million-dollar schemes to promote Theranos (United States v. Elizabeth A. Holmes, et al., 18-CR-00258-EJD), charging each with two counts of conspiracy to commit wire fraud and nine counts of wire fraud. The case was first assigned to Judge Lucy H. Koh. Both pleaded not guilty; at Holmes's trial her lawyer told the jury that, despite some mistakes, leading a failed start-up did not make her a criminal. An indictment is an accusation, not a finding of guilt: tried separately, Holmes was convicted on four of the investor counts and Balwani on every count, and the Ninth Circuit affirmed both convictions in 2025."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-afad4f569b3eebd9e49cc983","record":{"id":"display-claim-afad4f569b3eebd9e49cc983","kind":"analysis","text":"The indictment was superseded twice in July 2020. The third superseding indictment charged both with conspiring to defraud investors from 2010 to 2015 (Count 1) and patients from 2013 to 2016 (Count 2), six counts of wire fraud on investors who invested in 2013 and 2014 (Counts 3 to 8) and four counts of wire fraud on patients (Counts 9 to 12). The investor counts rest on six transfers into Theranos's Comerica Bank account, from $99,990 on December 30, 2013 to $99,999,984 on October 31, 2014, by investors identified only by number. The patient counts concern tests sold through Walgreens stores in California and Arizona and, in Count 12, a $1,126,661 payment to Horizon Media for Wellness Center advertising. The indictment also alleged that Holmes and Balwani told investors FDA approval was unnecessary when, by late 2013 and throughout 2014, the FDA was requiring Theranos to seek it. Horizon Media is named only as the payee for the advertising. These were the government's charges, and the verdicts set out below differed for the two defendants: Holmes was acquitted on the patient conspiracy and three patient wire-fraud counts, a fourth having been dismissed during her trial, and Balwani was convicted on all of them.","source_ids":["src-016","src-014","src-010"],"entity_ids":["united-states","holmes","balwani","theranos","walgreen-co","horizon-media","fda"],"premise_claim_ids":["c-crim-superseding","c-crim-investor-wires","c-wag-payment-for-tests","c-prt-horizon-media","c-lab-fda-requirement"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The indictment was superseded twice in July 2020. The third superseding indictment charged both with conspiring to defraud investors from 2010 to 2015 (Count 1) and patients from 2013 to 2016 (Count 2), six counts of wire fraud on investors who invested in 2013 and 2014 (Counts 3 to 8) and four counts of wire fraud on patients (Counts 9 to 12). The investor counts rest on six transfers into Theranos's Comerica Bank account, from $99,990 on December 30, 2013 to $99,999,984 on October 31, 2014, by investors identified only by number. The patient counts concern tests sold through Walgreens stores in California and Arizona and, in Count 12, a $1,126,661 payment to Horizon Media for Wellness Center advertising. The indictment also alleged that Holmes and Balwani told investors FDA approval was unnecessary when, by late 2013 and throughout 2014, the FDA was requiring Theranos to seek it. Horizon Media is named only as the payee for the advertising. These were the government's charges, and the verdicts set out below differed for the two defendants: Holmes was acquitted on the patient conspiracy and three patient wire-fraud counts, a fourth having been dismissed during her trial, and Balwani was convicted on all of them."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-32c50f085c419dd7c2c4d8bd","record":{"id":"display-claim-32c50f085c419dd7c2c4d8bd","kind":"analysis","text":"Holmes was tried first. On January 3, 2022 the jury convicted her of conspiracy to defraud investors (Count 1) and three counts of wire fraud on individual investors (Counts 6 to 8), involving transfers of more than $140 million; it acquitted her of the patient conspiracy and three patient counts and could not agree on three investor counts concerning C-1 investors, while a further patient count had been dismissed at trial. The amended judgment of May 30, 2023 records her as guilty on Counts 1, 6, 7 and 8, not guilty on Counts 2, 10, 11 and 12, with Counts 3, 4, 5 and 9 dismissed.","source_ids":["src-014","src-016","src-071"],"entity_ids":["holmes","united-states","theranos"],"premise_claim_ids":["c-crim-holmes-verdict"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Holmes was tried first. On January 3, 2022 the jury convicted her of conspiracy to defraud investors (Count 1) and three counts of wire fraud on individual investors (Counts 6 to 8), involving transfers of more than $140 million; it acquitted her of the patient conspiracy and three patient counts and could not agree on three investor counts concerning C-1 investors, while a further patient count had been dismissed at trial. The amended judgment of May 30, 2023 records her as guilty on Counts 1, 6, 7 and 8, not guilty on Counts 2, 10, 11 and 12, with Counts 3, 4, 5 and 9 dismissed."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-2a44caa8ba2c874db0c926ca","record":{"id":"display-claim-2a44caa8ba2c874db0c926ca","kind":"analysis","text":"Balwani was tried separately in a four-month trial and convicted on July 7, 2022 on all twelve counts, including both conspiracies and the patient counts. The precise division of responsibilities between the two was disputed at the trials, but evidence at both showed that Balwani oversaw the patient-testing laboratory and the retail relationships, according to the Ninth Circuit. After his conviction the U.S. Attorney summarised the evidence: although Theranos had no revenue in 2012 and 2013, Balwani and Holmes told investors in 2013 and 2014 that it earned hundreds of millions from pharmaceutical companies and the military, and Balwani conspired to induce Walgreens and Safeway to invest on the strength of false pharmaceutical endorsements and revenue projections.","source_ids":["src-014","src-016"],"entity_ids":["balwani","united-states","theranos","holmes","safeway","walgreen-co"],"premise_claim_ids":["c-crim-balwani-verdict","c-ld-balwani-responsibilities","c-crim-doj-evidence"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Balwani was tried separately in a four-month trial and convicted on July 7, 2022 on all twelve counts, including both conspiracies and the patient counts. The precise division of responsibilities between the two was disputed at the trials, but evidence at both showed that Balwani oversaw the patient-testing laboratory and the retail relationships, according to the Ninth Circuit. After his conviction the U.S. Attorney summarised the evidence: although Theranos had no revenue in 2012 and 2013, Balwani and Holmes told investors in 2013 and 2014 that it earned hundreds of millions from pharmaceutical companies and the military, and Balwani conspired to induce Walgreens and Safeway to invest on the strength of false pharmaceutical endorsements and revenue projections."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-38c16ce581299f47511b29a4","record":{"id":"display-claim-38c16ce581299f47511b29a4","kind":"analysis","text":"On November 18, 2022 Judge Edward J. Davila sentenced Holmes to 135 months in prison and three years of supervised release, without a fine, finding ten or more victims and a loss of $120 million, which gave a guideline range of 135 to 168 months. On December 7, 2022 he sentenced Balwani, with the same range, to 155 months on each count, concurrently, three years of supervised release, a $1,200 special assessment and a $25,000 penalty. Balwani was first ordered to surrender on March 15, 2023 and lost his bid to stay free pending appeal; his second amended judgment gives April 20, 2023. According to a business news site, he entered a California prison in April and Holmes reported to a Texas prison on May 30, 2023.","source_ids":["src-062","src-016","src-014","src-015","src-070","src-046"],"entity_ids":["holmes","united-states","balwani","theranos"],"premise_claim_ids":["c-crim-holmes-sentence","c-crim-balwani-sentence","c-crim-surrender"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On November 18, 2022 Judge Edward J. Davila sentenced Holmes to 135 months in prison and three years of supervised release, without a fine, finding ten or more victims and a loss of $120 million, which gave a guideline range of 135 to 168 months. On December 7, 2022 he sentenced Balwani, with the same range, to 155 months on each count, concurrently, three years of supervised release, a $1,200 special assessment and a $25,000 penalty. Balwani was first ordered to surrender on March 15, 2023 and lost his bid to stay free pending appeal; his second amended judgment gives April 20, 2023. According to a business news site, he entered a California prison in April and Holmes reported to a Texas prison on May 30, 2023."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-830fca2ba108bb0dc679f9b8","record":{"id":"display-claim-830fca2ba108bb0dc679f9b8","kind":"analysis","text":"In May 2023 the court ordered both, jointly and severally, to pay $452,047,268 in restitution: about $397 million to the twelve investors identified at sentencing and $54.5 million to Safeway and Walgreens, crediting what Theranos had already paid three investors in civil settlements but not any residual value of the shares. The HHS Departmental Appeals Board noted that Holmes's total restitution obligation comprised $322,747,296 owed to business entities and $129,299,972 to individuals. The largest payees in the schedule are Rupert Murdoch, RDV Corporation, Peer Ventures Group, PFM Funds and Walgreens; the schedule's printed total of $453,047,268 is $1 million more than the amount ordered.","source_ids":["src-016","src-071"],"entity_ids":["holmes","balwani","safeway","walgreen-co","united-states","murdoch","rdv","peer-ventures","pfm-funds","lucas-venture-group","moseley","black-diamond","kovacevich","hall-group","mendenhall","theranos"],"premise_claim_ids":["c-crim-restitution","c-crim-restitution-split","c-crim-restitution-payees"],"qualification":"","response":"","outcome":""},"reading":"Analysis: In May 2023 the court ordered both, jointly and severally, to pay $452,047,268 in restitution: about $397 million to the twelve investors identified at sentencing and $54.5 million to Safeway and Walgreens, crediting what Theranos had already paid three investors in civil settlements but not any residual value of the shares. The HHS Departmental Appeals Board noted that Holmes's total restitution obligation comprised $322,747,296 owed to business entities and $129,299,972 to individuals. The largest payees in the schedule are Rupert Murdoch, RDV Corporation, Peer Ventures Group, PFM Funds and Walgreens; the schedule's printed total of $453,047,268 is $1 million more than the amount ordered."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-da7a2760f3ea60ed516668b5","record":{"id":"display-claim-da7a2760f3ea60ed516668b5","kind":"analysis","text":"On February 24, 2025 a Ninth Circuit panel affirmed both convictions, the sentences and the $452 million restitution order (129 F.4th 636). It denied Holmes's petition for further hearings on May 8, 2025, a television news network reported, and on December 22, 2025 amended its opinion and denied Balwani's petitions for rehearing. Balwani petitioned the Supreme Court in May 2026 (No. 25-1330); the government waived its response, and the Court denied the petition on October 5, 2026.","source_ids":["src-016","src-070","src-057"],"entity_ids":["holmes","balwani","united-states"],"premise_claim_ids":["c-crim-ninth-circuit","c-crim-holmes-rehearing","c-crim-balwani-cert"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On February 24, 2025 a Ninth Circuit panel affirmed both convictions, the sentences and the $452 million restitution order (129 F.4th 636). It denied Holmes's petition for further hearings on May 8, 2025, a television news network reported, and on December 22, 2025 amended its opinion and denied Balwani's petitions for rehearing. Balwani petitioned the Supreme Court in May 2026 (No. 25-1330); the government waived its response, and the Court denied the petition on October 5, 2026."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-14780dd1fdfc02d2fd86099d","record":{"id":"display-claim-14780dd1fdfc02d2fd86099d","kind":"analysis","text":"On March 26, 2026, according to an excerpt of the decision published on a legal blog, Judge Davila cut Holmes's sentence by one year, to 10¼ years, under a retroactive guideline amendment for defendants who did not personally cause substantial financial hardship, accepting her argument that no individual investor-victim had shown such hardship. The government opposed, arguing that she had not accepted responsibility, had paid minimal restitution and was advising her partner on raising capital for a start-up whose prototype device it said resembled Theranos's; the court found that the scrutiny her notoriety brings reduced the risk that she could reoffend in the same way. Before the reduction, a television news network had reported a release date in August 2032.","source_ids":["src-069","src-070"],"entity_ids":["holmes","united-states"],"premise_claim_ids":["c-crim-holmes-reduction","c-aft-government-argument","c-crim-release-date"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On March 26, 2026, according to an excerpt of the decision published on a legal blog, Judge Davila cut Holmes's sentence by one year, to 10¼ years, under a retroactive guideline amendment for defendants who did not personally cause substantial financial hardship, accepting her argument that no individual investor-victim had shown such hardship. The government opposed, arguing that she had not accepted responsibility, had paid minimal restitution and was advising her partner on raising capital for a start-up whose prototype device it said resembled Theranos's; the court found that the scrutiny her notoriety brings reduced the risk that she could reoffend in the same way. Before the reduction, a television news network had reported a release date in August 2032."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-7a4d6ca13d534707f65708ac","record":{"id":"display-claim-7a4d6ca13d534707f65708ac","kind":"analysis","text":"Because of their convictions, the HHS Office of Inspector General excluded both from Medicare, Medicaid and all federal health care programs for 90 years. It excluded Balwani first, and on December 29, 2023 excluded Holmes, extending the five-year minimum on the basis of four aggravating factors. Holmes appealed, arguing among other things that the exclusion depended on Chevron deference, that 90 years was an unlawful lifetime bar and that investment amounts were the wrong measure of risk to federal programs; an administrative law judge upheld the exclusion on April 25, 2025, and the Departmental Appeals Board affirmed it on January 16, 2026.","source_ids":["src-072","src-071"],"entity_ids":["hhs-oig","holmes","balwani","theranos"],"premise_claim_ids":["c-exc-oig-release","c-exc-holmes"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Because of their convictions, the HHS Office of Inspector General excluded both from Medicare, Medicaid and all federal health care programs for 90 years. It excluded Balwani first, and on December 29, 2023 excluded Holmes, extending the five-year minimum on the basis of four aggravating factors. Holmes appealed, arguing among other things that the exclusion depended on Chevron deference, that 90 years was an unlawful lifetime bar and that investment amounts were the wrong measure of risk to federal programs; an administrative law judge upheld the exclusion on April 25, 2025, and the Departmental Appeals Board affirmed it on January 16, 2026."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-bc86fed1602929afb771b86a","record":{"id":"display-claim-bc86fed1602929afb771b86a","kind":"analysis","text":"In October 2016 the investors Partner Investments, L.P., PFM Healthcare Master Fund, L.P. and PFM Healthcare Principals Fund, L.P. sued Theranos, Holmes and Balwani in the Delaware Court of Chancery (C.A. No. 12816-VCL) for fraud, negligent misrepresentation, indemnification and violations of Delaware and California law. In April 2017 they sued Theranos, Holmes and directors Fabrizio Bonanni, William Foege and Daniel Warmenhoven for breach of fiduciary duty, self-dealing and waste (C.A. No. 2017-0262-JTL). These were the plaintiffs' claims and were never decided on the merits. According to an online encyclopaedia, Theranos said the funds had mischaracterised its exchange offer, and on settling its general counsel said the company was confident it would have prevailed. The parties settled in May 2017 and both actions were dismissed by stipulation; in April 2018 the court denied a documentary filmmaker access to unfiled deposition videos from the cases.","source_ids":["src-032","src-083"],"entity_ids":["partner-investments","pfm-master","pfm-principals","theranos","holmes","balwani","bonanni","foege","warmenhoven"],"premise_claim_ids":["c-civ-delaware-suits"],"qualification":"","response":"","outcome":""},"reading":"Analysis: In October 2016 the investors Partner Investments, L.P., PFM Healthcare Master Fund, L.P. and PFM Healthcare Principals Fund, L.P. sued Theranos, Holmes and Balwani in the Delaware Court of Chancery (C.A. No. 12816-VCL) for fraud, negligent misrepresentation, indemnification and violations of Delaware and California law. In April 2017 they sued Theranos, Holmes and directors Fabrizio Bonanni, William Foege and Daniel Warmenhoven for breach of fiduciary duty, self-dealing and waste (C.A. No. 2017-0262-JTL). These were the plaintiffs' claims and were never decided on the merits. According to an online encyclopaedia, Theranos said the funds had mischaracterised its exchange offer, and on settling its general counsel said the company was confident it would have prevailed. The parties settled in May 2017 and both actions were dismissed by stipulation; in April 2018 the court denied a documentary filmmaker access to unfiled deposition videos from the cases."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-06ac6968c608b1dc67071c8d","record":{"id":"display-claim-06ac6968c608b1dc67071c8d","kind":"analysis","text":"The SEC's complaints record the 2017 settlement of an investor's securities-fraud suit against Theranos, Holmes and Balwani. Several investment funds released their claims against Theranos when they took part in the 2017 share exchange.","source_ids":["src-003","src-002","src-073"],"entity_ids":["sec","theranos","holmes","balwani","bdv-xii-b","lvg-xi","pvg-iv"],"premise_claim_ids":["c-sec-prior-settlements","c-fin-tender-offer"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The SEC's complaints record the 2017 settlement of an investor's securities-fraud suit against Theranos, Holmes and Balwani. Several investment funds released their claims against Theranos when they took part in the 2017 share exchange."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-b285e6e7c6722fca02b00589","record":{"id":"display-claim-b285e6e7c6722fca02b00589","kind":"analysis","text":"Two indirect investors, who had bought interests in funds that purchased Theranos stock, filed a class action (N.D. Cal. No. 16-cv-06822-NC) on November 28, 2016 against Theranos, Holmes and Balwani for fraud, misrepresentation and market manipulation. The court dismissed the claim under sections 25401 and 25501 of the California Corporations Code, excluded direct investors from the proposed class and refused a July 2017 request to certify a limited-fund class or freeze the defendants' funds. On May 31, 2018 Magistrate Judge Nathanael M. Cousins denied class certification, finding that questions of reliance defeated predominance and that individual actions were superior; the allegations were not decided.","source_ids":["src-073"],"entity_ids":["theranos","holmes","balwani"],"premise_claim_ids":["c-civ-indirect-class"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Two indirect investors, who had bought interests in funds that purchased Theranos stock, filed a class action (N.D. Cal. No. 16-cv-06822-NC) on November 28, 2016 against Theranos, Holmes and Balwani for fraud, misrepresentation and market manipulation. The court dismissed the claim under sections 25401 and 25501 of the California Corporations Code, excluded direct investors from the proposed class and refused a July 2017 request to certify a limited-fund class or freeze the defendants' funds. On May 31, 2018 Magistrate Judge Nathanael M. Cousins denied class certification, finding that questions of reliance defeated predominance and that individual actions were superior; the allegations were not decided."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-ba6cb654448b5c85a4deaf98","record":{"id":"display-claim-ba6cb654448b5c85a4deaf98","kind":"analysis","text":"Patients who bought Theranos tests brought a consolidated class action in the District of Arizona, In re Arizona Theranos, Inc., Litigation (No. 2:16-cv-2138), against Theranos, Holmes, Balwani, Walgreens Boots Alliance, Inc. and Walgreen Arizona Drug Co. As the court summarised their allegations, Walgreens invested $140 million in Theranos, marketed its unreliable tests, including a September 2013 joint release promoting \"CLIA-certified laboratory services\", concealed material information and drew the blood in its stores; 90 percent of the testing was done at the Scottsdale laboratory; and state inspectors found deficiencies there in April 2015, which Theranos called routine and said it had fixed. Walgreens and Balwani denied all the allegations when they settled.","source_ids":["src-058"],"entity_ids":["theranos","holmes","balwani","wba","walgreen-az","walgreen-co"],"premise_claim_ids":["c-civ-arizona-class","c-wag-joint-marketing","c-lab-scottsdale-volume","c-lab-arizona-inspection"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Patients who bought Theranos tests brought a consolidated class action in the District of Arizona, In re Arizona Theranos, Inc., Litigation (No. 2:16-cv-2138), against Theranos, Holmes, Balwani, Walgreens Boots Alliance, Inc. and Walgreen Arizona Drug Co. As the court summarised their allegations, Walgreens invested $140 million in Theranos, marketed its unreliable tests, including a September 2013 joint release promoting \"CLIA-certified laboratory services\", concealed material information and drew the blood in its stores; 90 percent of the testing was done at the Scottsdale laboratory; and state inspectors found deficiencies there in April 2015, which Theranos called routine and said it had fixed. Walgreens and Balwani denied all the allegations when they settled."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-fdaa29254227392c62cf38d4","record":{"id":"display-claim-fdaa29254227392c62cf38d4","kind":"analysis","text":"On April 10, 2018 Judge H. Russel Holland dismissed, without leave to amend, the RICO claims based on mail fraud and several affirmative-misrepresentation claims against Walgreens and Theranos, but allowed fraud-by-omission claims against all defendants, negligence, contract and unjust-enrichment claims against Walgreens and Theranos, aiding-and-abetting claims against Walgreens and RICO claims based on wire fraud against all defendants to proceed. He held that the Arizona Attorney General's consent decree, under which Theranos had denied the allegations but refunded consumers' costs, did not moot the claims, because Walgreens, Holmes and Balwani had disgorged no profits and the decree did not address punitive damages.","source_ids":["src-058","src-031"],"entity_ids":["theranos","holmes","balwani","wba","walgreen-az","az-ag"],"premise_claim_ids":["c-civ-arizona-dismissal-ruling","c-civ-consent-decree-not-moot","c-lab-az-ag"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On April 10, 2018 Judge H. Russel Holland dismissed, without leave to amend, the RICO claims based on mail fraud and several affirmative-misrepresentation claims against Walgreens and Theranos, but allowed fraud-by-omission claims against all defendants, negligence, contract and unjust-enrichment claims against Walgreens and Theranos, aiding-and-abetting claims against Walgreens and RICO claims based on wire fraud against all defendants to proceed. He held that the Arizona Attorney General's consent decree, under which Theranos had denied the allegations but refunded consumers' costs, did not moot the claims, because Walgreens, Holmes and Balwani had disgorged no profits and the decree did not address punitive damages."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-06259638506f5b576099a788","record":{"id":"display-claim-06259638506f5b576099a788","kind":"analysis","text":"The court certified a class of test purchasers on March 6, 2020. All parties except Holmes settled: Walgreens Boots Alliance and Walgreen Arizona Drug Co. paid $44 million into a non-reversionary fund intended to repay consumers about twice their testing costs, with about $1,000 more for those whose blood was drawn at Walgreens; Balwani withdrew his claims to Theranos's remaining assets; and Theranos's assignee for the benefit of creditors contributed about $1.33 million. Walgreens and Balwani deny the allegations. Judge David G. Campbell gave final approval on February 6, 2024.","source_ids":["src-074","src-080","src-116"],"entity_ids":["wba","walgreen-az","balwani","theranos-abc","theranos","holmes"],"premise_claim_ids":["c-civ-arizona-settlement"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The court certified a class of test purchasers on March 6, 2020. All parties except Holmes settled: Walgreens Boots Alliance and Walgreen Arizona Drug Co. paid $44 million into a non-reversionary fund intended to repay consumers about twice their testing costs, with about $1,000 more for those whose blood was drawn at Walgreens; Balwani withdrew his claims to Theranos's remaining assets; and Theranos's assignee for the benefit of creditors contributed about $1.33 million. Walgreens and Balwani deny the allegations. Judge David G. Campbell gave final approval on February 6, 2024."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-21527d4599437dcde25ba010","record":{"id":"display-claim-21527d4599437dcde25ba010","kind":"analysis","text":"Walgreen Co. sued in Delaware on November 8, 2016 to recover the $100 million Innovation Fee and the $40 million paid for the note; Theranos announced on August 1, 2017 that the suit would be dismissed with no finding or implication of liability. A second suit, filed under seal on July 2, 2018, ended on October 1, 2018 with a $5,000,000 judgment against Theranos, whose basis was not retrieved. Walgreens then filed a claim in the assignment for the benefit of creditors, allowed at $45,000,000 in 2023.","source_ids":["src-041","src-042","src-059","src-080"],"entity_ids":["walgreen-co","theranos","theranos-abc"],"premise_claim_ids":["c-wag-suit-2016","c-wag-suit-2018","c-wag-abc-claim"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Walgreen Co. sued in Delaware on November 8, 2016 to recover the $100 million Innovation Fee and the $40 million paid for the note; Theranos announced on August 1, 2017 that the suit would be dismissed with no finding or implication of liability. A second suit, filed under seal on July 2, 2018, ended on October 1, 2018 with a $5,000,000 judgment against Theranos, whose basis was not retrieved. Walgreens then filed a claim in the assignment for the benefit of creditors, allowed at $45,000,000 in 2023."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-475d90af731e796de892361e","record":{"id":"display-claim-475d90af731e796de892361e","kind":"analysis","text":"In late 2017, according to the SEC's complaint, Theranos was on the verge of bankruptcy and obtained a term loan secured on the value of its patent portfolio, expected to fund about one more year of work on its miniLab device. The lender was Fortress, as Theranos's 2018 letter to stockholders shows; Fortress Investment Group LLC is a Delaware company based in New York (SEC Central Index Key 0001380393). David Taylor, then general counsel, says in his law-firm profile that he led the team that secured $100 million of debt financing.","source_ids":["src-002","src-009","src-089","src-025"],"entity_ids":["theranos","fortress","david-taylor"],"premise_claim_ids":["c-wd-loan","c-wd-fortress-entity","c-ld-taylor-profile"],"qualification":"","response":"","outcome":""},"reading":"Analysis: In late 2017, according to the SEC's complaint, Theranos was on the verge of bankruptcy and obtained a term loan secured on the value of its patent portfolio, expected to fund about one more year of work on its miniLab device. The lender was Fortress, as Theranos's 2018 letter to stockholders shows; Fortress Investment Group LLC is a Delaware company based in New York (SEC Central Index Key 0001380393). David Taylor, then general counsel, says in his law-firm profile that he led the team that secured $100 million of debt financing."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-e250ab8fabef4e1b6c6dfdfe","record":{"id":"display-claim-e250ab8fabef4e1b6c6dfdfe","kind":"analysis","text":"The loan's size and terms are known only from secondary accounts: a 2020 law-review article describes a $100 million loan from Fortress, then a division of SoftBank, secured in part by the patents, and notes reports that only $65 million was disbursed before Theranos defaulted; a trade journal, citing a national newspaper, reported a $65 million loan with a covenant allowing foreclosure if cash fell below a threshold; and an online encyclopaedia says it was made for 4 percent of the company. The loan agreement is not in the record.","source_ids":["src-038","src-030","src-083"],"entity_ids":["fortress","theranos"],"premise_claim_ids":["c-wd-loan-terms-attributed"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The loan's size and terms are known only from secondary accounts: a 2020 law-review article describes a $100 million loan from Fortress, then a division of SoftBank, secured in part by the patents, and notes reports that only $65 million was disbursed before Theranos defaulted; a trade journal, citing a national newspaper, reported a $65 million loan with a covenant allowing foreclosure if cash fell below a threshold; and an online encyclopaedia says it was made for 4 percent of the company. The loan agreement is not in the record."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-424ff796c6fe882663e9003a","record":{"id":"display-claim-424ff796c6fe882663e9003a","kind":"analysis","text":"On December 11, 2017 Theranos assigned its interest in 284 patent properties to Theranos IP Company, LLC, at the Newark laboratory address, including a patent on transmitting assay results with Holmes as inventor; the same day Theranos IP Company granted a security interest in them to Fortress Credit Corp., care of Fortress Investment Group. Both instruments were recorded at the patent office on December 12, 2017. The law-review article describes Theranos IP Company as a wholly owned subsidiary, and the 2018 letter says the company's intellectual property was owned by a \"special purpose subsidiary\" without naming it; no registry record of it was retrieved.","source_ids":["src-033","src-035","src-038","src-009"],"entity_ids":["theranos","tipc","holmes","fortress-credit","fortress"],"premise_claim_ids":["c-wd-patent-assignment","c-wd-security-interest","c-wd-tipc-subsidiary-attributed"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On December 11, 2017 Theranos assigned its interest in 284 patent properties to Theranos IP Company, LLC, at the Newark laboratory address, including a patent on transmitting assay results with Holmes as inventor; the same day Theranos IP Company granted a security interest in them to Fortress Credit Corp., care of Fortress Investment Group. Both instruments were recorded at the patent office on December 12, 2017. The law-review article describes Theranos IP Company as a wholly owned subsidiary, and the 2018 letter says the company's intellectual property was owned by a \"special purpose subsidiary\" without naming it; no registry record of it was retrieved."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-827690b2b96806086f4310ad","record":{"id":"display-claim-827690b2b96806086f4310ad","kind":"analysis","text":"On April 10, 2018 Theranos warned stockholders of an imminent cash shortage; an online encyclopaedia says it laid off most remaining workers that day, leaving fewer than 25 employees against about 800 at its peak. On June 15, 2018 Holmes stepped down as chief executive, remaining chair, and Taylor became chief executive and general counsel.","source_ids":["src-083","src-009","src-021"],"entity_ids":["theranos","holmes","david-taylor"],"premise_claim_ids":["c-wd-headcount-attributed","c-ld-taylor-ceo"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On April 10, 2018 Theranos warned stockholders of an imminent cash shortage; an online encyclopaedia says it laid off most remaining workers that day, leaving fewer than 25 employees against about 800 at its peak. On June 15, 2018 Holmes stepped down as chief executive, remaining chair, and Taylor became chief executive and general counsel."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-02f7c292f59838c8aef6b2a1","record":{"id":"display-claim-02f7c292f59838c8aef6b2a1","kind":"analysis","text":"In a September 2018 letter Taylor told stockholders that Theranos was in default under the Fortress facility, that Fortress could foreclose on all its assets, including the intellectual property held by the special purpose subsidiary, and that the company owed at least $60 million to unsecured creditors. A search for new investment and a sale through the investment bank Jefferies had failed. Theranos proposed that Fortress take its interest in the subsidiary and the intellectual property but give up its claim to the remaining cash, about $5 million net of fees, for unsecured creditors. It would make an assignment for the benefit of creditors under California law and then dissolve under Delaware law, and shareholders would receive nothing. A public radio network reported on September 5 that Taylor said Theranos would dissolve after trying to pay creditors.","source_ids":["src-009","src-008"],"entity_ids":["theranos","david-taylor","fortress","tipc"],"premise_claim_ids":["c-wd-letter-2018","c-wd-abc-plan","c-wd-dissolution-2018"],"qualification":"","response":"","outcome":""},"reading":"Analysis: In a September 2018 letter Taylor told stockholders that Theranos was in default under the Fortress facility, that Fortress could foreclose on all its assets, including the intellectual property held by the special purpose subsidiary, and that the company owed at least $60 million to unsecured creditors. A search for new investment and a sale through the investment bank Jefferies had failed. Theranos proposed that Fortress take its interest in the subsidiary and the intellectual property but give up its claim to the remaining cash, about $5 million net of fees, for unsecured creditors. It would make an assignment for the benefit of creditors under California law and then dissolve under Delaware law, and shareholders would receive nothing. A public radio network reported on September 5 that Taylor said Theranos would dissolve after trying to pay creditors."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-0936a9ad655b2985caa9e20d","record":{"id":"display-claim-0936a9ad655b2985caa9e20d","kind":"analysis","text":"According to an online encyclopaedia, Theranos told investors on September 4, 2018 that it would cease operations, having laid off most remaining staff on August 31. On September 12, 2018 it executed a General Assignment of all its assets and liabilities to Theranos (assignment for the benefit of creditors), LLC, a California company acting solely for the creditors, whose manager, Michael A. Maidy, signed a 2023 settlement on its behalf. Walgreens filed a claim against the assignee in March 2019, allowed at $45,000,000 under that settlement.","source_ids":["src-083","src-080"],"entity_ids":["theranos","david-taylor","fortress","theranos-abc","michael-maidy","walgreen-co"],"premise_claim_ids":["c-wd-shutdown-attributed","c-wd-general-assignment","c-wag-abc-claim"],"qualification":"","response":"","outcome":""},"reading":"Analysis: According to an online encyclopaedia, Theranos told investors on September 4, 2018 that it would cease operations, having laid off most remaining staff on August 31. On September 12, 2018 it executed a General Assignment of all its assets and liabilities to Theranos (assignment for the benefit of creditors), LLC, a California company acting solely for the creditors, whose manager, Michael A. Maidy, signed a 2023 settlement on its behalf. Walgreens filed a claim against the assignee in March 2019, allowed at $45,000,000 under that settlement."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-2d564a0293041918a10c9a31","record":{"id":"display-claim-2d564a0293041918a10c9a31","kind":"analysis","text":"The law-review article states that when Theranos defaulted it assigned ownership of Theranos IP Company to Fortress, and that Fortress took ownership of more than 700 Theranos patents worldwide when Theranos ceased operations; the transfer documents are not in the record. Patents continued to issue to Theranos IP Company, LLC, including U.S. Patent 10,533,994 in January 2020 and two point-of-care device patents in April and June 2020, with Holmes among the inventors. According to the same article, Fortress renamed Theranos IP Company as Labrador Diagnostics LLC in March 2020; no registry record of the change was retrieved, and the 2020 patents still name Theranos IP Company as assignee.","source_ids":["src-038","src-064"],"entity_ids":["theranos","tipc","fortress","holmes","labrador","biofire","biomerieux"],"premise_claim_ids":["c-wd-patents-to-fortress","c-wd-tipc-patents-2020","c-wd-labrador-rename-attributed"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The law-review article states that when Theranos defaulted it assigned ownership of Theranos IP Company to Fortress, and that Fortress took ownership of more than 700 Theranos patents worldwide when Theranos ceased operations; the transfer documents are not in the record. Patents continued to issue to Theranos IP Company, LLC, including U.S. Patent 10,533,994 in January 2020 and two point-of-care device patents in April and June 2020, with Holmes among the inventors. According to the same article, Fortress renamed Theranos IP Company as Labrador Diagnostics LLC in March 2020; no registry record of the change was retrieved, and the 2020 patents still name Theranos IP Company as assignee."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-856f65908fb855af90edb862","record":{"id":"display-claim-856f65908fb855af90edb862","kind":"analysis","text":"On March 9, 2020 Labrador Diagnostics sued BioFire Diagnostics and its parent bioMérieux in Delaware for infringing U.S. Patents 8,283,155 and 10,533,994, which it said it owned by assignment; the complaint alleged that bioMérieux's U.S. subsidiary had agreed with the former owner, on or about June 5, 2018, to inspect patent assets. A technology news site reported that the suit sought to block BioFire's technology, apparently including newly developed COVID-19 tests, and quoted a Stanford patent scholar's sharp criticism of its timing. Labrador said it had not known of BioFire's coronavirus test, offered royalty-free licences for COVID-19 tests and filed a notice of voluntary dismissal on June 28, 2020.","source_ids":["src-052","src-117","src-063"],"entity_ids":["labrador","biofire","biomerieux","fortress"],"premise_claim_ids":["c-wd-labrador-suit","c-wd-labrador-reaction"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On March 9, 2020 Labrador Diagnostics sued BioFire Diagnostics and its parent bioMérieux in Delaware for infringing U.S. Patents 8,283,155 and 10,533,994, which it said it owned by assignment; the complaint alleged that bioMérieux's U.S. subsidiary had agreed with the former owner, on or about June 5, 2018, to inspect patent assets. A technology news site reported that the suit sought to block BioFire's technology, apparently including newly developed COVID-19 tests, and quoted a Stanford patent scholar's sharp criticism of its timing. Labrador said it had not known of BioFire's coronavirus test, offered royalty-free licences for COVID-19 tests and filed a notice of voluntary dismissal on June 28, 2020."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-5abeeac0cc16af2f1fa9ab74","record":{"id":"display-claim-5abeeac0cc16af2f1fa9ab74","kind":"analysis","text":"Holmes left Stanford University to start Theranos in 2003, according to a business magazine. She signed the company's restated certificate as President in December 2004, was chief executive officer from 2003 until 2018 and chaired the board; the indictment says she owned and operated the company. In 2016 CMS correspondence listed her, with Balwani, as an owner of the Newark laboratory. She and Balwani were in a romantic relationship from 2004 to 2016, according to the Ninth Circuit.","source_ids":["src-060","src-086","src-016","src-071","src-072","src-096","src-028"],"entity_ids":["holmes","theranos","balwani","shultz","roughead","perry","nunn","mattis","kovacevich","kissinger","frist","foege","riley-bechtel","dhawan","cms"],"premise_claim_ids":["c-ld-holmes-stanford","c-id-incorporation","c-ld-holmes-ceo","c-ld-florida-2015","c-lab-newark-clia","c-ld-holmes-balwani-relationship"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Holmes left Stanford University to start Theranos in 2003, according to a business magazine. She signed the company's restated certificate as President in December 2004, was chief executive officer from 2003 until 2018 and chaired the board; the indictment says she owned and operated the company. In 2016 CMS correspondence listed her, with Balwani, as an owner of the Newark laboratory. She and Balwani were in a romantic relationship from 2004 to 2016, according to the Ninth Circuit."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-c3351b9e4525ae9d044fad1d","record":{"id":"display-claim-c3351b9e4525ae9d044fad1d","kind":"analysis","text":"Her control rested on a special class of shares. In early 2014, according to the SEC, she persuaded the board and shareholders, who were given only a few days to vote, to create Class B shares with 100 votes each, issued only to her; afterwards she owned just over half of the outstanding shares but over 99 percent of the votes. According to the SEC's complaint, between 2013 and 2015 she was paid $200,000 to $390,000 a year and exercised about 53.7 million stock options, and as of March 2018 she had never sold Theranos stock. She stepped down as chief executive on June 15, 2018, remaining chair.","source_ids":["src-002","src-021"],"entity_ids":["holmes","theranos","david-taylor"],"premise_claim_ids":["c-fin-class-b","c-ld-pay-holmes","c-ld-taylor-ceo"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Her control rested on a special class of shares. In early 2014, according to the SEC, she persuaded the board and shareholders, who were given only a few days to vote, to create Class B shares with 100 votes each, issued only to her; afterwards she owned just over half of the outstanding shares but over 99 percent of the votes. According to the SEC's complaint, between 2013 and 2015 she was paid $200,000 to $390,000 a year and exercised about 53.7 million stock options, and as of March 2018 she had never sold Theranos stock. She stepped down as chief executive on June 15, 2018, remaining chair."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-feea62168e641a9b8f1e06e8","record":{"id":"display-claim-feea62168e641a9b8f1e06e8","kind":"analysis","text":"On March 14, 2018 the SEC charged her, Theranos and Balwani with fraud on investors. She settled the same day without admitting or denying the allegations, agreeing to pay a $500,000 penalty, to a ten-year bar from serving as an officer or director of a public company, to return 18.9 million shares and to give up her voting control; the court entered final judgment on March 27, 2018. The SEC's charges were not court findings, and Balwani contested them.","source_ids":["src-002","src-003","src-007","src-008","src-075"],"entity_ids":["sec","theranos","holmes","balwani"],"premise_claim_ids":["c-sec-charges","c-sec-settlement"],"qualification":"","response":"","outcome":""},"reading":"Analysis: On March 14, 2018 the SEC charged her, Theranos and Balwani with fraud on investors. She settled the same day without admitting or denying the allegations, agreeing to pay a $500,000 penalty, to a ten-year bar from serving as an officer or director of a public company, to return 18.9 million shares and to give up her voting control; the court entered final judgment on March 27, 2018. The SEC's charges were not court findings, and Balwani contested them."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-91d691e9e579a006633a9d73","record":{"id":"display-claim-91d691e9e579a006633a9d73","kind":"analysis","text":"Indicted with Balwani on June 14, 2018, she pleaded not guilty, and at trial her lawyer told the jury that leading a failed start-up did not make her a criminal. The indictment was an accusation; on January 3, 2022 a jury convicted her of conspiracy to defraud investors and three counts of wire fraud on investors, acquitted her of the patient conspiracy and three patient counts and could not agree on three other investor counts, which were later dismissed; Balwani, tried separately, was convicted on all counts. Judge Davila sentenced her on November 18, 2022 to 135 months and three years of supervised release. The restitution of $452,047,268 owed jointly with Balwani comprises, according to the HHS Departmental Appeals Board, $322,747,296 owed to business entities and $129,299,972 to individuals.","source_ids":["src-062","src-010","src-043","src-065","src-014","src-016","src-071"],"entity_ids":["united-states","holmes","balwani","theranos","safeway","walgreen-co"],"premise_claim_ids":["c-crim-indictment-2018","c-crim-holmes-verdict","c-crim-holmes-sentence","c-crim-restitution","c-crim-restitution-split"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Indicted with Balwani on June 14, 2018, she pleaded not guilty, and at trial her lawyer told the jury that leading a failed start-up did not make her a criminal. The indictment was an accusation; on January 3, 2022 a jury convicted her of conspiracy to defraud investors and three counts of wire fraud on investors, acquitted her of the patient conspiracy and three patient counts and could not agree on three other investor counts, which were later dismissed; Balwani, tried separately, was convicted on all counts. Judge Davila sentenced her on November 18, 2022 to 135 months and three years of supervised release. The restitution of $452,047,268 owed jointly with Balwani comprises, according to the HHS Departmental Appeals Board, $322,747,296 owed to business entities and $129,299,972 to individuals."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-ea29bc9e9b493e81866936aa","record":{"id":"display-claim-ea29bc9e9b493e81866936aa","kind":"analysis","text":"The Ninth Circuit affirmed her conviction, sentence and restitution on February 24, 2025 and, a television news network reported, denied her petition for further hearings on May 8, 2025. On March 26, 2026, according to an excerpt of the decision published on a legal blog, Judge Davila reduced her sentence by a year, to 10¼ years, finding that no individual investor-victim had shown substantial financial hardship; before the reduction a television news network had reported a release date in August 2032.","source_ids":["src-016","src-070","src-069"],"entity_ids":["holmes","balwani","united-states"],"premise_claim_ids":["c-crim-ninth-circuit","c-crim-holmes-rehearing","c-crim-holmes-reduction","c-crim-release-date"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The Ninth Circuit affirmed her conviction, sentence and restitution on February 24, 2025 and, a television news network reported, denied her petition for further hearings on May 8, 2025. On March 26, 2026, according to an excerpt of the decision published on a legal blog, Judge Davila reduced her sentence by a year, to 10¼ years, finding that no individual investor-victim had shown substantial financial hardship; before the reduction a television news network had reported a release date in August 2032."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-c44bd79b0edbf6003df87b5b","record":{"id":"display-claim-c44bd79b0edbf6003df87b5b","kind":"analysis","text":"Because of the conviction, the HHS Office of Inspector General notified her on December 29, 2023 that she was excluded from Medicare, Medicaid and all federal health care programs for 90 years. She appealed, arguing among other things that the exclusion rested on Chevron deference, amounted to an unlawful lifetime bar and used the amounts invested as an improper measure of the risk to federal programs; an administrative law judge upheld it on April 25, 2025 and the Departmental Appeals Board affirmed it on January 16, 2026.","source_ids":["src-071","src-072"],"entity_ids":["hhs-oig","holmes","balwani","theranos"],"premise_claim_ids":["c-exc-holmes","c-exc-oig-release"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Because of the conviction, the HHS Office of Inspector General notified her on December 29, 2023 that she was excluded from Medicare, Medicaid and all federal health care programs for 90 years. She appealed, arguing among other things that the exclusion rested on Chevron deference, amounted to an unlawful lifetime bar and used the amounts invested as an improper measure of the risk to federal programs; an administrative law judge upheld it on April 25, 2025 and the Departmental Appeals Board affirmed it on January 16, 2026."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-22d5ec89b7b61463e2b897a3","record":{"id":"display-claim-22d5ec89b7b61463e2b897a3","kind":"analysis","text":"Her partner, Billy Evans, founded and runs Haemanthus, a privately held diagnostics start-up in Austin, Texas, incorporated in Delaware in late 2023 or February 2024, according to two online encyclopaedia articles that differ (no registry record of it was retrieved), which says it is developing a device to test blood, urine and saliva, similar to Theranos's Edison; the company reported raising $3.5 million from friends and family and seeking $15 million more. A public radio network reported in May 2025, citing sources, that Holmes had been advising Evans from prison, and a lawyer for Holmes did not reply to the network's request for comment; the company says she has no formal role and that it is \"not Theranos 2.0\", and a person familiar with it told a national newspaper that she is not involved. Her SEC bar applies only to public companies.","source_ids":["src-077","src-085","src-098"],"entity_ids":["haemanthus","billy-evans","holmes"],"premise_claim_ids":["c-aft-haemanthus","c-aft-holmes-advice"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Her partner, Billy Evans, founded and runs Haemanthus, a privately held diagnostics start-up in Austin, Texas, incorporated in Delaware in late 2023 or February 2024, according to two online encyclopaedia articles that differ (no registry record of it was retrieved), which says it is developing a device to test blood, urine and saliva, similar to Theranos's Edison; the company reported raising $3.5 million from friends and family and seeking $15 million more. A public radio network reported in May 2025, citing sources, that Holmes had been advising Evans from prison, and a lawyer for Holmes did not reply to the network's request for comment; the company says she has no formal role and that it is \"not Theranos 2.0\", and a person familiar with it told a national newspaper that she is not involved. Her SEC bar applies only to public companies."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-444a5c874b80681959303dc6","record":{"id":"display-claim-444a5c874b80681959303dc6","kind":"analysis","text":"In opposing her 2026 sentence reduction the government argued that she was advising her partner on raising capital for a start-up whose prototype device bore striking similarities to Theranos's; the court found that the scrutiny her notoriety brings reduced the likelihood that she could reoffend in the same way, and granted the reduction.","source_ids":["src-069"],"entity_ids":["holmes","united-states"],"premise_claim_ids":["c-aft-government-argument"],"qualification":"","response":"","outcome":""},"reading":"Analysis: In opposing her 2026 sentence reduction the government argued that she was advising her partner on raising capital for a start-up whose prototype device bore striking similarities to Theranos's; the court found that the scrutiny her notoriety brings reduced the likelihood that she could reoffend in the same way, and granted the reduction."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-290837ada6d974672cb50d73","record":{"id":"display-claim-290837ada6d974672cb50d73","kind":"analysis","text":"Under an Agreement and Plan of Reorganization of November 4, 1999, filed by Commerce One, Inc., COMMERCEBID.COM, Inc., a Delaware corporation whose principal shareholders included its chief executive Liron Petrushka and Ramesh Balwani, was to become a wholly owned subsidiary of Commerce One in exchange for up to 785,714 Commerce One shares. Commerce One announced that CommerceBid's chief executive, Liron Petrushka, and its President, Balwani, would join its executive management team. A newspaper reported in 2022 that Balwani had begun in software sales at Microsoft, that Commerce One reportedly paid $225 million and he left with almost $40 million, and that he met Holmes while studying computer science at Stanford, leaving the programme in 2008; the price and his proceeds are not documented in the Commerce One filing, which gives the consideration in shares.","source_ids":["src-044","src-068"],"entity_ids":["balwani","commercebid","commerce-one","holmes","theranos"],"premise_claim_ids":["c-bal-commercebid","c-bal-commerce-one-role","c-bal-career-attributed"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Under an Agreement and Plan of Reorganization of November 4, 1999, filed by Commerce One, Inc., COMMERCEBID.COM, Inc., a Delaware corporation whose principal shareholders included its chief executive Liron Petrushka and Ramesh Balwani, was to become a wholly owned subsidiary of Commerce One in exchange for up to 785,714 Commerce One shares. Commerce One announced that CommerceBid's chief executive, Liron Petrushka, and its President, Balwani, would join its executive management team. A newspaper reported in 2022 that Balwani had begun in software sales at Microsoft, that Commerce One reportedly paid $225 million and he left with almost $40 million, and that he met Holmes while studying computer science at Stanford, leaving the programme in 2008; the price and his proceeds are not documented in the Commerce One filing, which gives the consideration in shares."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-e33df910663a8d8689a0aad6","record":{"id":"display-claim-e33df910663a8d8689a0aad6","kind":"analysis","text":"In 2009, as Theranos neared the end of its money, Holmes asked Balwani, then her boyfriend, to guarantee a line of credit, the SEC said; he did, joined the company and became President and Chief Operating Officer that year. The 2010 Form D lists him as an executive officer and director, and he signed Theranos's 2013 annual report to the Florida registry as President. The SEC alleged that he and Holmes were the only senior managing executives. According to the Ninth Circuit, the division of responsibilities was disputed at the trials, but evidence at both showed that he oversaw the patient-testing laboratory and was the main contact for Safeway and Walgreens. He told the SEC, in testimony quoted by the Ninth Circuit, that he built and owned the company's financial model from about 2010. The SEC put his salary for 2013 to 2015 at between about $99,000 and $200,000, and the U.S. Attorney's Office said trial evidence showed he owned nearly 30 million Theranos shares, more than 6 percent of the company.","source_ids":["src-002","src-003","src-001","src-111","src-016","src-050","src-014"],"entity_ids":["balwani","holmes","theranos","donald-lucas","robertson","shapiro","peter-thomas","shultz","roughead","perry","nunn","kovacevich","mattis","kissinger","safeway","walgreen-co"],"premise_claim_ids":["c-ld-balwani-guarantee","c-ld-form-d-2010-persons","c-ld-florida-2013","c-ld-sole-executives","c-ld-balwani-responsibilities","c-prt-retail-outreach","c-ld-pay-balwani","c-fin-balwani-stake"],"qualification":"","response":"","outcome":""},"reading":"Analysis: In 2009, as Theranos neared the end of its money, Holmes asked Balwani, then her boyfriend, to guarantee a line of credit, the SEC said; he did, joined the company and became President and Chief Operating Officer that year. The 2010 Form D lists him as an executive officer and director, and he signed Theranos's 2013 annual report to the Florida registry as President. The SEC alleged that he and Holmes were the only senior managing executives. According to the Ninth Circuit, the division of responsibilities was disputed at the trials, but evidence at both showed that he oversaw the patient-testing laboratory and was the main contact for Safeway and Walgreens. He told the SEC, in testimony quoted by the Ninth Circuit, that he built and owned the company's financial model from about 2010. The SEC put his salary for 2013 to 2015 at between about $99,000 and $200,000, and the U.S. Attorney's Office said trial evidence showed he owned nearly 30 million Theranos shares, more than 6 percent of the company."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-9bf094da2e2407bcab3c5c86","record":{"id":"display-claim-9bf094da2e2407bcab3c5c86","kind":"analysis","text":"Regulatory records name him. The FDA's Form 483 of September 2015, which found Theranos shipping an uncleared device that press reports named as its Nanotainer tube, was addressed to him as President, and CMS's 2016 correspondence lists him with Holmes as an owner of the Newark laboratory; CMS's July 2016 letter said owners and operators would be barred from running a laboratory for at least two years on revocation; under an April 2017 settlement, Theranos said, CMS withdrew the revocation and Theranos agreed to stay out of the blood-testing business for at least two years. Sunil Dhawan, a dermatologist who knew him personally, testified at Holmes's trial, as press reports recounted, that Balwani recruited him as laboratory director in 2014; press reports said he replaced Adam Rosendorff.","source_ids":["src-079","src-028","src-078","src-065","src-090"],"entity_ids":["theranos","balwani","fda","dhawan","holmes","cms","rosendorff"],"premise_claim_ids":["c-lab-fda-483","c-lab-newark-clia","c-lab-owner-ban","c-lab-dhawan-testimony"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Regulatory records name him. The FDA's Form 483 of September 2015, which found Theranos shipping an uncleared device that press reports named as its Nanotainer tube, was addressed to him as President, and CMS's 2016 correspondence lists him with Holmes as an owner of the Newark laboratory; CMS's July 2016 letter said owners and operators would be barred from running a laboratory for at least two years on revocation; under an April 2017 settlement, Theranos said, CMS withdrew the revocation and Theranos agreed to stay out of the blood-testing business for at least two years. Sunil Dhawan, a dermatologist who knew him personally, testified at Holmes's trial, as press reports recounted, that Balwani recruited him as laboratory director in 2014; press reports said he replaced Adam Rosendorff."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-b4d12be947cb04a41bfcfd75","record":{"id":"display-claim-b4d12be947cb04a41bfcfd75","kind":"analysis","text":"The U.S. Attorney's Office said in 2018 that he had at times served as a member of the board as well as president and chief operating officer. Theranos announced on May 11, 2016 that he would retire and leave the board while supporting the transition. The SEC gives his tenure as September 2009 to May 2016; the U.S. Attorney's 2022 release says through July 2016.","source_ids":["src-027","src-018","src-002","src-010","src-014"],"entity_ids":["theranos","balwani","bonanni","foege","kovacevich"],"premise_claim_ids":["c-ld-may-2016","c-ld-balwani-tenure"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The U.S. Attorney's Office said in 2018 that he had at times served as a member of the board as well as president and chief operating officer. Theranos announced on May 11, 2016 that he would retire and leave the board while supporting the transition. The SEC gives his tenure as September 2009 to May 2016; the U.S. Attorney's 2022 release says through July 2016."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-d1825fd29855d7cc4b722050","record":{"id":"display-claim-d1825fd29855d7cc4b722050","kind":"analysis","text":"The SEC sued Balwani separately on March 14, 2018, seeking an injunction, a civil penalty and an officer-and-director bar. These were the SEC's charges, not court findings; Theranos and Holmes settled the same day without admitting or denying them, while he contested the charges, and his case was related to SEC v. Holmes in July 2018. Its final outcome is not in the record.","source_ids":["src-002","src-003","src-007","src-008","src-075"],"entity_ids":["sec","theranos","holmes","balwani"],"premise_claim_ids":["c-sec-charges","c-sec-relief-sought","c-sec-balwani-case"],"qualification":"","response":"","outcome":""},"reading":"Analysis: The SEC sued Balwani separately on March 14, 2018, seeking an injunction, a civil penalty and an officer-and-director bar. These were the SEC's charges, not court findings; Theranos and Holmes settled the same day without admitting or denying them, while he contested the charges, and his case was related to SEC v. Holmes in July 2018. Its final outcome is not in the record."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-25199e438b961eaf8607a5bc","record":{"id":"display-claim-25199e438b961eaf8607a5bc","kind":"analysis","text":"Indicted with Holmes on June 14, 2018, he pleaded not guilty and was tried separately; the indictment was an accusation, and on July 7, 2022 a jury convicted him on all twelve counts: conspiracy to defraud investors and patients, six counts of wire fraud on investors and four on patients; Holmes, tried first, had been convicted on four investor counts. On December 7, 2022 Judge Davila sentenced him to 155 months and three years of supervised release; he was ordered to surrender on March 15, 2023 and, under his second amended judgment, on April 20, 2023; a business news site reported that he entered prison in April 2023. With Holmes he owes $452,047,268 in restitution. The Ninth Circuit affirmed in February 2025 and denied rehearing in December 2025, and the Supreme Court denied his petition for certiorari on October 5, 2026.","source_ids":["src-062","src-010","src-043","src-065","src-014","src-016","src-015","src-070","src-046","src-071","src-057"],"entity_ids":["united-states","holmes","balwani","theranos","safeway","walgreen-co"],"premise_claim_ids":["c-crim-indictment-2018","c-crim-balwani-verdict","c-crim-balwani-sentence","c-crim-surrender","c-crim-restitution","c-crim-ninth-circuit","c-crim-balwani-cert"],"qualification":"","response":"","outcome":""},"reading":"Analysis: Indicted with Holmes on June 14, 2018, he pleaded not guilty and was tried separately; the indictment was an accusation, and on July 7, 2022 a jury convicted him on all twelve counts: conspiracy to defraud investors and patients, six counts of wire fraud on investors and four on patients; Holmes, tried first, had been convicted on four investor counts. On December 7, 2022 Judge Davila sentenced him to 155 months and three years of supervised release; he was ordered to surrender on March 15, 2023 and, under his second amended judgment, on April 20, 2023; a business news site reported that he entered prison in April 2023. With Holmes he owes $452,047,268 in restitution. The Ninth Circuit affirmed in February 2025 and denied rehearing in December 2025, and the Supreme Court denied his petition for certiorari on October 5, 2026."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"claims","id":"display-claim-a836479e0d8a5cd1f08a42c3","record":{"id":"display-claim-a836479e0d8a5cd1f08a42c3","kind":"analysis","text":"HHS-OIG excluded him from federal health care programs for 90 years after his conviction for conspiracy to commit wire fraud against Theranos's patients and investors. In the Arizona patients' class action he withdrew his claims to Theranos's remaining assets as part of the 2024 settlement, while denying the allegations; the settlement, funded mainly by $44 million from Walgreens, was intended to repay consumers about double what they had paid for Theranos tests.","source_ids":["src-072","src-074","src-080","src-116"],"entity_ids":["hhs-oig","holmes","balwani","theranos","wba","walgreen-az","theranos-abc"],"premise_claim_ids":["c-exc-oig-release","c-civ-arizona-settlement"],"qualification":"","response":"","outcome":""},"reading":"Analysis: HHS-OIG excluded him from federal health care programs for 90 years after his conviction for conspiracy to commit wire fraud against Theranos's patients and investors. In the Arizona patients' class action he withdrew his claims to Theranos's remaining assets as part of the 2024 settlement, while denying the allegations; the settlement, funded mainly by $44 million from Walgreens, was intended to repay consumers about double what they had paid for Theranos tests."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"theranos","record":{"id":"theranos","name":"Theranos, Inc.","type":"organization","group":"subject","claim_ids":["c-id-incorporation","c-id-founding-date","c-id-capital-2004","c-id-california-qualification","c-id-sec-registrant","c-id-sec-filings","c-id-form-d-2010","c-id-principal-places","c-id-addresses-registry","c-id-moves-attributed","c-id-florida","c-id-registrations-attributed","c-id-trademarks-attributed","c-ld-holmes-ceo","c-ld-holmes-stanford","c-ld-form-d-2010-persons","c-ld-robertson-attributed","c-ld-robertson-pay-attributed","c-ld-tevanian-attributed","c-ld-balwani-guarantee","c-ld-balwani-tenure","c-ld-balwani-responsibilities","c-ld-sole-executives","c-ld-pay-holmes","c-ld-pay-balwani","c-ld-shultz-joins","c-ld-board-2013-release","c-ld-florida-2013","c-ld-florida-2014","c-ld-florida-2015","c-ld-board-pay-testimony","c-ld-board-oct-2015","c-ld-board-restructure-2015","c-ld-board-counselors","c-ld-boies-counsel","c-ld-boies-board","c-ld-boies-stock-attributed","c-ld-heather-king","c-ld-may-2016","c-ld-dec-2016","c-ld-board-dec-2016","c-ld-warmenhoven-bechtel","c-ld-mattis-tenure","c-ld-mattis-testimony","c-ld-bonanni-committee","c-ld-form-d-2017","c-ld-board-2018","c-ld-taylor-ceo","c-ld-taylor-profile","c-pp-shapiro","c-pp-mcglynn","c-fin-early-rounds-attributed","c-fin-form-d-2010","c-fin-c1-c2","c-fin-series-order","c-fin-indirect-funds","c-fin-financial-position","c-fin-projections","c-fin-class-b","c-fin-balwani-stake","c-fin-investors-press","c-fin-bechtel-shareholder","c-fin-tender-offer","c-fin-form-d-2017","c-fin-murdoch-buyback","c-fin-2017-valuation-attributed","c-fin-holmes-sec-equity","c-wag-2010-agreement","c-wag-2010-meetings","c-wag-2010-representations","c-wag-msa-2012","c-wag-note-wvc","c-wag-pilot","c-wag-rollout-targets","c-wag-900-representation","c-wag-joint-marketing","c-wag-payment-for-tests","c-wag-breach-notice","c-wag-corrected-reports","c-wag-suit-2016","c-wag-settlement-2017","c-wag-suit-2018","c-wag-abc-claim","c-wag-investment-figures","c-prt-safeway-2010","c-prt-safeway-burd","c-prt-safeway-trex","c-prt-safeway-unwind","c-prt-retail-outreach","c-prt-pharma","c-prt-dod","c-prt-health-partners","c-prt-horizon-media","c-lab-newark-clia","c-lab-other-labs","c-lab-operating-period","c-lab-scottsdale-volume","c-lab-dhawan-testimony","c-lab-sawyer","c-lab-das","c-lab-former-directors","c-lab-fda-483","c-lab-fda-press","c-lab-fda-requirement","c-lab-arizona-inspection","c-lab-cms-survey","c-lab-cms-proposed","c-lab-cms-personnel","c-lab-tps-voided","c-lab-cms-sanctions","c-lab-owner-ban","c-lab-house-letter","c-lab-investigations-2016","c-lab-cms-settlement","c-lab-scottsdale-sanctions","c-lab-closure-attributed","c-lab-az-ag","c-sec-charges","c-sec-allegations","c-sec-relief-sought","c-sec-settlement","c-sec-two-phase","c-sec-prior-settlements","c-sec-retail-exit","c-crim-indictment-2018","c-crim-superseding","c-crim-investor-wires","c-crim-holmes-verdict","c-crim-balwani-verdict","c-crim-balwani-sentence","c-crim-doj-evidence","c-crim-restitution-payees","c-exc-oig-release","c-civ-delaware-suits","c-civ-indirect-class","c-civ-arizona-class","c-civ-arizona-dismissal-ruling","c-civ-consent-decree-not-moot","c-civ-arizona-settlement","c-wd-loan","c-wd-loan-terms-attributed","c-wd-patent-assignment","c-wd-tipc-subsidiary-attributed","c-wd-headcount-attributed","c-wd-letter-2018","c-wd-abc-plan","c-wd-dissolution-2018","c-wd-general-assignment","c-wd-shutdown-attributed","c-wd-patents-to-fortress","c-bal-career-attributed"],"badges":[{"label":"SEC fraud charges settled without admitting or denying them (2018)","claim_ids":["c-sec-charges","c-sec-settlement"],"code":"A3","category":"ENFORCEMENT","subject_id":"theranos"},{"label":"CMS sanctions on the Newark laboratory (2016), resolved by settlement (2017)","claim_ids":["c-lab-cms-sanctions","c-lab-cms-settlement"],"code":"A5","category":"REGULATORY_ACTION","subject_id":"theranos"},{"label":"FDA Form 483 inspection observations at the Newark site (2015)","claim_ids":["c-lab-fda-483"],"code":"A6","category":"REGULATORY_ACTION","subject_id":"theranos"},{"label":"Arizona Attorney General consumer-fraud suit; denied, consent decree (2017)","claim_ids":["c-lab-az-ag"],"code":"A7","category":"ENFORCEMENT","subject_id":"theranos"},{"label":"Walgreens contract suits (2016, settled 2017; 2018, $5 million judgment)","claim_ids":["c-wag-suit-2016","c-wag-settlement-2017","c-wag-suit-2018"],"code":"A8","category":"CIVIL_LITIGATION","subject_id":"theranos"},{"label":"Partner Fund investor suits in Delaware (2016-2017), settled and dismissed","claim_ids":["c-civ-delaware-suits"],"code":"A9","category":"CIVIL_LITIGATION","subject_id":"theranos"},{"label":"Indirect-investor class action, N.D. Cal. (2016); class certification denied (2018)","claim_ids":["c-civ-indirect-class"],"code":"A10","category":"CIVIL_LITIGATION","subject_id":"theranos"},{"label":"Arizona patient class action (2016); settled by all defendants except Holmes (2024)","claim_ids":["c-civ-arizona-class","c-civ-arizona-settlement"],"code":"A11","category":"CIVIL_LITIGATION","subject_id":"theranos"},{"label":"Default under the Fortress loan and assignment for the benefit of creditors (2018)","claim_ids":["c-wd-letter-2018","c-wd-general-assignment"],"code":"A12","category":"FINANCIAL_DISTRESS","subject_id":"theranos"}],"subtype":"company","jurisdiction":"us","aliases":["RealTime Cures, Inc.","Theranos"],"identifiers":[{"scheme":"company_register","value":"3789976","issuer":"Delaware Division of Corporations"},{"scheme":"other","value":"0001313697","issuer":"U.S. Securities and Exchange Commission (Central Index Key)"},{"scheme":"other","value":"20-1231826","issuer":"U.S. Internal Revenue Service (employer identification number)"},{"scheme":"company_register","value":"F12000001870","issuer":"Florida Division of Corporations (foreign profit corporation)"}],"same_as":["https://data.sec.gov/submissions/CIK0001313697.json"],"role":"","period":""},"reading":"Theranos, Inc. (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"tipc","record":{"id":"tipc","name":"Theranos IP Company, LLC","type":"organization","group":"group_companies","claim_ids":["c-wd-patent-assignment","c-wd-security-interest","c-wd-tipc-subsidiary-attributed","c-wd-letter-2018","c-wd-patents-to-fortress","c-wd-labrador-rename-attributed","c-wd-tipc-patents-2020"],"subtype":"company","aliases":["TIPC"],"role":"","period":""},"reading":"Theranos IP Company, LLC (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"theranos-abc","record":{"id":"theranos-abc","name":"Theranos (assignment for the benefit of creditors), LLC","type":"organization","group":"other","claim_ids":["c-wag-abc-claim","c-civ-arizona-settlement","c-wd-general-assignment"],"subtype":"company","jurisdiction":"us","aliases":["Theranos ABC"],"role":"","period":""},"reading":"Theranos (assignment for the benefit of creditors), LLC (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"holmes","record":{"id":"holmes","name":"Elizabeth Holmes","type":"person","role":"Founder; chief executive officer 2003-2018 and chair of the board","group":"leadership","claim_ids":["c-id-incorporation","c-id-founding-date","c-ld-holmes-ceo","c-ld-holmes-stanford","c-ld-form-d-2010-persons","c-ld-robertson-attributed","c-ld-robertson-pay-attributed","c-ld-balwani-guarantee","c-ld-balwani-responsibilities","c-ld-holmes-balwani-relationship","c-ld-sole-executives","c-ld-pay-holmes","c-ld-options-email","c-ld-shultz-joins","c-ld-board-2013-release","c-ld-florida-2013","c-ld-florida-2014","c-ld-florida-2015","c-ld-board-pay-testimony","c-ld-board-oct-2015","c-ld-board-restructure-2015","c-ld-dec-2016","c-ld-board-dec-2016","c-ld-warmenhoven-bechtel","c-ld-form-d-2017","c-ld-taylor-ceo","c-fin-c1-c2","c-fin-financial-position","c-fin-projections","c-fin-class-b","c-fin-bechtel-shareholder","c-fin-tender-offer","c-fin-murdoch-buyback","c-fin-holmes-sec-equity","c-wag-2010-meetings","c-wag-rollout-targets","c-wag-900-representation","c-prt-safeway-2010","c-prt-retail-outreach","c-prt-pharma","c-lab-newark-clia","c-lab-operating-period","c-lab-dhawan-testimony","c-lab-fda-requirement","c-lab-owner-ban","c-sec-charges","c-sec-allegations","c-sec-relief-sought","c-sec-settlement","c-sec-prior-settlements","c-sec-retail-exit","c-crim-indictment-2018","c-crim-superseding","c-crim-holmes-verdict","c-crim-holmes-sentence","c-crim-surrender","c-crim-doj-evidence","c-crim-restitution","c-crim-restitution-split","c-crim-ninth-circuit","c-crim-holmes-rehearing","c-crim-holmes-reduction","c-crim-release-date","c-exc-holmes","c-exc-oig-release","c-civ-delaware-suits","c-civ-indirect-class","c-civ-arizona-class","c-civ-arizona-dismissal-ruling","c-civ-consent-decree-not-moot","c-civ-arizona-settlement","c-wd-patent-assignment","c-wd-tipc-patents-2020","c-aft-haemanthus","c-aft-holmes-advice","c-aft-government-argument","c-bal-career-attributed"],"badges":[{"label":"Convicted of investor fraud (2022); affirmed on appeal (2025); sentence reduced (2026)","claim_ids":["c-crim-holmes-verdict","c-crim-holmes-sentence","c-crim-ninth-circuit","c-crim-holmes-reduction"],"code":"A1","category":"CRIMINAL_PROCEEDINGS","subject_id":"holmes"},{"label":"SEC fraud charges settled without admitting or denying them (2018)","claim_ids":["c-sec-charges","c-sec-settlement"],"code":"A3","category":"ENFORCEMENT","subject_id":"holmes"},{"label":"Partner Fund investor suits in Delaware (2016-2017), settled and dismissed","claim_ids":["c-civ-delaware-suits"],"code":"A9","category":"CIVIL_LITIGATION","subject_id":"holmes"},{"label":"Indirect-investor class action, N.D. Cal. (2016); class certification denied (2018)","claim_ids":["c-civ-indirect-class"],"code":"A10","category":"CIVIL_LITIGATION","subject_id":"holmes"},{"label":"Arizona patient class action (2016); settled by all defendants except Holmes (2024)","claim_ids":["c-civ-arizona-class","c-civ-arizona-settlement"],"code":"A11","category":"CIVIL_LITIGATION","subject_id":"holmes"},{"label":"Excluded from federal health care programs for 90 years (2023); upheld (2025-2026)","claim_ids":["c-exc-holmes","c-exc-oig-release"],"code":"A13","category":"ENFORCEMENT","subject_id":"holmes"}],"subtype":"person","aliases":["Elizabeth A. Holmes","Elizabeth Anne Holmes"],"period":""},"reading":"Elizabeth Holmes (person): Founder; chief executive officer 2003-2018 and chair of the board"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"balwani","record":{"id":"balwani","name":"Ramesh Balwani","type":"person","role":"President and chief operating officer 2009-2016","group":"leadership","claim_ids":["c-ld-form-d-2010-persons","c-ld-balwani-guarantee","c-ld-balwani-tenure","c-ld-balwani-responsibilities","c-ld-holmes-balwani-relationship","c-ld-sole-executives","c-ld-pay-balwani","c-ld-options-email","c-ld-board-2013-release","c-ld-florida-2013","c-ld-florida-2014","c-ld-florida-2015","c-ld-board-oct-2015","c-ld-board-restructure-2015","c-ld-may-2016","c-fin-c1-c2","c-fin-financial-position","c-fin-projections","c-fin-balwani-stake","c-wag-2010-meetings","c-wag-rollout-targets","c-wag-900-representation","c-prt-retail-outreach","c-lab-newark-clia","c-lab-dhawan-testimony","c-lab-former-directors","c-lab-fda-483","c-lab-fda-requirement","c-lab-owner-ban","c-sec-charges","c-sec-allegations","c-sec-relief-sought","c-sec-balwani-case","c-sec-prior-settlements","c-sec-retail-exit","c-crim-indictment-2018","c-crim-superseding","c-crim-balwani-verdict","c-crim-balwani-sentence","c-crim-surrender","c-crim-doj-evidence","c-crim-restitution","c-crim-ninth-circuit","c-crim-balwani-cert","c-exc-oig-release","c-civ-delaware-suits","c-civ-indirect-class","c-civ-arizona-class","c-civ-arizona-dismissal-ruling","c-civ-consent-decree-not-moot","c-civ-arizona-settlement","c-bal-commercebid","c-bal-commerce-one-role","c-bal-career-attributed"],"badges":[{"label":"Convicted on twelve fraud counts (2022); affirmed (2025); certiorari denied (2026)","claim_ids":["c-crim-balwani-verdict","c-crim-balwani-sentence","c-crim-ninth-circuit","c-crim-balwani-cert"],"code":"A2","category":"CRIMINAL_PROCEEDINGS","subject_id":"balwani"},{"label":"SEC fraud charges (2018); case related to SEC v. Holmes, outcome not in the record","claim_ids":["c-sec-charges","c-sec-balwani-case"],"code":"A4","category":"ENFORCEMENT","subject_id":"balwani"},{"label":"Partner Fund investor suit in Delaware (2016), settled and dismissed (2017)","claim_ids":["c-civ-delaware-suits"],"code":"A15","category":"CIVIL_LITIGATION","subject_id":"balwani"},{"label":"Indirect-investor class action, N.D. Cal. (2016); class certification denied (2018)","claim_ids":["c-civ-indirect-class"],"code":"A10","category":"CIVIL_LITIGATION","subject_id":"balwani"},{"label":"Arizona patient class action (2016); settled by all defendants except Holmes (2024)","claim_ids":["c-civ-arizona-class","c-civ-arizona-settlement"],"code":"A11","category":"CIVIL_LITIGATION","subject_id":"balwani"},{"label":"Excluded from federal health care programs for 90 years after conviction","claim_ids":["c-exc-oig-release"],"code":"A14","category":"ENFORCEMENT","subject_id":"balwani"}],"subtype":"person","aliases":["Sunny Balwani","Ramesh \"Sunny\" Balwani"],"period":""},"reading":"Ramesh Balwani (person): President and chief operating officer 2009-2016"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"david-taylor","record":{"id":"david-taylor","name":"David Taylor","type":"person","group":"leadership","claim_ids":["c-ld-taylor-ceo","c-ld-taylor-profile","c-wd-loan","c-wd-letter-2018","c-wd-dissolution-2018","c-wd-shutdown-attributed"],"subtype":"person","role":"","period":""},"reading":"David Taylor (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"heather-king","record":{"id":"heather-king","name":"Heather King","type":"person","group":"leadership","claim_ids":["c-ld-heather-king","c-prt-safeway-trex"],"subtype":"person","role":"","period":""},"reading":"Heather King (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"casey-mcglynn","record":{"id":"casey-mcglynn","name":"J. Casey McGlynn","type":"person","group":"historical","claim_ids":["c-id-california-qualification","c-pp-mcglynn"],"subtype":"person","role":"","period":""},"reading":"J. Casey McGlynn (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"robertson","record":{"id":"robertson","name":"Channing Robertson","type":"person","group":"leadership","claim_ids":["c-ld-form-d-2010-persons","c-ld-robertson-attributed","c-ld-robertson-pay-attributed"],"subtype":"person","role":"","period":""},"reading":"Channing Robertson (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"donald-lucas","record":{"id":"donald-lucas","name":"Donald L. Lucas","type":"person","group":"historical","claim_ids":["c-ld-form-d-2010-persons","c-pp-lucas"],"subtype":"person","aliases":["Donald Leo Lucas"],"role":"","period":""},"reading":"Donald L. Lucas (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"shapiro","record":{"id":"shapiro","name":"Robert B. Shapiro","type":"person","group":"historical","claim_ids":["c-ld-form-d-2010-persons","c-pp-shapiro"],"subtype":"person","aliases":["Robert Shapiro"],"role":"","period":""},"reading":"Robert B. Shapiro (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"peter-thomas","record":{"id":"peter-thomas","name":"T. Peter Thomas","type":"person","group":"historical","claim_ids":["c-ld-form-d-2010-persons","c-pp-thomas"],"subtype":"person","role":"","period":""},"reading":"T. Peter Thomas (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"tevanian","record":{"id":"tevanian","name":"Avie Tevanian","type":"person","group":"historical","claim_ids":["c-ld-tevanian-attributed","c-pp-tevanian"],"subtype":"person","aliases":["Avadis Tevanian, Jr."],"role":"","period":""},"reading":"Avie Tevanian (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"shultz","record":{"id":"shultz","name":"George P. Shultz","type":"person","group":"leadership","claim_ids":["c-ld-shultz-joins","c-ld-florida-2013","c-ld-florida-2014","c-ld-florida-2015","c-ld-board-pay-testimony","c-ld-board-oct-2015","c-ld-board-restructure-2015","c-ld-board-counselors","c-ld-dec-2016","c-ld-board-dec-2016","c-pp-shultz"],"subtype":"person","aliases":["George Shultz","George Pratt Shultz"],"role":"","period":""},"reading":"George P. Shultz (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"kissinger","record":{"id":"kissinger","name":"Henry A. Kissinger","type":"person","group":"leadership","claim_ids":["c-ld-shultz-joins","c-ld-board-2013-release","c-ld-florida-2013","c-ld-florida-2014","c-ld-florida-2015","c-ld-board-pay-testimony","c-ld-board-oct-2015","c-ld-board-restructure-2015","c-ld-board-counselors","c-ld-dec-2016","c-ld-board-dec-2016","c-pp-kissinger"],"subtype":"person","aliases":["Henry Kissinger"],"role":"","period":""},"reading":"Henry A. Kissinger (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"perry","record":{"id":"perry","name":"William J. Perry","type":"person","group":"leadership","claim_ids":["c-ld-shultz-joins","c-ld-board-2013-release","c-ld-florida-2013","c-ld-florida-2014","c-ld-florida-2015","c-ld-board-pay-testimony","c-ld-board-oct-2015","c-ld-dec-2016","c-ld-board-dec-2016","c-pp-perry"],"subtype":"person","aliases":["Bill Perry","William Perry"],"role":"","period":""},"reading":"William J. Perry (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"nunn","record":{"id":"nunn","name":"Sam Nunn","type":"person","group":"leadership","claim_ids":["c-ld-shultz-joins","c-ld-board-2013-release","c-ld-florida-2013","c-ld-florida-2014","c-ld-florida-2015","c-ld-board-pay-testimony","c-ld-board-oct-2015","c-ld-board-counselors","c-ld-dec-2016","c-ld-board-dec-2016","c-pp-nunn"],"subtype":"person","aliases":["Samuel Nunn"],"role":"","period":""},"reading":"Sam Nunn (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"frist","record":{"id":"frist","name":"William H. Frist","type":"person","group":"leadership","claim_ids":["c-ld-shultz-joins","c-ld-florida-2014","c-ld-florida-2015","c-ld-board-oct-2015","c-ld-dec-2016","c-ld-board-dec-2016","c-pp-frist"],"subtype":"person","aliases":["Bill Frist","William Frist"],"role":"","period":""},"reading":"William H. Frist (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"roughead","record":{"id":"roughead","name":"Gary Roughead","type":"person","group":"leadership","claim_ids":["c-ld-shultz-joins","c-ld-florida-2013","c-ld-florida-2014","c-ld-florida-2015","c-ld-board-pay-testimony","c-ld-board-oct-2015","c-ld-board-dec-2016","c-pp-roughead"],"subtype":"person","role":"","period":""},"reading":"Gary Roughead (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"mattis","record":{"id":"mattis","name":"James N. Mattis","type":"person","group":"leadership","claim_ids":["c-ld-options-email","c-ld-shultz-joins","c-ld-board-2013-release","c-ld-florida-2013","c-ld-florida-2014","c-ld-florida-2015","c-ld-board-pay-testimony","c-ld-board-oct-2015","c-ld-board-restructure-2015","c-ld-board-dec-2016","c-ld-mattis-tenure","c-ld-mattis-testimony","c-pp-mattis","c-prt-dod"],"subtype":"person","aliases":["James Mattis","Jim Mattis"],"role":"","period":""},"reading":"James N. Mattis (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"kovacevich","record":{"id":"kovacevich","name":"Richard Kovacevich","type":"person","group":"leadership","claim_ids":["c-ld-shultz-joins","c-ld-board-2013-release","c-ld-florida-2013","c-ld-florida-2014","c-ld-florida-2015","c-ld-board-pay-testimony","c-ld-board-oct-2015","c-ld-board-counselors","c-ld-may-2016","c-ld-board-dec-2016","c-ld-board-2018","c-pp-kovacevich","c-crim-restitution-payees"],"subtype":"person","aliases":["Dick Kovacevich","Richard M. Kovacevich"],"role":"","period":""},"reading":"Richard Kovacevich (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"riley-bechtel","record":{"id":"riley-bechtel","name":"Riley P. Bechtel","type":"person","group":"leadership","claim_ids":["c-ld-shultz-joins","c-ld-florida-2014","c-ld-florida-2015","c-ld-board-oct-2015","c-ld-board-restructure-2015","c-ld-dec-2016","c-ld-warmenhoven-bechtel","c-pp-riley-bechtel","c-fin-bechtel-shareholder"],"subtype":"person","aliases":["Riley Bechtel"],"role":"","period":""},"reading":"Riley P. Bechtel (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"foege","record":{"id":"foege","name":"William H. Foege","type":"person","group":"leadership","claim_ids":["c-ld-florida-2014","c-ld-florida-2015","c-ld-board-oct-2015","c-ld-board-counselors","c-ld-may-2016","c-ld-board-dec-2016","c-ld-form-d-2017","c-ld-board-2018","c-pp-foege","c-civ-delaware-suits"],"subtype":"person","aliases":["William Foege"],"role":"","period":""},"reading":"William H. Foege (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"boies","record":{"id":"boies","name":"David Boies","type":"person","group":"leadership","claim_ids":["c-ld-board-restructure-2015","c-ld-boies-counsel","c-ld-boies-board","c-ld-boies-stock-attributed","c-ld-board-dec-2016","c-pp-boies"],"subtype":"person","role":"","period":""},"reading":"David Boies (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"warmenhoven","record":{"id":"warmenhoven","name":"Daniel J. Warmenhoven","type":"person","group":"leadership","claim_ids":["c-ld-dec-2016","c-ld-board-dec-2016","c-ld-warmenhoven-bechtel","c-ld-form-d-2017","c-pp-warmenhoven","c-pp-warmenhoven-redback","c-fin-murdoch-buyback","c-civ-delaware-suits"],"subtype":"person","aliases":["Dan Warmenhoven","Daniel Warmenhoven"],"role":"","period":""},"reading":"Daniel J. Warmenhoven (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"bonanni","record":{"id":"bonanni","name":"Fabrizio Bonanni","type":"person","group":"leadership","claim_ids":["c-ld-may-2016","c-ld-board-dec-2016","c-ld-bonanni-committee","c-ld-form-d-2017","c-pp-bonanni","c-civ-delaware-suits"],"subtype":"person","role":"","period":""},"reading":"Fabrizio Bonanni (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"dhawan","record":{"id":"dhawan","name":"Sunil Dhawan","type":"person","group":"leadership","claim_ids":["c-lab-newark-clia","c-lab-dhawan-testimony","c-lab-sawyer","c-lab-cms-personnel","c-lab-owner-ban"],"subtype":"person","role":"","period":""},"reading":"Sunil Dhawan (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"das","record":{"id":"das","name":"Kingshuk Das","type":"person","group":"leadership","claim_ids":["c-wag-corrected-reports","c-lab-das"],"subtype":"person","role":"","period":""},"reading":"Kingshuk Das (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"rosendorff","record":{"id":"rosendorff","name":"Adam Rosendorff","type":"person","group":"historical","claim_ids":["c-lab-dhawan-testimony","c-lab-former-directors"],"subtype":"person","role":"","period":""},"reading":"Adam Rosendorff (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"pandori","record":{"id":"pandori","name":"Mark Pandori","type":"person","group":"historical","claim_ids":["c-lab-former-directors"],"subtype":"person","role":"","period":""},"reading":"Mark Pandori (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"sawyer","record":{"id":"sawyer","name":"Lynette Sawyer","type":"person","group":"historical","claim_ids":["c-lab-sawyer"],"subtype":"person","role":"","period":""},"reading":"Lynette Sawyer (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"daniel-young","record":{"id":"daniel-young","name":"Daniel Young","type":"person","group":"leadership","claim_ids":["c-lab-other-labs"],"subtype":"person","role":"","period":""},"reading":"Daniel Young (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"walgreen-co","record":{"id":"walgreen-co","name":"Walgreen Co.","type":"organization","group":"counterparties","claim_ids":["c-ld-balwani-responsibilities","c-fin-early-rounds-attributed","c-fin-investors-press","c-wag-walgreen-co","c-wag-subsidiaries","c-wag-2010-agreement","c-wag-2010-meetings","c-wag-2010-representations","c-wag-msa-2012","c-wag-note-wvc","c-wag-pilot","c-wag-rollout-targets","c-wag-900-representation","c-wag-joint-marketing","c-wag-payment-for-tests","c-wag-breach-notice","c-wag-suit-2016","c-wag-settlement-2017","c-wag-suit-2018","c-wag-abc-claim","c-wag-investment-figures","c-prt-safeway-unwind","c-prt-retail-outreach","c-crim-doj-evidence","c-crim-restitution","c-crim-restitution-payees"],"subtype":"company","jurisdiction":"us","aliases":["Walgreens"],"identifiers":[{"scheme":"other","value":"0000104207","issuer":"U.S. Securities and Exchange Commission (Central Index Key)"}],"same_as":["https://data.sec.gov/submissions/CIK0000104207.json"],"role":"","period":""},"reading":"Walgreen Co. (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"wba","record":{"id":"wba","name":"Walgreens Boots Alliance, Inc.","type":"organization","group":"counterparties","claim_ids":["c-wag-walgreen-co","c-civ-arizona-class","c-civ-arizona-dismissal-ruling","c-civ-consent-decree-not-moot","c-civ-arizona-settlement"],"badges":[{"label":"Arizona patient class action (2016); settled by all defendants except Holmes (2024)","claim_ids":["c-civ-arizona-class","c-civ-arizona-settlement"],"code":"A11","category":"CIVIL_LITIGATION","subject_id":"wba"}],"subtype":"company","role":"","period":""},"reading":"Walgreens Boots Alliance, Inc. (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"wvc","record":{"id":"wvc","name":"WVC Investments, LLC","type":"organization","group":"counterparties","claim_ids":["c-wag-subsidiaries","c-wag-note-wvc"],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"WVC Investments, LLC (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"walgreen-az","record":{"id":"walgreen-az","name":"Walgreen Arizona Drug Co.","type":"organization","group":"counterparties","claim_ids":["c-wag-subsidiaries","c-civ-arizona-class","c-civ-arizona-dismissal-ruling","c-civ-arizona-settlement"],"badges":[{"label":"Arizona patient class action (2016); settled by all defendants except Holmes (2024)","claim_ids":["c-civ-arizona-class","c-civ-arizona-settlement"],"code":"A11","category":"CIVIL_LITIGATION","subject_id":"walgreen-az"}],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"Walgreen Arizona Drug Co. (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"wade-miquelon","record":{"id":"wade-miquelon","name":"Wade Miquelon","type":"person","group":"counterparties","claim_ids":["c-wag-2010-meetings","c-wag-note-wvc"],"subtype":"person","role":"","period":""},"reading":"Wade Miquelon (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"safeway","record":{"id":"safeway","name":"Safeway Inc.","type":"organization","group":"counterparties","claim_ids":["c-ld-balwani-responsibilities","c-wag-2010-representations","c-prt-safeway-entity","c-prt-safeway-2010","c-prt-safeway-burd","c-prt-safeway-trex","c-prt-safeway-unwind","c-prt-retail-outreach","c-crim-doj-evidence","c-crim-restitution","c-crim-restitution-payees"],"subtype":"company","jurisdiction":"us","identifiers":[{"scheme":"other","value":"0000086144","issuer":"U.S. Securities and Exchange Commission (Central Index Key)"},{"scheme":"other","value":"94-3019135","issuer":"U.S. Internal Revenue Service (employer identification number)"}],"same_as":["https://data.sec.gov/submissions/CIK0000086144.json"],"role":"","period":""},"reading":"Safeway Inc. (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"steve-burd","record":{"id":"steve-burd","name":"Steve Burd","type":"person","group":"counterparties","claim_ids":["c-prt-safeway-burd"],"subtype":"person","role":"","period":""},"reading":"Steve Burd (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"pfizer","record":{"id":"pfizer","name":"Pfizer","type":"organization","group":"counterparties","claim_ids":["c-prt-pharma"],"subtype":"company","role":"","period":""},"reading":"Pfizer (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"dod","record":{"id":"dod","name":"U.S. Department of Defense","type":"organization","group":"counterparties","claim_ids":["c-prt-dod","c-sec-allegations"],"subtype":"other","role":"","period":""},"reading":"U.S. Department of Defense (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"cleveland-clinic","record":{"id":"cleveland-clinic","name":"Cleveland Clinic","type":"organization","group":"counterparties","claim_ids":["c-prt-health-partners"],"subtype":"company","role":"","period":""},"reading":"Cleveland Clinic (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"capital-bluecross","record":{"id":"capital-bluecross","name":"Capital BlueCross","type":"organization","group":"counterparties","claim_ids":["c-prt-health-partners"],"subtype":"company","role":"","period":""},"reading":"Capital BlueCross (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"amerihealth","record":{"id":"amerihealth","name":"AmeriHealth Caritas","type":"organization","group":"counterparties","claim_ids":["c-prt-health-partners"],"subtype":"company","role":"","period":""},"reading":"AmeriHealth Caritas (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"horizon-media","record":{"id":"horizon-media","name":"Horizon Media, Inc.","type":"organization","group":"counterparties","claim_ids":["c-prt-horizon-media"],"subtype":"company","role":"","period":""},"reading":"Horizon Media, Inc. (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"dfj","record":{"id":"dfj","name":"Draper Fisher Jurvetson","type":"organization","group":"counterparties","claim_ids":["c-fin-early-rounds-attributed","c-fin-investors-press"],"subtype":"company","role":"","period":""},"reading":"Draper Fisher Jurvetson (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"ata-ventures","record":{"id":"ata-ventures","name":"ATA Ventures","type":"organization","group":"counterparties","claim_ids":["c-pp-thomas","c-fin-early-rounds-attributed"],"subtype":"company","role":"","period":""},"reading":"ATA Ventures (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"murdoch","record":{"id":"murdoch","name":"Rupert Murdoch","type":"person","group":"counterparties","claim_ids":["c-fin-early-rounds-attributed","c-fin-investors-press","c-fin-murdoch-buyback","c-crim-restitution-payees"],"subtype":"person","aliases":["Keith Rupert Murdoch"],"role":"","period":""},"reading":"Rupert Murdoch (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"ellison","record":{"id":"ellison","name":"Larry Ellison","type":"person","group":"counterparties","claim_ids":["c-pp-lucas","c-fin-early-rounds-attributed","c-fin-investors-press"],"subtype":"person","aliases":["Lawrence J. Ellison"],"role":"","period":""},"reading":"Larry Ellison (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"devos","record":{"id":"devos","name":"Betsy DeVos","type":"person","group":"counterparties","claim_ids":["c-fin-investors-press"],"subtype":"person","role":"","period":""},"reading":"Betsy DeVos (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"bcbs","record":{"id":"bcbs","name":"BlueCross BlueShield","type":"organization","group":"counterparties","claim_ids":["c-fin-investors-press"],"subtype":"company","role":"","period":""},"reading":"BlueCross BlueShield (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"partner-investments","record":{"id":"partner-investments","name":"Partner Investments, L.P.","type":"organization","group":"counterparties","claim_ids":["c-fin-partner-investments","c-civ-delaware-suits"],"subtype":"company","jurisdiction":"us","identifiers":[{"scheme":"other","value":"0001343211","issuer":"U.S. Securities and Exchange Commission (Central Index Key)"}],"role":"","period":""},"reading":"Partner Investments, L.P. (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"partner-fund-mgmt","record":{"id":"partner-fund-mgmt","name":"Partner Fund Management, LLC","type":"organization","group":"counterparties","claim_ids":["c-fin-early-rounds-attributed","c-fin-partner-investments"],"subtype":"company","role":"","period":""},"reading":"Partner Fund Management, LLC (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"pfm-master","record":{"id":"pfm-master","name":"PFM Healthcare Master Fund, L.P.","type":"organization","group":"counterparties","claim_ids":["c-civ-delaware-suits"],"subtype":"company","jurisdiction":"ky","role":"","period":""},"reading":"PFM Healthcare Master Fund, L.P. (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"pfm-principals","record":{"id":"pfm-principals","name":"PFM Healthcare Principals Fund, L.P.","type":"organization","group":"counterparties","claim_ids":["c-civ-delaware-suits"],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"PFM Healthcare Principals Fund, L.P. (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"pfm-funds","record":{"id":"pfm-funds","name":"PFM Funds","type":"group","group":"counterparties","claim_ids":["c-crim-restitution-payees"],"subtype":"other","role":"","period":""},"reading":"PFM Funds (group)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"rdv","record":{"id":"rdv","name":"RDV Corporation","type":"organization","group":"counterparties","claim_ids":["c-crim-restitution-payees"],"subtype":"company","role":"","period":""},"reading":"RDV Corporation (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"peer-ventures","record":{"id":"peer-ventures","name":"Peer Ventures Group","type":"group","group":"counterparties","claim_ids":["c-crim-restitution-payees"],"subtype":"other","role":"","period":""},"reading":"Peer Ventures Group (group)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"pvg-iv","record":{"id":"pvg-iv","name":"Peer Ventures Group IV, LP","type":"organization","group":"counterparties","claim_ids":["c-fin-indirect-funds","c-fin-tender-offer"],"subtype":"company","role":"","period":""},"reading":"Peer Ventures Group IV, LP (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"lucas-venture-group","record":{"id":"lucas-venture-group","name":"Lucas Venture Group","type":"group","group":"counterparties","claim_ids":["c-crim-restitution-payees"],"subtype":"other","role":"","period":""},"reading":"Lucas Venture Group (group)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"lvg-xi","record":{"id":"lvg-xi","name":"Lucas Venture Group XI, LLC","type":"organization","group":"counterparties","claim_ids":["c-fin-series-order","c-fin-indirect-funds","c-fin-tender-offer"],"subtype":"company","role":"","period":""},"reading":"Lucas Venture Group XI, LLC (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"lvg-iv-lp","record":{"id":"lvg-iv-lp","name":"Lucas Venture Group IV, LP","type":"organization","group":"counterparties","claim_ids":["c-fin-indirect-funds"],"subtype":"company","role":"","period":""},"reading":"Lucas Venture Group IV, LP (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"black-diamond","record":{"id":"black-diamond","name":"Black Diamond Ventures","type":"group","group":"counterparties","claim_ids":["c-crim-restitution-payees"],"subtype":"other","role":"","period":""},"reading":"Black Diamond Ventures (group)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"bdv-xii-b","record":{"id":"bdv-xii-b","name":"Black Diamond Ventures XII-B, LLC","type":"organization","group":"counterparties","claim_ids":["c-fin-indirect-funds","c-fin-tender-offer"],"subtype":"company","role":"","period":""},"reading":"Black Diamond Ventures XII-B, LLC (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"celadon","record":{"id":"celadon","name":"Celadon Technology Fund VII, LLC","type":"organization","group":"counterparties","claim_ids":["c-fin-indirect-funds"],"subtype":"company","role":"","period":""},"reading":"Celadon Technology Fund VII, LLC (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"moseley","record":{"id":"moseley","name":"Moseley Family Holdings","type":"organization","group":"counterparties","claim_ids":["c-crim-restitution-payees"],"subtype":"company","role":"","period":""},"reading":"Moseley Family Holdings (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"mendenhall","record":{"id":"mendenhall","name":"Mendenhall TF Partners","type":"organization","group":"counterparties","claim_ids":["c-crim-restitution-payees"],"subtype":"company","role":"","period":""},"reading":"Mendenhall TF Partners (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"hall-group","record":{"id":"hall-group","name":"Hall Group","type":"organization","group":"counterparties","claim_ids":["c-crim-restitution-payees"],"subtype":"company","role":"","period":""},"reading":"Hall Group (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"fortress","record":{"id":"fortress","name":"Fortress Investment Group LLC","type":"organization","group":"counterparties","claim_ids":["c-fin-early-rounds-attributed","c-wd-fortress-entity","c-wd-loan","c-wd-loan-terms-attributed","c-wd-security-interest","c-wd-tipc-subsidiary-attributed","c-wd-letter-2018","c-wd-shutdown-attributed","c-wd-patents-to-fortress","c-wd-labrador-rename-attributed","c-wd-labrador-reaction"],"subtype":"company","jurisdiction":"us","aliases":["Fortress"],"identifiers":[{"scheme":"other","value":"0001380393","issuer":"U.S. Securities and Exchange Commission (Central Index Key)"}],"same_as":["https://data.sec.gov/submissions/CIK0001380393.json"],"role":"","period":""},"reading":"Fortress Investment Group LLC (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"fortress-credit","record":{"id":"fortress-credit","name":"Fortress Credit Corp.","type":"organization","group":"counterparties","claim_ids":["c-wd-security-interest"],"subtype":"company","role":"","period":""},"reading":"Fortress Credit Corp. (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"labrador","record":{"id":"labrador","name":"Labrador Diagnostics LLC","type":"organization","group":"other","claim_ids":["c-wd-labrador-rename-attributed","c-wd-tipc-patents-2020","c-wd-labrador-suit","c-wd-labrador-reaction"],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"Labrador Diagnostics LLC (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"biofire","record":{"id":"biofire","name":"BioFire Diagnostics, LLC","type":"organization","group":"other","claim_ids":["c-wd-labrador-rename-attributed","c-wd-labrador-suit","c-wd-labrador-reaction"],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"BioFire Diagnostics, LLC (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"biomerieux","record":{"id":"biomerieux","name":"bioMérieux S.A.","type":"organization","group":"other","claim_ids":["c-wd-labrador-rename-attributed","c-wd-labrador-suit","c-wd-labrador-reaction"],"subtype":"company","jurisdiction":"fr","role":"","period":""},"reading":"bioMérieux S.A. (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"michael-maidy","record":{"id":"michael-maidy","name":"Michael A. Maidy","type":"person","group":"other","claim_ids":["c-wd-general-assignment"],"subtype":"person","role":"","period":""},"reading":"Michael A. Maidy (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"bechtel-group","record":{"id":"bechtel-group","name":"Bechtel Group, Inc.","type":"organization","group":"other","claim_ids":["c-ld-warmenhoven-bechtel","c-pp-shultz","c-pp-bechtel-group","c-pp-riley-bechtel","c-pp-warmenhoven","c-pp-warmenhoven-redback"],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"Bechtel Group, Inc. (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"oracle","record":{"id":"oracle","name":"Oracle Corporation","type":"organization","group":"other","claim_ids":["c-pp-lucas"],"subtype":"company","role":"","period":""},"reading":"Oracle Corporation (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"boies-schiller","record":{"id":"boies-schiller","name":"Boies, Schiller & Flexner LLP","type":"organization","group":"other","claim_ids":["c-ld-boies-counsel","c-ld-heather-king","c-pp-boies"],"subtype":"company","role":"","period":""},"reading":"Boies, Schiller & Flexner LLP (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"commercebid","record":{"id":"commercebid","name":"CommerceBid.com, Inc.","type":"organization","group":"other","claim_ids":["c-bal-commercebid","c-bal-commerce-one-role","c-bal-career-attributed"],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"CommerceBid.com, Inc. (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"commerce-one","record":{"id":"commerce-one","name":"Commerce One, Inc.","type":"organization","group":"other","claim_ids":["c-bal-commercebid","c-bal-commerce-one-role","c-bal-career-attributed"],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"Commerce One, Inc. (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"sec","record":{"id":"sec","name":"U.S. Securities and Exchange Commission","type":"organization","group":"other","claim_ids":["c-fin-holmes-sec-equity","c-lab-investigations-2016","c-sec-charges","c-sec-allegations","c-sec-relief-sought","c-sec-settlement","c-sec-balwani-case","c-sec-two-phase","c-sec-prior-settlements","c-sec-retail-exit"],"subtype":"other","role":"","period":""},"reading":"U.S. Securities and Exchange Commission (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"united-states","record":{"id":"united-states","name":"United States (U.S. Attorney's Office, Northern District of California)","type":"organization","group":"other","claim_ids":["c-crim-indictment-2018","c-crim-superseding","c-crim-holmes-verdict","c-crim-holmes-sentence","c-crim-balwani-verdict","c-crim-balwani-sentence","c-crim-surrender","c-crim-doj-evidence","c-crim-restitution","c-crim-ninth-circuit","c-crim-holmes-rehearing","c-crim-balwani-cert","c-crim-holmes-reduction","c-aft-government-argument"],"subtype":"other","role":"","period":""},"reading":"United States (U.S. Attorney's Office, Northern District of California) (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"cms","record":{"id":"cms","name":"Centers for Medicare & Medicaid Services","type":"organization","group":"other","claim_ids":["c-lab-newark-clia","c-lab-other-labs","c-lab-das","c-lab-cms-survey","c-lab-cms-proposed","c-lab-cms-personnel","c-lab-tps-voided","c-lab-cms-sanctions","c-lab-owner-ban","c-lab-house-letter","c-lab-investigations-2016","c-lab-cms-settlement","c-lab-scottsdale-sanctions"],"subtype":"other","role":"","period":""},"reading":"Centers for Medicare & Medicaid Services (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"fda","record":{"id":"fda","name":"U.S. Food and Drug Administration","type":"organization","group":"other","claim_ids":["c-lab-fda-483","c-lab-fda-press","c-lab-fda-requirement"],"subtype":"other","role":"","period":""},"reading":"U.S. Food and Drug Administration (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"hhs-oig","record":{"id":"hhs-oig","name":"HHS Office of Inspector General","type":"organization","group":"other","claim_ids":["c-exc-holmes","c-exc-oig-release"],"subtype":"other","role":"","period":""},"reading":"HHS Office of Inspector General (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"az-ag","record":{"id":"az-ag","name":"Arizona Attorney General's Office","type":"organization","group":"other","claim_ids":["c-lab-az-ag","c-civ-consent-decree-not-moot"],"subtype":"other","role":"","period":""},"reading":"Arizona Attorney General's Office (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"haemanthus","record":{"id":"haemanthus","name":"Haemanthus","type":"organization","group":"other","claim_ids":["c-aft-haemanthus","c-aft-holmes-advice"],"subtype":"company","jurisdiction":"us","role":"","period":""},"reading":"Haemanthus (organization)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"entities","id":"billy-evans","record":{"id":"billy-evans","name":"Billy Evans","type":"person","group":"other","claim_ids":["c-aft-haemanthus","c-aft-holmes-advice"],"subtype":"person","role":"","period":""},"reading":"Billy Evans (person)"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-holmes-founder","record":{"id":"r-holmes-founder","from":"holmes","to":"theranos","status":"documented","role":"Founder","period":"2003","claim_ids":["c-ld-holmes-ceo","c-id-founding-date"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"holmes → theranos: Founder [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-holmes-president","record":{"id":"r-holmes-president","from":"holmes","to":"theranos","status":"documented","role":"President (signed the 2004 restated certificate and the 2010 Form D as President)","period":"Recorded on December 15, 2004 and July 8, 2010","claim_ids":["c-id-incorporation","c-ld-form-d-2010-persons"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"holmes → theranos: President (signed the 2004 restated certificate and the 2010 Form D as President) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-holmes-ceo","record":{"id":"r-holmes-ceo","from":"holmes","to":"theranos","status":"documented","role":"Chief executive officer","period":"2003 to June 15, 2018","claim_ids":["c-ld-holmes-ceo","c-ld-pay-holmes","c-ld-form-d-2017","c-ld-taylor-ceo","c-ld-board-dec-2016","c-ld-board-oct-2015","c-ld-board-2013-release","c-ld-florida-2013","c-ld-florida-2014","c-ld-florida-2015"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"holmes → theranos: Chief executive officer [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-holmes-chair","record":{"id":"r-holmes-chair","from":"holmes","to":"theranos","status":"documented","role":"Director and chair of the board","period":"Director in the Form D filings of July 2010 and May 2017; chair by 2013 and until at least June 2018","claim_ids":["c-ld-form-d-2010-persons","c-ld-form-d-2017","c-ld-pay-holmes","c-ld-board-oct-2015","c-ld-board-restructure-2015","c-ld-board-dec-2016","c-ld-taylor-ceo","c-civ-delaware-suits","c-ld-holmes-ceo","c-ld-board-2013-release","c-ld-florida-2013","c-ld-florida-2014","c-ld-florida-2015"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"holmes → theranos: Director and chair of the board [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-holmes-shareholder","record":{"id":"r-holmes-shareholder","from":"holmes","to":"theranos","status":"documented","role":"Controlling shareholder: just over half of the shares and over 99% of the votes after the 2014 Class B resolution; returned shares in 2017 and gave up voting control in the 2018 SEC settlement","period":"Early 2014 to March 2018 (control); shareholder until the company's dissolution (date not documented)","claim_ids":["c-fin-class-b","c-ld-pay-holmes","c-fin-tender-offer","c-fin-holmes-sec-equity"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"holmes → theranos: Controlling shareholder: just over half of the shares and over 99% of the votes after the 2014 Class B resolution; returned shares in 2017 and gave up voting control in the 2018 SEC settlement [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-holmes-lab-owner","record":{"id":"r-holmes-lab-owner","from":"holmes","to":"theranos","status":"documented","role":"Owner of record of the Newark clinical laboratory (CLIA 05D2025714) in CMS correspondence","period":"As of 2016","claim_ids":["c-lab-newark-clia","c-lab-owner-ban"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"holmes → theranos: Owner of record of the Newark clinical laboratory (CLIA 05D2025714) in CMS correspondence [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-balwani-coo","record":{"id":"r-balwani-coo","from":"balwani","to":"theranos","status":"documented","role":"President and chief operating officer","period":"September 2009 to May 2016 (July 2016 in a 2022 DOJ release)","claim_ids":["c-ld-balwani-tenure","c-ld-balwani-guarantee","c-ld-balwani-responsibilities","c-ld-may-2016","c-lab-fda-483","c-prt-retail-outreach","c-ld-form-d-2010-persons","c-ld-sole-executives","c-ld-pay-balwani","c-ld-board-oct-2015","c-ld-board-restructure-2015","c-bal-career-attributed","c-ld-board-2013-release","c-sec-retail-exit","c-ld-florida-2013","c-ld-florida-2014","c-ld-florida-2015"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"balwani → theranos: President and chief operating officer [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-balwani-director","record":{"id":"r-balwani-director","from":"balwani","to":"theranos","status":"documented","role":"Director","period":"Listed in the July 2010 Form D; left the board in May 2016","claim_ids":["c-ld-form-d-2010-persons","c-ld-balwani-tenure","c-ld-may-2016","c-ld-board-restructure-2015","c-ld-board-oct-2015","c-ld-board-2013-release"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"balwani → theranos: Director [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-balwani-guarantor","record":{"id":"r-balwani-guarantor","from":"balwani","to":"theranos","status":"documented","role":"Guarantor of a company line of credit","period":"2009","claim_ids":["c-ld-balwani-guarantee"],"kind":"pays","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"balwani → theranos: Guarantor of a company line of credit [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-balwani-shareholder","record":{"id":"r-balwani-shareholder","from":"balwani","to":"theranos","status":"documented","role":"Shareholder: nearly 30 million shares, more than 6% of the company","period":"As shown at trial; period not stated","claim_ids":["c-fin-balwani-stake"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"balwani → theranos: Shareholder: nearly 30 million shares, more than 6% of the company [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-balwani-lab-owner","record":{"id":"r-balwani-lab-owner","from":"balwani","to":"theranos","status":"documented","role":"Owner of record of the Newark clinical laboratory (CLIA 05D2025714) in CMS correspondence","period":"As of 2016","claim_ids":["c-lab-newark-clia","c-lab-owner-ban"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"balwani → theranos: Owner of record of the Newark clinical laboratory (CLIA 05D2025714) in CMS correspondence [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-holmes-balwani","record":{"id":"r-holmes-balwani","from":"balwani","to":"holmes","status":"documented","role":"Romantic partners (2004 to 2016 according to the Ninth Circuit)","period":"2004 to 2016","claim_ids":["c-ld-holmes-balwani-relationship","c-ld-balwani-guarantee","c-ld-options-email"],"kind":"other","direction":"undirected","role_group":"associations","temporal_status":"historical"},"reading":"balwani → holmes: Romantic partners (2004 to 2016 according to the Ninth Circuit) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-taylor","record":{"id":"r-taylor","from":"david-taylor","to":"theranos","status":"documented","role":"General counsel; chief executive officer and general counsel from June 15, 2018","period":"General counsel 2016 to 2018; CEO from June 15, 2018 through the September 2018 wind-down","claim_ids":["c-ld-taylor-ceo","c-ld-taylor-profile","c-wd-letter-2018","c-wd-dissolution-2018","c-wd-shutdown-attributed"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"david-taylor → theranos: General counsel; chief executive officer and general counsel from June 15, 2018 [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-king","record":{"id":"r-king","from":"heather-king","to":"theranos","status":"documented","role":"General counsel","period":"Appointed May 7, 2015; still general counsel in November 2015","claim_ids":["c-ld-heather-king","c-prt-safeway-trex"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"heather-king → theranos: General counsel [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-mcglynn","record":{"id":"r-mcglynn","from":"casey-mcglynn","to":"theranos","status":"documented","role":"Secretary (signed the California statement recording the 2004 name change)","period":"Statement filed in early 2005 (Delaware certified copy dated January 6, 2005)","claim_ids":["c-id-california-qualification","c-pp-mcglynn"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"casey-mcglynn → theranos: Secretary (signed the California statement recording the 2004 name change) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-lucas-dir","record":{"id":"r-lucas-dir","from":"donald-lucas","to":"theranos","status":"documented","role":"Director","period":"As of July 2010 (Form D)","claim_ids":["c-ld-form-d-2010-persons"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"donald-lucas → theranos: Director [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-robertson-dir","record":{"id":"r-robertson-dir","from":"robertson","to":"theranos","status":"documented","role":"Director (described as the company's first board member)","period":"Listed as a director in the July 2010 Form D; not among the directors in the 2013-2015 Florida reports; an online encyclopaedia says he served until 2018 (unconfirmed)","claim_ids":["c-ld-form-d-2010-persons","c-ld-robertson-attributed","c-ld-robertson-pay-attributed"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"robertson → theranos: Director (described as the company's first board member) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-robertson-consultant","record":{"id":"r-robertson-consultant","from":"robertson","to":"theranos","status":"reported","role":"Paid adviser (about $463,000 from March 2015 to February 2016, according to an online encyclopaedia)","period":"March 2015 to February 2016","claim_ids":["c-ld-robertson-pay-attributed"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"robertson → theranos: Paid adviser (about $463,000 from March 2015 to February 2016, according to an online encyclopaedia) [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-robertson-holmes","record":{"id":"r-robertson-holmes","from":"robertson","to":"holmes","status":"reported","role":"Stanford professor who taught Holmes and helped her start Theranos (online encyclopaedia account)","period":"2003","claim_ids":["c-ld-robertson-attributed"],"kind":"other","direction":"undirected","role_group":"associations","temporal_status":"historical"},"reading":"robertson → holmes: Stanford professor who taught Holmes and helped her start Theranos (online encyclopaedia account) [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-shapiro-dir","record":{"id":"r-shapiro-dir","from":"shapiro","to":"theranos","status":"documented","role":"Director (early board member)","period":"As of July 2010 (Form D)","claim_ids":["c-ld-form-d-2010-persons","c-pp-shapiro"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"shapiro → theranos: Director (early board member) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-thomas-dir","record":{"id":"r-thomas-dir","from":"peter-thomas","to":"theranos","status":"documented","role":"Director","period":"As of July 2010 (Form D)","claim_ids":["c-ld-form-d-2010-persons"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"peter-thomas → theranos: Director [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-tevanian-dir","record":{"id":"r-tevanian-dir","from":"tevanian","to":"theranos","status":"reported","role":"Director","period":"2006 to late 2007 (reported)","claim_ids":["c-ld-tevanian-attributed"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"tevanian → theranos: Director [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-shultz-dir","record":{"id":"r-shultz-dir","from":"shultz","to":"theranos","status":"documented","role":"Director","period":"From July 2011; listed in the Florida reports of 2013 to 2015; moved to the board of counselors in 2015 (company account)","claim_ids":["c-ld-shultz-joins","c-ld-board-oct-2015","c-ld-florida-2013","c-ld-florida-2014","c-ld-florida-2015"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"shultz → theranos: Director [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-kissinger-dir","record":{"id":"r-kissinger-dir","from":"kissinger","to":"theranos","status":"documented","role":"Director","period":"Listed in the Florida reports of 2013 to 2015; moved to the board of counselors in 2015 (company account)","claim_ids":["c-ld-shultz-joins","c-ld-board-oct-2015","c-ld-board-pay-testimony","c-ld-board-2013-release","c-ld-florida-2013","c-ld-florida-2014","c-ld-florida-2015"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"kissinger → theranos: Director [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-perry-dir","record":{"id":"r-perry-dir","from":"perry","to":"theranos","status":"documented","role":"Director","period":"Listed in the Florida reports of 2013 to 2015; moved to the board of counselors in 2015 (company account)","claim_ids":["c-ld-shultz-joins","c-ld-board-oct-2015","c-ld-board-pay-testimony","c-ld-board-2013-release","c-ld-florida-2013","c-ld-florida-2014","c-ld-florida-2015"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"perry → theranos: Director [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-nunn-dir","record":{"id":"r-nunn-dir","from":"nunn","to":"theranos","status":"documented","role":"Director","period":"Listed in the Florida reports of 2013 to 2015; moved to the board of counselors in 2015 (company account)","claim_ids":["c-ld-shultz-joins","c-ld-board-oct-2015","c-ld-board-pay-testimony","c-ld-board-2013-release","c-ld-florida-2013","c-ld-florida-2014","c-ld-florida-2015"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"nunn → theranos: Director [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-frist-dir","record":{"id":"r-frist-dir","from":"frist","to":"theranos","status":"documented","role":"Director","period":"Joined between July 2013 and August 2014; listed in the Florida reports of 2014 and 2015; moved to the board of counselors in 2015 (company account)","claim_ids":["c-ld-shultz-joins","c-ld-board-oct-2015","c-ld-florida-2014","c-ld-florida-2015"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"frist → theranos: Director [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-roughead-dir","record":{"id":"r-roughead-dir","from":"roughead","to":"theranos","status":"documented","role":"Director","period":"Listed in the Florida reports of 2013 to 2015; moved to the board of counselors in 2015 (company account)","claim_ids":["c-ld-shultz-joins","c-ld-board-oct-2015","c-ld-board-pay-testimony","c-ld-florida-2013","c-ld-florida-2014","c-ld-florida-2015"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"roughead → theranos: Director [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-mattis-dir","record":{"id":"r-mattis-dir","from":"mattis","to":"theranos","status":"documented","role":"Director","period":"From July 2013 (company release) to December 16, 2016","claim_ids":["c-ld-board-2013-release","c-ld-mattis-tenure","c-ld-shultz-joins","c-ld-board-oct-2015","c-ld-board-restructure-2015","c-ld-board-dec-2016","c-ld-mattis-testimony","c-ld-board-pay-testimony","c-ld-florida-2013","c-ld-florida-2014","c-ld-florida-2015"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"mattis → theranos: Director [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-kovacevich-dir","record":{"id":"r-kovacevich-dir","from":"kovacevich","to":"theranos","status":"documented","role":"Director","period":"From July 2013 (company release) to 2015, and again from May 2016; still listed in December 2016","claim_ids":["c-ld-board-2013-release","c-ld-shultz-joins","c-ld-board-oct-2015","c-ld-may-2016","c-ld-board-dec-2016","c-ld-board-2018","c-ld-board-pay-testimony","c-ld-florida-2013","c-ld-florida-2014","c-ld-florida-2015"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"kovacevich → theranos: Director [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-bechtel-dir","record":{"id":"r-bechtel-dir","from":"riley-bechtel","to":"theranos","status":"documented","role":"Director","period":"Joined between July 2013 and August 2014; retired on December 1, 2016","claim_ids":["c-ld-shultz-joins","c-ld-board-oct-2015","c-ld-board-restructure-2015","c-ld-dec-2016","c-ld-florida-2014","c-ld-florida-2015"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"riley-bechtel → theranos: Director [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-foege-dir","record":{"id":"r-foege-dir","from":"foege","to":"theranos","status":"documented","role":"Director","period":"Joined between July 2013 and August 2014 and served to 2015; again from May 2016; listed in May 2017 and still on the company website in March 2018","claim_ids":["c-ld-board-oct-2015","c-ld-may-2016","c-ld-board-counselors","c-ld-board-dec-2016","c-ld-form-d-2017","c-ld-board-2018","c-civ-delaware-suits","c-ld-florida-2014","c-ld-florida-2015"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"foege → theranos: Director [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-boies-dir","record":{"id":"r-boies-dir","from":"boies","to":"theranos","status":"documented","role":"Director","period":"From 2015 (reported in October 2015; February 2016 according to an online encyclopaedia); still listed in December 2016","claim_ids":["c-ld-boies-board","c-ld-board-restructure-2015","c-ld-board-dec-2016","c-ld-boies-counsel"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"boies → theranos: Director [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-warmenhoven-dir","record":{"id":"r-warmenhoven-dir","from":"warmenhoven","to":"theranos","status":"documented","role":"Director","period":"From December 1, 2016; listed in the May 2017 Form D","claim_ids":["c-ld-dec-2016","c-ld-board-dec-2016","c-ld-form-d-2017","c-civ-delaware-suits","c-fin-murdoch-buyback"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"warmenhoven → theranos: Director [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-bonanni-dir","record":{"id":"r-bonanni-dir","from":"bonanni","to":"theranos","status":"documented","role":"Director; chair of the Compliance and Quality Committee","period":"From May 2016; listed in the May 2017 Form D","claim_ids":["c-ld-may-2016","c-ld-board-dec-2016","c-ld-form-d-2017","c-ld-bonanni-committee","c-civ-delaware-suits"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"bonanni → theranos: Director; chair of the Compliance and Quality Committee [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-shultz-counselor","record":{"id":"r-shultz-counselor","from":"shultz","to":"theranos","status":"documented","role":"Member of the board of counselors (advisory)","period":"2015 to January 1, 2017","claim_ids":["c-ld-board-restructure-2015","c-ld-board-counselors","c-ld-dec-2016","c-ld-board-dec-2016"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"shultz → theranos: Member of the board of counselors (advisory) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-kissinger-counselor","record":{"id":"r-kissinger-counselor","from":"kissinger","to":"theranos","status":"documented","role":"Member of the board of counselors (advisory)","period":"2015 to January 1, 2017","claim_ids":["c-ld-board-restructure-2015","c-ld-board-counselors","c-ld-dec-2016","c-ld-board-dec-2016"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"kissinger → theranos: Member of the board of counselors (advisory) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-perry-counselor","record":{"id":"r-perry-counselor","from":"perry","to":"theranos","status":"documented","role":"Member of the board of counselors (advisory)","period":"Member by 2016; counselors retired January 1, 2017","claim_ids":["c-ld-dec-2016","c-ld-board-dec-2016"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"perry → theranos: Member of the board of counselors (advisory) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-nunn-counselor","record":{"id":"r-nunn-counselor","from":"nunn","to":"theranos","status":"documented","role":"Member of the board of counselors (advisory)","period":"2015 to January 1, 2017","claim_ids":["c-ld-board-counselors","c-ld-dec-2016","c-ld-board-dec-2016"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"nunn → theranos: Member of the board of counselors (advisory) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-frist-counselor","record":{"id":"r-frist-counselor","from":"frist","to":"theranos","status":"documented","role":"Member of the board of counselors (advisory)","period":"Member by 2016; counselors retired January 1, 2017","claim_ids":["c-ld-dec-2016","c-ld-board-dec-2016"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"frist → theranos: Member of the board of counselors (advisory) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-roughead-counselor","record":{"id":"r-roughead-counselor","from":"roughead","to":"theranos","status":"documented","role":"Member of the board of counselors (advisory)","period":"Member by December 2016; counselors retired January 1, 2017","claim_ids":["c-ld-board-dec-2016"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"roughead → theranos: Member of the board of counselors (advisory) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-kovacevich-counselor","record":{"id":"r-kovacevich-counselor","from":"kovacevich","to":"theranos","status":"documented","role":"Member of the board of counselors (advisory)","period":"2015 to May 2016","claim_ids":["c-ld-board-counselors"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"kovacevich → theranos: Member of the board of counselors (advisory) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-foege-counselor","record":{"id":"r-foege-counselor","from":"foege","to":"theranos","status":"documented","role":"Member of the board of counselors (advisory)","period":"2015 to May 2016","claim_ids":["c-ld-board-counselors"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"foege → theranos: Member of the board of counselors (advisory) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-foege-smab","record":{"id":"r-foege-smab","from":"foege","to":"theranos","status":"documented","role":"Member of the Scientific and Medical Advisory Board","period":"As of May 2016","claim_ids":["c-ld-board-counselors"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"foege → theranos: Member of the Scientific and Medical Advisory Board [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-kissinger-consultant","record":{"id":"r-kissinger-consultant","from":"kissinger","to":"theranos","status":"reported","role":"Paid consultant ($500,000 a year, according to Holmes's testimony)","period":"Period not stated","claim_ids":["c-ld-board-pay-testimony"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"kissinger → theranos: Paid consultant ($500,000 a year, according to Holmes's testimony) [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-mattis-investor","record":{"id":"r-mattis-investor","from":"mattis","to":"theranos","status":"reported","role":"Investor ($85,000, according to his testimony)","period":"Period not stated","claim_ids":["c-ld-mattis-testimony"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"mattis → theranos: Investor ($85,000, according to his testimony) [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-kovacevich-investor","record":{"id":"r-kovacevich-investor","from":"kovacevich","to":"theranos","status":"documented","role":"Investor (restitution award of $4,149,990)","period":"Investment period not stated","claim_ids":["c-crim-restitution-payees"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"kovacevich → theranos: Investor (restitution award of $4,149,990) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-bechtel-shareholder","record":{"id":"r-bechtel-shareholder","from":"riley-bechtel","to":"theranos","status":"documented","role":"Shareholder","period":"As of December 2016","claim_ids":["c-fin-bechtel-shareholder"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"riley-bechtel → theranos: Shareholder [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-boies-stock","record":{"id":"r-boies-stock","from":"boies","to":"theranos","status":"reported","role":"Reported agreement to be paid in Theranos stock for his firm's legal work; no holding documented","period":"Period not stated","claim_ids":["c-ld-boies-stock-attributed"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"boies → theranos: Reported agreement to be paid in Theranos stock for his firm's legal work; no holding documented [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-boies-counsel","record":{"id":"r-boies-counsel","from":"boies","to":"theranos","status":"documented","role":"Outside counsel","period":"2011 to November 2016","claim_ids":["c-ld-boies-counsel","c-ld-boies-board"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"boies → theranos: Outside counsel [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-bsf-counsel","record":{"id":"r-bsf-counsel","from":"boies-schiller","to":"theranos","status":"documented","role":"Law firm acting for Theranos (Theranos a client of the firm)","period":"Until November 2016","claim_ids":["c-ld-heather-king","c-ld-boies-counsel"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"boies-schiller → theranos: Law firm acting for Theranos (Theranos a client of the firm) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-king-bsf","record":{"id":"r-king-bsf","from":"heather-king","to":"boies-schiller","status":"documented","role":"Litigation partner in the Washington, D.C. office","period":"Until May 2015","claim_ids":["c-ld-heather-king"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"heather-king → boies-schiller: Litigation partner in the Washington, D.C. office [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-boies-bsf","record":{"id":"r-boies-bsf","from":"boies","to":"boies-schiller","status":"documented","role":"Founder and chairman","period":"From 1997","claim_ids":["c-pp-boies","c-ld-boies-counsel"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"boies → boies-schiller: Founder and chairman [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-shultz-bechtel","record":{"id":"r-shultz-bechtel","from":"shultz","to":"bechtel-group","status":"documented","role":"Director; former president","period":"Director as of October 2001; president for eight years earlier","claim_ids":["c-pp-shultz"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"shultz → bechtel-group: Director; former president [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-rbechtel-bechtel","record":{"id":"r-rbechtel-bechtel","from":"riley-bechtel","to":"bechtel-group","status":"documented","role":"Director from 1987; president and CEO 1990-2014; chairman 1996 to April 2017; then non-executive director","period":"From August 1987","claim_ids":["c-pp-riley-bechtel","c-ld-warmenhoven-bechtel"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"riley-bechtel → bechtel-group: Director from 1987; president and CEO 1990-2014; chairman 1996 to April 2017; then non-executive director [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-warmenhoven-bechtel","record":{"id":"r-warmenhoven-bechtel","from":"warmenhoven","to":"bechtel-group","status":"documented","role":"Director","period":"As of December 2016","claim_ids":["c-pp-warmenhoven","c-pp-warmenhoven-redback","c-ld-warmenhoven-bechtel"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"warmenhoven → bechtel-group: Director [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-warmenhoven-rbechtel","record":{"id":"r-warmenhoven-rbechtel","from":"warmenhoven","to":"riley-bechtel","status":"reported","role":"Fellow Bechtel Group directors; Warmenhoven met Holmes through Bechtel and replaced him on the Theranos board (reported)","period":"As of December 2016","claim_ids":["c-ld-warmenhoven-bechtel"],"kind":"other","direction":"undirected","role_group":"associations","temporal_status":"unknown"},"reading":"warmenhoven → riley-bechtel: Fellow Bechtel Group directors; Warmenhoven met Holmes through Bechtel and replaced him on the Theranos board (reported) [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-lucas-oracle","record":{"id":"r-lucas-oracle","from":"donald-lucas","to":"oracle","status":"documented","role":"Director from March 1980; chairman of the board October 1980 to March 1990","period":"From 1980 (as of 1999)","claim_ids":["c-pp-lucas"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"donald-lucas → oracle: Director from March 1980; chairman of the board October 1980 to March 1990 [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-ellison-oracle","record":{"id":"r-ellison-oracle","from":"ellison","to":"oracle","status":"documented","role":"Chairman of the board and chief executive officer","period":"As of 1999","claim_ids":["c-pp-lucas"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"ellison → oracle: Chairman of the board and chief executive officer [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-thomas-ata","record":{"id":"r-thomas-ata","from":"peter-thomas","to":"ata-ventures","status":"documented","role":"Managing director of ATA Management I, LLC, general partner of ATA Ventures I, L.P.","period":"As of February 2011","claim_ids":["c-pp-thomas"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"peter-thomas → ata-ventures: Managing director of ATA Management I, LLC, general partner of ATA Ventures I, L.P. [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-dhawan-labdir","record":{"id":"r-dhawan-labdir","from":"dhawan","to":"theranos","status":"documented","role":"Laboratory director, Newark laboratory (CLIA 05D2025714)","period":"From November 2014 until March 11, 2016","claim_ids":["c-lab-newark-clia","c-lab-dhawan-testimony","c-lab-cms-personnel","c-lab-owner-ban"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"dhawan → theranos: Laboratory director, Newark laboratory (CLIA 05D2025714) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-dhawan-balwani","record":{"id":"r-dhawan-balwani","from":"dhawan","to":"balwani","status":"reported","role":"Recruited by Balwani, who knew him personally, as laboratory director (trial testimony)","period":"2014","claim_ids":["c-lab-dhawan-testimony"],"kind":"other","direction":"directed","role_group":"associations","temporal_status":"historical"},"reading":"dhawan → balwani: Recruited by Balwani, who knew him personally, as laboratory director (trial testimony) [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-das-labdir","record":{"id":"r-das-labdir","from":"das","to":"theranos","status":"documented","role":"Laboratory director, Newark laboratory","period":"Laboratory director from March 2016 (regulatory duties from March 11, 2016); at Theranos until June 2018 (trial reporting)","claim_ids":["c-lab-das","c-wag-corrected-reports"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"das → theranos: Laboratory director, Newark laboratory [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-rosendorff-labdir","record":{"id":"r-rosendorff-labdir","from":"rosendorff","to":"theranos","status":"documented","role":"Laboratory director (former; reportedly replaced by Dhawan in 2014)","period":"Until 2014 (reported)","claim_ids":["c-lab-former-directors","c-lab-dhawan-testimony"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"rosendorff → theranos: Laboratory director (former; reportedly replaced by Dhawan in 2014) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-pandori-labdir","record":{"id":"r-pandori-labdir","from":"pandori","to":"theranos","status":"documented","role":"Laboratory director (former)","period":"Period not stated","claim_ids":["c-lab-former-directors"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"pandori → theranos: Laboratory director (former) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-sawyer-labdir","record":{"id":"r-sawyer-labdir","from":"sawyer","to":"theranos","status":"reported","role":"Laboratory co-director named on the licence (trial evidence)","period":"From November 2014","claim_ids":["c-lab-sawyer"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"sawyer → theranos: Laboratory co-director named on the licence (trial evidence) [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-young-labdir","record":{"id":"r-young-labdir","from":"daniel-young","to":"theranos","status":"documented","role":"Laboratory director, Scottsdale laboratory (CLIA 03D2077896)","period":"As of 2017 (CMS registry)","claim_ids":["c-lab-other-labs"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"daniel-young → theranos: Laboratory director, Scottsdale laboratory (CLIA 03D2077896) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-wag-msa","record":{"id":"r-wag-msa","from":"theranos","to":"walgreen-co","status":"documented","role":"Testing partner: Theranos Wellness Centers in Walgreens stores under the 2010 and 2012 agreements; received a $100 million Innovation Fee","period":"July 30, 2010 to termination on June 12, 2016","claim_ids":["c-wag-2010-agreement","c-wag-msa-2012","c-wag-pilot","c-wag-breach-notice","c-wag-2010-representations","c-wag-rollout-targets","c-wag-900-representation","c-wag-joint-marketing","c-wag-payment-for-tests","c-ld-balwani-responsibilities","c-wag-investment-figures","c-crim-doj-evidence"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"theranos → walgreen-co: Testing partner: Theranos Wellness Centers in Walgreens stores under the 2010 and 2012 agreements; received a $100 million Innovation Fee [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-wag-investor","record":{"id":"r-wag-investor","from":"walgreen-co","to":"theranos","status":"documented","role":"Investor: $40 million convertible note (bought through WVC Investments); restitution award of $40 million","period":"From June 5, 2012","claim_ids":["c-wag-msa-2012","c-wag-note-wvc","c-crim-restitution-payees","c-fin-investors-press","c-wag-investment-figures","c-crim-doj-evidence"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"walgreen-co → theranos: Investor: $40 million convertible note (bought through WVC Investments); restitution award of $40 million [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-wvc-note","record":{"id":"r-wvc-note","from":"wvc","to":"theranos","status":"documented","role":"Holder of the $40 million convertible note (debt convertible into equity)","period":"From June 5, 2012","claim_ids":["c-wag-note-wvc"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"wvc → theranos: Holder of the $40 million convertible note (debt convertible into equity) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-wba-wag","record":{"id":"r-wba-wag","from":"wba","to":"walgreen-co","status":"documented","role":"Corporate parent","period":"As of July 2018","claim_ids":["c-wag-walgreen-co"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"wba → walgreen-co: Corporate parent [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-wag-wvc","record":{"id":"r-wag-wvc","from":"walgreen-co","to":"wvc","status":"documented","role":"Parent (wholly owned subsidiary)","period":"As of August 31, 2012","claim_ids":["c-wag-subsidiaries","c-wag-note-wvc"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"walgreen-co → wvc: Parent (wholly owned subsidiary) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-wag-waz","record":{"id":"r-wag-waz","from":"walgreen-co","to":"walgreen-az","status":"documented","role":"Parent of the group (indirect, through Walgreens Hastings Co.)","period":"As of August 31, 2012","claim_ids":["c-wag-subsidiaries"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"walgreen-co → walgreen-az: Parent of the group (indirect, through Walgreens Hastings Co.) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-miquelon-wvc","record":{"id":"r-miquelon-wvc","from":"wade-miquelon","to":"wvc","status":"documented","role":"President (signed the convertible note)","period":"June 2012","claim_ids":["c-wag-note-wvc"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"wade-miquelon → wvc: President (signed the convertible note) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-miquelon-wag","record":{"id":"r-miquelon-wag","from":"wade-miquelon","to":"walgreen-co","status":"reported","role":"Chief financial officer (former)","period":"Finance chief at the time of the 2010 meetings (trial testimony)","claim_ids":["c-wag-2010-meetings"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"wade-miquelon → walgreen-co: Chief financial officer (former) [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-safeway-msa","record":{"id":"r-safeway-msa","from":"theranos","to":"safeway","status":"documented","role":"Testing partner under a 2010 Master Purchase Agreement for clinics in Safeway stores (program code-named T-Rex, reported)","period":"2010 to 2015","claim_ids":["c-prt-safeway-2010","c-prt-safeway-burd","c-prt-safeway-trex","c-prt-safeway-unwind","c-wag-2010-representations","c-ld-balwani-responsibilities","c-prt-retail-outreach","c-crim-doj-evidence"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"theranos → safeway: Testing partner under a 2010 Master Purchase Agreement for clinics in Safeway stores (program code-named T-Rex, reported) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-safeway-investor","record":{"id":"r-safeway-investor","from":"safeway","to":"theranos","status":"documented","role":"Investor (more than $10 million reported; restitution award of $14.5 million)","period":"Period not stated","claim_ids":["c-prt-safeway-trex","c-crim-restitution-payees","c-crim-doj-evidence"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"safeway → theranos: Investor (more than $10 million reported; restitution award of $14.5 million) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-burd-safeway","record":{"id":"r-burd-safeway","from":"steve-burd","to":"safeway","status":"documented","role":"Chief executive (led Safeway for more than 20 years)","period":"Until his retirement in 2013","claim_ids":["c-prt-safeway-burd"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"steve-burd → safeway: Chief executive (led Safeway for more than 20 years) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-pfizer","record":{"id":"r-pfizer","from":"theranos","to":"pfizer","status":"documented","role":"Research partnership to study Theranos technology; no meaningful dealings after 2008","period":"2008","claim_ids":["c-prt-pharma"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"theranos → pfizer: Research partnership to study Theranos technology; no meaningful dealings after 2008 [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-dod","record":{"id":"r-dod","from":"theranos","to":"dod","status":"documented","role":"Relationship to explore battlefield use of the Edison device (never fielded)","period":"Period not stated","claim_ids":["c-prt-dod","c-sec-allegations"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"theranos → dod: Relationship to explore battlefield use of the Edison device (never fielded) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-cleveland","record":{"id":"r-cleveland","from":"theranos","to":"cleveland-clinic","status":"documented","role":"Strategic alliance","period":"2015","claim_ids":["c-prt-health-partners"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"theranos → cleveland-clinic: Strategic alliance [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-capital-bc","record":{"id":"r-capital-bc","from":"theranos","to":"capital-bluecross","status":"documented","role":"Partnership for direct-to-consumer blood testing for its enrollees","period":"Announced July 2015","claim_ids":["c-prt-health-partners"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"theranos → capital-bluecross: Partnership for direct-to-consumer blood testing for its enrollees [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-amerihealth","record":{"id":"r-amerihealth","from":"theranos","to":"amerihealth","status":"reported","role":"Laboratory provider in Pennsylvania (start-up data publisher)","period":"Period not stated","claim_ids":["c-prt-health-partners"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"theranos → amerihealth: Laboratory provider in Pennsylvania (start-up data publisher) [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-horizon","record":{"id":"r-horizon","from":"theranos","to":"horizon-media","status":"documented","role":"Advertising customer ($1,126,661 paid on August 3, 2015 for Wellness Center advertisements)","period":"August 2015","claim_ids":["c-prt-horizon-media"],"kind":"pays","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"theranos → horizon-media: Advertising customer ($1,126,661 paid on August 3, 2015 for Wellness Center advertisements) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-dfj","record":{"id":"r-dfj","from":"dfj","to":"theranos","status":"reported","role":"Investor (led the June 2004 seed round, according to start-up funding data)","period":"From 2004","claim_ids":["c-fin-early-rounds-attributed","c-fin-investors-press"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"dfj → theranos: Investor (led the June 2004 seed round, according to start-up funding data) [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-ata","record":{"id":"r-ata","from":"ata-ventures","to":"theranos","status":"reported","role":"Investor (led the 2006 Series B, according to start-up funding data)","period":"2006","claim_ids":["c-fin-early-rounds-attributed"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"ata-ventures → theranos: Investor (led the 2006 Series B, according to start-up funding data) [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-murdoch","record":{"id":"r-murdoch","from":"murdoch","to":"theranos","status":"documented","role":"Investor: $125 million stake, sold back to Theranos for $1 in 2017 (reported); restitution award of $124,999,997","period":"Until March 2017","claim_ids":["c-crim-restitution-payees","c-fin-murdoch-buyback","c-fin-investors-press","c-fin-early-rounds-attributed"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"murdoch → theranos: Investor: $125 million stake, sold back to Theranos for $1 in 2017 (reported); restitution award of $124,999,997 [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-ellison","record":{"id":"r-ellison","from":"ellison","to":"theranos","status":"reported","role":"Investor (reported)","period":"Period not stated","claim_ids":["c-fin-investors-press","c-fin-early-rounds-attributed"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"ellison → theranos: Investor (reported) [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-devos","record":{"id":"r-devos","from":"devos","to":"theranos","status":"reported","role":"Investor (reported)","period":"Period not stated","claim_ids":["c-fin-investors-press"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"devos → theranos: Investor (reported) [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-bcbs","record":{"id":"r-bcbs","from":"bcbs","to":"theranos","status":"reported","role":"Investor (reported)","period":"Period not stated","claim_ids":["c-fin-investors-press"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"bcbs → theranos: Investor (reported) [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-pi-investor","record":{"id":"r-pi-investor","from":"partner-investments","to":"theranos","status":"documented","role":"Investor","period":"Before October 2016","claim_ids":["c-civ-delaware-suits"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"partner-investments → theranos: Investor [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-pfm-investor","record":{"id":"r-pfm-investor","from":"partner-fund-mgmt","to":"theranos","status":"reported","role":"Investor (according to start-up funding data)","period":"Period not stated","claim_ids":["c-fin-early-rounds-attributed"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"partner-fund-mgmt → theranos: Investor (according to start-up funding data) [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-pfm-gp","record":{"id":"r-pfm-gp","from":"partner-fund-mgmt","to":"partner-investments","status":"documented","role":"General partner","period":"As of February 2014","claim_ids":["c-fin-partner-investments"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"partner-fund-mgmt → partner-investments: General partner [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-rdv","record":{"id":"r-rdv","from":"rdv","to":"theranos","status":"documented","role":"Investor (restitution award of $99,999,984)","period":"Investment period not stated","claim_ids":["c-crim-restitution-payees"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"rdv → theranos: Investor (restitution award of $99,999,984) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-peer","record":{"id":"r-peer","from":"peer-ventures","to":"theranos","status":"documented","role":"Investor (restitution award of $93,499,912)","period":"Investment period not stated","claim_ids":["c-crim-restitution-payees"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"peer-ventures → theranos: Investor (restitution award of $93,499,912) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-pfmfunds","record":{"id":"r-pfmfunds","from":"pfm-funds","to":"theranos","status":"documented","role":"Investor (restitution award of $52,639,998)","period":"Investment period not stated","claim_ids":["c-crim-restitution-payees"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"pfm-funds → theranos: Investor (restitution award of $52,639,998) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-lvg","record":{"id":"r-lvg","from":"lucas-venture-group","to":"theranos","status":"documented","role":"Investor (restitution award of $7,570,005)","period":"Investment period not stated","claim_ids":["c-crim-restitution-payees"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"lucas-venture-group → theranos: Investor (restitution award of $7,570,005) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-moseley","record":{"id":"r-moseley","from":"moseley","to":"theranos","status":"documented","role":"Investor (restitution award of $5,999,997)","period":"Investment period not stated","claim_ids":["c-crim-restitution-payees"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"moseley → theranos: Investor (restitution award of $5,999,997) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-bdv","record":{"id":"r-bdv","from":"black-diamond","to":"theranos","status":"documented","role":"Investor (restitution award of $5,349,900)","period":"Investment period not stated","claim_ids":["c-crim-restitution-payees"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"black-diamond → theranos: Investor (restitution award of $5,349,900) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-hall","record":{"id":"r-hall","from":"hall-group","to":"theranos","status":"documented","role":"Investor (restitution award of $1,875,000)","period":"Investment period not stated","claim_ids":["c-crim-restitution-payees"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"hall-group → theranos: Investor (restitution award of $1,875,000) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-mendenhall","record":{"id":"r-mendenhall","from":"mendenhall","to":"theranos","status":"documented","role":"Investor (restitution award of $1,312,500)","period":"Investment period not stated","claim_ids":["c-crim-restitution-payees"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"mendenhall → theranos: Investor (restitution award of $1,312,500) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-lvgxi","record":{"id":"r-lvgxi","from":"lvg-xi","to":"theranos","status":"documented","role":"Shareholder: 471,333 Series C-1 shares; took part in the 2016-2017 exchange and released its claims","period":"From the C-1 round (2013)","claim_ids":["c-fin-series-order","c-fin-indirect-funds","c-fin-tender-offer"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"lvg-xi → theranos: Shareholder: 471,333 Series C-1 shares; took part in the 2016-2017 exchange and released its claims [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-pvgiv","record":{"id":"r-pvgiv","from":"pvg-iv","to":"theranos","status":"documented","role":"Fund holding Theranos stock; took part in the 2016-2017 exchange and released its claims","period":"Period not stated","claim_ids":["c-fin-indirect-funds","c-fin-tender-offer"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"pvg-iv → theranos: Fund holding Theranos stock; took part in the 2016-2017 exchange and released its claims [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-lvgivlp","record":{"id":"r-lvgivlp","from":"lvg-iv-lp","to":"theranos","status":"documented","role":"Fund holding or buying Theranos stock","period":"Period not stated","claim_ids":["c-fin-indirect-funds"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"lvg-iv-lp → theranos: Fund holding or buying Theranos stock [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-bdvxiib","record":{"id":"r-bdvxiib","from":"bdv-xii-b","to":"theranos","status":"documented","role":"Fund holding Theranos stock; took part in the 2016-2017 exchange and released its claims","period":"Period not stated","claim_ids":["c-fin-indirect-funds","c-fin-tender-offer"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"bdv-xii-b → theranos: Fund holding Theranos stock; took part in the 2016-2017 exchange and released its claims [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-celadon","record":{"id":"r-celadon","from":"celadon","to":"theranos","status":"documented","role":"Shareholder: bought 410,000 Series C Preferred shares from another investor","period":"From December 15, 2015","claim_ids":["c-fin-indirect-funds"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"celadon → theranos: Shareholder: bought 410,000 Series C Preferred shares from another investor [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-fortress-loan","record":{"id":"r-fortress-loan","from":"fortress","to":"theranos","status":"documented","role":"Lender: term loan of late 2017 secured on the patent portfolio (reported as a $100 million facility with $65 million drawn); in default by September 2018","period":"December 2017 to September 2018","claim_ids":["c-wd-loan","c-wd-loan-terms-attributed","c-wd-letter-2018","c-fin-early-rounds-attributed"],"kind":"pays","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"fortress → theranos: Lender: term loan of late 2017 secured on the patent portfolio (reported as a $100 million facility with $65 million drawn); in default by September 2018 [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-theranos-fortress-patents","record":{"id":"r-theranos-fortress-patents","from":"theranos","to":"fortress","status":"reported","role":"Transferred its interest in the patent subsidiary and the patents to Fortress in the September 2018 settlement (reported)","period":"September 2018","claim_ids":["c-wd-letter-2018","c-wd-shutdown-attributed","c-wd-patents-to-fortress"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"historical"},"reading":"theranos → fortress: Transferred its interest in the patent subsidiary and the patents to Fortress in the September 2018 settlement (reported) [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-theranos-tipc","record":{"id":"r-theranos-tipc","from":"theranos","to":"tipc","status":"documented","role":"Sole owner of the special purpose subsidiary and assignor of 284 patent properties to it (December 11, 2017)","period":"December 2017 to September 2018","claim_ids":["c-wd-patent-assignment","c-wd-tipc-subsidiary-attributed"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"theranos → tipc: Sole owner of the special purpose subsidiary and assignor of 284 patent properties to it (December 11, 2017) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-tipc-fcc","record":{"id":"r-tipc-fcc","from":"tipc","to":"fortress-credit","status":"documented","role":"Granted a security interest in 284 patent properties","period":"From December 11, 2017","claim_ids":["c-wd-security-interest"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"tipc → fortress-credit: Granted a security interest in 284 patent properties [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-fortress-tipc","record":{"id":"r-fortress-tipc","from":"fortress","to":"tipc","status":"reported","role":"Took ownership of the patent subsidiary after Theranos defaulted (reported)","period":"From 2018","claim_ids":["c-wd-patents-to-fortress","c-wd-tipc-subsidiary-attributed"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"fortress → tipc: Took ownership of the patent subsidiary after Theranos defaulted (reported) [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-labrador-tipc","record":{"id":"r-labrador-tipc","from":"tipc","to":"labrador","status":"reported","role":"Reportedly renamed Labrador Diagnostics LLC in March 2020 (law-review account)","period":"From March 2020","claim_ids":["c-wd-labrador-rename-attributed","c-wd-tipc-patents-2020"],"kind":"other","direction":"directed","role_group":"associations","temporal_status":"historical"},"reading":"tipc → labrador: Reportedly renamed Labrador Diagnostics LLC in March 2020 (law-review account) [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-fortress-labrador","record":{"id":"r-fortress-labrador","from":"fortress","to":"labrador","status":"reported","role":"Controls the renamed patent holder (law-review account)","period":"From March 2020","claim_ids":["c-wd-labrador-rename-attributed","c-wd-labrador-reaction"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"fortress → labrador: Controls the renamed patent holder (law-review account) [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-abc-assignee","record":{"id":"r-abc-assignee","from":"theranos","to":"theranos-abc","status":"documented","role":"Assigned all its assets and liabilities to the assignee for the benefit of creditors (General Assignment)","period":"From September 12, 2018; the assignee was still acting in 2023-2024","claim_ids":["c-wd-general-assignment","c-civ-arizona-settlement"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"theranos → theranos-abc: Assigned all its assets and liabilities to the assignee for the benefit of creditors (General Assignment) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-maidy-abc","record":{"id":"r-maidy-abc","from":"michael-maidy","to":"theranos-abc","status":"documented","role":"Manager","period":"As of September 2023","claim_ids":["c-wd-general-assignment"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"unknown"},"reading":"michael-maidy → theranos-abc: Manager [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-wag-abc","record":{"id":"r-wag-abc","from":"walgreen-co","to":"theranos-abc","status":"documented","role":"Creditor: general unsecured claim filed March 11, 2019, allowed at $45,000,000 in the 2023 settlement","period":"From March 11, 2019","claim_ids":["c-wag-abc-claim"],"kind":"business","direction":"directed","role_group":"business","temporal_status":"unknown"},"reading":"walgreen-co → theranos-abc: Creditor: general unsecured claim filed March 11, 2019, allowed at $45,000,000 in the 2023 settlement [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-sec-theranos","record":{"id":"r-sec-theranos","from":"sec","to":"theranos","status":"documented","role":"Plaintiff: civil fraud action SEC v. Holmes and Theranos (N.D. Cal. 5:18-cv-01602), settled; final judgment March 27, 2018","period":"Investigation reported in 2016; action March 14-27, 2018","claim_ids":["c-sec-charges","c-sec-settlement","c-lab-investigations-2016"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"historical"},"reading":"sec → theranos: Plaintiff: civil fraud action SEC v. Holmes and Theranos (N.D. Cal. 5:18-cv-01602), settled; final judgment March 27, 2018 [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-sec-holmes","record":{"id":"r-sec-holmes","from":"sec","to":"holmes","status":"documented","role":"Plaintiff: civil fraud action SEC v. Holmes and Theranos, settled without admitting or denying the allegations; $500,000 penalty and 10-year officer and director bar","period":"March 14-27, 2018 (bar for 10 years)","claim_ids":["c-sec-charges","c-sec-settlement","c-sec-relief-sought","c-fin-holmes-sec-equity"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"historical"},"reading":"sec → holmes: Plaintiff: civil fraud action SEC v. Holmes and Theranos, settled without admitting or denying the allegations; $500,000 penalty and 10-year officer and director bar [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-sec-balwani","record":{"id":"r-sec-balwani","from":"sec","to":"balwani","status":"documented","role":"Plaintiff: civil fraud action SEC v. Balwani (N.D. Cal. 5:18-cv-01603); outcome not documented in the record","period":"From March 14, 2018","claim_ids":["c-sec-charges","c-sec-balwani-case","c-sec-relief-sought"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"unknown"},"reading":"sec → balwani: Plaintiff: civil fraud action SEC v. Balwani (N.D. Cal. 5:18-cv-01603); outcome not documented in the record [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-us-holmes","record":{"id":"r-us-holmes","from":"united-states","to":"holmes","status":"documented","role":"Prosecution (5:18-cr-00258-EJD): convicted on four investor counts and acquitted on four patient counts; 135-month sentence, reduced to 10¼ years in 2026","period":"Indicted June 14, 2018; convicted January 3, 2022; affirmed 2025","claim_ids":["c-crim-indictment-2018","c-crim-holmes-verdict","c-crim-holmes-sentence","c-crim-ninth-circuit","c-crim-holmes-reduction","c-crim-superseding","c-crim-restitution","c-crim-surrender","c-crim-holmes-rehearing","c-aft-government-argument"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"historical"},"reading":"united-states → holmes: Prosecution (5:18-cr-00258-EJD): convicted on four investor counts and acquitted on four patient counts; 135-month sentence, reduced to 10¼ years in 2026 [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-us-balwani","record":{"id":"r-us-balwani","from":"united-states","to":"balwani","status":"documented","role":"Prosecution (5:18-cr-00258-EJD): convicted on all twelve counts; 155-month sentence; certiorari denied October 5, 2026","period":"Indicted June 14, 2018; convicted July 7, 2022; final October 5, 2026","claim_ids":["c-crim-indictment-2018","c-crim-balwani-verdict","c-crim-balwani-sentence","c-crim-ninth-circuit","c-crim-balwani-cert","c-crim-superseding","c-crim-restitution","c-crim-surrender"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"historical"},"reading":"united-states → balwani: Prosecution (5:18-cr-00258-EJD): convicted on all twelve counts; 155-month sentence; certiorari denied October 5, 2026 [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-cms-theranos","record":{"id":"r-cms-theranos","from":"cms","to":"theranos","status":"documented","role":"CLIA regulator: survey and sanctions on the Newark laboratory (2015-2016), sanctions on the Scottsdale laboratory (2017); settlement April 2017","period":"November 2015 to April 2017","claim_ids":["c-lab-cms-survey","c-lab-cms-proposed","c-lab-cms-sanctions","c-lab-scottsdale-sanctions","c-lab-cms-settlement","c-lab-newark-clia"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"historical"},"reading":"cms → theranos: CLIA regulator: survey and sanctions on the Newark laboratory (2015-2016), sanctions on the Scottsdale laboratory (2017); settlement April 2017 [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-fda-theranos","record":{"id":"r-fda-theranos","from":"fda","to":"theranos","status":"documented","role":"Inspected the Newark device-manufacturing site and issued a Form FDA-483","period":"August 25 to September 16, 2015","claim_ids":["c-lab-fda-483","c-lab-fda-press"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"historical"},"reading":"fda → theranos: Inspected the Newark device-manufacturing site and issued a Form FDA-483 [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-azag-theranos","record":{"id":"r-azag-theranos","from":"az-ag","to":"theranos","status":"documented","role":"Plaintiff: Arizona Consumer Fraud Act suit, resolved by consent decree ($4,652,000 restitution); allegations denied","period":"April 2017; refunds from December 2017","claim_ids":["c-lab-az-ag"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"historical"},"reading":"az-ag → theranos: Plaintiff: Arizona Consumer Fraud Act suit, resolved by consent decree ($4,652,000 restitution); allegations denied [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-oig-holmes","record":{"id":"r-oig-holmes","from":"hhs-oig","to":"holmes","status":"documented","role":"Excluded her from federal health care programs for 90 years","period":"From December 29, 2023 (upheld 2025 and January 16, 2026)","claim_ids":["c-exc-holmes","c-exc-oig-release"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"current"},"reading":"hhs-oig → holmes: Excluded her from federal health care programs for 90 years [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-oig-balwani","record":{"id":"r-oig-balwani","from":"hhs-oig","to":"balwani","status":"documented","role":"Excluded him from federal health care programs for 90 years","period":"Before January 2024","claim_ids":["c-exc-oig-release"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"current"},"reading":"hhs-oig → balwani: Excluded him from federal health care programs for 90 years [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-pi-suit","record":{"id":"r-pi-suit","from":"partner-investments","to":"theranos","status":"documented","role":"Plaintiff in Delaware Chancery suits against Theranos and its officers and directors; settled May 2017","period":"October 2016 to May 2017","claim_ids":["c-civ-delaware-suits"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"historical"},"reading":"partner-investments → theranos: Plaintiff in Delaware Chancery suits against Theranos and its officers and directors; settled May 2017 [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-pfm-master-suit","record":{"id":"r-pfm-master-suit","from":"pfm-master","to":"theranos","status":"documented","role":"Plaintiff in Delaware Chancery suits against Theranos and its officers and directors; settled May 2017","period":"October 2016 to May 2017","claim_ids":["c-civ-delaware-suits"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"historical"},"reading":"pfm-master → theranos: Plaintiff in Delaware Chancery suits against Theranos and its officers and directors; settled May 2017 [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-pfm-principals-suit","record":{"id":"r-pfm-principals-suit","from":"pfm-principals","to":"theranos","status":"documented","role":"Plaintiff in Delaware Chancery suits against Theranos and its officers and directors; settled May 2017","period":"October 2016 to May 2017","claim_ids":["c-civ-delaware-suits"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"historical"},"reading":"pfm-principals → theranos: Plaintiff in Delaware Chancery suits against Theranos and its officers and directors; settled May 2017 [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-wag-suit-2016","record":{"id":"r-wag-suit-2016","from":"walgreen-co","to":"theranos","status":"documented","role":"Plaintiff: breach-of-contract suit (D. Del. 16-1040), settled August 2017","period":"November 8, 2016 to August 2017","claim_ids":["c-wag-suit-2016","c-wag-settlement-2017"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"historical"},"reading":"walgreen-co → theranos: Plaintiff: breach-of-contract suit (D. Del. 16-1040), settled August 2017 [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-wag-suit-2018","record":{"id":"r-wag-suit-2018","from":"walgreen-co","to":"theranos","status":"documented","role":"Plaintiff: second suit (D. Del. 1:2018cv00989); $5,000,000 judgment","period":"July 2 to October 1, 2018","claim_ids":["c-wag-suit-2018"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"historical"},"reading":"walgreen-co → theranos: Plaintiff: second suit (D. Del. 1:2018cv00989); $5,000,000 judgment [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-labrador-biofire","record":{"id":"r-labrador-biofire","from":"labrador","to":"biofire","status":"documented","role":"Plaintiff: patent infringement suit (D. Del. 1:20-cv-00348), voluntarily dismissed","period":"March 9 to June 28, 2020","claim_ids":["c-wd-labrador-suit","c-wd-labrador-reaction"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"historical"},"reading":"labrador → biofire: Plaintiff: patent infringement suit (D. Del. 1:20-cv-00348), voluntarily dismissed [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-labrador-biomerieux","record":{"id":"r-labrador-biomerieux","from":"labrador","to":"biomerieux","status":"documented","role":"Plaintiff: patent infringement suit (D. Del. 1:20-cv-00348), voluntarily dismissed","period":"March 9 to June 28, 2020","claim_ids":["c-wd-labrador-suit","c-wd-labrador-reaction"],"kind":"legal","direction":"directed","role_group":"legal","temporal_status":"historical"},"reading":"labrador → biomerieux: Plaintiff: patent infringement suit (D. Del. 1:20-cv-00348), voluntarily dismissed [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-biomerieux-biofire","record":{"id":"r-biomerieux-biofire","from":"biomerieux","to":"biofire","status":"documented","role":"Parent (BioFire described as a wholly owned subsidiary)","period":"As of March 2020","claim_ids":["c-wd-labrador-suit"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"unknown"},"reading":"biomerieux → biofire: Parent (BioFire described as a wholly owned subsidiary) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-balwani-commercebid","record":{"id":"r-balwani-commercebid","from":"balwani","to":"commercebid","status":"documented","role":"President and principal shareholder","period":"Until the 1999 merger into Commerce One","claim_ids":["c-bal-commercebid","c-bal-commerce-one-role","c-bal-career-attributed"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"balwani → commercebid: President and principal shareholder [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-balwani-commerceone","record":{"id":"r-balwani-commerceone","from":"balwani","to":"commerce-one","status":"documented","role":"Announced to join the executive management team under the 1999 merger agreement (his CommerceBid shares to be exchanged for Commerce One stock)","period":"Announced November 1999","claim_ids":["c-bal-commerce-one-role","c-bal-commercebid"],"kind":"employs","direction":"directed","role_group":"people","temporal_status":"historical"},"reading":"balwani → commerce-one: Announced to join the executive management team under the 1999 merger agreement (his CommerceBid shares to be exchanged for Commerce One stock) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-commerceone-commercebid","record":{"id":"r-commerceone-commercebid","from":"commerce-one","to":"commercebid","status":"documented","role":"Acquirer under a November 1999 merger agreement (CommerceBid to become a wholly owned subsidiary)","period":"From November 1999","claim_ids":["c-bal-commercebid"],"kind":"owns","direction":"directed","role_group":"ownership","temporal_status":"historical"},"reading":"commerce-one → commercebid: Acquirer under a November 1999 merger agreement (CommerceBid to become a wholly owned subsidiary) [documented]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-evans-haemanthus","record":{"id":"r-evans-haemanthus","from":"billy-evans","to":"haemanthus","status":"reported","role":"Founder and chief executive","period":"Chief executive since 2022 (self-described); incorporated in Delaware by 2024 (accounts differ)","claim_ids":["c-aft-haemanthus","c-aft-holmes-advice"],"kind":"directs","direction":"directed","role_group":"people","temporal_status":"current"},"reading":"billy-evans → haemanthus: Founder and chief executive [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-holmes-haemanthus","record":{"id":"r-holmes-haemanthus","from":"holmes","to":"haemanthus","status":"reported","role":"Informal adviser from prison (reported; the company says she has no formal role)","period":"Reported in 2025","claim_ids":["c-aft-holmes-advice"],"kind":"other","direction":"directed","role_group":"associations","temporal_status":"unknown"},"reading":"holmes → haemanthus: Informal adviser from prison (reported; the company says she has no formal role) [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"relationships","id":"r-holmes-evans","record":{"id":"r-holmes-evans","from":"holmes","to":"billy-evans","status":"reported","role":"Personal partners (reported); Haemanthus says Holmes has no formal role in the company","period":"Reported in 2025-2026","claim_ids":["c-aft-haemanthus","c-aft-holmes-advice"],"kind":"other","direction":"undirected","role_group":"associations","temporal_status":"current"},"reading":"holmes → billy-evans: Personal partners (reported); Haemanthus says Holmes has no formal role in the company [reported]"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2003-founding","record":{"id":"e-2003-founding","date":"2003","title":"Elizabeth Holmes founds Theranos","claim_ids":["c-id-founding-date","c-ld-holmes-ceo"]},"reading":"2003 Elizabeth Holmes founds Theranos"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2004-incorporation","record":{"id":"e-2004-incorporation","date":"2004-04-13","title":"RealTime Cures, Inc. is incorporated in Delaware","claim_ids":["c-id-incorporation"]},"reading":"2004-04-13 RealTime Cures, Inc. is incorporated in Delaware"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2004-rename","record":{"id":"e-2004-rename","date":"2004-12-15","title":"RealTime Cures, Inc. becomes Theranos, Inc.","claim_ids":["c-id-incorporation"]},"reading":"2004-12-15 RealTime Cures, Inc. becomes Theranos, Inc."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2009-balwani","record":{"id":"e-2009-balwani","date":"2009","title":"Balwani guarantees a credit line and becomes President and Chief Operating Officer","claim_ids":["c-ld-balwani-guarantee","c-ld-balwani-tenure"]},"reading":"2009 Balwani guarantees a credit line and becomes President and Chief Operating Officer"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2010-safeway","record":{"id":"e-2010-safeway","date":"2010","title":"Safeway signs a Master Purchase Agreement with Theranos for testing in its stores","claim_ids":["c-prt-safeway-2010"]},"reading":"2010 Safeway signs a Master Purchase Agreement with Theranos for testing in its stores"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2010-formd","record":{"id":"e-2010-formd","date":"2010-07-08","title":"Theranos files a Form D reporting $45 million sold of a $100 million offering","claim_ids":["c-fin-form-d-2010","c-ld-form-d-2010-persons"]},"reading":"2010-07-08 Theranos files a Form D reporting $45 million sold of a $100 million offering"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2010-walgreens","record":{"id":"e-2010-walgreens","date":"2010-07-30","title":"Theranos and Walgreens sign their first Master Services Agreement","claim_ids":["c-wag-2010-agreement"]},"reading":"2010-07-30 Theranos and Walgreens sign their first Master Services Agreement"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2011-shultz","record":{"id":"e-2011-shultz","date":"2011-07","title":"George Shultz joins the board","claim_ids":["c-ld-shultz-joins"]},"reading":"2011-07 George Shultz joins the board"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2012-msa","record":{"id":"e-2012-msa","date":"2012-06-05","title":"Walgreens and Theranos sign the 2012 Master Services Agreement, which provides for a $40 million convertible note","claim_ids":["c-wag-msa-2012","c-wag-note-wvc"]},"reading":"2012-06-05 Walgreens and Theranos sign the 2012 Master Services Agreement, which provides for a $40 million convertible note"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2013-pilot","record":{"id":"e-2013-pilot","date":"2013-03-20","title":"First Wellness Center opens in a Walgreens store in Phoenix","claim_ids":["c-wag-pilot"]},"reading":"2013-03-20 First Wellness Center opens in a Walgreens store in Phoenix"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2013-launch","record":{"id":"e-2013-launch","date":"2013-09-09","title":"Theranos announces the Wellness Center roll-out in Walgreens stores","claim_ids":["c-wag-pilot"]},"reading":"2013-09-09 Theranos announces the Wellness Center roll-out in Walgreens stores"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2014-classb","record":{"id":"e-2014-classb","date":"2014","title":"Class B shares give Holmes over 99 percent of the voting power","claim_ids":["c-fin-class-b"]},"reading":"2014 Class B shares give Holmes over 99 percent of the voting power"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2015-fda","record":{"id":"e-2015-fda","date":"2015-09-16","title":"FDA inspection of the Newark site ends with a Form 483","claim_ids":["c-lab-fda-483"]},"reading":"2015-09-16 FDA inspection of the Newark site ends with a Form 483"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2015-cms-survey","record":{"id":"e-2015-cms-survey","date":"2015-12-23","title":"CMS completes its survey of the Newark laboratory","claim_ids":["c-lab-cms-survey"]},"reading":"2015-12-23 CMS completes its survey of the Newark laboratory"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2016-ij","record":{"id":"e-2016-ij","date":"2016-01-25","title":"CMS notifies Theranos of immediate jeopardy in hematology","claim_ids":["c-lab-cms-survey"]},"reading":"2016-01-25 CMS notifies Theranos of immediate jeopardy in hematology"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2016-breach","record":{"id":"e-2016-breach","date":"2016-01-28","title":"Walgreens sends a notice of breach","claim_ids":["c-wag-breach-notice"]},"reading":"2016-01-28 Walgreens sends a notice of breach"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2016-proposed","record":{"id":"e-2016-proposed","date":"2016-03-18","title":"CMS proposes revoking the Newark laboratory certificate","claim_ids":["c-lab-cms-proposed"]},"reading":"2016-03-18 CMS proposes revoking the Newark laboratory certificate"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2016-balwani-leaves","record":{"id":"e-2016-balwani-leaves","date":"2016-05-11","title":"Theranos announces Balwani's retirement and three new directors","claim_ids":["c-ld-may-2016","c-ld-balwani-tenure"]},"reading":"2016-05-11 Theranos announces Balwani's retirement and three new directors"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2016-termination","record":{"id":"e-2016-termination","date":"2016-06-12","title":"Walgreens terminates the agreement; it then closes the Wellness Centers","claim_ids":["c-wag-breach-notice"]},"reading":"2016-06-12 Walgreens terminates the agreement; it then closes the Wellness Centers"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2016-sanctions","record":{"id":"e-2016-sanctions","date":"2016-07-07","title":"CMS imposes sanctions including revocation of the Newark certificate","claim_ids":["c-lab-cms-sanctions"]},"reading":"2016-07-07 CMS imposes sanctions including revocation of the Newark certificate"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2016-pfm-suit","record":{"id":"e-2016-pfm-suit","date":"2016-10","title":"Partner Fund investors sue in the Delaware Court of Chancery","claim_ids":["c-civ-delaware-suits"]},"reading":"2016-10 Partner Fund investors sue in the Delaware Court of Chancery"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2016-walgreens-suit","record":{"id":"e-2016-walgreens-suit","date":"2016-11-08","title":"Walgreen Co. sues Theranos in Delaware","claim_ids":["c-wag-suit-2016"]},"reading":"2016-11-08 Walgreen Co. sues Theranos in Delaware"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2016-indirect-class","record":{"id":"e-2016-indirect-class","date":"2016-11-28","title":"Indirect-investor class action is filed against Theranos, Holmes and Balwani","claim_ids":["c-civ-indirect-class"]},"reading":"2016-11-28 Indirect-investor class action is filed against Theranos, Holmes and Balwani"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2016-board","record":{"id":"e-2016-board","date":"2016-12-01","title":"Warmenhoven joins the board; the board of counselors is to be retired","claim_ids":["c-ld-dec-2016"]},"reading":"2016-12-01 Warmenhoven joins the board; the board of counselors is to be retired"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2017-cms-settlement","record":{"id":"e-2017-cms-settlement","date":"2017-04","title":"Theranos settles with CMS and the Arizona Attorney General","claim_ids":["c-lab-cms-settlement","c-lab-az-ag"]},"reading":"2017-04 Theranos settles with CMS and the Arizona Attorney General"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2017-pfm-settlement","record":{"id":"e-2017-pfm-settlement","date":"2017-05","title":"Partner Fund suits settled; exchange offer to preferred holders","claim_ids":["c-civ-delaware-suits","c-fin-form-d-2017"]},"reading":"2017-05 Partner Fund suits settled; exchange offer to preferred holders"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2017-walgreens-settlement","record":{"id":"e-2017-walgreens-settlement","date":"2017-08-01","title":"Theranos announces its settlement with Walgreens","claim_ids":["c-wag-settlement-2017"]},"reading":"2017-08-01 Theranos announces its settlement with Walgreens"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2017-patents","record":{"id":"e-2017-patents","date":"2017-12-11","title":"Patents assigned to Theranos IP Company and pledged to Fortress Credit Corp.","claim_ids":["c-wd-patent-assignment","c-wd-security-interest"]},"reading":"2017-12-11 Patents assigned to Theranos IP Company and pledged to Fortress Credit Corp."}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2018-sec","record":{"id":"e-2018-sec","date":"2018-03-14","title":"SEC charges Theranos, Holmes and Balwani; Theranos and Holmes settle","claim_ids":["c-sec-charges","c-sec-settlement"]},"reading":"2018-03-14 SEC charges Theranos, Holmes and Balwani; Theranos and Holmes settle"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2018-indictment","record":{"id":"e-2018-indictment","date":"2018-06-14","title":"Holmes and Balwani are indicted","claim_ids":["c-crim-indictment-2018"]},"reading":"2018-06-14 Holmes and Balwani are indicted"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2018-taylor","record":{"id":"e-2018-taylor","date":"2018-06-15","title":"Holmes steps down as CEO; David Taylor takes over","claim_ids":["c-ld-taylor-ceo"]},"reading":"2018-06-15 Holmes steps down as CEO; David Taylor takes over"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2018-assignment","record":{"id":"e-2018-assignment","date":"2018-09-12","title":"Theranos assigns its assets for the benefit of creditors","claim_ids":["c-wd-general-assignment"]},"reading":"2018-09-12 Theranos assigns its assets for the benefit of creditors"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2018-walgreens-judgment","record":{"id":"e-2018-walgreens-judgment","date":"2018-10-01","title":"Walgreens obtains a $5,000,000 judgment in its second suit","claim_ids":["c-wag-suit-2018"]},"reading":"2018-10-01 Walgreens obtains a $5,000,000 judgment in its second suit"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2020-labrador","record":{"id":"e-2020-labrador","date":"2020-03-09","title":"Labrador Diagnostics sues BioFire and bioMérieux on Theranos patents","claim_ids":["c-wd-labrador-suit","c-wd-tipc-patents-2020"]},"reading":"2020-03-09 Labrador Diagnostics sues BioFire and bioMérieux on Theranos patents"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2020-superseding","record":{"id":"e-2020-superseding","date":"2020-07-28","title":"Third superseding indictment","claim_ids":["c-crim-superseding"]},"reading":"2020-07-28 Third superseding indictment"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2022-holmes-verdict","record":{"id":"e-2022-holmes-verdict","date":"2022-01-03","title":"Jury convicts Holmes on four investor counts and acquits her on four patient counts","claim_ids":["c-crim-holmes-verdict"]},"reading":"2022-01-03 Jury convicts Holmes on four investor counts and acquits her on four patient counts"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2022-balwani-verdict","record":{"id":"e-2022-balwani-verdict","date":"2022-07-07","title":"Jury convicts Balwani on all twelve counts","claim_ids":["c-crim-balwani-verdict"]},"reading":"2022-07-07 Jury convicts Balwani on all twelve counts"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2022-holmes-sentence","record":{"id":"e-2022-holmes-sentence","date":"2022-11-18","title":"Holmes is sentenced to 135 months","claim_ids":["c-crim-holmes-sentence"]},"reading":"2022-11-18 Holmes is sentenced to 135 months"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2022-balwani-sentence","record":{"id":"e-2022-balwani-sentence","date":"2022-12-07","title":"Balwani is sentenced to 155 months","claim_ids":["c-crim-balwani-sentence"]},"reading":"2022-12-07 Balwani is sentenced to 155 months"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2023-restitution","record":{"id":"e-2023-restitution","date":"2023-05","title":"Court orders $452,047,268 in restitution","claim_ids":["c-crim-restitution"]},"reading":"2023-05 Court orders $452,047,268 in restitution"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2023-exclusion","record":{"id":"e-2023-exclusion","date":"2023-12-29","title":"HHS-OIG excludes Holmes from federal health care programs for 90 years","claim_ids":["c-exc-holmes"]},"reading":"2023-12-29 HHS-OIG excludes Holmes from federal health care programs for 90 years"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2024-az-approval","record":{"id":"e-2024-az-approval","date":"2024-02-06","title":"Final approval of the Arizona patient class settlements","claim_ids":["c-civ-arizona-settlement"]},"reading":"2024-02-06 Final approval of the Arizona patient class settlements"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2025-affirmed","record":{"id":"e-2025-affirmed","date":"2025-02-24","title":"Ninth Circuit affirms both convictions, the sentences and the restitution order","claim_ids":["c-crim-ninth-circuit"]},"reading":"2025-02-24 Ninth Circuit affirms both convictions, the sentences and the restitution order"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2026-dab","record":{"id":"e-2026-dab","date":"2026-01-16","title":"Departmental Appeals Board affirms Holmes's exclusion","claim_ids":["c-exc-holmes"]},"reading":"2026-01-16 Departmental Appeals Board affirms Holmes's exclusion"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2026-reduction","record":{"id":"e-2026-reduction","date":"2026-03-26","title":"Holmes's sentence is reduced by one year","claim_ids":["c-crim-holmes-reduction"]},"reading":"2026-03-26 Holmes's sentence is reduced by one year"}
{"case_id":"theranos-inc","version":"1.0","as_of":"2026-10-21","record_type":"events","id":"e-2026-cert","record":{"id":"e-2026-cert","date":"2026-10-05","title":"Supreme Court denies Balwani's petition for certiorari","claim_ids":["c-crim-balwani-cert"]},"reading":"2026-10-05 Supreme Court denies Balwani's petition for certiorari"}